e roche annual report key figure key figure index figure annual report exceptional item index global reporting initiative gri propose board director indicator report development phase iv wwwrochecomreportingandindice calculation ecoefficiency rate wwwrochecomenvironment e roche ance report roche annual r eport fhopfufmbalnshnelda roche ltd f bhaosfefml asnwnitzear lranodc trademark legally protec ted wwwrochecom excellence science umschlagausgeschossenengindd key figure key figure index figure annual report exceptional item index global reporting initiative gri propose board director indicator report development phase iv wwwrochecomreportingandindice calculation ecoefficiency rate wwwrochecomenvironment lrochearengkey figuresindd year brief group group sale increase billion swiss franc swiss franc dollar division gain market share operating profit exceptional item increase swiss franc billion swiss franc strong sale growth continue productivity improvement time investment research development increase billion swiss franc effective march roche obtain ownership genentech price billion dollar billion swiss franc genentech integration complete net income billion swiss franc compare previous year exceptional item relate genentech transaction integration exclude exceptional item genentech transaction contribute income income attributable roche shareholder increase billion swiss franc core ep constant exchange rate swiss francs board propose dividend increase swiss franc rd consecutive year dividend growth increase payout ratio pharmaceutical pharma sale grow swiss franc dollar twice global market growth rate drive lead cancer medication tamiflu influenza medicine lucentis ophthalmology medicine tamiflu sale grow sharply billion swiss franc follow substantially increase demand pandemic influenza ahn virus swine flu outbreak operate profit margin exceptional item increase percentage point constant exchange rate percentage point swiss franc strong rd pipeline new molecular entity latestage clinical testing new compound enter phase iii clinical trial actemra approve treatment rheumatoid arthritis january diagnostic sale increase swiss franc dollar billion swiss franc twice market growth rate operating profit margin constant exchange rate increase percentage point percentage point swiss franc outlook fullyear sale pharmaceutical group expect grow midsingledigit range expect decrease tamiflu sale billion swiss franc diagnostic sale expect grow ahead market plan research development expense decline slightly compare roche confirm target doubledigit core earning share growth base strong operating free cash flow roche expect reduce debt progressively return net cash position maintain attractive dividend policy state growth rate local currency tamiflu sale constant exchange rate bar unforeseen event lrochearenghighlightsindd pharmaceuticals pipeline focus compound firstinclass bestinclass potential phase phase ii phase iii registration project d projectproduct indication project d projectproduct indication project d projectproduct indication project d projectproduct indication oncology oncology oncology oncology rg secretase inh solid tumour rg avastin multiple myeloma rg mabtherarituxan indolent nhl maint stline rg mabtherarituxan chronic lympocytic leukemia rg antiegfr humab solid tumour rg avastin metastatic melanoma rg xelodaavastin adj colon cancer stline rg cifmek inh solid tumour rg pertuzumab neoadj breast cancer rg xeloda adj breast cancer rg mabtherarituxan chronic lympocytic leukemia rg solid tumour rg trastuzumabdm metastatic bc rdline rg avastinmabthera diffuse large b cell lymphoma relapse rg antiplgf mab solid tumour rg trastuzumabdm metastatic bc stline rg avastin adj colon cancer rg xeloda adj colon cancer combo rg antinrp mab solid tumour rg hedgehog pathway inh basal cell carcinoma rg avastin prostate cancer oxaliplatin rg mdm antag solid hematologic tumour rg hedgehog pathway inh colocrectal cancer rg avastin adj breast cancer rg avastin mbc stline combo docetaxel rg dulanermin cancer rg hedgehog pathway inh ovarian cancer rg avastin ovarian cancer stline rg avastin mbc stline combo standard rg mek inh solid tumour rg anticd humab nonhodgkin lymphoma rg avastinherceptin mbc stline chemotherapy rg pi kinase inh solid hematologic tumour rg antimet humab metastatic nsclc rg avastin adj nsclc rg herceptin meet gastric cancer rg pi kinase inh solid tumour rg abt solid hematologic tumour rg avastin meet gastric cancer rg tarceva nsclc stline maintenance rg antiegfl mab solid tumours chu topoisomerase inh gastric cancer rg avastin adj breast cancer chu antiglypican mab liver cancer rg avastin adj bc triple negative inflammation autoimmune disorder inflammation autoimmune disorder rg avastin mbc combo hormonal rg mabtherarituxan rheumatoid arthritis dmard inflammation autoimmune disorder rg palovarotene emphysema therapy inadequate responder rg antibeta rhumab ulcerative colitis rg lebrikizumab asthma rg avastin ovarian cancer platinum rg xolair pediatric asthma rg antilt alpha mab rheumatoid arthritis rg oxl humab asthma sensitive chu eldecalcitol ed osteoporosis bti vap inflammatory disease rg rontalizumab systemic lupus erythematosus rg avastin mbc ndline rg xolair chronic idiopathic urticaria rg avastin highrisk carcinoid virology virology rg avastin gbm stline rg valcyte cytomegalovirus extension chu serine palmitoyltran hepatitis c virology rg herceptin sc formulation bc treatment ferase inh rg hpv immunotherapy cervical neoplasia rg herceptin adj bc yr treatment chu nitazoxanide hepatitis c rg nucleoside inh prodrug hepatitis c rg pertuzumab mbc ophthalmology rg protease inh hepatitis c rg tarceva nsclc egfr mutation rg lucentis retinal vein occlusion cardiovascular metabolic disease positive stline rg yr peptide agonist type diabete cardiovascular metabolic disease rg tarceva adj nsclc rg antip selectin humab peripheral vascular disease rg aleglitazar cardiovascular risk reduction rg tarcevaavastin nsclc maint stline chu epogin epoch chemoinduced anemia rg hsd inh type diabetes rg sglt inh type diabetes rg anticd humab chronic lymphocytic leukemia rg hsd inh type diabetes rg braf inh malignant melanoma rg abca inducer dyslipidemia central nervous system rg trastuzumabdm mbc ndline rg craf inh polycystic kidney disease rg ocrelizumab relapsingremitte ms rg antioxldl mab secondary prevention rg glyt inh schizophrenia inflammation autoimmune disorder cardiovascular event rg nicotinic receptor alzheimer disease rg mabtherarituxan ancaassociate vasculitis rg bht type diabetes agonist rg actemraroactemra jia systemic onset rg mglur antag treatmentresistant depression rg actemraroactemra early rheumatoid arthritis central nervous system rg ocrelizumab rheumatoid arthritis pjd rg gantenerumab alzheimer disease rg xolair asthma addon therapy rg mglur antag depression rg gabaa agonist alzheimer disease select abbreviation cardiovascular metabolic disease legend rg igf peg amyotrophic lateral sclerosis adj adjuvant treatment inh inhibitor rg taspoglutide type diabete therapeutic protein biologic rg triple reuptake inh depression amd agerelate macular jia juvenile idiopathic arthritis rg dalcetrapib dyslipidemia small molecule degeneration mab monoclonal antibody rg taar partial agonist depression blue type indication antag antagonist maint maintenance treatment rg antiamyloid peptide alzheimer disease bc breast cancer meet metastatic cancer ophthalmology black type additional indication mab combo combine ms multiple sclerosis rg lucentis diabetic macular edema dmard diseasemodifye nhl nonhodgkin lymphoma evo nmda receptor antag treatmentresistant depression antirheumatic drug nsclc nonsmall cell lung cancer rg lucentis amd high dose rgno roche andor genentech manage gbm glioblastoma multiforme pjd prevention joint chu chugai manage ophthalmology herpositive destruction bti biotie optin hernegative r recombinant evo evotec rg antifactor mab geographic atrophy hpv human papilloma virus sc subcutaneous rg tnkase catheter clearance hu humanise phase initial study healthy volunteer possibly patient phase ii efficacy tolerability dosefinde study patient phase iii largescale study patient statistical confirmation safety efficacy registra marketing application file eu andor japan tion approve eu current january umschlagausgeschosseneng indd business innovation answer medical challenge daily work save patient live help million people world excellence science focus unsolved medical problem year roche play pioneer include cancer viral infection metabolic ing role healthcare today world leader central nervous system disorder inflammatory vitro diagnostic supply wide range diag disease roche pioneer personalise health nostic instrument test rapid reliable care aim fit treatment closely pos sible disease detection monitor doctor labora patient need healthcare well safe tory patient world large costeffective biotech company roche bring highly effective drug market world lead supplier prescription drug cancer treatment daily work focus disease area medical need great lrochearengtable contentsindd content key figure inside cover pharmaceutical pipeline inside cover year brief letter shareholder roche group group results outlook group strategy pharmaceuticals pharmaceutical division brief result sale review development highlight research development diagnostic diagnostic division brief result business area highlight research development corporate governance remuneration report corporate governance remuneration report corporate responsibility brief responsible practice patient people society safety security health environmental protection independent assurance report gri statement lrochearengtable contentsindd roche business report letter shareholder letter shareholder franz b humer dear shareholder despitethesustainedglobalfinancialandeconomiccrisiswasaverysuccessfulyearforrochesale inboththepharmaceuticalsandthediagnosticsdivisiongrewtwiceasfastasthemarketgroupsales increasedbyinlocalcurrenciestobillionswissfrancsmainlydrivenbyourleadingmedicine totreatpatientswithcancerviralinfectionsagerelatedblindnessandotherseriousdiseasessalesof theinfluenzamedicinetamifluatbillionswissfrancsalsocontributedsignificantlytorevenuegrowth operatingprofitbeforeexceptionalitemsgrewevenmorestronglythansalesadvancinginlocal currenciestobillionswissfranc willberememberedasoneofthemostimportantyearsinyourcompanyslonghistoryfollowingthe mergeragreementwithgenentechinmarchandtherapidfinalisationofthetransactionwewere abletocompletetheintegrationbytheendoftheyearbycombiningrocheandgenentechwearenotonly increasingoperationalefficiencybutalsopromotinginternalknowledgetransferwearecommittedto strengtheningtherochegroupsinnovativepowerinthelongtermandto providingpatientswithinno vativemedicinesthroughresearchofthehighestquality excellentresearchisandwillremainabasicrequirementforthedevelopmentoftherapiesthataredecisive forpatientshealthandqualityoflifeafterconcludingthegenentechintegrationwewillcontinueto systematicallypursuediverseresearchapproachesforinnovativehealthcaresolutionsthiscreatesscope forcreativityandincreasesthechancesofdevisingsustainablemedicalandtherapeuticprogressfor thisreasongenentechresearchandearlydevelopmentwillcontinuetofunctionasanindependentunit lrochearengletter shareholdersindd severin schwan inadditioncombiningtheactivitiesofthetwocompaniesintheareasofproductdevelopmentproduction andsaleshasalreadygeneratedsignificantincreasesinproductivityouraimistoachievepretaxannual savingsofapproximatelybillionswissfrancsby theoperatingfreecashflowofthegroupincreasedbytobillionswissfrancsdespitesignificant negativecurrencyeffectsrochesstrongoperatingperformanceisalsoclearlyreflectedincoreearning persharewhichadvancedinlocalcurrenciesinswissfranc asaresultofexceptionalcostsofbillionswissfrancswhichwereprimarilyintegrationrelate thegroupsoperatingprofitindeclinedbyinlocalcurrenciesinswissfrancstobillion swissfrancsexceptionalitemsalsoimpactednetincomewhichdeclinedbycomparedwiththe previousyearperiodtobillionswissfrancsexcludingexceptionalitemsnetincomeattributableto rocheshareholdersincreasedby inviewofrochesstrongfullyearoperatingresultsattheannualgeneralmeetingtheboardofdirector willproposeanincreaseofinthedividendfortoswissfrancspershareandnonvote equitysecurityswissfrancssubjecttoyourapprovalthiswillbetherdconsecutive annualdividendincrease lrochearengletter shareholdersindd roche business report letter shareholder therapidspreadofthepandemicahninfluenzavirusswinefluwhichbeganinaprilpre sentedamajorchallengenotonlyforgovernmentsworldwidebutalsoforrocheduringthepastyearwe havebeensupportingtheworldhealthorganizationwhoandnationalgovernmentsinglobaleffort tofightthenewvirusinmayrocheannouncedthatanadditionalmilliontreatmentcoursesoftamiflu wouldbedonatedtoreplenishthewhosregionalandrapidresponsestockpileswehadpreviously grantedsublicencestothreemanufacturerstoproducegenericoseltamivirforpandemicuseinchina indiaandspecifieddevelopingcountriestoensurethatlocalpopulationsintheseareashaveaccessto themedicationinadditioninjulyweinitiatedthetamiflureservesprogramtofurtherimprovetamiflu accessindevelopingcountriesinresponsetotheincreasedwhopandemicthreatlevelournetworkof manufacturingpartnersscaledupproductiontoapproximatelymilliontreatmentcoursespermonth andwearenowabletosupplyuptomillionpacksannuallyifrequire therochegroupreceivedsignificantrecognitionforachievementsinseveralareasduringthepastyear thedowjonessustainabilityindexesnamedrochethenewsupersectorleaderinhealthcare rankingusasthemostsustainablehealthcarecompanyworldwiderocheandgenentechwerealso againvotedbestemployerinanumberofcountries wewouldliketotakethisopportunitytothankthemorethangroupemployeesworldwideforthe outstandingdedicationandprofessionalismduringthiseventfulandchallengingtime scientificexcellenceandinnovationinourcorepharmaanddiagnosticsbusinesseswillcontinuetobethe foundationofoursuccessasidefromoncologywearedevelopingnewtherapeuticsformetabolicand autoimmunediseasesviralinfectionsanddisordersofthecentralnervoussystemastheworldslarg biotechcompanywehaveoneofthemostpromisingrdpipelinesintheworldfromatotalofnew molecularentitiesinclinicaltestingtenarealreadyinlatestagedevelopmentwhichisremarkablebyany standardsinourindustryinthelastyearalonesixnewcompoundsenteredlatephasedevelopment includingpotentialnewtherapiesforbreastcancerandtypediabete duringtheyearwepublishedexcitingearlyphaseclinicaltrialdataonatargetedtreatmentandcom paniondiagnosticinmalignantmelanomapatientswhosecancercellscarryaspecificgeneticmutation malignantmelanomaisthedeadliestformofskincancerthenewcompoundeffectivelyslowedtumor progressionandincreasedpatientsqualityoflifethisisabeaconofhopeinthefightagainstacancer thatuntilnowhasbeenregardedasvirtuallyuntreatable amongthekeyachievementsinourdiagnosticsdivisionarethestartoftherolloutofthecobas modularanalyserseriesforlargemedicallaboratoriesandthelaunchofnewproductsintheaccuchek lineofbloodglucosemonitorsforpeoplewithdiabetes attheendofwilliammburnsceoofthepharmaceuticalsdivisionjrgenschwiezerceoofthe diagnosticsdivisionandjonathankcknowlesheadofrochegroupresearchleftthecorporate executivecommitteeasplannedeachofthemhasmadesignificantcontributionstorochessuccessand helpedwriteanimportantchapterinthecompanyshistoryeverygenerationofmanagershasthetask ofensuringrocheshealthyfutureasanindependentcompanybillburnsjonathanknowlesandjrgen schwiezerhavefulfilledthistaskinanexemplarymannerdrivenbyprofoundconvictiontheyhave lrochearengletter shareholdersindd bringing genentech fully roche group major step road create strong innovative organisation significantlycontributedtorochesstrongmarketpositionandsuccessonbehalfoftheentireboardof directorsandthecorporateexecutivecommitteewewouldliketothankthemfortheirmanyyearsof invaluableserviceloyaltytorocheandforthegreatworkingrelationshipweenjoye inviewoftheiroutstandingindustryknowledgetheboardofdirectorswillproposeappointingwilliam mburnsandarthurdlevinsonchairmanofgenentechboardofdirectorstotheboardofdirectorsof rocheholdingltdattheannualgeneralmeetingonmarch profhorstteltschikandpeterbrabeckhavedecidednottostandforreelectionattheannual generalmeetingweareverygratefulfortheirvaluablecontributionstothecompanyoveraperiodofmany year barringunforeseeneventsweexpectsalesinforthepharmaceuticalsdivisionandforthegroup toincreaseinthemidsingledigitrangeinlocalcurrenciesinthediagnosticsdivisionweexpectfullyear salestogrowconsiderablyaheadofthemarketfurthermoreweareaimingtoachievedoubledigit coreearningspersharegrowthatconstantexchangeratesinweanticipatethatwewillalreadyhave repaidofthedebtraisedtofinancethegenentechtransactionbytheendofbasedonthe groupsstrongoperatingfreecashflowrocheexpectstoreturntoanetcashpositionbytheendof wewillsimultaneouslymaintainourattractivedividendpolicy franzbhumer severinschwan chairmanoftheboard chiefexecutiveofficer exclude tamiflu sale lrochearengletter shareholdersindd bildstreckeengsindd s work starvation diet aggressive brain tumour roche tackle modern medicine great challenge search medicine combat illness effective treatment exist quest require sophisticated technological capability deep insight molecular biology select optimal target drug treatment need understand complex biological mechanism drive disease case avastin target blockade bloodvessel growth factor approach develop genentech scientist starve tumour nutrients oxygen need grow spread fundamentally change way fight cancer avastin currently approve treat type cancer investigate possible treatment different tumour type give hope thousand patient avastin monoclonal antibody treat advanced colorectal breast nonsmall cell lung kidney cancer approve country treatment relapse glioblastoma multiforme aggressive type brain tumour bildstreckeengsindd roche group strong operating performance group sale ope rating profit exceptional item core earning share increase double digit roche anticipate doubledigit rise core eps group remain firmly focus prescription drug vitro diagnostic follow successful integration genentech roche well equip healthcare innovator lrochearenggroupindd roche group thegroupsoperatingfreecashflowincrease stronglyrisinginlocalcurrenciesinswiss strong sale trading result francstobillionswissfrancsthegroup totalsalesgrewbyinlocalcurrenciesin freecashflowremainedstronginincreasingby swissfrancsinusdollarstobillionswiss billionswissfrancstobillionswissfrancs francswiththepharmaceuticalsdivisionaccounting forofgroupsalesandthediagnosticsdivision coreepswhichexcludesexceptionalitem contributingsalesgrowthinbothdivision andamortisationandimpairmentofintangibleasset exceededmarketgrowth increasedinlocalcurrenciesinswiss francs salesbythepharmaceuticalsdivisionincrease inlocalcurrenciesinswissfrancsin significant impact genentech integration usdollarstobillionswissfrancsoralmost change group organisation doubletheglobalmarketgrowthratedemandfor effectivemarchthegroupobtainedfull thegroupscancermedicinesavastinherceptin ownershipofgenentechsubsequentlythegroup mabtherarituxantarcevaandxelodacontinuedto commencedarestructuringofitsuspharmaceuticals growstronglyadditionalmajorgrowthdriversin businessaswellasanumberofglobalfunction thepharmaceuticalsdivisionweretamifluinvirology duringrestructuringandintegrationcostsof andlucentisinophthalmology billionswissfrancswereincurredmainlyin connectionwiththediscontinuationofaconstruction thediagnosticsdivisionachievedsalesgrowthof projectatthemanufacturingsiteatvacavillecalifornia inlocalcurrenciesinswissfrancsinusdol terminationcostsfortheclosureofmanufacture larstobillionswissfrancstherebystrengthene operationsatnutleynewjerseytheclosureofthe thedivisionsleadingmarketshareofaround researchanddevelopmentsiteatpaloaltocalifornia andcostsassociatedwiththeconsolidationofthe thegroupsoperatingprofitbeforeexceptionalitems usadministrativefunctionsinsouthsanfrancisco increasedbyinlocalcurrenciesinswiss approximatelybillionswissfrancsoftheseexcep francstobillionswissfrancsoperatingprofit tionaloperatingexpensesarenoncash itemsrelate inlocalcurrenciesgrewtobillionswiss mainlytoimpairmentsofmanufacturingasset francsbeforeexceptionalitemsinthepharmaceutical divisionandtobillionswissfrancsinthe thegroupfinancedthegenentechtransactionby diagnosticsdivision acombinationofthegroupsownfundsbondsnote andcommercialpaperthegroupraisednetpro atconstantexchangeratesthegroupsoperate ceedsofbillionswissfrancsthroughaserie profitmarginbeforeexceptionalitemsincrease ofbondandnoteofferingsasaconsequenceinter percentagepointswiththepharmaceuticalsdivi expensesincreasedsubstantiallyinand sionimprovingpercentagepointsandthedia financingcostsexceededfinancialincomebybil gnosticsdivisionpercentagepointsduetoan lionswissfrancsbytheendofthegroup unfavourablecombinationofexchangeratemove hadalreadyrepaiddebtofbillionswissfranc mentshoweverthegroupsoperatingprofitmargin beforeexceptionalitemsinswissfrancsincrease comparedtonetincomedecreasedbyto onlyslightlybypercentagepointstowith billionswissfrancsprimarilyduetoexceptional thepharmaceuticalsdivisionimprovingpercent itemsnetincomeattributabletorocheshareholder agepointstoandthediagnosticsdivision declinedtobillionfrancsexcludingexcep decreasingpercentagepointsto tionalitemsnetincomewasdownandnetincome lrochearenggroupindd roche business report roche group attributabletorocheshareholderswashigher weexpecttorepayofthedebtraisedtofinance comparedto thegenentechtransactionbytheendof bythegroupaimstoachievepretaxannual thenetdebtpositionofthegroupisbillion synergiesofapproximatelybillionswissfrancs swissfrancsamovementofbillionswissfranc basedonthegroupsstrongoperatingfreecashflow fromanetcashpositionofbillionswissfranc weexpecttoreducedebtprogressivelyandto ondecemberduetothebillionswiss returntoanetcashpositionbywewillsimulta francsusedinthegenentechtransaction neouslymaintainourattractivedividendpolicy outlook barringunforeseeneventsrocheexpectssale inforthepharmaceuticalsdivisionandfor thegrouptoincreaseinthemidsingledigit range inlocalcurrenciesexcludingtamifluinthe diagnosticsdivisionweexpectfullyear salesto growsignificantlyaheadofthemarketdespite ananticipateddecreaseintamiflusalesfrom tobillionswissfrancsweareaimingtoachieve doubledigit coreearningspersharegrowthat constantexchangerate rocheexpectsresearchanddevelopmentexpendi turestodeclineslightlyinhoweverthegroup focusremainsfirmlyoninnovationanditwill continuetoinvesttosupportitsrichpharmaceutical developmentpipelinewhichcurrentlyinclude tennewmolecularentitiesandadditionalindica tionsforexistingproductsinlatestagedevelopment overthenextmonthsthepharmaceutical divisionexpectstofilemarketingapplicationsfor severalmajorlineextensionsofourkeycancermedi cinesincludingavastinmabtherarituxanand xelodaaswellasfortaspoglutidefortypediabetes lrochearenggroupindd corporate sustainability key achievement responsible name healthcare super sector leader dow jones sustainability index djsi practice reselecte djsi world stoxx indices ftsegood index produce new position paper stem cell clone nanotechnology biobank personalise healthcare value product service launch groupwide phone line webbase system report violation code conduct develop new supplier code conduct describe requirement ethic safety health environment innovation supplier diversity economic sustainability social responsibility patient access oneworld health complete screen roche chemical compound library healthcare find new drug treat diarrhea join publicprivate partnership novo nordisk world diabetes foundation improve care child diabete africa donate million additional tamiflu course replenish stockpile launch tamiflu reserve program increase access develop country provide free treatment patient rochegenentech access programme disclose financial inkind support patient organisation website people global employee listening survey result employee express job satisfaction roche genentech vote science magazine employer seventh time roll globally align performance management compensation principle begin align genentech roche expand global leadership programme portfolio provide key programme stage leadership development talent pipeline society launch new corporate policy philanthropic donation noncommercial sponsorship launch cancer awareness campaign rural south africa train nursing staff offer free screening breast cervical prostate cancer raise awareness disease safety health produce manual energy efficient design standard building environmental launch elearne programme safety security health environmental protection protection employee launch roche environmental awareness chemical technology react programme reduce environmental impact product learn roche achievement area corporate responsibility section report page lrochearenggroupindd roche business report roche group group strategy roche focus develop medicine diagnostic help patient live long well life strive address unmet medical need excellence science genentech fully integrate roche group research development team collaborate project share resource integration ensure future organisation maintain diversity approach essential successful innovation lrochearenggroupindd roche business model change practice medicine focus fitting treatment patient distinctiveness excellence science delivery value stakeholder roche group business webelievethatmedicallydifferentiatedproduct whilethedemandfornewandimprovedtreatment aremorelikelytoobtainregulatoryapprovalandbe keepsgrowingsodoesthepressuretocontrol acceptedbypatientsphysiciansandpayer healthcarecostsinthischangingandchallenge environmentweseektodevelopmedicallydif delivery ferentiatedproductsmedicinesanddiagnostic rocheaimstobenefitallstakeholder offeringsignificantclinicalandhealtheconomic wewanttoimprovethetreatmentoption benefitsoverexistingoptionstoadvancethisgoal availabletopatientsanddoctorsenablemedical wehaverefinedourbusinessmodelalongthree laboratoriestoworkmoreefficientlyandhelp dimensionsourfocusourdistinctivenessandour societiescontainhealthcarecostsweseekto delivery ensurethatpeoplewhoneedourmedicine anddiagnosticshaveaccesstothemseepage focus oursuccessasacompanyisbuiltonscientific peoplewhoworkatrochehaveachancetomake discoveryandinnovationwefocusonprescription theirmarkandimprovelivesweseektoprovide pharmaceuticalsandin vitrodiagnosticsandhave everyrocheemployeewithopportunitiesto nointentionofbranchingoutintootherhealthcare contributeexcellearnandgrowinroche sectorssuchasgenericsoverthecounter medi andgenentechagainreceivedbestemployer cinesormedicaldevice awardsinanumberofcountrie weaimtoprovideourinvestorswithatotal innovationisessentialtoaddressingthemanymedi shareholderreturninthetopquartileofour calneedsthatarestillunmetdespitesignificant industrypeerset progressinthefightagainstsomeofmankindsmost weconductourbusinessesresponsiblyandseek seriousdiseasestherearestillsomedisease tohaveasustainablepositiveimpactonsociety forwhichnotreatmentexistsandpatientsresponse andtheenvironmentinwewereratedasthe ratestomanyavailabletreatmentsareunsatisfactory newsupersectorleaderinhealthcareonthe todaybreakthroughsinscienceandtechnology dowjonessustainabilityindexesrankingusa aretransformingourunderstandingofdiseasebiology theworldsnocompanyforsustainabilityinour andpromisetotransformthepracticeofmedicine sector atrocheweareworkingtoharnessthesediscoverie tomaketomorrowstreatmentssafermoreeffective andmorepersonalisedtobetterfitthemto patientsgeneticprofilesandothercharacteristic lrochearenggroupindd roche business report roche group excellence science distinctiveness roche approach innovation excellence science distinctive way wepromotea diversity approach inourpursuitof innovationgenentechresearchandearlydevelopment gredpharmaresearchandearlydevelopment predrochediagnosticsandchugaioperateinde pendentlywithinthegroupformingthehubsofan innovationnetworkthatincludesallianceswithover outsidecompanies wetakea longterm perspective backedby astablemajorityownershipdatingbackoveryear wekeepoursightsonsustainablelongterm growth ratherthanshortterm gainsthisisreflectedinthecom panysincentivesystemandapproachtosuccession managementandinfarsighte businessmovessuch asourearlyinvestmentsinbiotechnology weseamlessly integrate pharma diag nosticscapabilitiesalongthewholevaluechain fromdiscoverytocommercialisationourworldclass pharmaceuticalsanddiagnosticsresearchorganisation areworkingtogethertocreatebettermorecost effectivetreatmentoptionstailoredtopatientsneed c oec lh ono glo ygie n flm amet mh ao tid os n n e u r c e n c e e tb ai bo ol lo isg virolo dp gh iaa gr nm oa stic u se tinu rv c ep ir hs na np io goh r n ta la hoslr el gm nyaa le tv bc hede rs u oie n et ui x sc gp ua hine sls itr ntrta hy tin eis sl rd e e nfa d ai edn lli da nmg egn w vo io ehnls le oct eci phc lu l mes tl c h ead e nr ui v tabi acls ni oo po dnrln oo ts aipg n ceh u qra e utv b ie soo nh tionsthisexpertiseequipsrochetoplayapioneere roleinadvancingpersonalisedhealthcare gnnaatns aetunesvt pre gre chugai pharmaceutical research early development cinical development commercialsaion tsaelgecet io n lgeeande r aio phase phase phase ii phase ii flng pha ar sk ee iv btarogmeta idkeenrt idiecvaetloonpment c peaoatmseinpbtai snietiyo e nac nd idoia n ugtnloisytic tdaxi oaeudn cphrespcorsbtnga uanncdh aosnsieosrsinmgent diagnostic rna inrm ee rd fe ri nn e nbl cic eo eci sns cu ecuebase duna gn dte ech sn io gog ny omuatonssec mes vra resstance neurodegeneratio sn ignalng pathway ango mge yn ee lsi os ap n ncp e alo l ts es b moo mg uy niy glycoengneee cell boogy dna l sifee nq su mm iec cbnie oc e rn rgcg ae ye n ss cobas r el ai g tih mec pc cl rer mmunom assu acl soi bp al sex potein anx acc lyoc se b ie sl sl ai ng ae ynscise lrochearenggroupindd roche management model enable innovationdriven culture people integrity courage passion decision make accountable transparent structure build innovation roche group management structure ourmanagementmodelisaimedatsustainingand ourorganisationalstructureisdesignedforinnova strengtheningourcultureofinnovationlikeour tionourautonomousresearchanddevelopment businessmodelithasthreeelementsourpeople centresandallianceswithexternalpartnersfoster ourdecisionmakingandourstructure diversitythetrulyglobalscaleofthegroupsre searchdevelopmentmanufacturingandmarkete people operationsprovidesleverageaswellasaglobal oursuccessindrugresearchanddevelopmentour reachforinnovationandmarketsuccess abilitytodeployourcombinedexpertiseinpharma ceuticalsanddiagnosticstoadvancepersonalise healthcareandourskillinbalancinglongerterm investmentdecisionswithneartermdeliverablesall ultimatelydependononethingourpeoplesee pagesrochesemployeesrepresent everycontinentandvirtuallyeverycountryonthe globeandtheybringtotheirworkadiversityof perspectivesandexperiencesthatareakeyingredi entofcreativityrespectfordiversityasharedset ofstandardsofintegritythecouragetoreachbeyond boundariesandapassionaboutwhatwedoarethe elementsthatbindustogetherasacompany decision make thesecondcomponentofourmanagementmodel dse et cs iso iu ot np sr nin ec ei dpl te os bfo er inef fofe rc mti ev de bd yec ais dio ian lom ga uk ein thg tis systematicfactbasedopenandtransparentfor everydecisionthereshouldbeasingleaccountable decisionmakerwhocollectsandcriticallyreview informationandcompetingviewsempowermentis crucialsofaraspossibledecisionmakingshould bedelegatedtothelowestqualifiedlevelinthe organisation lrochearenggroupindd bildstreckeengsindd s pave way new drug rheumatoid arthritis search safe effective new medicine like look needle haystack thousand potential candidate complete journey idea pharmacy shelf know diversity approach produce prom ise idea fast roche build unique innovation network independent research development r centre add tion roche pharmaceutical diagnostic r unit com prise genentech research early development chugai r laboratories japan alliance partner worldwide recent product successful collaboration kind actemraroactemra biological medicine new target use patient rheu matoid arthritis discover chugai codevelope roche actemraroactemra available patient world thank global reach roche group actemraroactemra firstinclass monoclonal antibody treatment rheumatoid arthritis bind interleukin receptor block effect signal protein il key driver inflammation rheumatoid arthritis bildstreckeengsindd pharmaceutical demand key medicine efficiency gain result doubledigit increase sale operating profit thirteen major marketing approval positive result phase iii clinical trial confirm division growth potential pharmaceutical division focus translate excellence science effective medicine patient combine cuttingedge research roche genentech chugai japan partner worldwide global scale reach clinical development manufacture commercial operation lrochearengpharmaceuticalsindd pharmaceutical division brief key figure change change millions chf chf local currency sale sale united states western europe japan international asiapacific cemai latin america canada operate profit exceptional item operate free cash flow research development cemai central eastern europe middle east africa central asia indian subcontinent pharma executive committee december william burns ceo division roche pharmaceutical george b abercrombie north america jennifer allerton informatics silvia ayyoubi human resource ian clark global product strategy jeanjacque garaud development peter hug western europe jonathan kc knowles group research dominic p moorhead finance control christopher murray commercial operation chugai pascal soriot commercial operation ceo genentech klaus strein pharma research jan van koeveringe global technical operation dan zabrowski pharma partnering december corporate governance january ceo genentech clark chief operating ofiicer pharmaceutical division p soriot extend team ad interim lrochearengpharmaceuticalsindd roche business report pharmaceutical pharmaceutical division sale region operational term wasatransformationalyearforthepharma ceuticalsdivisionafterobtainingfullownershipof united states good year genentechinmarchrochemovedswiftlyto asiapacific pharmaceuticals combinethetwocompaniesclinicaldevelopment latin america division double manufacturingandcommercialoperationsgenentech region digit increase sale researchandearlydevelopmentremainsaninde cemai operating profit pendentunitwithintherochegrouppreservingthe integration diversityofscientificapproacheswebelievehelps genentech pro todriveinnovationtheintegrationofgenentechwas western europe ceede swiftly largelycompletebytheendoftheyear japan largely complete end italic growth rate local currency inoperationaltermswasanotherverygood year cemai central eastern europe middle east africa yearforthepharmaceuticalsdivisionwithdouble central asia indian subcontinent digitincreasesachievedinbothsalesandoperate profitabovemarketsalesgrowthwasdriven primarilybystrongdemandforkeymedicinesfrom rdpipelineisnowoneoftherichestinthe thegroupsvirologyandoncologyportfoliosthe industrywitheightnewmolecularentitiescurrently globalspreadofthepandemicahn inphaseiiiregistrationinphaseiiandin influenzavirusledtounprecedenteddemandfor phaseiclinicaldevelopment tamiflufromthesecondquarteronrocheiscooper atingwiththeworldhealthorganizationandnational governmentstoaddressthethreatposedbythe result main newinfluenzastrainandhasincreasedproduction business development capacitytoensureadequatesuppliesoftamiflu inadditiontomarketingauthorisationforthetar salesbythepharmaceuticalsdivisionrosein getedbiologicactemraroactemraforrheumatoid localcurrenciesinswissfrancsandusdollar arthritisintheeuropeanunionandinjanuary tobillionswissfrancsoralmostdoublethe theunitedstatesthedivisionalsogainedapproval globalpharmaceuticalsmarketgrowthratethe fornewindicationsformarketedproductssuch worldwidespreadofthepandemicahn asavastincancerandmabtherarituxancancer influenzavirusledtoverystrongdemandfortamiflu rheumatoidarthritisprogrammesaimedat fromthesecondquarteronoveralltamiflucon expandingtheuseofkeyproductsorsupporte tributedbillionfrancsorpercentagepoint plannedmarketingapplicationsfornewcompound tofullyearpharmaceuticalssalesgrowthexclude resultedinpositivedatafrommajorphaseiii tamifluthedivisionssalesincreaseddriven clinicaltrialssomeoftheseresultshavealreadybeen bydemandforkeyproductsincludingavastin usedtosupportregulatoryfilingsgoodprogress herceptinmabtherarituxanlucentismircera wasmadeintheclinicaldevelopmentofpromising tarcevaactivasetnkaseandactemraroactemra newproductcandidatessuchasocrelizumab rheumatoidarthritismultiplesclerosistdm breastcancerrgmalignantmelanoma pharmaceutical market growth accord im taspoglutidetypediabetesandrg end september schizophreniathecombinedrocheandgenentech state growth rate local currency lrochearengpharmaceuticalsindd integration genentech operational restructuring transformational year pharmaceutical division yearonyearsalesgrowthinthefourthquarter combinedrocheandgenentechportfolioseebelow washeavilyimpactedbyplannedreductionsin pformoreinformationonthedivisionsoperat wholesalerinventorylevelsinseveralmajormarket ingresultsseethefinancereportpartofthis theseresultedinpartfromacomprehensivereview annualreport ofdistributionchannelexposureagainsttheback groundoftheglobalfinancialcrisisinaddition thedivisioncontinuedtogenerateastrongcashflow theharmonisationofdistributionsystemsintheus inoperatingfreecashflowincreasedin followingthemergerofgenentechandroche localcurrenciesinswissfrancstobillion pharmaceuticalstriggeredareviewofwholesaler swissfrancsdrivenbythestrongoperatingper inventorypolicyandsubsequentdestocke formancecontinuouscostmanagementandcash flowgenerationarekeyprioritiesatrochethis allregionscontributedtothedivisionsstrongsale isreflectedinongoingglobalinitiativestoincrease growthintheunitedstatesgrowthofkeyoncology operationalefficiencyandproductivityinarea productstamifluandlucentismorethancompen suchasinformationtechnologymanufacturingand satedforlowersalesofcellceptandbonivaandthe administrationfurtherstimulusisnowbeingprovided voluntarywithdrawalofraptivasalesinwestern bythegenentechintegrationwhichinvolveda europeweredrivenbydemandfortamifluavastin majorreorganisationnotonlyofuspharmaceutical mabtheraandmircerawhichmorethanoffset operationsbutalsoofthedivisionsglobalfunction decliningsalesofneorecormonsalesbychugaiin synergiesarealreadybeinggeneratedasaresult japanincreasedstronglyduetodemandfortamiflu oftheconsolidationinsouthsanfranciscoofadmin keycancermedicinesandactemrasalesinthe istrativefunctionsforthecombinedusorganisation internationalregionasiapacificcemailatin theclosureofthepaloaltositeandthereshapingof americacanadaothersweredrivenbydemand globalmanufacturingoperationsseemanufacture fortamiflukeycancermedicinesandpegasys infrastructure belowweaimtoachievepretax annualsynergiesofapproximatelybillionswiss inthepharmaceuticalsdivisionsoperate francsby profitbeforeexceptionalitemsadvancedsignificantly fasterthansalesrisinginlocalcurrencie inswissfrancstobillionswissfrancsthisstrong manufacturing infrastructure increasewasdrivenmainlybytheperformanceof ourkeypharmaceuticalproductsandongoingmea thecompanyiswellontrackwiththeintegrationand surestoimproveefficiencytheoperatingprofit optimisationofthecombinedrocheandgenentech marginincreasedpercentagepointsinlocalcur supplynetworkandisreshapingitsglobalmanu renciespercentagepointsinswissfrancsto facturingorganisationtoconcentrateactivitiesalign despiteincreasedinvestmentsfornewproduct capacityrequirementsandimproveefficiencyaspart launchesandinresearchanddevelopmentthe oftherealignmentasecondbulkdrugproduction significantincreaseinrdcostsuptobillion unitatgenentechsvacavilleusafacilitywillnotbe swissfrancsreflectsinvestmentinthedivision commissionedandanewunitatrochespenzberg stronglatestage pipelineincludingpromisingcom germanyplantwillnotbecomplete poundssuchasdalcetrapibtaspoglutidepertuzumab andtdmtheriseinrdexpenseswasalso thepharmaceuticalsdivisioncurrentlyoperate drivenbyhigherimpairmentsofintangibleassetsat productionsitesworldwidealthoughconsolidation milliontheseweremillionfrancshigherthan indueprimarilytotheterminationofanumber central eastern europe middle east africa central asia ofprojectsfollowingacomprehensivereviewofthe indian subcontinent lrochearengpharmaceuticalsindd roche business report pharmaceutical collaboration istakingplaceinmanufacturingrochecontinuesto andresearchandtechnologycollaborationsin external partner investinitssupplynetworktoensuredeliveryof additiontenproductoutlicensingagreementswere integral marketedmedicinesandproductsinclinicaldevelop signedamongthemaintransactionswereasecond roche r strategy mentinmayrocheopenedanadditionallargescale licensingagreementwithplexxikonannounce roche multipurposechemicalproductionunitinflorence injanuaryforplxrganovelkinase genentech sign new southcarolinausaanewproductioncentre inhibitorforpolycystickidneydiseaseandafurther partnering agree inkaiseraugstswitzerlandforthemanufactureof agreementwithevotecannouncedinmarchfor ment medicinesinsterileformsincludingliquidand phaseiidevelopmentofevtfortreatment include product lyophilisedvialsandprefilledsyringeswasinaugu resistantdepressionrocheenteredintoaproduct transaction ratedinjuneinaugustrocheexercisedanoption developmentagreementwithtekmirapharmaceutical research technol previouslyheldbygenentechtopurchaseabiologic inmaytoadvancerochesfirsttwornainterfer ogy collaboration manufacturingfacilitybuiltbylonzainsingapore enceproductcandidatesintohumanclinicalteste thestateoftheartfacilitywhichismechanically bothproductcandidateswillbebasedontekmiras completehasbeenmergedwithanexistingbiologic stablenucleicacidlipid particlesnalptechnol manufacturingfacilitybuiltbygenentechthecom ogy binedsingaporeoperationsrochesfirstsuch facilitiesinasiawillplayakeyroleinthegroup genentechpartneringcompletedfourproducttrans globalmanufacturingnetworkinnovemberthe actionsoneoutlicensingdealandresearch toppingout ceremonyforanewtechnicalresearch andtechnologycollaborationsduringtheyearthese anddevelopmentbuildinginbaselswitzerland includeanagreementsignedinjunewithbayhill tookplacethenewfacilityscheduledforcompletion therapeuticsforanexclusivecollaborationforbayhills inwillhouseacentreforthedevelopmentof promisingdrugcandidatebhtcurrentlyin productionmethodsandthemanufactureofclinical phaseidevelopmentfortypediabetesinoctober trialssample genentechsignedanagreementwithsurmodic grantinggenentechanexclusivelicencetouse inresponsetotheworldwidespreadofthepandemic surmodicsproprietarybiodegradablemicroparticle ahninfluenzavirusourmanufacturingorgani drugdeliverysystemtodevelopandcommercialise sationandsupplychainmanagementalsometthe asustaineddrugdeliveryformulationoflucentisthe challengeofensuringadequatetamiflusuppliesto agreementalsoprovidesrocheandgenentech patientsworldwiderocheanditsmanufacture withopportunitiestodevelopadditionalcompound partnersrapidlyincreasedproductioncapacityfor forthetreatmentofophthalmicdisease tamiflutoapproximatelymilliontreatmentcourse permonthandarenowabletosupplyuptomil lionpacksannuallyifrequire sale review select key product pharma partnering update thepharmaceuticalsdivisionssalesgrowthis collaborationwithexternalpartnersisanintegralpart broadlybasedinelevenproductsfromsix ofrochesrdstrategyaccesstoexternalinno therapeuticareasgeneratedsalesofoverbillion vationthroughlicensingandtargetedacquisitionsis swissfrancseachofthesemedicinesthetop asignificantmeansofstrengtheningtherdportfolio threeachievedsalesofoverbillionswissfranc andexpandingthegroupstechnologycapabilitie eachcombinedsalesofthegroupstoppharma inrochepharmaceuticalssignedatotalof ceuticalsamountedtobillionswissfrancsor newagreementsincludingfourproducttransaction oftotaldivisionalsale lrochearengpharmaceuticalsindd product therapeutic area generate sale billion franc sale therapeutic area oncology inflammatory autoimmune disease transplantation central nervous system respiratory metabolic disease bone disease infectious disease cardiovascular disease virology renal anemia ophthalmology italic growth rate local currency salesofthedivisionsoncologyportfoliorose canceruptakeinjapanwhereavastiniscurrently sale division tobillionswissfrancsinledbythekey marketedforadvancedcolorectalcancerremain oncology portfolio productsavastinherceptinmabtherarituxan particularlystrongandisexpectedtobeenhance rise billion swiss franc tarcevaandxelodatogetherthesefivemedicine bytheproductsrecentapprovalforadvancednon lead avastin accountedforaroundhalfoftotalpharmaceutical smallcelllungcancersalesgrowthintheunite herceptin mabthera salesanincreaseofbillionswissfranc statesisbeingdrivenmainlybyuseinadvance rituxan tarceva insalesofantiviralmedicinesforafullyeartotalof breastcancerandthenewindicationsglioblastoma xeloda billionfrancswasdrivenprimarilybydemand andkidneycancerwhilehighpenetrationrate medicine fortamifluoverallsalesoftherenalanemiaportfolio weremaintainedinestablishedindicationssucha account half total pharma remainedstableatbillionswissfrancsinan lungandcolorectalcancer ceutical sale increasinglycompetitivecostsensitivemarketsale inthecombinedinflammationautoimmunetransplan overallsalesoncologyandrheumatoidarthritisof tationportfoliodeclinedtobillionfrancswith mabtherarituxanrituximabfornonhodgkin theexpectednegativeimpactofthecellceptpatent lymphomanhlchroniclymphocyticleukemia expiryintheunitedstateslargelyoffsetbythe cllandrheumatoidarthritisraroseto continuedsuccessofmabtherarituxaninrheuma billionswissfrancssustainedgrowthinthe toidarthritisaswellasstronguptakeofactemra oncologysegmentwasdrivenbyuptakeincll roactemrainjapananditsinitiallaunchmarketsin followingapprovalintheeuforfirstline treatment westerneuropeandelsewhere andintherelapsedrefractorydiseasesettinginthe firstandthirdquartersrespectivelylowersale oncology growthintheusreflectsthehighlevelsofadoption salesofavastinbevacizumabforadvance ofrituxaninitscancerindicationssalesinthera colorectalbreastlungandkidneycancerandfor segmentwereanestimatedmillionswissfranc relapsedglioblastomaatypeofbraintumourrose oroftheproductstotalsalesgrowthinthis tobillionswissfrancssoliddoubledigit segmentisbeingdrivenbyincreasingandearlieruse growthwasrecordedinallregionsdrivenprimarily bycontinueduptakeincolorectalbreastandlung firstline treatment initial treatment give diagnosis lrochearengpharmaceuticalsindd roche business report pharmaceutical excellence science unique diversity approach partner understand complex biology disease big challenge face develop new well medicine diagnostic scientific breakthrough likely occur scientist free tackle problem different angle different way scientist freedom believe diversity view culture approach promote creativity especially research early development autonomous research development hub augment alliance provide natural climate innovation pre gre chugai gre pre genentechresearchand rochepharmaresearchand earlydevelopment earlydevelopment nmes phase ii oncology followingtheintegrationofgenentechpredandgredoperate asautonomousinnovationcentresfocusingonnewdrug targetsandnewmolecularentitiesnmestheyhavetheirown inflammation immunology budgetsandexternalnetworksandtakedifferentapproache toturningexcellentscienceintoadvancesinmedicalcarethisnew central nervous system organisationalstructurepreservesthevaluesandculturethat enabledthegenentechsuccessstorywhileatthesametime strengtheningrochepharmasabilitytodevelopnovelmedicine ophthalmology italsomakesiteasierforourpharmaceuticalsanddiagnostic researcherstoshareknowledgeandtechnologiesacrossdivisional virology boundary metaboliccardiovascular lrochearengpharmaceuticalsindd ofmabtherarituxaninpatientswithaninadequate virology roche cooperate responsetooneormoretumournecrosisfactor globalsalesoftheantiinfluenza medicinetamiflu closely world tnfinhibitorsmabtheraiswellestablishedasthe oseltamiviramountedtobillionswissfrancsin health organization government medicineofchoicefollowinginadequateresponse anincreaseoforbillionswissfranc worldwide support totnfinhibitortreatmentandiscurrentlythemarket comparedwiththisveryhighgrowthwa pandemic prepare leaderinthatsegmentintheeu drivenbyunprecedenteddemandfromgovernment ness supply andintheretailpharmacysectorfollowingthepan tamiflu patient salesofherceptintrastuzumabforherpositive demicahninfluenzavirusswineflu need breastcancerincreasedtobillionswiss outbreakwhichbeganinaprilandspreadrapidly francssolidgrowththroughouttheyearwasdriven worldwidesalesforpandemicstockpilingamounted bycontinuinguptakeforearlybreastcancerespe tobillionfrancsforthefullyear ciallyinjapanandanumberofemergingmarket aswellasincreasingmarketpenetrationineastern rocheisworkingwithnationalhealthauthoritiesto europemoderatesalesgrowthintheusand expandapprovalforpandemicuseoftamifluto westerneuropereflectsthehighmarketpenetration includechildrenunderoneyearofageaswellas achievedinbothearlyandadvancedbreastcancer pregnantandlactatingwomenandtogainregulatory intheseregion approvalforalternativemethodsofadministeringthe medicinetoinfantsandyoungchildrenthecompany salesoftarceva erlotinibforadvancedlungand alsocontinuestocooperatecloselywiththeworld pancreaticcancerincreasedtobillionswiss healthorganizationandgovernmentsworldwideto francsdemandisbeingdrivenbyincreaseduse supportpandemicpreparednessandsupplytamifluto ofthemedicineinsecondlinenonsmall celllung allpatientsinneed cancernsclcoutsidetheusandinmetastatic pancreaticcancerthemainsalescontributionscame salesofpegasyspeginterferonalfaa forhepatitis fromwesterneuropeandtheunitedstatesthemore bandctotalledbillionswissfrancsin modestgrowthinussalesreflectsstablepenetration anincreaseofoverthepreviousyeardrivenby innsclcandpancreaticcancerthecompetitive marketshare gainsinmajormarketsgrowthis environmentandreserveadjustmentstakendure beinghelpedbynewstudydatademonstratingthe theyearprimarilyforgovernmentprogramme superiorityofpegasysoverothertreatmentoption involvingdiscount increaseduseinthetreatmentofhepatitisband increasingratesofhepatitisdiagnosisandtreatment salesofxelodacapecitabineforcolorectal inemergingmarket stomachandbreastcancerincreasedtobillion francsdrivenprimarilybystronggainsintheunite ophthalmology statesjapanandchinagrowthisbeingdriven ussalesoflucentisranibizumabforwetage byuseinmetastaticbreastcanceradjuvantcolon relatedmaculardegenerationamdthemost cancerandmetastaticcolorectalcancerinchina commonformofagerelate blindnessroseto themajorityofgrowthiscomingfromuseinpatient billionswissfrancsstrongdoubledigit growth withadvancedstomachcancerwhileinjapanchugai throughoutwasdrivenprimarilybyanincrease recordedsignificantadditionalgrowthinthefourth inthenumberofinjectionsadministeredtopatient quarterfollowingapprovalofanexpandedmetastatic colorectalcancerindication secondline treatment give initial firstline treatment work cancer stop respond adjuvant treatment give surgical removal tumour low risk relapse lrochearengpharmaceuticalsindd roche business report pharmaceutical topselling pharmaceutical roche group millions chf avastin mabtherarituxan herceptin tamiflu pegasys active substance active substance active substance active substance active substance bevacizumab rituximab trastuzumab oseltamivir peginterferon alfaa indication indication indication indication indication colorectal cancer breast nonhodgkin lymphoma herpositive breast treatment prevention hepatitis b c cancer nonsmall cell chronic lymphocytic cancer influenza b lung cancer kidney leukemia rheumatoid cancer glioblastoma arthritis lrochearengpharmaceuticalsindd abovemarket sale growth drive primarily strong demand key virology oncology medicine cellcept neorecormon epogin tarceva xeloda lucentis active substance active substance active substance active substance active substance mycophenolate mofetil epoetin beta erlotinib capecitabine ranibizumab indication indication indication indication indication transplantation anemia advanced nonsmall cell colorectal cancer breast wet agerelate macular lung cancer advanced cancer stomach cancer degeneration pancreatic cancer image scale yearonyear sale growth local currency jointly market genentech novartis lrochearengpharmaceuticalsindd roche business report pharmaceutical fda inthefirstandsecondyearoftreatmentgrowthinthe transplantation grant accelerated numberofpatientstreatedforwetamdandeasier salesofcellceptmycophenolatemofetilforthe approval reimbursement preventionofsolidorgantransplantrejection use avastin decreasedcomparedwithtobillion relapse glioblas anemia swissfrancssalesintheustheproductslarg toma aggressive form inahighlycompetitivepricesensitive marketsale marketdeclinedsharplyfrommayonwardsfollowe brain tumour oftherenalanemiamedicationmirceramethoxy expiryoftheuspatentthecontinuingerosionof january polyethyleneglycolepoetinbetawhichisnow ussalesthroughgenericcompetitionisbeingoffset agency approve availableinovermarketsworldwideshowe tosomeextentbysolidgrowthelsewhereespecially actemra treat consistentgrowththroughoutrisingto inlatinamericaandjapan ment adult patient millionswissfrancssalesarebeingdriven rheumatoid primarilybythesuccessoftheproductinthepre arthritis respond tnf dialysissegmentcombinedsalesofthegroup atthebeginningofaprilrocheandgenentech inhibitor therapy establishedanemiamedicinesrochesneorecormon announcedaphasedvoluntarywithdrawalofthe andchugaisepoginepoetinbetadeclinedto psoriasismedicineraptivaefalizumabfromthe billionswissfrancsoutsidejapanthecombined usmarketthedecisionreflectsourcommitment marketshareofrochesanemiafranchisemircera topatientsafetyandwasbasedontheassociation andneorecormoncontinuestoincreasedespite ofraptivawithanincreasedriskofprogressive competitionfromnewmarketentrantsthedecline multifocalleukoencephalopathypmlarareand inneorecormonsalesofwasduemainlyto usuallyfataldiseaseofthecentralnervoussystem increasedpricepressureasnewbiosimilarsenterthe aspartofthemeasuresagreedbetweentheus marketincontrasttheslightdeclineofepoginin foodanddrugadministrationfdaandgenentech japanreflectsstabilisationoftheproducts theraptivamarketinglicencewasrevokedinjuly marketshareinthedialysissegmentandcontinue genentechcontinuestomonitorpatientsafety expansioninthepredialysissette inflammation autoimmune disorder development highlight followingeumarketingapprovalinjanuaryby key marketed product yearendthenovelrheumatoidarthritisramedicine roactemratocilizumabknownasactemraoutside europehadbeenlaunchedinteneucountrie inthepharmaceuticalsdivisionfiledmajor includinggermanyfrancespainandtheunite newmarketingapplicationsandgainedmajor kingdomsalesuptakeintheinitialeuropeanlaunch regulatoryapprovalsseetableppositiveresult marketshasbeenstrongfollowinglaunchesin frommajorphaseiiiclinicaltrialsinvestigate additionalmarketsincludingswitzerlandindiaand additionalindicationsforexistingkeyproductsorwith brazilactemraroactemraisnowavailableinover newproductssuchastaspoglutideandocrelizumab countriesworldwidetheresponsefromphysician werealsoreportedseetablepthefollowe isveryencouragingglobalsalesroseto summariespresentapprovalsfilingsandmajor millionswissfrancsininjapanwhereactemra clinicaltrialresultsforkeymarketedproductsby wasapprovedforrainadultsandforrelatedpedi indication atricindicationsinapriladoptionandmarket penetrationareprogressingwellwithdoctorsalready actemraroactemra usingthemedicineasafirstlinebiologictreatmentin approval injanuarytheusfoodand manypatientssalesinjapanamountedtomillion drugadministrationfdaapprovedactemrafor swissfrancsanincreaseof thetreatmentofadultpatientswithmoderatelyto lrochearengpharmaceuticalsindd division file major marketing application gain major approval major regulatory filing product active substance indication andor dosage form country avastin bevacizumab relapse glioblastoma multiforme switzerland firstline metastatic breast cancer combination eu usa japan standard chemotherapy switzerland ed eldecalcitol osteoporosis japan epogin epoetin beta chemotherapyinduced anemia japan herceptin trastuzumab advance herpositive gastric cancer eu switzerland lucentis ranibizumab macular edema follow retinal vein occlusion usa mabthera rituximab rheumatoid arthritis patient inadequate eu switzerland rituxan response diseasemodifye antirheumatic drug prevention joint damage firstline chronic lymphocytic leukemia usa relapse refractory chronic lymphocytic leukemia eu usa switzerland rg methoxy renal anemia japan mircera poly ethylene glycolepoetin beta tarceva erlotinib nonsmall cell lung cancer firstline maintenance eu usa switzerland chemotherapy advance pancreatic cancer japan xeloda capecitabine adjuvant colon cancer combination oxaliplatin eu switzerland major regulatory approval product active substance indication andor dosage form country avastin bevacizumab relapse glioblastoma multiforme usa switzerland metastatic breast cancer combination docetaxel eu switzerland firstline metastatic renal cell carcinoma combination usa interferon alfaa unresectable advanced recurrent nonsquamous japan nonsmall cell lung cancer mabthera rituximab relapse refractory chronic lymphocytic leukemia eu switzerland rituxan firstline chronic lymphocytic leukemia eu rheumatoid arthritis patient inadequate response usa diseasemodifye antirheumatic drug actemra tocilizumab rheumatoid arthritis sign symptom eu usa roactemra xeloda capecitabine advanced refractory colorectal cancer combination japan oxaliplatin avastin include supplemental indication update january indication use patient previously treat methotrexate long pursue p accelerate approval fda lrochearengpharmaceuticalsindd roche business report pharmaceutical excellence science take longterm view biotech milestone sale biotech medicine sale estimatedsale biotechmedicinesorbiologic todayaccountforof rochespharmaceuticalsale apercentagethathasrisen significantlyinrecentyear biologicsnormallyhaveamore targetedeffectandarebetter toleratedthanconventional chemicalmedicine rochefound researchon rocheand recombinant roferona rocheacquires mabthera neorecormon avastin actemra institutefor monoclonal genentech insulin rituxan herceptin roactemra molecular antibody firstjoint genentech biology production project discover develop commercialise new medicine take time vision stay leading edge innovation essential invest early promise new technology pharmaceutical company embrace biotechnology lead acquire majority stake genentech today biotech product helping improve live countless patient variety disease area number maker biologic invest polymerase chain reaction pcr technology infancy decision help global market leader molecular diagnostic technology invest today rna interference rnai offer way target turn specific gene rnaibase medicine prove ground break new approach fight disease help patient lrochearengpharmaceuticalsindd avastin test study different tumour type positive outcome achieve major phase iii trial disease area product indication study oncology mabtherarituxan indolent nonhodgkin lymphoma prima firstline maintenance treatment avastin secondline metastatic breast cancer ribbon xeloda adjuvant treatment colon cancer xeloxa herceptin herpositive stomach cancer toga tarceva nonsmall cell lung cancer firstline maintenance treatment saturn overall survival data tarceva avastin nonsmall cell lung cancer firstline maintenance treatment atlas inflammation actemra rheumatoid arthritis progression joint damage lithe year datum actemra juvenile idiopathic arthritis systemic onset tender ocrelizumab rheumatoid arthritis patient inadequate response stage previous treatment methotrexate ophthal lucentis macular edema follow central retinal vein occlusion cruise mology lucentis macular edema follow branch retinal vein occlusion bravo metabolism taspoglutide type diabete temerge severelyactiverheumatoidarthritisrawhohave regulatoryfilingsinthisindicationsjiaadebilitate hadaninadequateresponsetooneormoretumour anddifficulttotreat diseasethataffectsthewhole necrosisfactortnfinhibitorsactemrathefirst bodyrepresentsanareaofhighunmetmedicalneed interleukin receptorinhibite monoclonalanti bodyapprovedtotreatramaybeusedaloneorin avastin combinationwithmethotrexateorotherdisease theglobaldevelopmentprogrammeforavastinisone modifyingantirheumaticdrug ofthemostcomprehensiveundertakingsincancer researchsincechemotherapymorethanclinical filing inseptemberrochefiledanapplication trialsworldwidewitharoundpatientsare withtheeuseuropeanmedicinesagencyemea currentlyinvestigatingtheuseofavastininapproxi toexpandthemarketingauthorisationforroactemra matelydifferenttumourtypesincludingcolorectal toincludeinhibitionoftheprogressionofjointdamage breastnonsmallcelllungbrainstomachovarian andimprovementofphysicalfunctioninpatient prostateandothersandindifferentsetting withratheeufilingissupportedbypositivetwo advancedorearlystagediseaseresultsfrom yeardatafromthephaseiiilithetrial phaseiiitrialsinvestigatingthemedicinespotential inpatientswithmetastaticprostateovarianand clinical milestone aninternationalphaseiii stomachcancerareexpectedin studytendermetitsprimaryendpointinnovem bershowingthatactemraroactemrasignificantly approval inmaythefdaapprovedtheuseof improveddiseasesignsandsymptomsinchildren avastininpatientswithpreviouslytreatedrelapse withsystemiconsetjuvenileidiopathicarthritissjia glioblastomamultiformegbmthemostaggressive andconfirmingtheresultsofearlierjapanese formofbraintumourundertheagencysaccelerate studiesrocheplanstousethedatatosupportglobal approvalprogrammetheeuscommitteefor lrochearengpharmaceuticalsindd roche business report pharmaceutical follow eu medicinalproductsforhumanusechmpissueda suggestthatavastinisactiveinpatientswithearly market application negativeopinioninseptemberregardingroches stagecoloncancerfurthertrialsinvestigatingavastin roche sep applicationforapprovalofthesameindicationthe intheadjuvantsettingearlystage diseaseafter tember chmp usandeufilingswerebasedonstrongclinical surgerytoremovethetumourincolonbreastand issue positive resultsfromthephaseiibrainstudyseveral lungcancerareongoingresultsareexpectedin recommendation december investigatorle studiescontinuetoexploretherole fromaseparaterochesponsoredinternational use herceptin ofavastininrelapsedgbminadditionalarge phaseiiistudyavantassessingavastinincom advance rochesponsoredphaseiiistudyavaglioinover binationwithchemotherapyforearlystage colon positive stomach patientswithnewlydiagnosedgbmiscurrently cancerinoctoberpatientrecruitmentwascomplete cancer filing underwaywiththeaimofglobalfiling forbeatriceaphaseiiitrialinvestigatingavastin base strong inearlyhernegativeandhormonereceptor phase iii datum rochereceivedeuapprovalinjulyforavastinin negativebreastcancer ing herceptin extend survival combinationwithdocetaxelacommonlyusedchemo patient therapyinthefirstline treatmentofmetastatic fullresultsofribbonaphaseiiitrialofavastin operable breastcancertheexpandedindicationfollowseu assecondline treatmentinwomenwithadvance positive stomach approvalforcombinedavastinandpaclitaxelin hernegativebreastcancerwhohadpreviously cancer inadditioninaugustthefdaapprovedavastinin receivedchemotherapywerepresentedatthesan combinationwithinterferonalfaa forthetreatment antoniobreastcancersymposiumindecemberthe ofmetastaticrenalcellcarcinomathemostcommon studymetitsprimaryendpointshowingthatwoman typeofkidneycancerthisfollowseuapprovalof whoreceivedavastinincombinationwithcommonly thesameindicationin usedchemotherapiesassecondline treatmenthad aimprovementinprogressionfree survival innovemberchugaireceivedapprovalinjapanfor comparedwithchemotherapyalonegenentechand avastinforthetreatmentofadvancednonsmallcell rocheplantofiletheribbondataintheus lungcancer andtheeuin filing chugaifiledasupplementaryapplication herceptin inoctobertoexpandtheapprovedindicationsfor filings followinganeumarketingapplicationby avastininjapantoincludemetastaticbreastcancer rocheinseptemberthechmpissuedapositive basedontheresultsoftheeavadoand recommendationindecemberfortheuseofherceptin ribbon trialsandjapanesestudiesinnovember inadvancedmetastaticherpositivestomach genentechfiledtheavadoandribbon datawith cancerthisrecommendationwasissuedinrecord thefdawiththeaimofconvertingthecurrent timereflectingthehighunmetmedicalneedandthe acceleratedapprovalforhernegative breastcancer strengthofthedatafromtogaseebelow receivedintofullapprovalandallowe avastintobecombinedwithfurtherstandard clinical milestone resultsfromtheinternational chemotherapiesinnovemberrochealsofiledthe phaseiiitogatrialpresentedattheascomeetingin ribbon datawiththeeuauthoritie juneshowedthatcombiningherceptinwithstandard chemotherapyxelodaorintravenousfluorouracil clinical milestone fullresultsofthefirstphaseiii pluscisplatinextendsthelivesofpatientswith trialofavastininearlystagecoloncancernsabp cwerepresentedattheannualmeetingofthe americansocietyofclinicaloncologyascoin june mayalthoughthestudydidnotmeetitsprimary progressionfree survival time patient live endpointofimprovingdiseasefreesurvivalthedata disease get bad lrochearengpharmaceuticalsindd fiveyear followup data confirm long term benefit year adjuvant herceptin treatment herpositive breast cancer advancedinoperableherpositive stomachcancer mabtherarituxan oncology onaveragebynearlythreemonthstomonth approval rochereceivedeuapprovalinfebruary patientswithtumoursexhibitinghighlevelsofher formabtheraincombinationwithchemotherapyfor experiencedevengreaterbenefitfromtheaddition previouslyuntreatedchroniclymphocyticleukemia ofherceptintheirliveswereextendedbymorethan cllandinaugustforuseinpatientswithrelapse fourmonthstomonthsonaverage orrefractorydiseasecllisthemostcommonform ofadultleukemiainnovembertheusfoodand inoctoberrocheandhalozymeannouncedthe drugadministrationfdaissuedacomplete startofaphaseiiitrialinvestigatinginfusionfree responsetotwosupplementalbiologicslicense subcutaneousadministrationofherceptinfor applicationssubmittedbygenentechandbiogen womenwithherpositive breastcancerthenew idecforapprovalofrituxanplusstandardchemo subcutaneousformulationisbasedonhalozyme therapyinpreviouslyuntreatedortreatedcllthe enhanzetechnology fdahasnotrequestedanynewdatatocomplete itsreviewoftheseapplicationsthecompanieswill fiveyear followupdata fromtwolargestudie continuefinallabeldiscussionswiththeagencyand evaluatingadjuvantherceptininherpositive early remaincommittedtomakingrituxanincombination stagebreastcancerwerepresentedatthesan withchemotherapyanfdaapprove optionforpeople antoniobreastcancersymposiumindecembercon withcll firmingthelongterm benefitsofoneyearoftreatment withherceptinnandbcirgconducte clinical milestone inseptemberrochegenentech bythenorthcentralcancertreatmentgroupand andbiogenidecannouncedpositiveresultsfroman thebreastcancerinternationalresearchgroup internationalphaseiiistudyprimashowingthat respectively showedthatherceptinreducedtherisk mabtherarituxanmaintenancetherapycansignifi ofthecancerreturningbyaboutonethirdcompare cantlyincreasethetimeuntilthediseaseprogresse withpatientsreceivingchemotherapyaloneinboth innewlytreatedpatientswithadvancedfollicular studiesormoreofwomenreceivingoneyear lymphomaacommontypeofnonhodgkins lym ofherceptinwerealiveandfreeofthediseaseatfive phomabecauseprimametitsendpointduringa yearsfollowup preplanned interimanalysisthestudywasstoppe earlyrocheandgenentechplantofiledatafrom lucentis primawiththeeuandushealthauthoritiesto filing basedontheresultsofbravoandcruise expandthecurrentmarketingapproval seebelowindecembergenentechfiledasupple mentaryapplicationwiththefdaforapprovalofuse updatedresultsfromthephaseiiicllstudywere inpatientswithmacularedemafollowingretinalvein presentedattheannualmeetingoftheamerican occlusion societyofhematologyindecembertheyshowe thatpatientswithpreviouslyuntreatedcllsurvive clinical milestone resultsofthephaseiiibravo theirdiseaselongerwhentreatedwithmabthera andcruisestudiesannouncedinjulyshowedthat rituxancomparedwithchemotherapyaloneclli lucentisimprovedvisioninpatientswithswellingin thefirsttrialtodemonstrateimprovedoverallsurvival theretinamacularedemaduetobranchretinalvein withaspecificfirstline treatmentforcll andcentralretinalveinocclusionrvorespectively rvooccurswhenbloodflowthrougharetinalvein mabtherarituxan rheumatoid arthritis becomesblockedcausingswellingmacularedema approval inoctoberthefdaapprovedupdate andhemorrhagesintheretinawhichmayresultin rituxanprescribinginformationthatincludesguidance blurringorvisionlossinallorpartofoneeye onretreatmentoflaterstage rheumatoidarthritis lrochearengpharmaceuticalsindd roche business report pharmaceutical rapatientswithaninadequateresponsetoanti thefdasoncologicdrugsadvisorycommittee tumournecrosisfactortherapiesclinicaltrialdataon recommendedagainstapprovingtarcevaforthisuse themedicinesabilitytoimprovephysicalfunction theagencyisnotboundbythisrecommendation andslowjointdamageforuptotwoyearswerealso injanuaryfollowingthesubmissionbyosioffurther addedatthesametimegenentechreceivedacom datathefdaextendedthereviewperiodforthe pleteresponsefromthefdafortheuseofrituxan applicationandisnowexpectedtomakeadecision plusmethotrexateinpatientswithmoderatelyto byaprilinseptemberchugaifiledasupple severelyactiverawhonolongerrespondtotreat mentarymarketingapplicationinjapanforapproval mentwithadiseasemodifyingantirheumaticdrug oftarcevainpancreaticcancer includingmethotrexategenentechisworkingwith thefdatodeterminenextstepsregardingthefile clinical milestone resultsfromaphaseiiistudy forthisindication atlasreleasedinfebruaryshowedthattarceva incombinationwithavastinforfirstlinemaintenance filing injunerochesubmittedacombine treatmentofpatientswithadvancednsclcsignifi filingtotheeuhealthauthoritiestoextendthemar cantlydelayedthetimetodiseaseprogressioninjuly ketingapprovalformabtheraasafirstline biologic rochegenentechandosiannouncedthatthe therapyforrheumatoidarthritisrathenewindi saturntrialhadmetanimportantsecondaryend cationsbeingsoughtareforpatientswhohavehad pointofextendingoverallsurvivalinpatientswith aninadequateresponsetomethotrexatethecurrent advancednsclcwhoreceivedtarcevaimmediately standardtreatmentoptionandfortheprevention afterinitialchemotherapythisbuildsonearlier ofjointdamageacrossallrapatientpopulationsthe resultsfromsaturnshowingthattarcevaimprove combinedfilingfollowedpositiveresultsfromthe progressionfree survivalthetrialsprimaryendpoint imagesereneandmirrortrialswhichshowe thatmabtheraimprovesthesignsandsymptom xeloda ofraandcansignificantlyreducetheprogression approval inseptemberchugaireceivedapproval ofjointdamagerocheisnolongerpursuingapproval injapanforadditionalindicationsforxelodaand forathirdindicationoriginallyincludedinthecom avastinxelodacannowbeusedincombinationwith binedfilingforuseinpatientswhohavenothad oxaliplatinchemotherapywithorwithoutavastin previoustreatmentwithmethotrexatebasedona inthetreatmentofpatientswithmetastaticcolorectal reassessmentoftheriskbenefit ratiointhispatient cancer population filing rochefiledanapplicationintheeuin tarceva decemberforapprovalofxelodaincombinationwith approval inseptemberthechinesehealthauthor oxaliplatinfortheadjuvantpostsurgicaltreatment itiesapprovedtarcevaforthesecondline treatment ofpatientswithearlycoloncancerbasedon ofpatientswithadvancednonsmallcelllungcancer datafromthephaseiiinoxeloxatrial nsclc filing inmarchrocheandosipharmaceutical research development submittedapplicationstotheemeaandthefda respectivelyforapprovaloftarcevaasmaintenance toensureastrongflowofsuitablecandidatemolecules therapyinpatientswithlocallyadvancedormetastatic intoitsdevelopmentpipelinerochehasbuilta nsclcwhosediseasehasnotprogressedfollowe uniqueinnovationnetworkofindependentresearch firstline chemotherapybothfilingswerebasedon anddevelopmentcentresinadditiontorocheand datafromthephaseiiisaturntrialindecember genentechitincludeschugaiinjapanandalliance lrochearengpharmaceuticalsindd roche genentech chugai partner worldwide form unique innovation network base diversity approach withmorethanpartnerorganisationsworldwide areabouttostartphaseiiidevelopmentatthe rg target thispromotesadiversityofresearchapproache sametimewearealsoexploringnewindicationsand inhibitor abnormal aswellasenablingaccesstonewtechnologiesand formulationsforexistingproductsincludingformu braf exemplify roche group promisingdrugcandidate lationsofherceptinseeabovepandother personalise health biologicmedicinesthatcanbeadministeredbymore care approach genentechresearchandearlydevelopmentgre convenientsubcutaneousinjectioninsteadofintra currently latestage continuestooperateasanindependentunitsimilarly venousinfusion clinical development thenewlyformedpharmaresearchandearlydevel malignant opmentorganisationpredenjoysfulloperational followingtheintegrationofgenentechsrd melanoma roche develop autonomygredcontinuestobeinspiredbythe projectsintothegroupsglobalpharmaceutical dia g nostic test valuesandculturethatledtogenentechssuccess portfoliorocheandgenentechconducteda identify patient whilepredwillexpandrochescapabilitiesto comprehensivereviewoftherdpipelineinthe tumour bringnovelmedicinestopatientsatthesametime fourthquarterthisresultedindecisionstoterminate carry abnormal subjecttoexistingthirdparty obligationsbothunit anumberofearlystage developmentproject braf gene arenowfreetoshareinformationandtechnologie omeofwhichhaverevertedtopartnercompanie thatcansupportandenhancetheiractivitie theterminationswhichwereprimarilydrivenby clinicaldataarepartofanongoingefforttoprioritise closecooperationbetweenthepharmaceutical resourcestowardsahighlydifferentiateddevelopment divisionandrochediagnosticsisakeystrategic portfoliooffirstinclass orbestinclass medicine advantageforourcompanythetwodivisionscan shareintellectualpropertytechnologiesandresearch atthebeginningofthedivisionsrdpipeline findingsfreelyamongotherthingsthisallowsroche includedprojectsinclinicaldevelopmentphasei tocombineandleveragebothdivisionsleadership toiiioftheseinvolvednewmolecularentitie inthekeyfieldofmolecularbiologyinadditionit nmesandinvolvedadditionalindicationsten enablesdiagnosticsexpertisetobeseamlesslyinte nmesareinorabouttoenterlatestage develop gratedintoallpartsofthepharmaceuticalsrd mentseetablepthirtyprojectsinvestigating processseepthisiscentraltorochesgoalof additionalindicationsforexistingproductsarein advancingpersonalisedhealthcareanapproach phaseiiithepharmaceuticalspipelineisshownin thatseekstotailortreatmentstospecificpatientsub thefoldoutinsidethefrontofcoverofthisreport populationsbasedonemergingscientificunder furtherdetailsareavailableatwwwrochecom standingofbiologyanddiseaseatthemolecularlevel oncology overthenextfewyearsthedivisionaimstoexpand rochesclinicaldevelopmentpipelineinoncology itsproductportfoliowithanewgenerationof includesnewmolecularentitiesthepharma medicinesforpatientssufferingfromcancermeta ceuticalsdivisionisfurtherstrengtheningitsoncology bolicandautoimmunediseasesviralinfection portfoliothroughnewtargetedtherapeuticoption anddisordersofthecentralnervoussystemcns andexpandingintonewindicationsfourcompound latestagedevelopmentofpromisinganticancer progressedintolatestageclinicaltestingin compoundssuchaspertuzumabandtdm herpositivebreastcancerrgmalignant rgplxcollaborationwithplexxikonisa melanomaandrgleukemialymphomaison targetedinhibitorofabnormalbrafthatexemplifie trackinadditiontwonovelcompoundsinthe therochegroupspersonalisedhealthcareapproach metabolicandcnsportfoliosaleglitazarcardio usingbiomarkersanddiagnostictoolsbrafisa vasculardiseaseinhighrisk typediabetespatient proteinthatrelaysgrowthsignalsinsidecellsincer andrgnegativesymptomsofschizophrenia taintypesofcancergeneticchangesmutation lrochearengpharmaceuticalsindd roche business report pharmaceutical excellence science seamless collaboration process lead healthcare company strength pharmaceutical diagnostic equip advance personalise healthcare organisational realignment imple mente pharmaceutical diagnostic division year enable collaborate seamlessly value chain discovery commerciali sation particularly important personalised healthcare start early drug development process diagnostic division begin technology expertise help identify potential drug target screen lesspromise candidate compound select suitable patient clinical trial case collaboration result drug couple companion diagnostic guide treatment pharmaceutical research early development clinical development commercialisation market target lead phase phase phase ii phase iii filing selection generation phase iv discovery exploratory proof confirmatory phase phase concept phase companion diagnostic biomarker development dx launchpostlaunch assessment feasibility utility target identification tailor prescribing monitor patient selection diagnostic lrochearengpharmaceuticalsindd close cooperation pharma ceutical diagnostic division key strategic advantage roche leadtoproductionofabnormalbrafthatisalway tdmgpresentedatthesanantoniobreast activeandcausesuncontrolledproliferationofcancer cancersymposiumindecembershowedanobjective cellsmutatedbrafisfoundinapproximately responsetumourshrinkageinofwomenwith ofmalignantmelanomasthemostdeadlyformofskin advancedmetastaticherpositivebreastcancer cancerfollowingpositivephaseiresultsaphaseii thathadworsenedfollowingprevioustreatment clinicaltrialwasinitiatedinseptembertoinvestigate rginpreviouslytreatedpatientswithbraf rggdccollaborationwithcurisisa mutationpositivemalignantmelanomaandaphase novelcompoundtargetingthehedgehogsignalle iiitrialinpreviouslyuntreatedpatientsbeganin pathwaywhichisthoughttobeimplicatedinseveral januaryadiagnostictestisbeingdevelopedin cancersfollowingpositivephaseiresultsapivotal collaborationwithrochemoleculardiagnosticsto phaseiistudyinvestigatingrgasapotential identifypatientswhosetumourscarrytheabnormal treatmentforadvancedbasalcellcarcinomacom brafgeneandarethereforemostappropriatefor mencedinfebruaryrgisalsobeingevaluate treatmentwithrg inphaseiistudiesasafirstline therapyformeta staticcolorectalcancerandinthemaintenancetreat rggathefirsttypeiiglycoengineere mentofovariancancer fullyhumanisedanticdmonoclonalantibody iscurrentlybeinginvestigatedinlatestageclinical inflammation autoimmune disorder trialsasapotentialtreatmentforchroniclymphocytic rochehaseightnewcompoundsindevelopmentfor leukemiacllandnonhodgkinslymphoma chronicandprogressiveautoimmuneandinflammatory nhldatafromphaseiistudieswerepresente diseasessuchasrheumatoidarthritisraand attheeuropeanhematologyassociationmeete asthmafiveofwhichareinphaseiioriiiclinicaltest injunecllandtheamericansociety ingphaseiiiprogrammesarecurrentlyinvestigate ofhematologyindecembercllandnhl thenextgeneration anticd antibodyocrelizumab aphaseiiistudyinpatientswithcllwasinitiate inseveralrasettingsincludinginpatientswho indecember respondinadequatelytothecurrentstandardofcare methotrexateortotumournecrosisfactortnf pertuzumabrgisaherdimerisation inhibitorsthefirstofthesestageinpatientswho inhibitorthatisbeingstudiedincombinationwith didnotrespondtotreatmentwithmethotrexate herceptinandstandardtherapyinherpositive wasreportedtohavemetitsprimaryendpointin breastcanceraphaseiiistudycleopatra decemberwhileoveralladverseeventsreportedin evaluatingtheadditionofpertuzumabtoherceptin thisstudywerecomparablebetweentheocrelizumab andchemotherapyinthefirstline treatmentof andplacebotreatmentgroupsahigherpercentage patientswithadvancedmetastaticdiseaseanda ofseriousinfectionswasobservedinthepooledocre phaseiitrialneosphereinvestigatingneoadjuvant lizumabgroupscomparedwiththeplacebogroupan presurgicaltreatmentwithpertuzumabareongoe additionalmajorphaseiiistudyscriptinpatient withinadequateresponsetotnfinhibitorsisex trastuzumabdmtdm rganovelanti pectedtoreportindosinginthefilmstudy bodydrugconjugatethatcombinesanantiher inpatientsnotpreviouslytreatedwithmethotrexate monoclonalantibodyandapowerfulcytotoxicagent hasbeenstoppedfollowingreassessmentoftherisk isbeinginvestigatedinthesecondandthirdline benefitprofileinthispatientpopulationaphaseiii treatmentofmetastaticherpositivebreastcancer programmeinvestigatingocrelizumabinthetreatment aphaseiiitrialemiliainvestigatingtdm oflupusnephritisbelongwasalsodiscontinued inthesecondline treatmentsettingbeganinthe followingreassessmentoftheriskbenefit profile firstquarterpositiveresultsfromaphaseiistudy lrochearengpharmaceuticalsindd roche business report pharmaceutical new molecular entity ongoing plan latestage study compound indication status market potential ocrelizumab rheumatoid arthritis phase iii study stage meet primary endpoint good class fourth quarter result additional study expect trastuzumabdm herpositive metastatic phase iii start quarter class breast cancer secondline treatment pertuzumab herpositive metastatic phase iii start class breast cancer rg ga nonhodgkin lymphoma phase iii start fourth quarter good class chronic lymphocytic chronic lymphocytic leukemia leukemia rg plx malignant melanoma registration study start january class rg advanced basal pivotal phase ii start quarter class gdc cell carcinoma rg negative symptom positive phase ii result fourth quarter class schizophrenia phase iii plan start aleglitazar cardiovascular high risk phase iii plan start quarter class type diabete taspoglutide type diabete positive phase iii result temerge fourth good class quarter additional result expect dalcetrapib dyslipidemia phase iii enrolment ongoing class cardiovascular high risk metabolic cardiovascular disease patientswithtypediabetesaleglitazarrg rochesmetabolicandcardiovascularportfolioof isaperoxisomeproliferatoractivatedreceptorppar newmolecularentitiesatvariousstagesofclinical coagonistwithdemonstratedeffectsonbloodfat developmentincludesthreepromisinglatestage bloodpressureandbloodglucoseforthereductionof compoundsdalcetrapibrgjttlicense cardiovascularmorbidityandmortalityinpatientswith fromjapantobaccoisanovelcholesterolest typediabetesaphaseiiiprogrammealecar transferproteincetpinhibitorforthemanagement dioisexpectedtobeginrecruitmentearlyin ofcholesterollevelsinthebloodrecruitmentforthe phaseiiidalheart programmeisontrackanew virology imagingstudydalplaquewasannouncedinthe rochecurrentlyhastwodirectantiviralagentsin lastquarterofandpatientrecruitmenthas developmentforthetreatmentofhepatitisc commencedtaspoglutidergbim thenucleosidepolymeraseinhibitorrgcolla licensedfromipsenisaonceweekly humangluca borationwithpharmassetandtheproteaseinhibitor gonlikepeptideglphormoneanalogueforthe rgitmn collaborationwithintermune controlofbloodglucoselevelsinlateinitial bothoftheseoralagentsenteredphaseiibstudie resultsfromfivephaseiiitrialsinthetemerge duringtheyearrgandrgarebeinginve programmeshowedthattaspoglutideconsistently tigatedincombinationwithpegasysandcopegus providespowerfulanddurableglycemiccontrolin ribavirinandincombinationwitheachotherin lrochearengpharmaceuticalsindd cancer disease group distinct disorder medical challenge aninterferonfree regimenresultsfromaphasei focus unmet medical studyinform investigatingrgcombine need withrginhepatitiscwerepresentedatthe annualamericanassociationforthestudyofliver diseasescongressinnovembertheyshowedforthe cancer accordingtothelatestinternational glyt inhibitor firsttimethatanalloralinterferonfreeregimen agencyforresearchoncanceriarcestimate rg canleadtosignificantviralsuppressioninpreviously inovermillionpeopleworldwidewere codevelope chugai treat untreatedpatientsandpatientsinwhomprevious diagnosedwithcancerandsomemilliondiedof ment negative treatmenthasfaile thediseasetheiarcanticipatesthatcancerwill symptom schizo surpassheartdiseaseastheleadingcauseofdeath phrenia area central nervous system worldwideinandalsoforecaststhatby high unmet medical therocheportfoliohasnovelcompoundsin therewillbeovermillionnewcasesandmillion need rg developmentfordisordersofthecentralnervoussys deathsperyearfromcancerineuropealoneone potential enable patient temincludingschizophreniamultiplesclerosisand inthreepeoplecanexpecttodevelopcancerintheir well establish social otherseriousconditionsoneofthesecompoundsis lifetimecancerisnotonediseasebutagroupof relationship rgaglycinetransportertypeglytinhibitor morethandistinctdisorderseachwithitsown parti cipate discoveredbyrocheitisbeingcodevelopedglobally medicalchallenge day activity withchugaiforthetreatmentofthenegativesymp ducing burden tomsofschizophreniaanareaofhighunmetmedical nonhodgkin lymphoma agroupofover patient caregiver alike needrghasthepotentialtoenablepatientsto cancersthataffectthelymphaticsystemthisclass betterestablishsocialrelationshipsandparticipate ofcancercurrentlyaffectsovermillionpeople ineverydayactivitiesreducingtheburdenforpatient worldwidefollicularlymphomaaccountsforabout andcaregiversalikeindecemberrocheannounced oneinfourofallcasesofnonhodgkinslymphoma thataphaseiitrialwithrghadmetitsprimary itcanoccuratanytimeduringadulthoodthough andsecondaryendpointsimprovingboththenegative peoplearetypicallydiagnosedduringtheirsixtie symptomsandthepersonalandsocialfunctione anditaffectsasmanymenasitdoeswoman ofpatientswithschizophreniathecompoundwas welltoleratedatalldosestestedrochehasnow chronic lymphocytic leukemia themostcommon decidedtoinitiatephaseiiiclinicaltestingwiththe typeofleukemiainadultsaccountingforapproximately firsttrialplannedtostartin ofallformsofleukemiatheincidenceof cllinwesterncountriesisaroundper alsoindecemberrocheanditsdevelopmentpartner anditistwiceascommoninmenasinwoman biogenidecreportedpositiveresultsfromaphaseii trialwiththehumanisedanticdmonoclonal colorectal cancer cancerofthelargeintestine antibody ocrelizumab rginpatientswith orrectumwhichaccountsforovermillionnew relapsingremitte multiplesclerosisoneofthelead casesaroundofallnewlydiagnosedcancer ingcausesofneurologicaldisabilityinyoungadult worldwideeachyearitisthesecondmostcommon ocrelizumabshowedastrongeffectversusplacebo causeofcancerdeathsineuropeandthethird withahighlystatisticallysignificantreductioninsign mostcommonworldwide ofdiseaseactivityasmeasuredbybrainlesionsthe primaryendpoint kidney cancer thistypeofcancerisnewlydiag nosedinaroundpeopleandcause deathsworldwideeveryyearratesthatareexpecte toincreaserenalcellcarcinomaaccountsfor ofallkidneycancer lrochearengpharmaceuticalsindd roche business report pharmaceutical breast cancer themostcommoncanceramong hepatitis b c thehepatitisbandcviruse womenworldwideovermillionwomenarenewly hbvhcvwhicharecommonlytransmittedthrough diagnosedandoverdiefromthedisease bloodtoblood contactcauseacuteandchronicliver eachyearasthereareseveraldifferenttypesof diseasepotentiallyleadingtoliverfailurecirrhosis breastcancerknowledgeoftumourcharacteristic andlivercancerworldwidemillionpeopleare isimportantfortreatmentdecisionssome thoughttobechronicallyinfectedwithhbvahighly ofwomenwithbreastcancerhavetumourswith infectiousvirusthatisresponsibleforanestimated abnormallyhighlevelsofaproteinknownasher onemilliondeathsannuallymorethanmillion herpositive tumoursareparticularlyaggressive peoplearoundtheworldareinfectedwithhcvand fastgrowing andlikelytorelapse tomillionnewcasesoccureachyearhepatitisc isthemainreasonforlivertransplantationarecent lung cancer themostcommonformofcancer studyonthehcvrelate burdenofdiseasein worldwideandtheleadingcauseofcancerdeath europeancountriesestimatedthatbetweenseven thereareanestimatedmillionnewcasesannually andninemillionpeopleoroverofthepopulation nonsmall celllungcanceristhemostcommon areinfectedwithhcv formaccountingforapproximatelyofallcase influenza flu ahighlycontagiousdebilitate pancreatic cancer aparticularlyaggressivedisease viralillnessthatoccursmainlyintheautumnand thatisextremelydifficulttotreatitkillsahigher wintermonthsintemperateclimatesandyearround proportionofpatientsinthefirstyearafterdiagnosis intropicalareasitcanbeparticularlydangerous thananyothercancerthefifthleadingcauseof foryoungchildrentheelderlyandpeoplewith cancerdeathsinthedevelopedworldpancreatic chronichealthproblemswhoareatgreaterriskof cancerclaimsnearlyliveseveryyear influenzarelate complicationspandemicsorglobal epidemicsarecausedbynovelstrainsofinfluenza gastric stomach cancer accountsforovermillion towhichpeoplehavenoimmunitypandemicsoccur newcasesandsomedeathseachyearmaking everytoyearsandhavebeenassociatedwith itthesecondlargest causeofcancerdeathsworld significantlevelsofillnessanddependingontheviral widethevastmajorityofcasesoccurinasiawhere straindeathaccordingtotheworldhealthorgani withlungcanceritistheleadingmalignancyadvanced zationthecurrentlycirculatingpandemicahn stomachcancerisassociatedwithapoorprognosis influenzavirusappearstobeascontagiousas themediansurvivaltimeafterdiagnosisisapproxi seasonalinfluenzaandisspreadingfastparticularly matelymonthswithcurrentlyavailabletherapie amongpeopleagedtoyearsthediseaseis generallyclinicallymildbutsevereillnesscanoccur anemia occurswhenthelevelofredbloodcell andorthehemoglobintheycontainfallsbelow autoimmune disorder occurasaresultofa normalstarvingorgansandtissuesofoxygenitis mistakenimmuneresponsetothebodysowntissue seeninoverofpatientswithchronickidney thecausesareunknownrheumatoidarthritis renaldiseasewhichaffectsmorethanmillion multiplesclerosisandlupuserythematosusareamong peopleworldwideinadditionanemiaaffectsthree themostcommonautoimmunedisorderswhichaffect outoffourcancerpatientsundergoingchemotherapy millionsofpeopleworldwide patientswithuntreatedanemiamayneedblood transfusionsthepotentiallongterm effectsofanemia rheumatoid arthritis ra achronicprogressive includecardiovasculardiseaseinrenalpatient inflammatorydiseaseofthejointsandsurrounde whileinpatientswithcanceritisassociatedwith tissuesthatisassociatedwithintensepainirrever diminishedqualityoflife iblejointdestructionandsystemiccomplication lrochearengpharmaceuticalsindd bcellsatypeofimmunecellareknowntoplaya keyroleintheinflammationassociatedwithra severalkeycytokinesorproteinsarealsoinvolve includingtnfalfainterleukin il andinter leukin il il hasbeenidentifiedashaving apivotalroleintheinflammationprocessaround millionpeopleworldwidearethoughttobe affectedbyra diabete recognisedasaglobalepidemicbythe worldhealthorganizationtheinternationaldiabete federationestimatesthatsomemillionpeople worldwidewillhavediabetesbyaccordingto thewhotypeadultonsetdiabetesaccountsfor aroundofallcasesuncontrolledtypediabete canleadtoseverecomplicationssuchascardio vasculardiseasestrokeblindnessamputation andkidneyfailureresultinginsignificanthealthcare burdenstosociety schizophrenia aseverementaldisordercharacter isedbyprofounddisruptionsinthinkingthataffect languageperceptionandthesenseofselfaccorde towhoestimatesschizophreniaaffectsapproxi matelymillionpeopleworldwideandismostcom moninadultsagedbetweenandyearsthe symptomsofschizophreniaarebroadlycategorise aspositivenegativeandcognitivepositivesymptom arepsychoticbehaviourssuchashallucinationsand delusionsnegativesymptomsareassociatedwith disruptionofnormalbehaviourandemotionssuchas inabilitytosustainplannedactivityoralackofmotiva tionandinterestindaytoday livingcognitive symptomsincludetroublefocusingorpayingattention persistentnegativesymptomsareamajorcauseof chronicdisabilitythereiscurrentlynomarkete productavailabletotreatthenegativesymptomsof schizophrenia lrochearengpharmaceuticalsindd take aim innovative medicine skin cancer roche world leader vitro diagnostic syste atically apply diagnostic expertise research development new medicine help develop pharmaceutical target biological mechanism rise cancer example rg plx currently test phase ii clinical trial possible treatment malignant melanoma type skin cancer rg novel highly selective braf kinase inhibitor target destroy cancer cell harbour specific cancer cause gene mutation call braf identify patient tumour carry mutation consider likely respond target medicine roche develop companion diagnostic test rg promise compound development treatment braf mutationpositive patient malignant melanomas deadly form skin cancer oral medicine selective kinase inhibitor develop roche collaboration plexxikon bildstreckeengsindd bildstreckeengsindd diagnostic sale grow ahead market strong uptake new product contribute market share gain key segment immunoassay tissue diagnostic business area launch major new product roche believe help drive abovemarket growth effort enhance operational efficiency ongoing division contribute high operating profit division continue expand effort order improve productivity profitability lrochearengdiagnosticsindd diagnostic division brief key figure change change millions chf chf local currency sale sale professional diagnostic diabetes care molecular diagnostic apply science tissue diagnostic operating profit operate free cash flow research development diagnostic executive committee december jrgen schwiezer ceo division roche diagnostic manfre baier apply science roland diggelmann asiapacific dirk h ehler professional diagnostic christian hebich finance service michael heuer emea europe middle east africa latin america alexander keller global platform support frank lennartz human resource hany massarany tissue diagnostic daniel oday molecular diagnostic frank pitzer regulatory affair quality management clausjoerg ruetsch legal michael tillmann north america robert yates business development december corporate governance chief operating officer roche diagnostic january associate member lrochearengdiagnosticsindd roche business report diagnostic diagnostic division sale region roche diagnostic rochesdiagnosticsdivisionistheworldsleade division global supplierofin vitro diagnosticsivdsivdtest europemiddle leader billion testsperformedinalaboratoryoratthepointofcare eastafrica dollar vitro onbloodandothersamplesfrompatientsarea japan diagnostic market criticalsourceofobjectiveinformationabouthealth asiapacific division strive develop system anddiseaserochesdiagnosticinstrumentsand testing reagentshelpdoctorsdetectdiseasesselectappro latin america efficient provide priatetreatmentsandmonitorpatientsresponsesto result high medi careinadditionscientistsusethedivisionsresearch north america cal value productstogainabetterunderstandingofthe causesofdiseaseanddiscovernewtreatment italic growth rate local currency inovercountriesthedivisionservescustomer spanningtheentirehealthcarespectrumfrom hospitalsandcommercialmedicallabstophysicians togetherrochespharmaceuticalsanddiagnostic topatientswithconditionsrequiringthemtoselft division work advance personalise inrochehadashareoftheglobalivd healthcare activity align help increase marketvaluedatanestimatedbillionusdollar drug rd productivity discover target inannualsale medicine drive development companion diagnostic potential revalue diagnostic inform majority clinical strategic priority decision account medical spending changingdemographicsnewtechnologiesand diagnostic division outperform mountingpressureonbudgetsandpricingareamong market emerge seven e country thetrendsshapingthehealthcaremarket notably china accelerate growth thediagnosticsdivisionsstrategicprioritiesare expand local organisation designedtorespondtothesetrendsandcapitalise investing programme bring product onthegrowthopportunitiestheypresent market quickly test efficiency pillar division division intend improve profitability business roche automate diagnostic system combination strong sale embody decade engineering innovation growth efficiency initiative target virtually future advance include enhance workflow area operation report contain integration capability support elec information progress tronic patient record management testing efficiency product high medical value critical sustain competitiveness growth novel roche test mark significant advance oncology cardiology major therapy area increase invest ment biomarker research trial figure market growth market share market size demonstrate clinical utility new test estimate base company independent report roche analysis yield innovation e market brazil russia india china south korea mexico turkey lrochearengdiagnosticsindd sale instrument placement strongly result main business onscheduleintheeuandothermarketsinthe divisional sale secondhalfoftheyearrocheexpectsthismajor growth broad development additiontoitscobasfamilyofmodularserum base extend busi workareasystemstoenhanceitscompetitiveness ness area inthediagnosticsdivisionrecordedsale significantlyinbothclinicalchemistryandimmuno major regional ofbillionswissfrancsanincreaseofinlocal assaysaltogetherthedivisionlaunchedover market japan currenciesinswissfrancsinusdollars majorproductsin business area overthiswasmorethantwicetheestimate launch major ivdmarketgrowthrate thediagnosticdivisionsoperatingprofitrosein new product localcurrenciesinswissfrancstomillion allfivedivisionalbusinessareascontributedtosale swissfrancsandtheoperatingmarginatconstant growthledbyprofessionaldiagnosticsanddiabete exchangeratesadvancedpercentagepoint careimmunoassaysandsinglestripbloodglucose theseincreaseslargelyreflectsalesgrowthtightcost monitoringsystemsremainedthesebusinesse managementandthesignificantonetimeexpense primarygrowthdriversmoleculardiagnosticscore recordedinincludingthoserelatingtotheven bloodscreeningandvirologysegmentsdelivereda tanaacquisitioninswissfrancsthemargindecrease solidsingledigitriseinoverallsalesintheapplie bypercentagepointstoduetoaparti scienceunitstrongdemandforthemagnapureand cularlyunfavourablecombinationofexchangerate lightcyclerproductlinesfuelledfurtherabovemarket movementsformoreinformationonthedivision growththetissuediagnosticsbusinessacquire operatingresultsseethefinancereportpart incontinuedtogrowwellaheadofthemarket ofthisannualreport drivenmainlybyitsadvancedtissuestainingportfolio instrumentplacementswereagainupsignificantly efficiency gain forthedivisionasawholeandwereamajorgrowth initiativestosimplifycoreprocessesconsolidate driver servicesstreamlineproductportfoliosandreduce timetomarketareinplaceatanumberofmajorsite geographicallytheemeaandasiapacificregion insuchinitiativescontributedtosignificant contributedmosttogrowthwithallfivebusiness costsavingsandhelpedthedivisionlimitheadcount areasrecordingsolidsalesgainsinthesemarket growthdespitetheacquisitionofswisslaband tissuediagnosticsremainedtheprimarygrowth innovatisanddespiteasubstantialsalesforce driverinnorthamericainjapanprofessionaldiag increaseinchinanotablesuccessesincludedthe nosticsandappliedsciencegrewmoderatelyand consolidationofregionalcallcentresthecreation tissuediagnosticsachievedhighdoubledigitgrowth ofsharedservicecentresinnorthamericaand butdivisionalsalestherewereflatoveralllargely reductionsinmanufacturingcostsexistingandnew duetoreducedgovernmentivdreimbursementand programmeswillbeintroducedatmoresitesto lowerresearchfunde improveproductivityfurtherandachieveadditional costsaving salesintheemarketsgrewandaccountedfor overoftotaldivisionalsalesrevenuesincrease investmentinthesemarketsandstrongdemandfor immunoassaysandotherleadingedgerocheproduct contributedtothisstrongabovemarketgrowth thefirsttwomodulesofthecobasanalyser state growth rate local currency seriesforhighthroughputlaboratorieswerelaunched emea europe middle east africa lrochearengdiagnosticsindd roche business report diagnostic roche topselle diagnostic sale millions chf accuchekmobile cobase cobasc cobastaqman cobastaqscreen mpxt accuchek blood glucose cobas e module cobas c module cobas ampliprep cobas ampliscreen meter insulin pump modular analytic modular analytic cobas taqman cobas taqscreen system elecsys cobas integra market segment market segment market segment market segment market segment diabete management immunoassay clinical chemistry virology blood screen lrochearengdiagnosticsindd industryleade portfolio product clinical testing blood screen life science research coaguchekxs ventanaihcreagent magnapurelc sysmexxti genomesequencerflx coaguchek meter immunohistochemistry magna pure system sysmex analyser genome reagent light cycler system sequencer market segment market segment market segment market segment market segment coagulation advanced gene expression hematology dna sequence monitor tissue stain research image scale yearonyear sale growth local currency lrochearengdiagnosticsindd roche business report diagnostic business area highlight coagulationmonitoringsalesincrease reinforcingrochesleadershipinthissegment immunoassay sale professional diagnostic abovemarket growth salesofthetopsellingcoaguchekxsmonitor major major new product forpatientusewereupstronglyagainhelpe growth driver increa rocheprofessionaldiagnosticsisaleadingsupplier bycontinuedrobustdemandineuropeandexpande ing roughly ofinstrumentstestssoftwareandservicesfor medicarereimbursementforhomecoagulation time market laboratoriesandofdecentralisedtestingproductsto testingintheusstudiesindicatethatselftesting growth rate new cobas modular supportclinicaldecisionmakingatthepointofcare helpspatientsonanticoagulantstokeeptheir system inthebusinessareahadashareof medicationwithinthetherapeuticrangeandcan roche professional aglobalmarketestimatedatbillionusdollar reducecomplication diagnostic strong competitor professionaldiagnosticsfullyearsalesgrewnearly inaugustprofessionaldiagnosticsbeganrollingout immunoassay twiceasfastasthemarketrisingtomillion thecobasmodularanalyserseriesforhigh testing clinical swissfrancsimmunoassayandclinicalchemistry throughputlaboratoriesineuropeandothermarket chemistry systemsforlaboratoriesthetwolargestsegment thatrecognisecemarkcertificationtheresponse bysalesremainedtheprimarygrowthdriver tothisnewflagshipcobasplatformhasbeen regionallysalesoutpacedmarketgrowtheverywhere overwhelminglypositivewithmorethanorder exceptnorthamericawheretheindustryasawhole shippedbytheendoftwoclinicalchemistry experiencedflatornegativesalesgrowthinmost modulescandcwerelaunchedin segmentsasaresultoftheeconomicdownturn bytheendoffourcobasclinicalchemistry andimmunoassaymoduleswillbeavailableworld theimmunoassaybusinessgainedfurthermarket wideincustomisableconfigurationsthenew shareonsalesgrowthofthiswasroughlythree platformisbasedonthesameproventechnologie timesthemarketgrowthrateclinicalchemistrysale asthesmallercobasandcobassystem grewaheadofthemarketadvancingtheplace withexpandedsamplehandlingandworkflow mentrateforcobasmodularanalysersparticularly capabilitiesandenhancedqualitymanagement thecobasseriesformidsizelaboratorie featurestomeettheneedsoflaboratoriesperforme remainedhighfuellingsalesinboththesesegment uptomilliontestsperyear professionaldiagnosticsimmunoassaybusiness inseptemberrocheconcludedanexclusivelicense hasconsistentlygrownatdoubledigitratesforthe agreementwithstvincentshospitalsydney lastnineyearsthankstoalargeinstalledbaseand australiaforworldwidepatentrightsrelatingto steadilyexpandingtestmenunewtestsintroduce theuseofgrowthdifferentiationfactorgdf inliketheelecsysilinterleukinimmuno forthediagnosisofcardiacdysfunctionelevate assayanaidinthemanagementofcriticallyill circulatinglevelsofgdfcanhelpidentifyhigh patientsandthehighsensitivityelecsystroponint riskindividualswithavarietyofcardiovascular assaydiagnosisofheartattackandcardiacrisk conditionsfromstablecoronaryarterydiseaseto stratificationwereimportantgrowthdriversin heartfailuretogetherwithanagreementsignedwith professionaldiagnosticslaunchedsiximmunoassays hannovermedicalschoolhannovergermanyin andfiveneworsecondgenerationclinicalchemistry januaryalsorelatingtogdfandroches testsforavarietyoftherapyareasincludingcardi ownpatentsinthisfieldthislatestagreement ologywomenshealthandcriticalcarein willfurtherstrengthenrochesleadingpositionin thebusinessareawillexpanditstestmenufurther thediagnosisofcardiovasculardisease particularlyintheuswhereitexpectstolaunch eightimmunoassays lrochearengdiagnosticsindd new accuchek portfolio deliver solid sale growth difficult market diabete care market leadership strengthen combowhichwaslaunchedinninemarketsdure excellent uptake rochediabetescaredevelopsandcommercialise andbycontinuedstrongdemandforaccu late accuchek bloodglucosebgmonitoringandinsulindelivery chekinfusionset product helped drive abovemarket sale systemsthatenablepeoplewithdiabetestomanage growth diabete theirconditionmoreeffectivelyitistheindustry inseptemberdiabetescareannouncedinterim care leaderwithashareoftheglobalbgmonitore datafromitsaccuchekviewoutcomestudy marketworthnearlybillionswissfrancsinglobal thedataindicatethatpeoplewithtypediabete salesselfmanagementisacornerstoneofdiabete whoarenotreceivinginsulincanimprovetheir carebecausesomanydailyactivitiesaffectblood glycemiccontrolbytestingandanalysingtheirbg glucoselevelsfrequentbgtestingcanlowertherisk levelsinastructuredwayandtranslatingtheresult ofseriouslongtermdiabeticcomplicationslike intoappropriateactionthemonthstudyunder strokeamputationandblindnesswhilehelpingpeople scoresrochescommitmenttoenhancingthemedical withdiabetestomaintainandimprovetheirquality valueofdiabetesselfmanagementthefinalresult oflife willbeannouncedinjune indiabetescaressalesincreasedto molecular diagnostic new product lie molecular diagnostic millionswissfrancsthiswassignificantly foundation future growth important aheadofglobalmarketgrowthwhichwasflat rochemoleculardiagnosticsdevelopsandcommer new blood screening account duetotheeconomicdownturnallregionsexcept cialisesadvanceddiagnosticandbloodscreene contribute signifi japandeliveredsalesgrowthwithstrongsale platformsandtestsbasedonrochesproprietary not competitive gain contributionsfromemergingmarketstheaccuchek realtimepolymerasechainreactionpcrtechnology market avivaandaccuchekperformabgmonitore thefastgrowinghighlycompetitivemolecu systemsremainedtheprimarygrowthdriversaccu lardiagnosticsmarketisvaluedatbillionswiss chekavivarochestopsellingbgmonitore francsrocheistheleaderwithamarketshare systemcontinuedtopoststrongdoubledigitsale growth moleculardiagnosticsfullyearsalesadvance tomillionswissfrancsgrowthwasledbysolid introducedinfebruarytheaccuchekmobile gainsintheemearegionespeciallyinthecore thefirstandonlystripfreebgmonitoringsystem bloodscreeningbusinessthefullyautomatedcobas experiencedexcellentuptakeinitslaunchmarket taqscreenmpxtestavailableineuropesince andcontributedtomarketsharegainsinthehigh andlaunchedlastyearintheuscontributedstrongly valuecustomersegmentattheendofitwa togrowthinthissegmentwithsignificantcom availableinnineeuropeancountriesaccuchek petitivegainsinseveralmarketsthismultiplexblood mobilesenhancedeaseofuseisappreciate screeningtestdetectsfiveviraltargetsinvirology especiallybypeoplewithinsulindependentdiabete thelargestsegmentbysalesmoleculardiagnostic whoneedtotesttheirbgfrequentlythelaunch retaineditsleadingmarketsharewithsale ofthesleekaccuchekavivananoandaccuchek growthstrongvirologysalesandnewbloodscreene performananodesignedespeciallyforyounger accountsinportugalspainthailandandtheuk usershasalsobeenasignificantsuccessattheend resultedinabovemarketdoubledigitsalesgrowth ofthesenewsinglestripmeterswereavailable intheasiapacificandemearegion inovermarket sinceitseulaunchinaprilrocheslightcycler salesofinsulindeliverysystemsshoweddoubledigit mrsaadvancedtesthasexperiencedpositiveuptake growthfortheyearhelpedbyexcellentuptakeof incountrieswherereportingmethicillinresistant thenewinteractiveinsulinpumpsystemaccuchek staphylococcus aureusmrsainfectionsiscustomary lrochearengdiagnosticsindd technolo ggi lyre cns oa e na grm ie ne e rt ed f ee h r ri n e ts nd ii gbl cis c e ec se n st c r u e c u b se r un gn dte ec h sn io g lo g n fo rm ula tio n lle c e ts vir alresi sta nce n eur ode ge ner atio sn gn al li ng p h w ay n gi mg e yn ee ls ib ip n oi ncpo e alol tl e sg b c iy emol llo bg uy ioni loty gy pharma oncology inflammation neuroscience metabolism virology diagnostic anatnev gniniat eussit roche business report diagnostic excellence science expertise molecular biology major disease area year roche division amass tremendous expertise molecular biology today apply knowledge wide range technology pursuit new test target treatment major focus area oncology inflammation neuroscience metabolism virology time work gain insight molecular mechanism cause drive disease cancer drug development programme roche example involve biomarker research aim validate treatment target identify patient likely respond new drug year cancer research molecular level help develop new strategy close ultimate goal day cure cancer n l sif ee q ec ni ce ngce xc ce el lll ai ng ae lyn sc ise ni mm icb rl oe arg ayn cobas r el ai lg tiht mec pc cl rer u n ss ayu c solt bi ap slex protein anac lo ysb isas lrochearengdiagnosticsindd roche develop test new pandemic flu virus week virus report orrequiredstudiesindicatethatthetestsspeed ofdevelopingcervicalcancercouldhelpincrease test hospital itreliablyidentifiesmrsacarriersinlessthantwo thesensitivityofscreeningforhpvinfectionsthatcan acquire infection hoursversusonetothreedaysusingconventional leadtocervicalcancerwhenhpvdnatestingis like mrsa human papillomavirus methodscanhelpsignificantlyreducethespreadof performedinconjunctionwithapapsmearmore infection thispotentiallydeadlymicrobeinhospitalsscreene womenwillbeidentifiedwithprecancerouscervical fastestgrowing formrsaisoneofthefastestgrowingsegment diseaseduringthefirstroundofcancerscreene segment molecu inthenorthamericanmoleculardiagnosticsmarket enablingappropriatemedicalinterventionaddition lar diagnostic andisexpandinginemeaandsomeasiapacific allybecauseofthegreatersensitivityofhpvdna roche launch marketsrocheexpectstolaunchthelightcycler testingwomenwhoarehpvdnanegativemay competitive new product mrsaadvancedtestintheusin potentiallybedeferredtolongerscreeninginterval segment moreoveridentificationofhpvgenotypesand europe indecembermoleculardiagnosticslaunchedit providesactionableinformationguidingtheclinician newfullyautomatedcobassystemineurope toinvestigatefurtherthosewomenatthehighestrisk andothermarketsthatacceptcemarkcertification forcancer thesystemisdesignedtomeetthecurrentand longtermmoleculardiagnostictestingneed apply science broadbase growth demand instru ofmidtohighthroughputlaboratoriesandroche rocheappliedsciencesuppliesscientistsinacade ment reagent expectsittobecomeasignificantgrowthdriver miaandthebiotechandpharmaceuticalindustrie pandemic flu testing major thetestmenucurrentlycomprisesdualtargettest withinstrumentsandhighlyspecificreagentsandtest sale driver roche forchlamydia trachomatisctandneisseria kitsforabroadrangeofresearchapplicationsthe applied science gonorrhoeaengthebacteriathatcausechlamydia globallifescienceresearchmarketvaluedatbillion infectionsandgonorrheaandascreeningand usdollarsgrewapproximatelyin genotypingtestforhumanpapillomavirushpv themostcommonsexuallytransmittedinfection appliedsciencessalesfortotalledmillion whichisresponsiblefornearlyallcervicalcancer swissfrancsanincreaseofovertheprevious worldwideinaustraliaandnewzealandwhere yearthemagnapureandlightcyclerproductline thecobassystemhasbeenavailablewiththe nucleicacidsamplepreparationnapandquanti ctngtestssinceseptemberthemarketresponse tativepolymerasechainreactionqpcranalysis hasbeenverystrongnextgenerationoncology wereagainthebiggestcontributorstogrowthwith andmicrobiologyassaysforthesystemareindevel salesuphelpedbystrongdemandforinstrument opment andreagentsforpandemicinfluenzatestingand surveillanceinmayappliedsciencedevelopedand inaugustmoleculardiagnosticscompletedenrolment launchedtherealtimereadyinfluenzaahn ofpatientsintoitspivotalathenaclinicaltrial detectionsetforresearchusejustweeksafterfirst thetrialinvolvingapproximatelywoman reportsofthenewpandemicfluvirusinmexico isdesignedtoassessthevalueofscreeningwomen thesetenablesrapidaccuratedetectionoftheviruss forcervicalcancerusingrochescobashpv rnageneticmaterialthefdagrantedemergency assaytogetherwithastandardpapsmearinitialtrial useauthorizationofthekitinnovembermakingit datawillbeavailableinfebruaryandrocheexpect availableforclinicaluseinspeciallycertifiedlaborato tofilethefullathenadatasetwiththefoodand riesintheusothersignificantnewproducts drugadministrationfdainthesecondquarterof includethefullyautomatedmagnapuresystem ifapprovedtheassaywhichprovidesan forhighthroughputnapuptakebyacademic aggregateresultforhighriskhpvgenotypesand andindustrialcustomershasbeenrobustsincethe individualresultsforhpvgenotypesand systemsgloballaunchinseptember thegenotypesthatputwomenatthegreatestrisk lrochearengdiagnosticsindd roche business report diagnostic significant product launch business area total cellanalysissystemsshowedverystrongsalesgrowth throughputbenchtopversionofthegenome indrivenmainlybythexcelligenceproduct sequencergsflxsysteminisexpectedto l linebutalsopartlyattributabletotheacquisitionof spurfurthergrowththegsjuniorsystemwillclose innovatisaginmarchappliedscienceslatestreal themarketgapbetweenlowthroughputtraditional timecellanalyserthexcelligencertcadp sequencingandtheultrahighthroughputofinstru dualplateinstrumenthasbeenagrowthdriver mentslikethegsflxsystemputtingnextgeneration sinceitsworldwidelaunchinaprilitsvalueasa sequencingtechnologywithinthereachofthousand cancerresearchtoolwasenhancedfurtherbythe ofadditionalresearchersworldwide novemberlaunchofthexcelligencesystem cimplateacultureplateenablingscientist tissue diagnostic rapid penetration new l tostudycellmigrationandinvasiondynamically market e inrealtimeovertheentiretimespanofanexperiment rochetissuediagnosticsventanamedicalsystem thismayhelpresearchersidentifymoleculartarget innorthamericaistheworldsleadingsupplierof fornewdrugsthatinhibitcancercellsabilityto tissuebasedcancerdiagnosticsitsinstrumentsand invadenearbytissuesandmigratemetastasise reagentsystemsareusedinhistologycytologyand todistantpartsofthebody drugdiscoverylaboratoriesworldwideinthe unithadashareofthetissuediagnosticsmarket microarraysalesrosenearlyfourtimesthe whichisvaluedatoverbillionswissfranc globalarraymarketgrowthrategrowthwasfuelle bycontinuedstrongperformanceofnimblegen tissuediagnosticsrecordedsalesofmillion innovativesequencecapturetechnologieswhich swissfrancsinaincreaseovertheeleven ideallycomplementthebusinessareasnextgenera monthssalesconsolidatedayearearlierfollowingthe tionsequencingsystemsandbytheintroduction ventanaacquisitioninfebruaryonacompa ofthehighresolutionhighthroughputms rablebasissalesrosesignificantlyoutpace microarrayscanner themarketwhichisestimatedtobegrowingat salesofdnasequencingreagentsshowedarobust thebusinessareascoreadvancedtissuestaine increasebutoverallsalesofdnasequencing portfolioremainedtheprimarygrowthdriverwith systemswereflatduetotheeconomicdownturnand immunohistochemistryihcreagentsforcancer theresultingdeclineinresearchfundingparticularly diagnosisandadvancedstaininginstrumentsfuelle intheustheusadministrationsstimulus robustgrowthinthissegmentplacement packageforbiomedicalresearchisexpectedtoalle ofthefullyautomatedbenchmarkultrasuccessfully viatethesituationinthelaunchofamedium launchedinnorthamericaandeuropein lrochearengdiagnosticsindd roche biomarker programme drug develop acceleratedsteadilyduringtheyearthisisthefirst research development andonlysystemtoperformsimultaneousihcand situhybridisationishtestingonasinglecontinu rochesdiagnosticsdivisioncontinuestoinv diagnotic divi ousandrandomaccessplatformenablingsample heavilyininnovationinresearchanddevelop sion focus tobeaddedandremovedatanytimewithoutinter mentrdcoststotalledmillionswissfranc r spending highgrowth area ruptingworkflowfullyearsalesofthesymphony anincreaseofoverrdcostsasaper like molecular diag slidestaininginstrumentandhematoxylinandeosin centageofsalesremainedstableatproject nostics immuno reagentsforthehighvolumeprimarystainingmarket accountingforasignificantshareofrdspende assays tissue grow inandwhichwillremainfundingprioritiesin diagnostic includetheathenatrialofrochemolecular tissuediagnosticswonmarketshareinallregion diagnosticscobashpvscreeningandgeno withespeciallystronggainsinasiapacificandlatin typingtestintheusdevelopmentofthecobas roche work americaitsuccessfullyleveragedtheexistingroche modularanalyserseriesanddevelopmentof potential companion infrastructuretoexpeditethehiringofsalesperson anextgenerationmoleculardiagnosticplatform diagnostic test group key nelandtheintroductionofnewproductsinemea formidtohighthroughputivdtestingandblood disease area inter asiapacificandlatinamericacontributingto screeningthedivisionalsoinvestedindeveloping est particularly oncol abovemarketgrowthintheseregionsbythecloseof newproductsinitstissuediagnosticsbusiness ogy thebusinessareahadestablisheditsownsale expansionoftheimmunoassaymenuwillbeafurther organisationsinsixoftheemarketsandmostofit majorfocusofrdinvestmentin majorinstrumentsandihcreagentswerealready registeredandavailableinbrazilindiachinaand thedivisionsrdproductivityhasimprovedin mexicorocheisaddressingtheincreasingdemand recentyearssincethenumberofmajorproduct forfullyautomatedproductsinemergingmarket launcheshasincreasedsignificantlyandthedivision whichiscontributingtostrongmarketsharegain expectstobeanotherexcellentyearinterm ofstrengtheningitsproductportfolioseecharton pandthetablesofmajor product launch intissuediagnosticslaunchednewihc pp reagentstoaidindiagnosingvariouscancersinclud ingleukemialymphomaandcancersofthecolon thediscoveryandvalidationofbiomarkersisessential andprostateworkingcloselywithrochespharma torealisingthepromiseofpersonalisedhealthcare ceuticalsdivisionitcontinuedtodevelopexploratory inpharmaceuticalrdtheyhavemanyusesfrom teststhatmayonedayleadtocompaniondiagnostics identifyingnewtherapeutictargetsandscreeningout forrochetherapiesasadirectresultofthiscollabo unpromisingdrugcandidatestoselectingappropriate rationtissuediagnosticsexpectstwoherassay patientpopulationsforclinicaltrialsintheclinic toreceiveceivdmarkinginthefirsthalfof biomarkertestsincreasinglyprovideinvaluableinfor foruseasaidsinassessingbothbreastandgastric mationforearlydiagnosisandaboutdiseasepre cancerpatientsforwhomherceptintreatmentis dispositionprognosisandthelikelihoodoftreatment beingconsidere responseresponsepredictioncontributingtoear liermoretargetedtherapeuticinterventionsroche ivdportfolioalreadyincludescompaniondiagnostics contributingtomoreeffectivetreatmentinanumber ofconditionsincludingherpositivebreastcancer precancerouscervicalchangescausedbyhuman papillomavirusinfectionhepatitisbandcinfection andcytomegalovirusdisease lrochearengdiagnosticsindd roche business report diagnostic everydrugbeingdevelopedatrochehasabiomarker morelikelythanseronegativepatientstoachieve programmeassociatedwithitanddiagnosticsex asignificantimprovementintheirdiseasefollowe pertiseandadvicearemadeavailableforeachof mabtherarituxantreatmentthiscouldsignal theseprogrammesattheendofrochehad amajoradvanceoverthecurrenttrialanderror fivebiomarkertestsinlatestageandsixinearlystage approachtotreatingrainwhichpatientscycle clinicalvalidationforuseaspotentialcompanion throughvarioustreatmentoptionsuntilanoptimum diagnostictestsandoverexploratorystage responseisachievedrochealreadymarketsassays diagnosticprogrammesintheareasofoncology forrheumatoidfactorandanticcp metabolismvirologyautoimmuneandinflammatory diseaseandcentralnervoussystemdisordersthere hastobeastrongcaseforabiomarkersabilityto detectdiseaseorpredictaclinicaloutcomebeforeit movesintolatestagevalidationwheretheaimisto establishclinicalvalidityconclusivelythroughfurther testingonsamplescollectedinongoingdrugtrial giventhepharmaceuticalsdivisionsstrongoncology portfolioidentifyingandvalidatingbiomarkersto supporttheuseofrochesmarketedanddevelop mentalcancermedicinesisnaturallyamajorfocusof researchencouragingprojectsincludeapcrbase testforbrafveacancercausinggenemutation associatedwithpoorprognosisinseveralcancer includingmalignantmelanomadevelopedbyroche moleculardiagnosticsthetestwasprovenessential forselectingsuitablepatientsinaphaseitrial withthebrafkinaseinhibitorrginmetastatic melanomargwhichselectivelytarget andinducescelldeathintumoursharbouringthe brafvemutationmarkedlyprolongedprogression freesurvivalinpatientsinthetrialwhotestedpositive forthemutationthetesthasalsobeenuse successfullyinclinicaltrialstoidentifymutation positivecolorectalcancersifrgisapprove rocheexpectstolaunchthebrafvetestasthe companiondiagnostic twootherhighlypromisingbiomarkersthathave alreadyreachedlatestageclinicalvalidationarerheu matoidfactorandanticycliccitrullinatedpeptide anticcpantibodiesthatarefoundinthebloodof manyrheumatoidarthritisrapatientsananalysis ofpooleddatafromtwoclinicaltrialswithmabthera rituxaninrashowthatpatientswhoareseropositive foreitheroftheseantibodiesaretwotothreetime lrochearengdiagnosticsindd glossary immunoassay alaboratorytestthatdetectsor measuresatargetsubstanceinasampleusing biomarker acharacteristicthatcanbemeasure animmunochemicalreactioninwhichanantibody andevaluatedasanindicatorofanormalbiological bindstoaspecificantigenthetargetcanbeadrug processadiseaseprocessoraresponsetoathera aproteinoravirusforexample peuticinterventionelevatedlevelsoftheprotein herincancerforexampleareabiomarkerfora immunohistochemistry ihc amethodofstaine highprobabilityofresponsetoherceptin biologicaltissuesamplestodeterminethepresence levelandlocationofspecificproteinsincellsusedin cell analysis methodsofmeasuringthepropertie thediagnosisofcancerandotherdisease ofcellsincludingtheirsizeandshapecellular parameterssuchasthepresenceofspecificprotein situ hybridisation ish amethodofstaine andcellularprocessessuchasproliferationand biologicaltissuesamplestoidentifythepresenceand growthcellanalysistechnologiesplayanimportant copynumberofspecificgenesorgeneticmutation roleindrugdevelopmentandproduction incellsusedinthediagnosisofcancerandother disease ce mark certification certificationthatanin vitro diagnosticivdproductcomplieswithallsafety polymerase chain reaction pcr alaboratory healthandenvironmentalrequirementsforuseinthe methodwidelyusedinresearchandindustrytomake europeanunioncertifieddiagnosticsarereferre millionsofcopiesofadnasequenceofinterest toasceivds veryquicklyrealtimepcrsimultaneouslyamplifie copiesandquantifiesthetargeteddnamolecule clinical chemistry abranchofdiagnosticscom prisingteststhatdetectandmeasurechangesin virology inmoleculardiagnosticstestingtodetect thechemicalcompositionofbodyfluidsandtissue certainseriousandprevalentviralinfectionseghiv todiagnoseorpredictthecourseofadisease andhepatitiscortomonitortheirtreatment dna sequence methodsofdeterminingthe orderofnucleotidesmolecularbuildingblocksin geneticmaterialknowinganindividualsdna sequencecanprovideinsightsintogeneticchange whichcontributetohumandiseaseorinfluence treatmentresponsehighthroughputtechnologie readthousandsofsequencesatonce human epidermal growth factor receptor aproteininvolvedinnormalcell growthandfoundatincreasedlevelsinsome cancersincludingsomebreastandgastriccancer cancercellsmaybetestedinthelaboratoryfor herlevelstohelpchoosethemostappropriate treatment lrochearengdiagnosticsindd roche business report diagnostic product launch diagnostic division major product launch business area product market quarter professional diagnostic elecsys immunoassay plgf placenta growth factor sflt eu q soluble fmslike tyrosine kinase diagnosis preeclampsia elecsy il interleukin immunoassay aid management eu q critically ill patient elecsys troponin assay test cardiacspecific troponin level eu q predict mortality risk patient acute coronary syndrome highsensitivity elecsys troponin immunoassay diagnosis eu q heart attack cardiac risk stratification q sysmex xti mid highthroughput hematology analyser contractual territory test capability blood body fluid emea q cobas c clinical chemistry module cobas analyser series eu q highthroughput laboratory throughput testshour cobas p cobas p automate storage retrieval modules eu q barcode primary secondary sample tube cobas c clinical chemistry module cobas analyser series eu q throughput testshour diabetes care accuchek mobile integrate lance blood glucose monitor eu q device employ unique strip technology replace test strip continuous tape test accuchek aviva nano accuchek performa nano sleeker version eu q accuchek aviva accuchek performa meter offer enhance feature set accuchek combo interactive insulin delivery system combine insulin eu q pump blood glucose meter broad datum management capability meter function pump remote control accuchek active new version exist meter feature extend eu q memory number failsafe capability molecular diagnostic lightcycler mrsa advanced test automate realtime pcrbase test eu q methicillinresistant staphylococcus aureus test identify mrsa carrier hour cobas p instrument amplilink software preanalytical eu q instrument unite primary tube handle fully automate sample prepa ration amplification detection molecular diagnostic cobas platform automate dna extraction realtime pcr eu q amplification detection test human papillomavirus chlamydia trachomatis neisseria gonorrhoeae apply science nimblegen ms fully automate highresolution microarray scanner worldwide q use nimblegen dna microarray xcelligence rtca dp dual plate system highly flexible mediumthroughput worldwide q system realtime noninvasive cell analysis lightcycler system highthroughput quantitative pcr analysis worldwide q magna pure highthroughput system prepare nucleic acid sample worldwide q pcr analysis tissue diagnostic inform egfr dna probe detect extra copy epidermal growth emea apac q factor receptor egfr gene abnormality associated nonsmall cell lung cancer benchmark xt advance stain instrument latam apac q benchmark ultra advanced staining system continuous random additional european processing stat capability market latam q japan q intend use confirm antiherneu primary antibody inform emea apac q dna probe expand include analytical claim perfor mance gastric breast tissue sample eu european union emea europe middle east africa apac asiapacific latam latin america united states lrochearengdiagnosticsindd major product launch plan business area product market quarter professional diagnostic cobas e immunoassay module cobas modular analyser series eu q highvolume laboratory throughput testshour q elecsy immunoassay eu qq cobas c cobas c clinical chemistry module cobas q modular analyser series throughput testshour respec tively cobas p cobas p automate storage retrieval module q barcode primary secondary sample tube cobas c advanced clinical chemistry module cobas modular eu q analyser series feature automate reagent loading enable consolidation broad test menu throughput testshour cobas b benchtop multiparameter analyser blood gas electrolyte eu q cooximetry metabolite use point care hiv combi min improved combination assay hiv antigen p eu q hiv antibodie enable reliable early detection infection human immunodeficiency virus diabetes care accuchek mobile integrate lance blood glucose monitor device additional eu employ unique strip technology replace test strip market qq continuous tape test apac q accuchek combo interactive insulin delivery system combine insulin additional eu pump blood glucose meter broad data management capability market q meter function pump remote control apac q qq accuchek aviva nano sleeker version accuchek performa meter qq offer enhance feature set molecular diagnostic lightcycler mrsa advanced test automate realtime pcrbase test q methicillinresistant staphylococcus aureus cobas ampliprepcobas taqman cmv ce ivd viral load monitoring test eu q enable physician improve management cytomegalovirus cmv disease solid organ transplant patient coba taqscreen dpx test multidye blood screening test design eu q simultaneously provide quantitative result parvovirus b qualitative result hepatitis virus cobas ampliprepcobas taqman hiv v secondgeneration test q unique dualtarget design enable detection separate region hiv genome cobas taqman hiv v ce ivd high pure virology test offer manual eu q sample preparation option customer lowvolume workload apply science gs junior system economical benchtop nextgeneration dna sequence worldwide q system small laboratory nimblegen cgx multiplex arrays microarray highresolution analysis worldwide q chromosomal abnormality capable analyse sample simultaneously xcelligence rtca ht instrument automate highthroughput cell analyse worldwide q screening seqcap ez exome v insolution enrichment capture technology target worldwide q nextgeneration sequence nextgeneration ultrahigh density nimblegen microarray worldwide qq tissue diagnostic dual colourdual hapten situ hybridisation ish kit enable target gene eu q detection control single slide use molecular marker specifically support test ventana antiher neu b primary antibody ventana dna eu qq probe ce ivds assess likelihood response herceptin treatment breast gastric cancer patient benchmark gx economical lowvolume advanced tissue stain platform eu apac q automates slide processing step bake stain ceivd molecular probe target enzyme topa cell surface eu qq receptor igfr use aid diagnose manage breast lung cancer discovery ultra platform immunohistochemistry situ hybridisation eu q research offer significant improvement ease use workflow apac japan flexibility latam q plan launch delay occur result adverse regulatory decision factor eu european union emea europe middle east africa apac asiapacific latam latin america united states lrochearengdiagnosticsindd read gene help save life day precision speed count modern molecular diagnostic work improve genome sequencer read build block highly variable gene matter day instead week long take achieve precision conventional sequence method day help extend improve live transplant patient currently investigate use sequencer hla human leukocyte antigen genotype blood stem cell stem cell transplantation perform treat number disease include leukemia donor recipient cell need hlacompatible possible treatment successful study show genome sequencer flx system power ful research tool highresolution hla genotype critical people need transplant close match donor recipient hla gene small risk transplant rejection life science research use diagnostic procedure bildstreckeengsindd bildstreckeengsindd corporate governance roche commitment stakeholder reflect operate business focus value creation management culture conform modern standard corporate governance group policy communicating transparently remuneration report roche success depend ability dedication people recognition form basis remuneration policy system lrochearengcorporate governanceindd corporate governance rochecomplieswithallrelevantcorporategovernance attheagmonmarchtheboardofdirector requirementsinparticularwithallapplicablelaws willnominatedeannejuliusandbeatriceweder theswissstockexchangesixswissexchange dimauroforreelection totheboardandarthurd directivesincludingthecommentariestheretoand levinson william burn election new theswisscodeofbestpracticeforcorporategover member board term year nancepromulgatedbytheswissbusinessfederation asprovidedbythearticlesofincorporationpeter economiesuissethecompanysinternalgovernance brabeckletmatheandhorstteltschikhavedecide frameworkparticularlyitsarticlesofincorporation toretireasmembersoftheboardofdirectorsafter andbylawsembodiesall theprinciplesneededto manyyearsofdistinguishedservicetheboardof ensurethatthecompanysbusinessesaremanage directorsthanksfortheirdedicationandtheirmany andsupervisedinamannerconsistentwithgood contributionstoroche corporategovernanceincludingthenecessarycheck andbalances corporate executive ourprintedannualreportcontainsselectedlinksto committee therochewebsitewwwrochecomreadersare thusprovidednotonlywithasnapshotofourcom panyatthereportingdatebutarealsodirectedto william burns ceo division roche pharma sourceswhichtheycanconsultatanytimeforupto ceutical jrgen schwiezer ceo division roche date informationabout corporate governance diagnosticsandjonathanknowlesasheadgroup rochewhereaseachannualreportcoversasingle researchretiredondecemberandtherefore financialyearendingdecemberourwebsite steppeddownasmembersofthecorporateexecutive containsinformationofamorepermanentnaturea committeetheboardofdirectorsthankstheleave wellasthelatestrochenewsamendmentsto membersofthecorporateexecutivecommitteefor ourcompanysarticlesofincorporationandbylaw theirdedicationandtheirmanycontributionstoroche andchangesinthecurriculavitaeofthemember oftheboardofdirectorsandthecorporateexecutive theboardofdirectorsofrocheholdingltdwill committee publish timely fashion nominatewilliammburnsforelectiontotheboard ourwebsitewheretheycanbeaccessedbyanyone attheagmonmarch lookingforthisinformation aspartofthegenentechtransactionpascalsoriot wasappointedasceoofgenentechincandas board director anewmemberofthecorporateexecutivecommittee inaprilpascalsoriotrelinquishedhisrole attheth annualgeneralmeetingagmof asceogenentechincasofdecemberand rocheholdingltdonmarchshareholder wasappointedascoodivisionrochepharmaceu reelectedjohnibellandrhoffmannandfranzb ticalsstartingonjanuary humerasmembersoftheboardofdirectorsfor atermofthreeyearsasprovidedbythearticlesof incorporationatitsorganisingmeetingimmediately followingtheagmtheboardofdirectorshas approveditscommitteesstructureanditscommittee membershipsasshownonpage httpwwwrochecomaboutrochecorporategovernancehtm lrochearengcorporate governanceindd roche business report corporate governance board director december leave dr franz b humer prof bruno gehrig andr hoffmann prof pius baschera prof sir john irving bell peter brabeckletmathe lodewijk jr de vink dr andreas oeri dr deanne julius walter frey prof beatrice weder di mauro prof horst teltschik dr wolfgang ruttenstorfer lrochearengcorporate governanceindd board director year birth term end elect board director dr franz b humer e chairman prof bruno gehrig c e vicechairman andr hoffmann c e vicechairman prof pius baschera e prof sir john irving bell c e peter brabeckletmathe e lodewijk jr de vink c e walter frey b e dr deanne julius b e dr andreas oeri e dr wolfgang ruttenstorfer b e prof horst teltschik b e prof beatrice weder di mauro b e new propose member board director nominate election annual general meeting william burns march dr arthur levinson secretary board directors dr gottlieb keller honorary chairman board directors dr fritz gerber corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director committee chairperson january lrochearengcorporate governanceindd roche business report corporate governance corporate executive committee december leave dr severin schwan william burns dr jrgen schwiezer dr erich hunziker silvia ayyoubi prof jonathan knowles dr gottlieb keller pascal soriot burkhard g piper osamu nagayama perolof attinger richard scheller ren kissle right new member january leave daniel jeanjacque garaud dan zabrowski lrochearengcorporate governanceindd corporate executive committee year birth position corporate executive committee dr severin schwan ceo roche group dr erich hunziker chief financial officer deputy head corporate executive committee william burns ceo division roche pharmaceutical dr jrgen schwiezer ceo division roche diagnostic prof jonathan kc knowles head group research dr gottlieb keller general counsel silvia ayyoubi head human resource pascal soriot ceo genentech inc coo division roche pharmaceutical january daniel oday coo division roche diagnostic enlarge corporate executive burkhard g piper head business area roche diabete care committee perolof attinger head communications osamu nagayama president ceo chugai richard scheller head genentech research early development gre head roche pharma january jeanjacques garaud research early development pre dan zabrowski head pharma partnering secretary corporate executive committee ren kissle kpmg klynveld peat marwick goerdeler sa reporting year statutory auditor kpmg ag roche holding ltd auditor charge john morris chief compliance officer dr urs jaisli member december new member january leave daniel jeanjacque garaud dan zabrowski lrochearengcorporate governanceindd roche business report corporate governance asofjanuarydanielodaywasappointedas majorshareholdersarelistedinthefinancereport coodivisionrochediagnosticsandasanew note roche group consoli memberofthecorporateexecutivecommitteea date financial statement equity attributable ofdecemberburkhardpipersteppe roche shareholder related party downasamemberoftheenlargedcorporateexecu pagesandandinnotetothefinancial tivecommitteeandisreportingtodanieloday statement roche holding ltd significant shareholderspage inaprilrichardschellerwasappointedto andrhoffmannvicechairmanoftheboardof theenlargedcorporateexecutivecommittee directorsandandreasoerimemberoftheboard hereportsdirectlytogroupceoseverinschwan ofdirectorsandchairmanoftheboardscorpo astheformerheadofgenentechresearchhe rategovernanceandsustainabilitycommittee leadsgenentechsresearchandearlydevelopment serveintheirrespectivecapacitiesontheboardand gredwhichwilloperateasanindependentcentre committee representative share withintherochegroup holdersgroupwithpooledvotingrightsandreceive theremunerationsetforthintheremuneration jeanjacque garaudwasappointedasheadof reportonpageandinthefinancereport rochepharmaresearchandearlydevelopment notetotherochegroupconsolidatedfinancial predandasanewmemberoftheenlarge statementsrelatedpartiespageandnote corporateexecutivecommittee tothefinancialstatementsofrocheholdingltd boardandexecutiveremunerationpage danzabrowskiasheadofpharmapartneringwas nootherrelationshipsexistwiththeshareholder appointedasanewmemberoftheenlargedcorpo withpooledvotingright rateexecutivecommittee therearenocrossshareholding capital structure information relate informationonrochescapitalstructureisprovide inthefinancereportnotestothefinancial corporate governance statement roche holding ltd additionaldetailsarecontainedinthe group structure shareholder articlesofincorporationofrocheholdingltd rochesoperatingbusinessesareorganisedinto changesinequityaredetailedinthefinance twodivisionspharmaceuticalsanddiagnosticsthe report note financial statement pharmaceuticalsdivisioncomprisesthetwobusiness rocheholdingltdpage segment roche pharmaceutical chugai thecompanyhasasharecapitalof whereasgenentechastheformerthirdsegmentha swissfrancsdividedintofullypaid beenintegratedintorochepharmaceuticalsthe bearershareswithanominalvalueofswissfranc diagnostic division consist follow eachtherearenorestrictionsontheexercise businessareasappliedsciencediabetescare ofthevotingrightsofthesesharesupondeposit moleculardiagnosticsprofessionaldiagnosticsand sharescanbevotedwithoutanyrestriction tissuediagnosticsbusinessactivitiesarecarriedout thereisnoauthorisedorconditionalcapital throughgroupsubsidiariesandassociatedcompa inadditionnonvotingequity niessignificantsubsidiariesandassociatedcom securitiesneshavebeenissuedinbearerform paniesarelistedinthefinancereportnoteto therochegroupconsolidatedfinancialstatement httpwwwrochecomaboutrochecorporategovernance subsidiariesandassociatespagesto articleofincorporationhtm lrochearengcorporate governanceindd theydonotformpartofthesharecapitaland withtheexceptionoffranzbhumernoneofthe confernovotingrightseachnesconfersthesame membersoftheboardofdirectorshasbeena right share participate available memberofrochescorporateexecutivecommittee earningsandinanyliquidationproceedsfollowe orservedinanexecutivecapacityatanygroup repaymentofthesharecapitalrochesne subsidiaryduringthethreefinancialyearsprecede andtherightspertainingtheretoincludingthe thecurrentreportingperiod provisionsprotectingtheinterestsofnesholder theinternalorganisationoftheboardofdirector aredescribedinofthearticlesofincorporation andthedivisionofauthorityandresponsibilitie ofrocheholdingltd betweentheboardandmanagementtheremitsof information debt instrument theboardcommitteesandtheinformationand beenissuedandonoutstandingbondsisprovided controlmechanismsavailabletotheboardinit finance report note roche dealingswithcorporatemanagementaregoverne groupconsolidatedfinancialstatementsdebt bythebylaw board director roche holding ltd additionalinformationonemployeestockoption organise ensure group isprovidedinthefinancereportnoteto business conduct responsibly therochegroupconsolidatedfinancialstatement focusonlongtermvaluecreationtothisendthe employeestockoptionsandotherequity roche board delegate certain responsibility compensationbenefitspage committee composition rochehasissuednooptionsapartfromemployee chairperson january describe stockoptionsstocksettledstockappreciation committee authority rightsssarsandoptionsissuedinconnection responsibility define detail bylaw withdebtinstrument board director neithertheoptionsawardedtoemployeesnor allthecommitteesexceptthepresidiumarechaire thedebtinstrumentswhichhavebeenissuedhave byindependentdirector anyeffectonrochessharecapital accordingtothebylawsoftheboardofdirector attherequestofanyofitsmembersaboard board director corporate executive meeting chairman present committee convene roche board meet year informationoneachmemberoftheboardof assessthechairmansperformancethismeete director include year attend chairman chair electedandtheyearsinwhichtheirtermsend byoneofthevicechairman member corporate executive committeeislistedonpagestocurricula vitaeandotherinformationincludinginformation httpwwwrochecomaboutrochemanagement boardofdirectorshtm board membership available httpwwwrochecomaboutrochemanagement internet executivecommitteehtm theannualgeneralmeetingelectsthemember httpwwwrochecomaboutrochecorporategovernance oftheboardofdirectorsinstaggeredelection articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance inwhicheachnomineeisvotedonseparatelysee annualgeneralmeetingshtm article incorporation roche httpwwwrochecomaboutrochecorporategovernance hold ltdand minutes thannual articleofincorporationhtm general meeting roche holding ltd hold httpwwwrochecomaboutrochecorporategovernance committeeshtm march httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm lrochearengcorporate governanceindd roche business report corporate governance theboardofdirectorshasestablishedasystemof remunerationcommitteethreemeeting controlswhichiscontinuouslymonitoredbythe approxtohourseach auditcommitteeandbythecorporategovernance themembersofthecorporateexecutivecommittee andsustainabilitycommitteeandconsistsofthe areinvitedtoattendforandreportinpersonon followingelements agenda item concern reportsonfinancialandoperatingrisksrisk situation warrant member enlarge managementsystem corporateexecutivecommitteemayalsobeinvite systemofinternalcontrolsoverfinancialreport toattendtheboardcommitteesinvitethechair ingseepageandinthefinancereport man board corporate executive internalaudit committeememberstodeliverreportsatcommit groupcomplianceofficerandcompliance tee meeting elect commission officersinsubsidiarie independentexpertreportsandcallontheservice safetyhealthandenvironmentalprotection consultant risk management system department subject continuous review finding corporatesustainabilitycommittee present audit committee scientificandethicsadvisorygroupseag board internalauditregularlybriefstheaudit forissuesrelatingtogeneticsandgeneticengi committeewithreferencetoongoingauditreport neeringestablishedin membersofinternalauditattendauditcommittee eachyearseveralblackoutperiodsareimpose meetingsasdoexternalauditorsforinformation duringwhichsenioremployeesareprohibitedfrom ontheexternalauditorsseepage tradingincompanystockthefollowingblackout management contract fall periodsareineffectfor scope subsection decembertofebruary sixdirectiveoninformationrelatingtocorporate apriltoapril governance junetojuly octobertooctober remuneration shareholding loan blackoutperiodscanbechangedbythechairman alldetailsregardingremunerationshareholding oftheboardofdirectorsifcircumstanceswarrant andloansaresetforthintheseparateremuner intheboardofdirectorsmetforfivemeet ationreportonpagestoandinthefinance ingseachfromtohoursinlengthoncefora reportnotesandtotherochegroup fulldaymeetingandonceforathreedayvisit consolidatedfinancialstatementsequityattribut toamajorsubsidiarywhichincludedaboardof abletorocheshareholdersandrelatedpartie directorsmeetingtheboardcommitteesmet pagesandandarelistedinthenote asfollowsin andtothefinancialstatementsofrochehold presidiumoftheboardofdirectorsnomination ing ltd board executive remuneration committeethreemeetingsapproxhour boardandexecutiveshareholdingspages auditcommitteefourmeetingsapproxto hourseach corporategovernanceandsustainabilitycom mitteethreemeetingsapproxhourseach remuneration committee member permit con tribute attend remuneration committee meeting matter concern deliberate decide figure indicate actual length meeting additional information provide finance report note include director extensive premeeting preparation roche group consolidated financial statement risk postmeete followup activity management lrochearengcorporate governanceindd participatory right shareholder auditcommitteeseearticleofthebylaw theparticipatoryrightsofshareholdersaredefine thestatutoryauditorsparticipatedinallfour inrochesarticlesofincorporation asroche meetingsoftheauditcommitteein sharesareissuedtobearertherearenorestriction onadmissiontoannualgeneralmeetingswith thereportsofstatutoryauditorsontheconsoli theexceptionthatsharesmustbedepositedwithin datedfinancialstatementsandonthefinancial aspecifiedperiodbeforethedateofameeting statementscanbefoundonpagesand andanadmittancecardmustbeissuedintheshare respectivelyofthisyearsfinancereport holder nameasprovidedinofthearticle incorporation shareholder elect kpmgreceivedthefollowingremunerationfor berepresentedbyanothershareholderatanannual theirservicesasstatutoryauditorsofrochehold general meeting article incorporation ingltdandotherrochecompanie contain restriction exercise voting right quorum requirement stipulate conformity millions chf swiss codeofobligation auditing service underofthearticlesofincorporation auditrelated service shareholdersrepresentingshareswithanominal tax consultancy service valueofatleastmillionswissfrancscanrequ total theplacementofitemsontheagendaofan annualgeneralmeetingthismustbedoneno thestatutoryauditorsareelectedeachyearbythe laterthandaysbeforethedateofthemeete annualgeneralmeeting change control defensive measure ernstyoungltdreceivedthefollowingremunera thearticlesofincorporationcontainnoprovision tionfortheirservicesastheauditorsofgenentech onthemandatorybidruleswisslawapplie andchugai therearenochangeofcontrolclausesthose componentsofremunerationbasedonrochene wouldbeterminatedintheeventofanacquisition millions chf andvestingperiodrestrictionsonpreexiste chugai genentech awardswouldberemovedsothatallsuchoption chugai audits couldbeexercisedimmediately consult service provide genentech relationship statutory auditor chugai attheannualgeneralmeetingofrocheholde total ltdonmarchtheshareholdersvote toappointkpmgagkpmgasstatutoryauditor informationonhowlongtheauditorsandauditor inchargehavebeenservinginthesecapacitiesis providedonpagethestatutoryauditor participateinauditcommitteemeetingstheypre httpwwwrochecomaboutrochecorporategovernance parewrittenandoralreportsontheresultsoftheir articleofincorporationhtm auditstheauditcommitteeoverseesandassesse httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm theauditorsandmakesrecommendationstothe httpwwwrochecomaboutrochecorporategovernance boardforinformationontheresponsibilitiesofthe articleofincorporationhtm lrochearengcorporate governanceindd roche business report corporate governance information policy irregularitiesorcomplaintsintheircorresponding provide article incorpora motherlanguageviaaspeakup hotlinethe tion corporatenoticesarepublishedintheswiss chiefcomplianceofficerreportsregularlytothe official gazette commerceandinotherdaily corporategovernanceandsustainabilitycommittee newspapersdesignatedbytheboardofdirector basler zeitung finanz und wirtschaft lagefi nonapplicabilitynegative disclosure le temps neue zrcher zeitung itisexpresslynotedthatanyinformationnot rochereportsitshalfyearandfullyearresultsin containedormentionedhereinisnonapplicable businessreportspublishedinprintandonline oritsomissionistobeconstruedasanegative formatsandatmediaeventsinadditiondetaile declarationasprovidedinthesixswissexchange firstandthirdquartersalesfiguresarepublishe corporategovernancedirectiveandthecom eachyearinaprilandoctoberthemostcurrent mentarythereto listofpublicationdatesisavailableinenglishand germanontheinternet allrelevantinformationanddocumentsinclude allmediareleasesinvestorupdatesandpre sentationstoanalystandinvestorconferencesare availableontheinternetfurtherpublication canbeorderedbyemail faxortelephonebasel webmasterrochecomtel fax thecontactaddressforinvestorrelationsis f hoffmannla roche ltd investor relations corporatefinancebaselswitzerland telfax additionalinformationincludingdetailsonspecific contactpersonsisavailableontheinternet chief compliance officer thechiefcomplianceofficerwithhiscompliance officersnetworkiscommittedtoensuringthat rochecorporateprinciplesareconsistentlycom pliedwiththroughouttherochegroupand alsoservesasacontactpersonforshareholder employeescustomerssuppliersandthegeneral publiconissuesrelatingtotheimplementationof andcompliancewiththeseprinciplesemployees andotherpartieswhobecomeawareofviolation ofrochecorporateprinciplescanbringthem totheattentionoftheirmanagersorsupervisorsor reportthemtothechiefcomplianceofficerur jaislidirectphonenumber emailursjaislirochecomsuchdisclosures httpwwwrochecommediahtm willbetreatedconfidentiallyinadditionasofthe httpwwwrochecominvestorshtm endofemployeesmayanonymouslyreport httpwwwrochecominvestorscontactshtm lrochearengcorporate governanceindd remuneration report summary tionpolicyisdesignedtofostervaluecreationand rochessuccessdependsontheabilitiesand reinforceacultureofperformanceandinnovation dedicationofitspeoplerecognitionofthisforms anditappliestononmanagerialemployeesaswell thebasisofourremunerationpolicyandsystem astomanagersthekeyprinciplesunderpinningthis policyare oneoftheprimaryaimsofourremunerationpolicyis focusonvaluecreation toencouragealongtermfocusandalignmanage payforperformance mentsinterestswiththeinterestsofrochesshare enablingemployeestoshareinthecompany holdersandholdersofrochesnonvotingequity success securitiesne fairnessandtransparencyinremuneration decision thisremunerationreportwillbesubmitte abalancedmixoflongandshortterm separatelyforapprovalattheannualgeneral remunerationcomponent meet marketcompetitiveness theremunerationofcorporateexecutive committeececmembersandothersenior basepaybonusesblockednonvotingequity rocheexecutivesiscomprisedof securitiesnesawardsofstocksettledstock basesalary appreciationrightsssarsandaperformance bonus shareplansupporttheseprinciplestheseremu specialstockawardsnonvotingequity nerationcomponentsarelinkedtoourcompanys securitiessubjecttovestingperiodyear financialperformanceandcommercialsuccessand stocksettledstockappreciationright thusaligntheinterestsofrocheemployeeswith ssar thoseoftheshareholderstheamountoftheseparate performanceshareplanpspawards componentsofremunerationforeachindividual withtheexceptionofseverinschwanandsilvia memberofthecorporateexecutivecommitteeis ayyoubinoneofthececmembersreceivedan shownintheindividualdescriptionoftheremunera increaseinbasesalaryin tionofthecorporateexecutivecommitteeinthis basedonrochessharepriceperformanceno report neswillbeawardedforthepspcycle thessarsgrantedinand base pay havestrikepricesabovethecurrentnespriceand basepaylevelsaredeterminedaccordingtomarket havenovaluefortherecipientsthiscanchange dataforspecificpositionsandindividualemployees ifrochesfuturenespriceimprove abilitiesexperienceandperformanceovertimepay therehasbeennochangeinthebaseremunera increasesarelinkedtoindividualperformanceand tionoftheboardofdirectorssince stock optionsstocksettle stock appreciation right pleaseseetherestofthisreportforfulldetail ssar april base pay corporate executive remuneration policy committee generally increase time gottlieb keller result difference base pay rochefundamentallyreneweditsremunerationpolicy receive calendar year table inandreviseditwithminorchangesin increase base pay april itispartofaframeworkofemployeepoliciesaimedat finance report note roche group consolidate financial statement relate party motivatingandretainingcurrentemployeesattracting note financial statement roche holding talentednewonesandhelpingallrocheemployee ltd board executive remuneration board execu toperformatconsistentlyhighlevelsourremunera tive shareholding lrochearengremuneration reportindd roche business report remuneration report alsotakeintoaccountprevailingmarketcondition isbasedonathreeyearcomparisonofthetotal affordabilityandthecompanysoveralleconomic shareholderreturntsrwithcompetingcompa situation niesintherewerethreeoverlappingperfor mancecyclespsppspand bonus pspofwhichpspclose bonusesareawardedinrecognitionofindividualcon ondecember tributionstovaluecreationwhichgobeyondnormaljob expectationsandtheyaremeanttobeanincentive detailsforthepspcalculationandaddi tocreateorstrengthennewbusinessopportunitie tionalinformationaresetforthinremuneration andstriveforoutstandingresultsbonusamountsare ofmembersofthecorporateexecutivecommittee linkedtogroupordivisionalbusinessperformance dperformanceshareplanpsppage achievement individual functional measurableandqualitativeperformanceobjective remuneration board director theremunerationcommitteeoftheboardofdirector corporate executive committee define corporate executive committee eachyeartheremunerationcommitteewhichis membersbonusesindecemberbasedonresult entirelycomprisedofindependentexternalmember achievedfor oftheboardofdirectorssetsremunerationforthe membersoftheboardofdirectorsandthecorporate special stock award executivecommitteecashpaymentsbonuse innonvotingequitysecuritieshavebeen optionsstocksettledstockappreciationrightsand grantedtoaselectednumberofrocheemployee policydecisionsaboutpensionbenefitstheterm theawardsvestimmediatelybutareblockedfor oftheperformanceshareplanaredeterminedannu threeyearsrecipientshavetheoptiontoextendthe allybytheboardofdirectorsactinguponrecommen blockingperiodtotenyearsthegrantofthosenon dationsfromtheremunerationcommitteethe votingequitysecuritieswasawardedaspartofthe remunerationcommitteecontinuouslytrackssalary bonuspaymentsforwiththeaimtobothimme trendsinthemarketandreportstotheboardof diatelyrewardtheachievementofspecificobjective directorsinformationonthiscommitteesremitand andtofostertheinterestinalongtermpositive itsproceduresformakingremunerationdecision development canbefoundinthebylawsoftherocheboardof director stocksettle stock appreciation right ssar stocksettledstockappreciationrightswereintro followingtherevisionoftheremunerationpolicy ducedonjanuarythusestablishingauniform includingmarketcomparisonswiththeworldsmajor systemofremunerationthroughoutrochessar pharmaceuticalcompaniestheremunerationcom entitleholderstobenefitfinanciallyfromanyincrease mitteehasdeterminedthebonusesandremuneration inthevalueofrochesnonvotingequitysecuritie ofthechairmanoftheboardofdirectorsthemem betweenthegrantdateandtheexercisedatedetaile bersofthecorporateexecutivecommitteetakinginto informationisavailableonpageandpageto considerationpersonnelchangesindoingsothe followingchangeswerenote performance share plan themembersofthecorporateexecutivecommittee peer set abbott laboratories amgen astella astra andothermembersofseniormanagementcurrently zeneca bayer becton dickinson biogen idec bristolmyers someindividualsworldwideparticipateinthe squibb eli lilly gilead glaxosmithkline johnson johnson merck co novartis pfizer sanofiaventis takeda performanceshareplanpspthepspwasestab httpwwwrochecomaboutrochecorporategovernance lishedinforperiodsofthreeyearseachand articleofincorporationhtm lrochearengremuneration reportindd afurtherimportantstepforthetransferofdutie boardofdirectorsandbyeachmemberofthecorpo fromthechairmantotheceohasbeencomplete rateexecutivecommitteeforincomparison withthecompletionoftheintegrationofgenen withfiguresforpreviousyearsandanoutlookonthe techaccordinglytheboardplanstoreducethe chairmansremunerationdevelopmentfor chairmansbasepayinfordetailedinfor mationseepage remuneration ondecemberwilliammburnsjonathan remuneration member board kcknowlesandjrgenschwiezerretiredfrom director inthemembersoftheboard company consequently step ofdirectorsreceivedtheremunerationshown membersofthecorporateexecutivecommittee inthetableremunerationofmembersoftheboard asofjanuarydanielodayhastaken ofdirectorsbelowfortheirboardactivitie overaschiefoperatingofficercooofthe diagnosticsdivision remunerationofallmembersoftheboardofdirector asofjanuarypascalsoriothastakenover willagainremainunchangedforthenon hisnewfunctionascooofthepharmaceuticals executivemembersoftheboardofdirectorswerenot division awardedanysharesnonvotingequitysecuritie thefollowingpagesprovidedetailedinformationon list member position committee mem theremunerationearnedbyeachmemberofthe berships chairmanship remuneration member board director additional compensation remuneration committee memberschairs chf chf additional special compensation fb humer remuneration chairman board director b gehrig hoffmann p baschera ji bell p brabeckletmathe ljr de vink w frey da julius oeri w ruttenstorfer h teltschik compensation serve board roche subsidiary b weder di mauro exception member presidium vicechairmen board member receive chf year committee serve chf year committee chair g high total remuneration member board director remuneration serve vicechairman board lrochearengremuneration reportindd roche business report remuneration report remuneration member corporate executive committee base pay chf annual salary annual salary annual salary schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer p soriot total member corporate executive committee stocksettledstockappreciationrightsssar dollarsswissfrancsforherparticipation stockoptionsorrestrictedstockunitsrsusin atacourseonauditcommitteesinaneweraof horstteltschikreceivedhonorariaamountingto governanceatharvardbusinessschool eurosswissfrancsforservingon theboardsofseveralrochesubsidiariesingermany stock optionsstocksettle stock appreciation right beatricewederdimaurowasreimbursedus ssar bonus bonus bonus bonus special stock award block nonvoting equity security cash payment block value total cash payment cash payment chf number period year chf chf chf chf schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer p soriot total member corporate executive committee day value grant nonvoting equity security chf ne calculation value consideration reduction value block period reduce market value year year exclude contribution ahvivalv swiss social security programme provide retirement disability unemployment benefit day value grant nonvoting equity security chf ne calculation value consideration reduction value block period reduce market value year lrochearengremuneration reportindd forthemembersoftheboardofdirectors b bonus receivedremunerationtotallingswiss inthebonusforsomeofthemembersofthe franc corporateexecutivecommitteeisdividedintwopart forthreeortenyearsblockednonvotingequity noadditionalremunerationwaspaidtomembersof securitiesgrantedinand theboardofdirector cashpaymentdueforpaymentattheendof april remuneration member corporate executive committee thegeneralprovision withtheelementofblockednonvotingequity assigningauthorityfordecisionsoncorporateexecu securitiesthebonusreflectsanevenstrongerlink tivecommitteeremunerationtotheremuneration tothelongtermperformanceofthecompany committeeandtotheboardofdirectorsareoutline onpageofthisremunerationreportfor themembersofthecorporateexecutivecommittee remuneration member board director receivedremunerationtotallingswiss remuneration member corporate executive franc committee af h exclude ahvivalv c stocksettle stock appreciation right ssar ssar ssar ssar value chf value chf value chf schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer p soriot total member corporate executive committee stock optionsstocksettle stock appreciation right ssar blackschole value describe stock optionsstocksettle stock appreciation right ssar value accord annual report atthepresenttimethestocksettledstockappreci franciscofrommarchtodecember ationrightsgrantedinandmostof receivedallowancesandtaxequalisationtotalle whichcannowbeexercisedfollowingtheendof swissfranc thevestingperiodinfebruaryhavenovaluefor therecipient membersofthecorporateexecutive committeeadditionallyreceiveannualexpenseallow ancesofswissfrancstotallingswiss strike price table stock option ssar francswhilepascalsoriotwhowasbasedinsan lrochearengremuneration reportindd roche business report remuneration report performance share plan psp thesecuritiesmarketpricesanddividendyield themembersofthecorporateexecutivecommittee ieontotalshareholderreturntsrtoreducethe andothermembersofseniormanagementcurrently effectofshorttermmarketfluctuationssecurity someindividualsworldwideparticipateinthe pricesareaveragedoverthethreemonthsoctoberto performanceshareplanpsp decemberpriortothestartofaperformancecycle andoverthethreemonthsoctobertodecember inthepspmovedtooverlappingthreeyear attheendofthecycleifrochesecuritiesperform performancecycleswithanewcyclebeginningeach aswellasorbetterthanthoseofofthepeer yearintherewerethusthreecyclesinprogress setandinadditionrochestsrincreasesatleast psppspandpsp duringacycletheboardofdirectorscanelect thepspendedondecember toincreasethemaximumnesawardbyasmuch astwofoldintheeventthataninvestmentinroche undertheprovisionsofthisplananumberofnon securitiesunderperformstheaveragereturndelivere votingequitysecuritiesneshavebeenreservedfor bythepeercompaniesfewerornoneswillbe theparticipantsineachcyclethenumberofsecu award ritiesactuallyawardedwilldependonwhetherandto whatextentaninvestmentinrochesecuritiesshare inneswerereservedundertheplanformember andnesoutperformstheaveragereturnonan ofthecorporateexecutivecommitteeasshownin investmentinsecuritiesissuedbyapeersetofcom paratorcompaniescomparisonsarebasedon footnote performance share plan psp total estimate total estimate value value value psp award psp award psp award target number target number ne ne psp ne psp award psp value chf value chf value chf schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer p soriot total member corporate executive committee total estimate value psp originally target ne award psp estimate value calculate yearend price december chf non vote equity security ne base number ne originally target subject change number value ne awardable plan december december respectively spread relevant period time ie year board director vote actual allocation ne originally target december december respectively accord tsr achieve detailed calculation annual report lrochearengremuneration reportindd thetableonpagetheboardofdirectorswill nonvotingequitysecuritiesnesuptoanamount decideontheactuallevelofnesorcashequivalent equaltooftheirannualsalaryatadiscount awardsfor cycle nespurchasedunderthisplanaresubjecttoa close theandfinancialyears holdingperiodwhichisfouryearsinswitzerland respectivelytheaimofthepspistoprovidean incentivetoparticipantstoachievesteadyvalue f remuneration emolument loan growth gottliebkellerreceivedanonrecurringspecial payment swiss franc year attheendofthepspcyclebasedona serviceforthecompanyin pensionstotalle threemonthmovingaverageatconstantexchange swissfrancswerepaidtotwoformer rateswithdistributeddividendstotallingbil corporateexecutivecommitteemembersfour lionswissfrancsbillionswissfrancs membersofthecorporateexecutivecommittee billionswissfrancsbillion receivedatotalofusdollarsswiss swissfrancsthetsroftherochesecuritiesne francsforservingonthechugaiboard andsharesrankedcomparedwithitspeer setofcompaniesoperatinginthesameindustry g high total remuneration member thereforeaccordingtothetermsoftheplanthe board director participantsreceivednoneoftheoriginallytargete franzbhumerasthechairmanwasthemember nesseetableonpagefordetail oftheboardwiththehighesttotalremunerationfor seeremunerationofmembersoftheboard e indirect benefit ofdirectorspagetothechairmansremu employercontributionsmadeintosocialsecurity nerationconsistsofbasesalaryandbonusaward schemespensionplansandagroupwideemployee chairman board handover stockpurchaseplanrocheconnectinrespect executivefunctionasceoattheannualgeneral ofmembersofthecorporateexecutivecommitteeare meeting march receive showninthetableindirectbenefitsinbelow additionalssarsornesfromnewpspcyclesand rocheconnectisavoluntarystockpurchaseplan wasnolongerenrolledinanyrochestockoption offeringemployeestheopportunitytobuyroche planorssar indirect benefit payment pension fundsmgb ahvivalv roche connect tax consulting service chf chf chf chf schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer p soriot total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit ahvivalv swiss social security programme provide retirement disability unemployment benefit lrochearengremuneration reportindd roche business report remuneration report theboardofdirectorsintendstoreducethechair familieswhoarecloselyassociatedwiththembelong mansbasesalaryintomillionswissfranc toashareholdergroupwithpooledvotingright asofaprilhistotalremunerationinclude attheendofthisgroupheldshare bonusescontributionstopensionfundsandaddi ofissuedsharesdetailedinformationabout tionalcompensationexpenseallowancewilldepend thisgroupcanbefoundinthefinancereportnote ingontheachievementofobjectivesnotexceedthe totherochegroupconsolidatedfinancialstate maximumamountofmillionswissfrancs mentsrelatedpartiespageandinthenote tothefinancialstatementsofrocheholdingltd h high total remuneration member significantshareholderspageinadditiona corporate executive committee ofdecemberthemembersoftheboard severin schwan ceo member ofdirectorsandpersonscloselyassociatedwiththem corporateexecutivecommitteewiththehighesttotal andthemembersoftheexecutivecommitteeand remunerationforseeremunerationofmem personscloselyassociatedwiththemheldsharesand ber corporate executive committee af nesasshowninthetableonpage pagetopagenoadditionalremunerationwas pay current member corporate stock optionsstocksettle stock appreciation executive committee right ssar atdecemberfranzb humerbeingtheonlymemberoftheboardofdirec security holding directorsandrhoffmann torsholdingoptionsandasofjanuaryssar andandreasoeriandmembersofthefounder duetohisformerpositionasceoandthemember high total remuneration member board director chf chf salary cash bonus special stock award year block nonvoting equity security total performance share plan total award pension fundsmgb roche connect total value detailed calculation remuneration chairman ceo annual report bonus form year block nonvoting equity security nonvoting equity security nes day value grant nonvoting equity security chf ne calculation value include contribution ahvivalv consideration reduction value block period reduce market value year franz b humer psp psp originally target ne award psp award mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit include additional compensation committee member payment tax consulting service remuneration serve chugai board include employer contribution ahvivalv chf lrochearengremuneration reportindd high total remuneration member corporate executive committee chf chf salary cash bonus special stock award year block nonvoting equity security total ssar blackschole value grant minus performance share plan total pension fundsmgb roche connect total value detailed information annual report calculation remuneration member corporate executive committee b bonus blackschole value describe stock optionsstocksettle stock appreciation right ssar basic rule detailed calculation remuneration member corporate executive committee performance share plan footnote respectively mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit include annual expense allowance payment tax consulting service remuneration serve chugai board exclud e employer contribution ahvivalv payment ofthecorporateexecutivecommitteeheldoption forreasonsotherthanretirementwhileveste andstocksettledstockappreciationrightsssar optionsmustbeexercisedwithinalimitedperiodof firstintroducedonjanuaryasshowninthe timethefairvalueoftheoptionsiscalculatedat tablestockoptionsandssarsonpage thedateofissueusingtheblackscholesformula andasiftheoptionsweretradablewithan alloftheoptionsshowninthetablewereissuedby deductionfortheaveragetwoyearvestingperiod rocheasemployeestockoptionseachoptionentitle theholdertopurchaseonerochenonvotingequity thessarsshowninthetableonpagewere securityne introducedbyrocheonjanuaryinplace ofstockoptionsssarsentitleholderstobenefit underthetermsofthismultiyearoptionplanthestrike financiallyfromanyincreaseinthevalueofroche priceforoptionsshownwastheclosingpricefor nesbetweenthegrantdateandtheexercisedate rochenesonthelastdayoftradingpriortotheroche thestrikepriceforssarsunderthetermsofthis annualmediaconferencealloftheoptionsshown multiyearplanwastheclosingpriceforrochene arenontradableonethirdoftheoptionsaresubject onthefirstdayoftradingaftertherocheannual toavestingperiodofoneyearonethirdhavea mediaconferenceallssarsvestwithinthreeyear vestingperiodoftwoyearsandonethirdaveste ofthegrantdateieonethirdvestattheendof periodofthreeyearsunvestedoptionslapsewithout oneyearonethirdattheendoftwoyearsandone compensationifemploymentisterminatedvoluntarily thirdattheendofthreeyearsvestedssarsmust lrochearengremuneration reportindd roche business report remuneration report security holding december close relative share ne security holding number number numbertype number board director fb humer stock option ssar b gehrig hoffmann ubs longshort certificate link roche bearer sharesroche nonvoting equity securities valor isin ch otc option ubs ag roche nonvoting equity securities valor p baschera ji bell p brabeckletmathe ljr de vink american depository receipts adr rhhby isin w frey da julius nes oeri ubs longshort certificate link roche bearer sharesroche nonvoting equity securities valor isin ch w ruttenstorfer h teltschik b weder di mauro total nes corporate executive committee schwan ne stock option ssar ayyoubi stock option ssar wm burn stock option ssar e hunziker stock option ssar ga keller ne stock option ssar jkc knowle stock option ssar j schwiezer stock option ssar p soriot stock option ssar total ne share hold shareholder group pool voting right list sharesettle loan transaction august report swiss exchange lrochearengremuneration reportindd stock option ssar number stock option ssar hold current member corporate executive committee december ssar issue total corporate execu tive committee schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer p soriot total corporate executive commit tee member fb humer strike price chf market price ne december chf expiry date grant value option start ssar chf blackschole value minus ssar stock option franz b humer receive additional ssar beexercisedconvertedintoneswithinsevenyear strike price expiry date grant value ofthegrantdateandunexercisedssarslapse optionsandssarsareshowninthetableabove withoutcompensationthefairvalueoftheoption thenumbersofoptionsandssarsascalculate iscalculatedatthedateofissueusingtheblack atthetimeofissuehavebeenenteredasvaluesin scholesformulaandasiftheoptionsweretradable thetableremunerationofmembersofthecorporate withandeductionfortheaveragetwoyear executivecommitteecstocksettledstockappre vestingperiod ciationrightsssarsonpage lrochearengremuneration reportindd s sharpen weapon fight advanced breast cancer biotechnology infancy thirty year ago guessed day rise completely new class powerful target medicine monoclonal antibodie mab today mab successfully fight cancer treat rheumatoid arthritis take courage skilful management longterm commitment enable roche invest technology early stage skill dedication people vital transforming mabs medical business success story today third roche drug base biotechnology new approach join mab chemotherapy promise treatment cancer target few effect tdm novel antibodydrug conjugate combine antitumour strategy medicine direct bind monoclonal antibody highly express cancer protein lead target delivery potent chemotherapy agent selectively kill cancer cell minimise damage healthy tissue bildstreckeengsindd bildstreckeengsindd corporate responsibility lead healthcare company goal develop available product service address unmet medical need real value society aim provide tangible improvement patient health quality length life core contribution responsible sustainable manner respect need individual society environment possible committed finding retain talented people develop skill lrochearengcorporate responsibility partindd brief ourpursuitofscientificexcellenceenablesusto reportandonourwebsiteoureffortswererewarde addressunmetmedicalneedshelpingpatientslead inwhenrochewasnamedhealthcaresuper longerandbetterliveswepioneerdifferentiated sectorleaderinthedowjonessustainabilityindexe medicinesandtranslatethoseintobenefitsforpatient djsiforthefirsttimerochehasbeenincludedin throughoutreachprogrammesoureffortstounder thedjsiworldindexesforsixconsecutiveyearsand standdiseasebiologyandtodevelopmedicines isincludedintheftsegoodindex anddiagnosticsthatpreventdetectcorrectlydiag noseandeffectivelytreatdiseasehelpusachieve manage corporate responsibility ourgoalofpersonalisedhealthcarephcthroughout corporateresponsibilityisanintegralpartofourdaily ourvaluechain workratherthanthedutyofasingledepartment ourcorporatesustainabilitycommitteecscco asweseeitourgreatestresponsibilityistokeepup ordinatesourapproachwithrepresentativesfromall thisworkourmedicinestakebetweeneightand corefunctionsandbusinessesacrossthegroupthe twelveyearstobringtomarketsoafocusonlong cscreportstothecorporateexecutivecommittee termsuccessiscriticalwerunourbusinessina andtheboardscorporategovernanceandsustain sustainablemannerthatrespectsindividualssociety abilitycommitteethecscworkstoidentifyand andtheenvironmentandwefindretainanddevelop assesssignificantsocialethicalandenvironmental talentedpeopletomakethispossibleourvaluesof risksaswellasrelatedopportunitiesitalsodevelop integritycourageandpassionguidethedailybe andrevisescorporatepositionsandguidelineson haviouranddecisionsofallemployeesandweseek topicsofkeyinteresttoourstakeholdersinoctober evidenceofthesevaluesfromleadersinparticular thecschelditsfifthannualworkshop thesevaluesencapsulatetheworkingenvironment attendedbyaroundemployeesacrossthegroup andattitudesrequiredtocreateinnovativethinke maintopicsdiscussedwereaccesstohealthcare andthevalueofourproductsandservicesdure approach theyearthecscdevelopedfivenewpositionpaper wetrytobalanceeconomicprosperitysocialcommit ontopicsrelatedtocorporateresponsibility mentandenvironmentalprotectionineveryaspect ofourbusinesswebelievethiscreatesvalueforall objective ourstakeholdersandhelpsearntheirtrustand remainoneofthetophealthcarecompanie commitmentengagingwithrelevantgroupsensure inthedjsi ourapproachiseffectivewehaveidentifiedsix integratebestpracticesfromgenentech materialcorporateresponsibilityarea sustainabilityactivitie innovationcapacitie improveenergyefficiencygigajoulesper valueofrocheproductsandservice employeebybyfrom pricingandreimbursementcondition accesstorocheproductsandservice web relationshipwithstakeholder sustainability principle strategy management beinganattractiveandresponsibleemployer wwwrochecomprinciple stakeholder engagement wwwrochecomstakeholderdialogue wemonitortheeffectivenessofourapproachandour corporate sustainability committee charter progressintheseareasusingasetofkeyperfor wwwrochecomcsrcommittees manceindicatorskpisforwhichwenowhavetwo key performance indicator wwwrochecomsuskpipdf fullyearsofdatawhilethesekpisareforinternal safety health environment performance managementonlyweincludearangeofperformance wwwrochecomshefiguresandfact measuresthroughoutthissectionofourannual employee topline figure wwwrochecomemployee lrochearengcorporate responsibility partindd roche business report corporate responsibility responsible practice howwedothingsisasimportantaswhatwedo providinginstantreportsandinformationbasedon thetrustofthemanydiversegroupsweencounterin historicalinformationcustomerfeedbackandmarket thecourseofourworkdependsonuscarryingout analysistoaidourplanne eachandeveryaspectofourbusinessresponsibly asaninnovationdrivencompanywefocusonunder customersatisfactionisparticularlyimportantin standingthemechanismsunderlyingthedisease consumerbusinessespatientswithdiseasessucha andtranslatingthisintodevelopingproductsthat diabeteswhouseourproductsdailytendtogive improvepatientshealththisoftenmeansexploring regularfeedbackwhichispivotaltofutureproduct emergingtechnologiesastheycouldprovideim developmentwealsousedetailedmarketresearch portantmedicalbreakthroughsandformthebasisof andfocusgroupstodevelopproductsandservice ourproductpipelineinthelongtermatthesame thatsimplifydailydiabetesmanagement timewemustassessanyrisksorethicaldilemmas thatcuttingedgetechnologiesposewithgreat halfourdiagnosticsemployeesworkincustomer scrutinybeforeandwhileusingthem serviceandsupportwealsoencourageemployee withlittleornocontactwithcustomerstospend customer relationship timelearningabouttheirneedsforexampleroche ourcustomersrangefrompatientshealthcarepro diagnosticsinrotkreuzswitzerlandhasacustomer fessionalshospitalsandreferencelaboratoriesto orientationprogrammeduringwhichtechnical publicandprivatehealthcarepayersunderstanding specialistsspendninemonthsattendingworkshop andrespondingtotheirdifferentneedsandexpec visitinglaboratoriesandhospitalsandevaluate tationshelpstoimproveourcommercialeffectiveness whattheyhavelearnedbeforepresentingtheir variouscustomergroupsprovideinputinto findingstomanagementtheyworkedonproject productprofilesforexampletheeaseofuseof includinganonlinesurveytohelpimprovetheway medicationinstrumentspecification healthcareproviderscopewithmethicillinresistant clinicaldevelopmentplansforexampleby staphylococcus aureusamajorprobleminhospital designingandparticipatingintrial publicationoftrialresult pandemic preparedness regulatoryfile intheworldhealthorganizationwho developmentofhealthoutcomestudie declaredaglobalpandemicofhninfluenzainfor diseaseawarenessplansandproductinformation mationfromthewhoandtheuscenterfordis educationandawarenessprogramme easecontrolandpreventioncdcindicatedthat treatmentguideline tamifluwasoneofonlytwoapprovedantiviralswith activityagainstthenovelstraintheseeventstrig wealsoobtainfeedbackfromcustomergroups geredrochetoimplementitspandemicplanwhich throughourmedicalliaisonsandclinicalresearch hadbeenindevelopmentsincewithafocus associatesadvisoryboardsandeducationand onincreasingtamifluproductionanddistributionto awarenessprogrammesweareinvolvedin meetincreaseddemandandensurelowincome countrieshadaccesstothedrugourpoliciesforthe wecarryoutcomprehensivemarketresearchand prioritisationofdrugsupplywereinaccordancewith analysisoftenatadivisionalorlocalleveltohelpus prepare influenza pandemic role meetspecificmarketneedseachcountryorgani responsibility roche stakeholder sationisresponsibleformanagingitsrelationship publishedinmay withitscustomersandsharingrelevantinformation withinthegroupwehavearangeofinitiativesto tamiflu stockpile wehaveworkedwiththewho enablethissuchasuniteacompanywidedatabase andgovernmentstobuildstockpilesoftamifluand lrochearengcorporate responsibility partindd helpprepareforaflupandemicinwedo ahntestitallowsrapidandaccurateidentification natedthreemilliontreatmentcoursesforthewhos ofpatientsinfectedwiththevirussoappropriate rapidresponsestockpilewestoredthestockpile patientmanagementcanstartasearlyaspossible untilwhenthewhodistributedittoof theworldsneediestcountriesinwedonate emergingdataunderscoretheimportantrolethedrug andshippedanadditionaltwomilliontreatment playedinreducingtheimpactofthismostrecent coursesforthewhosregionalstockpilewhichha flupandemicforexamplearecentstudybyjainetal alsobeendistributedtocountriesinneed fromtheuscentrefordiseasecontrolpublishe inthenewenglandjournalofmedicinereportedon inmayweagreedtodonateafurtherfivemil theclinicaloutcomeofpatientshospitalisedwith lioncoursestoreplenishbothstockpileswealso hninfluenzainthestudyshowedthatanti agreedtoestablishastockpileoftreatment viraldrugsweretheonlytreatmentthatmadeastatis coursesofpediatriccapsuleswhichweprovide ticallysignificantdifferenceinhelpingpatientsto alongwithinstructionsformixingthecontentswith recoverandthatoseltamivirwastheantiviraltaken foodforchildrenunabletoswallowthemwhole inaroundofcase thisbringsthetotalnumberoftreatmentcourse donatedtoaroundmillion public policy theprivatesectorhasacrucialandlegitimaterole sincewehavebeenprovidinggovernment toplayindevelopingpublicpolicyweshareour tamifluatsubstantiallyreducedpricestoassisttheir expertisewithpolicymakerstohelpdevelopeffective pandemicpreparednesshoweverwerecognise lawsregulationsandpoliciesrelatingtopublic thatmanydevelopingcountrieswereunabletocreate healthaswellasmoregeneralareasaffectingour anadequatestockpileevenatreducedpricesinjuly businesssuchastaxpolicyourgoodpractice welaunchedthetamiflureservesprogramme guidelinesforworkingwithgovernmentofficialsguide toincreaseaccessinthesecountriesweproduce ouremployeesondoingsoinanappropriateand andstoretamifluforspecifieddevelopingcountriesat professionalmann asignificantlyreducedpriceandspreadthecost overanumberofyearswewillshipthestockpileif muchofourpublicpolicyworktakesplacethrough thewhoannouncesaflupandemicorwhenagov ourmembershipofindustrybodiessuchasthe ernmentrequestsittodealwithanationaloutbreak europeanfederationofpharmaceuticalindustriesand associationsefpiatheeuropeandiagnostic tofurtherincreaseavailabilitywehavelicense manufacturersassociationedmaandtheinterna companiesinchinaandindiatomanufacturegeneric tionalfederationofpharmaceuticalmanufacturers oseltamivirwehavealsosupportedtheeffortsofa andassociationsifpmaaswellastheirnational southafricanmanufacturerbygivingthemaccess memberswealsomeetdirectlywithpolicymaker totheknowledgeandskillsneededtoproduce suchasgovernmentspublichealthorganisation oseltamivirtheycannowproducethedrugfreelyas thinktanksandacademic wedonotenforcepatentsinsubsaharanafrica ourmajorpublicpolicyworkininclude rochediagnosticsproducedapolymerasechain workingwiththeworldbusinesscouncilfor reactionpcrbasedtestforthehnstrainofthe sustainabledevelopmenteuropeanroundtable fluvirususingourlightcyclersystemwithinweek ofindustrialistsandprinceofwalescorporate ofthevirusbeingidentifiedinnovemberthe leadersgrouponclimatechangeonpolicy usfoodanddrugadministrationgrantedemergency statementsaheadofthecopenhagenclimate useauthorisationofthisrealtimereadyinfluenza conferenceindecember lrochearengcorporate responsibility partindd roche business report corporate responsibility showingmembersoftheeuropeanparliament andareobtainedfromlivingsystemsusingadvance aroundouranimalfacilityinbaselduringthe processesthatareverydifficulttoreproducemore developmentoftheanimalresearchdirectiveto testingisneededtodemonstratethesimilaritysafety demonstrateourwelfarestandardsandthe andefficacyoffollowonproductscomparedwiththe importanceofanimalresearchinhealthcare original coorganisingadinnerdebateonanimal researchintheeuropeanparliamentwiththe webelievebiosimilarsshouldbesubjecttowell europeanplatformforpatientorganisation definedandtransparentregulationsthatcoverdevel scienceandindustryepposi opmentapprovalandpostauthorisationprocedure explainingourpositiononproposedlegislation basedonthosefortheoriginalproduct coveringpharmacovigilanceinformationto patientsandcounterfeitmedicinestomembers inweworkedwithregulatoryauthoritiesand oftheeuropeanparliament industrybodiesparticularlytheinternationalfedera tionofpharmaceuticalmanufacturersandassocia combat counterfeit counterfeitpharmaceuti tionstoensurepolicymakersfullyunderstandbiosim calanddiagnosticproductsareillegalandaserious ilarsciencethisworkwillsupportthecreationof globalpublichealthproblemtheyendangerpatient appropriatepoliciesregardingfuturebiosimilarmono undermineconfidenceinhealthcaresystemsand clonalantibodiesandthenamingofbiopharmaceuti companiesinfringeintellectualpropertyrightsand calsrochehasalsomadescientificandmedical wastevaluablehealthcarebudget presentationsonbiosimilarstoregulatorsscientist andotherkeyaudiencesandcontributedtoscientific wecontinuouslymonitorandimproveproductsecu journal rityandusetechnologytoquicklyidentifycounterfeits wetakepartinnationalandinternationalindustry political contribution rochedoesnotfinancially andgovernmentaleffortstostrengthenthelawim supportindividualpoliticiansanywhereusemploy proveenforcementtrainlocalofficialsandeducate eescanmakepersonalcontributionsthroughthe thepublic hoffmannlarochegoodgovernmentcommittee ggcavoluntarypoliticalactioncommitteeorpar inweupdatedourpositiononcounterfeite ticipateintherocheactionprogramme whichisavailableonourwebsitewearetakingpart inanefpiapilotprojectinswedenofatracke integrity compliance systemwhichtracesdrugsbacktotheirsource therochegroupcodeofconductguidesour improvingpatientsafetyweapplyauniquebarcode employeesbusinessbehaviour toeachpackofmedicineproducedwhichpharma cistsscanwhendispensingthemedicinetocheckit indecemberwelaunchedtherochegroup isauthenticwecontinuetoprovideinputthrough speakuptelephonelineandwebservicefor efpiaintotheproposedeulegislationoncounter employeestoraiseconcernsaboutcompliancewith feite thecodeofconductanonymouslyifpreferred athirdpartyorganisationoperatesspeakupand generic biosimilar product thepatentperi pricewaterhousecoopershasprovidedassurancethat odsforsomeinnovativebiologicalproductssuchas thesystemprotectsemployeesidentitie proteinsandantibodiesareexpiringandproduct claimingtobesimilarareappearingonthemarket inbusinessethicsincidentswerereporte whileitisrelativelyeasytocopychemicaldrugsbio tothechiefcomplianceofficerweinvestigatedthem logicalproductshavecomplexmolecularstructure allandtookcorrectiveactionswherenecessarywith lrochearengcorporate responsibility partindd employmentcontractsbeingterminatedasaresult inweintroducedasustainabilityriskmanage ofunethicalbehaviour mentprocessandtargetsforourmarketingagencie wealsointroducedanewstandardoperatingpro welaunchedseveralinitiativestostimulatetheshar cedureandrelatedtrainingtostrengthencompliance ingofbestpracticesamongrocheslocal withmarketingcodesinourpharmaceuticaland complianceofficersincludingacomplianceofficer diagnosticsbusinesse networkaseriesofregionalcompliancemeeting andadedicatedintranetsitethecomplianceofficer wedonotselloverthecountermedicinesandso helplinemanagerstocontrolriskslocallyandmeet donotadvertisedirectlytoconsumersinthemajority therequirementsofourgroupcodeofconduct ofourmarketsintheuswhereitislegaltoadver tiseprescriptionmedicineswehavedetailedpolicie wealsoupdatedourperformancemanagement inplacetoensurethisisdonelegallyandethically systemtoensureweassessemployeesnotjuston wesendalltelevisionadvertisingcampaignstothe whethertheyachievetheirobjectivesbutalsoon foodanddrugadministrationforapprovalbefore howtheyachievethem broadcast finallywesetupanexportcompliancecouncilto wedecidedtoendourmembershipofthepharma ensureourmanufacturinganddistributionsitesmeet ceuticalresearchandmanufacturersassociation thecomplexlegalrequirementsforsellingand phrmaintheunitedstatesandinsteadjointhe exportingourproduct biotechnologyindustryorganizationbioofwhich genentechwasalreadyamember risk crisis management ourriskmanagementcharterdefinesourrisk sustainable supply chain managementapproachandresponsibilitiesandis rochespentaroundbillionswissfrancsonprod availableonourwebsitealongwithafulllistof uctsandservicesintheserangefromraw riskstoourbusinessweincludesignificantsocial materialsandactivepharmaceuticalingredientsto environmentalandethicalrisksidentifiedinthe equipmentlaboratoryandofficesuppliesandser groupriskmanagementprocess viceslikeconsultancytravelandmarketingwemust ensurethesesuppliersmeetthenecessarysocialand responsible marketing environmentalstandardstosecurereliablesupplie therearestrictregulationsandindustryguideline andenablethesustainablegrowthofourcompany onthesaleandmarketingofmedicinesanddiagnos ticstomakesuretheyareprescribedadministere ourapproachisto andusedcorrectlyandthatpatientsunderstand raiseawarenesswithoursupplyofficer thebenefitsandrisksoftakingthem raiseawarenesswithsupplier helpsuppliersimprovetheirstandard healthcareprofessionalsneedtobeabletoselect developjointinitiativestoincreasetheirperfor thebesttreatmentoptionfortheirpatientswe mance providescientificandclinicallyrelevantinformation thatenablesthemtoprescribeoruseourproductsin weendorsethepharmaceuticalindustryprinciple circumstanceswhichdeliverthegreatestmedical psciprincipleswhichrequiresupplierstoimple benefittothepatientalistoftheexternalguideline mentresponsiblesupplychainmanagementinthe andcodesofpracticewefollowwhenmarkete areasofethicssafetyhealthandenvironmentshe ourproductsisavailableonourwebsite socialresponsibilitymanagementsystemsinnovation andeconomicsustainabilityandarecommittedto lrochearengcorporate responsibility partindd roche business report corporate responsibility integratingtheseprinciplesintoourbusinessin clinicalresearchsuchaswhatthedifferenttrial wedevelopedanewsuppliercodeofconductwhich phasesareandwhattheendofatrialmeansforthe includesthepsciprinciplesandnowrequireallour patientstakingpart supplierstosignourcodeofconduct aspartofourclinicaltrialsprogrammewestore ourpharmaceuticalsanddiagnosticsdivisionsaudit biologicalmaterialsuchastissueorgansbloodand businesscriticalsuppliersandassessnewsupplier otherbodilyfluidsinhumanspecimenrepositorie toidentifyandcorrectproblemsusingexternaland orbiobankstheseareinvaluableforlearningmore internalauditorsweshareourexpertiseandprovide aboutdiseaseandexploringpossibletreatment trainingtohelpsuppliersimplementanyrequire theyalsocontainsensitiveinformationaboutthe improvementsinternalauditorscarryoutfollowup personwhoprovidedthesamplewearededicatedto inspectionstoensuresuppliershavemadethe protectingdonorsprivacyandensuringtheyarefully necessarychangesinweauditedsocialand informedabouthowtheirsampleanddatawillbe safetyhealthandenvironmentalstandardsat usedbeforetheyagreetotakepart existingsuppliersandcarriedoutfollowupaudit atfivewerejectedorceasedtradingwithonesup wehaveaclearprocedureforresolvingethical plierthatwecouldnothelptoimprovethemain dilemmasemployeesencounterintheirworkifthey areaforimprovementourauditsflaggedupwa cannotresolvetheissuewithintheirteamemployee industrialhygiene cancontactourglobalethicsliaisonofficewhich willconsultpeersandinternalexpertstofinda weareintheprocessofextendingoursustainable solutionaninternalcommitteehandlesanyremaine procurementactivitiestosuppliersofnonproduction concernsandourindependentclinicalresearch materialsandservice ethicsadvisorygroupcreagprovidescounselon thetoughestchallengeswealsoprovideregular wehaveestablishedafinancialriskmanagement onlineethicstrainingforemployeesintheglobal processinprocurementtoidentifysuppliersatriskof ethicsliaisonofficereceivedqueriesallwere bankruptcyandtomitigatethoseriskswecontinue resolvedwithoutescalation toapplyoursupplychainriskmanagementprocess toallsuppliersofkeyrawmaterialsdrugsubstance thecreagmeetsannuallytoreviewconcernsraise anddrugproductswealsoworkedwithsupplier withtheglobalethicsliaisonofficeanddiscuss ofmaterialsforkeyrochedrugproductstoensure otherrelevanttopicsinweupdatedthecreag theyhavebusinesscontinuityplansforpandemicrisk onrecentquerieshandledbytheglobalethicsliai sonofficeaswellasonthestatusoftheemployee research practice ethicseducationprogrammesthecreagalso ethicalconcernssometimesariseaswepushscientific reviewedthelatestrevisionstothedeclarationof boundariesandexplorenewtechnologiestodevelop helsinkiastatementofethicalprinciplesformedical innovativenewtherapiesanddiagnosticswemust researchinvolvinghumansubjectsreleasedbythe exploreandcarefullymanagetheseconcernsto worldmedicalassociation ensuretheopportunitiespresentedarenotlost anotherindependentpanelthescienceandethics ethic r ourglobalpositiononclinical advisorygroupseagadvisesandguidesus researchcommitsustohighethicalstandardsand ongeneticsgenomicsandproteomicsinthe clarifiesourpositiononspecificareasofconcern seagadvisedonissuesincludingtheuseand weupdatedthispositionintoincludestraight storageofhumanbiologicalmaterialsinspecific forwardanswerstofrequentlyaskedquestionsabout researchprojectsweexpandedtheseagsadvisory lrochearengcorporate responsibility partindd breakdown animal research inthescientificcategoryfirstplacewenttoateam whichfoundanewinvitrotestfordetectingtoxic compoundsbeforetestingnewdrugsonanimalsour mouse diagnosticsbusinessdevelopedthetestwhichisnow rat availableforpharmaceuticalpreclinicalresearchthe winningprojectinthelabcareandanimalmanage guinea pig mentcategorygraduallyrehabilitatedmonkeysthat hamster hadbeenhousedindividuallybackintolargergroup gerbil increasingtheirsocialinteractionandimprovingtheir fish wellbeingwewillimplementtheseandotherproject frog intoouroperationswhereverpossibleandrunthe dog rsawardagainin rabbit primate inwecreatedanewjointscienceandtechnol ogylaboratoryinbaselbetweenthepharmaceutical anddiagnosticsdivisionsaimedatinvestigate organtoxicitiesofdrugsusinganinnovativecellana functionswiththeiragreementtocoverallinnovative lysersystemxcelligenceresearcherscant technologiessuchasnanotechnologyandstemcell whetherpharmacologicallyactivesubstancesare research likelytoprovetoxictoorganssuchastheheartand liverbycontinuousrealtimeviewingofthecell animal welfare werecogniseandtakeseriously reactiontothemoleculethiscanbeperformedin publicconcernaboutanimalresearchhoweverwe theearlypreclinicalstageofresearchmakingmany couldnotdeveloplifesavingmedicinessuchascan animalstudiesredundant cerdrugswithoutitwhileweworkhardtofindand usealternativemethodsthelimitationsofthose wealsoestablishedaninternalanimalwelfareethics methodsmeanwestillneedtotestnewdrugsand committeetoexamineallstudiesinnonhuman technologiesonanimalsforsafetyandlegalreason primatesbeforeregulatoryapprovalandtoadvise employeesworkingwithanimalsthiscommittee inweusedatotalofanimalsinour willbecomefullyoperationalin researchofwhicharoundweremiceandrat innovation new technologies evolvingtech wearecommittedtothersconceptofreplacing nologiessuchasnanotechnologystemcellresearch animaltestswherepossiblereducingthenumberof andsystemsbiologyhavemanypotentialbenefitsin animalsweuseandrefiningexistingscientificprac pharmaceuticalsanddiagnosticstheseadvantage ticesanimalwelfareandhusbandryallemployee mustbecarefullybalancedwiththeethicaldilemmas andcontractorswhoperformanimaltestingforus andpotentialrisksposedandweassessthesewith mustcomplywithapplicablelawsandmeetorexceed greatscrutinybeforeenteringnewfield industrystandards nanotechnologyisthemanipulationofmaterialson wecontinuedourrsawardforinnovationand ascaletimessmallerthanthediameterofa continualimprovementinanimalwelfarewithin humanhairithaspotentialinmanyareasparticularly rocheinfifteenteamsofscientistsandanimal drugdeliveryregenerativemedicineandsmallscale carespecialistsfromourresearchsitesenteredfor portablediagnosticshowevermanyquestion awardsintwocategorie remainabouttheeffectsnanotechnologymayhaveon lrochearengcorporate responsibility partindd roche business report corporate responsibility peopleandtheenvironmenttherisksandbenefit lobbythroughefpiaontheproposedeu havetobecarefullyevaluatedbeforenanotechnology legislationoncounterfeitmedicinalproduct isusedinmedicalproductswebelievethatexiste establisharsdatabaseforsharingbestpractice safetytestsandregulationsprovideanappropriate inanimaltestingwithinroche frameworkfordoingso launchrochesethicscommitteeonanimal welfare stemcellsandtheirapplicationsofferanenormous commenceauditofsuppliersinindirectspend potentialforthetreatmentandreliefofchronic painandevenforthecureofdiseasesextendingand web enhancingthequalityoflifehowevertheresearch responsible marketing risk management compliance alsoraisesethicalquestionsbecausesomepeople wwwrochecombusinessintegrityandresponsiblemarkete wwwrochecomriskmanagementandcompliance believeembryonicstemcellsarehumanswitha pandemic influenza tamiflu information righttolifeandshouldnotbeusedinresearchor wwwrochecomrocheinfluenza treatment wwwpandemictoolkitcom pharmaceutical industry principle responsible supply chain management rocheiskeenlyawareofthetremendouspotentialof httppharmaceuticalsupplychainorg thisresourceforbasicscienceandfuturehealth patent counterfeit biosimilar careapplicationswehavethereforeenteredinto wwwrochecommedicalvaluepatentsandpricing wwwrochecompatent researchcollaborationsforexampleweworkwith innovation new product technology stemcellssafermedicinesscsmintheuk wwwrochecomcsrresearchanddevelopment andwithcellulardynamicsinternationalincinthe wwwrochecominnovationandtechnologie usrochebeganstemcellresearchanditsrelated position paper wwwrochecompoliciesguidelinesandposition applicationasadiscoverytoolandweplantobegin researchtousestemcellsasapotentialtherapeutic modalityrochealsoplanstodevelopexpertise tobecometechnicallyenabledinthisresearcharea andtoconductresearchonhumanembryonicstem cellsandtheiruseindrugdiscovery inweheldastemcellresearchworkshopin partnershipwithcambridgeuniversityintheuk attendeesincludedrochespecialistsand academicexpertstheydiscussedstemcellscience andpossibleapplicationsaswellasstepsforindus trytotaketomaximisethemedicalandbusiness opportunitiespresente objective implementtherochegroupspeakupline launchtherevisedrochegroupcodeofconduct andupdatethebehaviourinbusinesselearne programme rolloutnewsuppliercodeofconductandinclude compliancewiththisinourexistingsupplieraudit programme lrochearengcorporate responsibility partindd patient patientsinallaspectsofhealthcarebenefitfromour themajorityofhealthcarepayersrecognisethemedical productsandservicesourdifferentiatedmedicine andeconomicvalueofourproductsforexample anddiagnosticscomefromdiverseapproachesto whilecancerdrugssuchasherceptinandxeloda researchanddevelopmentweconstantlypursue mayseemcostlynotonlydotheyextendthelivesof scientificexcellencewhichhelpsustailorourprod patientswithterminalillnessandpreventdisease uctsandservicesinawaythatensurespersonalised recurrenceinpatientswithearlierstagecancer healthcarethismeanspatientscanleadlonger theycanalsoeasepressureonhealthcarebudget andbetterlivesbecausetheyreceivetreatmentsthat byreducingorpreventinghospitalvisitssurgeryand moreeffectivelypreventandcurediseasealleviate theneedforpalliativecareinmanycasestheyhelp symptomsandhastenrecovery patientsreturntoworkmorequickly wecanamplifythiscontributiontosocietyby inwepublishedanewpositiononassessing helpingtoimproveaccesstoourproduct thevalueofourproductsandserviceswhichcontain ensuringtheyprovidevalueformoney aseriesofguidingprinciplesforcarryingoutsuch providingfactualinformationonourproduct assessmentsweemployexperiencedhealthecono listeningandrespondingtocustomersview mistswhoworkwithhealthauthoritiestounderstand andproviderobustevidenceregardingtheeconomic value medicine diagnostic andhealthbenefitsofourproductsandservice differentpeopleexperiencediseaseandrespond withintherelevantregionalandlocalhealthcare totreatmentindifferentwaysourapproachof system personalisedhealthcarephctakesthisintoaccount andfitstreatmenttodifferentgroupsofpatient wealsoengagewithhealthcarepayersthroughout weuseourdiagnosticexpertisetodeepenourunder aproductslifecycleweprovideguidanceonassess standingofdiseasehowtreatmentsworkandhow ingthevalueofourproductsandserviceshealth differentpatientsrespondthishelpsusdevelop technologyassessmenthtapriortothemdecid bettersaferdrugsandidentifythepatientswhowill ingreimbursementandfundingcondition benefitmostimprovingclinicaloutcomesand increasingcosteffectivenessinwepublishe global access healthcare anewpositiononpersonalisedhealthcareto patientscanaccessourproductsthroughdoctor describeourapproachinmoredetail hospitalslaboratoriesandpharmaciesinroughly countrieswhilewesellthemajorityofourprod healthcarepayershavetomakedifficultdecisions uctsindevelopedcountrieswithadvancedhealth aboutgrantingaccesstoorprovidingreimbursement caresystemsaroundathirdoftheworldspopulation forhealthcareproductsandservicesbasedon lacksadequateaccesstohealthcaretheworld costeffectivenessandbudgetconstraintsaswellas healthorganizationwholistsmanyofourproduct medicalneedandclinicalimpactthesedecision asessentialmedicine haveaprofoundeffectonpatientsandtheirfamilie andcaninfluencewhereresearchbasedcompanie ourindustryhasanimportantroletoplayinpart likerochefocustheirfutureinvestmentobjective oftheworldwherehealthcarestandardsandaware consistentandopenprocessesareessential nessofthecausespreventionandtreatmentof forassessingthetotalvalueofmedicalproduct diseasearelowerbuttherearemanyothersystemic toindividualpatientsandtosocietyasawhole problemscontributingtohealthinequalitiesand throughouttheirlifecyclesothatthedecisionsmade wecannottacklethesealoneweworkwithgovern arefair mentsnongovernmentalorganisationsngo patientgroupsandhealthcareproviderstotackle lrochearengcorporate responsibility partindd roche business report corporate responsibility healthinequalitiesandincreaseaccesstoour servicetospeedupthedeliveryofhivtestresultsin productswetailorourapproachindifferentregion remoteareas tocaterfortheirspecificneed cancerkillsmorepeopleindevelopingcountrieseach access need theworldsleast yearthanaidsmalariaandtuberculosiscombine developedcountriesldcsarehardesthitbydis morethanhalfofallcancercasesareinthedevelop easeandhavethepooresthealthcaresystemstodeal ingworldbutonlyaboutofglobalcancer withthisburdentherearetoofewhospitalslabora resourcesarespentthereinternationalhealthcare toriesandhealthcareprofessionalstomeetdemand programmesfocusoninfectiousdiseasesandthere weaimtoincreaseaccesstohealthcareinpoor isverylittleoncologyinvestmentinfrastructureor countriesinsustainablewaysthatinclude expertiseasaleadingproviderofcancertherapie fairpatentandpricingpolicie wehaveanimportantroletoplayintacklingthis rdintodiseaseswithunmetmedicalneed badlyneglectedproblem partnershipswithgovernmentsngosandother educationtrainingandknowledgetransfer inweevaluatednewpartnershipstoimprove trainingincancercareforhealthcareworkersinsub ourapproachistojointlydevelopaccessprogrammes saharanafricawewillfocusonsharingourexpertise thatraiseawarenesseducateandtrainandassist ratherthansimplycashordrugdonationsaswe indevelopinghealthcareinfrastructurethiscollabo believethatbuildinglocalcapabilitieswillmakeabig rativeapproachensuresneedsaremetwhilefuture gerdifferenceinthelongtermtrainingwilltake businessopportunitiesforbothsidesareenhance placelocallytoencouragehealthcareprofessional throughtheincreasedcapabilityofinstitutionsand tostayintheirhomecountryratherthanleavingfor organisationsindevelopingcountrie opportunitiesabroad theillustrationshowsthecircumstancesunderwhich wealsojoinedthechangingdiabetesinchildren wedonotfileorenforceanypatentsitalsoillustrate programmeinthisisapublicprivatepartn ournoprofitpricingpolicyinaction shipbetweennovonordisktheworlddiabete foundationandgovernmentsinafricancountrie inwecompletedourtechnologytransferini theprojectaimstomakelifebetterforthegrowe tiativettithroughwhichwesharedtheknowledge numberofdiabetespatientsinafricawherethe requiredtoproduceourhivtreatmentsaquinavir standardofcareisoftenpoortheobjectiveistopro withlocalmanufacturersfreeofchargeweworke ducecareguidelineseducatehealthcareworkersand withallinterestedmanufacturersandreache ensureallchildrenenteringtheprogrammeareregis agreementwithcompaniesintheldcswhichare teredandmonitoredsotheirconditioncanbecon nowfreetoproducesaquinavirorusethisknow trolledthefirstphasewilltargetcameroonthe ledgetoproduceotherproductswealsoheldthree democraticrepublicofcongoguineaconakry africangoodmanufacturingpracticegmptrain tanzaniaanduganda ingseminarstoimprovelocallyproducedessential medicine inwegavetheinstituteforoneworldhealth accesstoourchemicalcompoundlibrarysoitcould wealsocontinuedourpartnershipwiththeclinton searchfornewmedicinestotreatchildhooddiarrhea foundationshivaidsinitiativechaitogetherwe oneworldhealthcompletedthefirstscreeningin haveestablishedandtrainedsevenlabsforhivt andidentifiedcompoundstoinvestigateas ingdevelopedanovelsolutionfordiagnosingand possiblenewtreatment monitoringhivininfantsanddevisedatextmessage lrochearengcorporate responsibility partindd people live hiv cover profit price antiretroviral medicine global access healthcare pricing patent nopatentsfiledorenforcedonanymedicine leastdevelope country twoantiretroviralhivmedicinessoldatnoprofitcoveringofhivpatient valcytesoldatreducedpricestongostreatingaidsrelatedcytomegalovirus pricing patent nopatentsfiledorenforcedonantiretroviralhivmedicines subsaharan african country twoantiretroviralhivmedicinessoldatnoprofit valcytesoldatreducedpricestongostreatingaidsrelatedcytomegalovirus price low low twoantiretroviralhivmedicinessoldatreducedprofit middleincome economy plan pandemic influenza tamifludonatedtoworldhealthorganizationstockpilesforcountriesmostinnee tamiflusoldatreducedpricestodevelopingcountrie tamiflureservesprogrammecreatesstockpilesfordevelopingcountrie tamiflusublicensingagreementsinchinaandindiaandtechnologytransfer agreementinsouthafrica access programme rochepatientassistanceprogramandgenentechaccesssolutionsprovideadvice wealthy nation andfinancialsupportforuninsuredorunderinsuredpatient overpatientsbenefittedfromthesepatientassistanceprogrammesin tackle hivaid aidstechnologytransferagreementsinbangladeshethiopiakenyasouthafrica develop world tanzaniaandzimbabwe employeesecondmentsinethiopianigerswazilandandtogo unicefeuropeancoalitionofpositivepeopleaidsorphanprogrammesinmalawi amplicaresupplieshivviralloadtestsinsubsaharanafricasouthamericaand theleastdevelopedcountrie clintonfoundationhivaidsinitiativechaiinsubsaharanafrica broad healthcare partnership phelophepahealthcaretraininruralsouthafrica develop world newoncologysustainabilityinitiativeinsubsaharanafricain changingdiabetesinchildrenwithnovonordiskandtheworlddiabetesfoundation incameroonthedemocraticrepublicofcongoguineaconakrytanzaniaanduganda instituteforoneworldhealthoninfectiousdisease googleorgoninfectiousdiseasesinkenya lrochearengcorporate responsibility partindd roche business report corporate responsibility injulyweteamedupwithgoogleorgonanini access develop world weworkclosely tiativetohelppredictandpreventemerginginfectious withpayersinallcountriestodemonstratethemedi diseasesineastafricarochedonatedagenome calandeconomicvalueofourproductsandwe sequencingsystemtobeinstalledintheinternational establishpricesthatenableaccesshowevermany livestockresearchinstitutelaboratoryinnairobi peopleindevelopedcountriescannotaffordtreat kenyatheinitiativewillbeginbyinvestigatingrift mentortheinsurancetopayforitintheuswhere valleyfeveradiseasespreadbymosquitoeswhich asyetthereisnouniversalhealthcaresystemwe ispotentiallylethaltopeopleandlivestock providefreedrugstothoseinneedthroughboththe rochepatientassistanceprogrampapandthe weproducedourfirstaccesstomedicinesanddiag genentechaccesstocarefoundationgatcfin nosticsreportinthiscontainsmoredetailsof patientsbenefitedfromthepapand allourpoliciesandprogrammestoincreaseaccessto patientsreceivedfreetreatmentthrough ourproductsandisavailableonourwebsite gatcfwealsosupportindustryeffortstoraise awarenessofassistanceprogramsviathepartnership access emerge market healthcareinmiddle forprescriptionassistance incomecountriesisimprovingandpresentsasub stantialopportunityforrochehowevereachcoun infollowingthemergerofrocheandgenen tryshealthcaresystemisatadifferentstageof techgatcfwillassumeresponsibilityfortheroche developmentandhasitsownspecificneedswe pappatientstocreateoneofthefivelargestcharita workinpartnershipwithgovernmentsinthesecoun blefoundationsintheus triestohelpestablishprocessesandclinicaltrialpro grammesandimproveeducation gatcfispartofgenentechsbroaderprogramme tohelppatientsgainaccesstoprescribedtherapie ourdedicatedmedicalaffairsgroupdevelop thegenentechaccesssolutionsdepartmentcom specificprogrammesforindividualemergingmarket prisesnearlyemployeeswhohelppatientsnavi wheremanypatientscannotaffordthelongterm gatethecomplexusreimbursementlandscape treatmentnecessaryfordiseasessuchascancer hepatitiscandrheumatoidarthritisinchinafor forinsuredpatientsgenentechaccesssolution exampleweoffercostsharingprogrammesforour clarifiesbenefitscoverageandreimbursementre oncologydrugstoensureaccesstothepatientswho quirementshelpingfindwaystoassistincovere willbenefitmostinsouthkoreaourreducedprice patientexpenseswherepossibleuninsuredpatient forcancerdrugscovertheentirepopulationwhilein orpatientswhoqualifyforassistancecanobtainfree egyptwhichhasoneofthehighestratesofhepatitis medicinefromgatcf cinfectionintheworldweprovidepegasysata speciallowpriceforpublicsectorpatients intheserviceadvisedpeopleaboutcov erageandreimbursementissuesandgatcfprovide wealsosupplyourproductstoprivatepayersin patientswithfreetreatmentworthatotalof emergingmarketsandworkwithinsuranceand millionusdollar reinsurancecompaniesinchinaandrussiato expandprivateinsurancecoverageandincrease injapanchugaiestablishedtheacademyforad accesstoourmedicineswecontinuetosupply vancedoncologychaaointohelpbre twohivmedicinesatreducedpricesinthelow standardsofcancerresearchandtreatmentuptothe andlowermiddleincomecountriesdefinedbythe samestandardsasthoseineuropeandnorthamerica worldbank lrochearengcorporate responsibility partindd impact access programme patient facility benefit clinical trial exclude genentech hivinfecte patient live country eligible number clinical trial noprofit medicine number healthcare centre hivinfecte patient involve living country eligible number patient phase reducedprice medicine iiv clinical trial patient benefit usa patient assistance programme presentbothresearchandclinicalfindingsatmedical andscientificmeetingsandengagewithkeyleader clinical trial ineachfield clinicaltrialsareessentialtodemonstratethesafety andefficacyofnewdrugstheyalsoprovideeduca wecollecttheinformationgainedthroughclinical tionalfinancialandmedicalsupportforparticipating trialsandpostmarketingsurveillanceandusethisfor hospitalsandaccesstothelatesttreatmentsfor acontinuousassessmentofthebenefitsandrisk cancerarthritisandotherdiseasespatientstake ofaproductindevelopmentoranestablishedmedi partintrialsreceivefreeaccesstothemostadvance cinewealsouseittobetterplannewclinicaldevel therapiesduringthetrialandwhentherearenovalid opmentprogrammesweprovidethisinformationto therapeuticalternativesthiscontinuesuntilthedrug regulatoryauthoritiesasrequire isavailableforsaleoronprescriptionwedonot performclinicaltrialsincountrieswherewedonot weapplystrictdataprotectionprinciplestoall plantomarketthedrug personalmedicaldatacollectedduringclinicaltrial inlinewithourdirectiveontheprotectionofpersonal peopleseekingnewclinicaltrialstotakepartinor datatheseprinciplesapplyequallytodataabout wishingtolearnfromtheresultsofcompletedtrial ourcustomerssuppliersandemployee canaccessthisinformationatwwwrochetrialscom patient safety asofdecemberthesitecontaineddetail allmedicinesmaycauseadverseeffectssideeffect ofpharmaceuticalprotocolsdiagnosticproto insomepatientsourpriorityistomakesuretheben colsandtrialresultsthesestudiescovermore efitsoftakingourproductsinclinicaldevelopment thanconditionsincludingalzheimersdisease andourmedicinesoutweighanyidentifiedorexpec asthmaaroundcancerscardiovasculardisease tedsafetyriskwehaverobustprocessesoperate depressiondiabeteshepatitishivaidsinfluenza worldwidetounderstandourmedicinesandtheir andobesitythewebsitehadmorethan adverseeventsandtominimisetheirlikelihoodmedi pagevisitsinrepresentingmorethan cinesareregularlyanalysedagainstvariousreference visitorsdetailsofourclinicaltrialsarealsoavailable databasestohelpusdetectpotentialsafetysignal throughtheinternationalfederationofpharmaceu allourproductsinclinicaldevelopmenthavean ticalmanufacturersandassociationsifpmaclinical individualsafetymanagementplanandallourmedi trialsportalatwwwifpmaorgclinicaltrialsand cineshaveariskmanagementplanreviewedand theusnationalinstitutesofhealthsglobalregistry approvedbymajorhealthauthoritie atwwwclinicaltrialsgovwepublishourclinical trialdatatoensurethatalllessonsfromthesetrial continuousmonitoringandworkingwiththehealth aremadeaccessibletothewidercommunitywealso authoritiesenableregularupdatestoprescription lrochearengcorporate responsibility partindd roche business report corporate responsibility instructionslabellingandproductinformation wesupportwepubliclylistpatientgroupswegive includingemergingsafetyinformationcontraindica nonfinancialsupporttoifthesupportissignificantor tionandspecialprecautionsofusewhennecessary meaningfulasguidedbyeuropeanfederationof lettersaresenttophysiciansandhealthcareprovid pharmaceuticalefpiaindustriesandassociations ersallowingthemtoadjusttheirmedicalpractice examplesofpatientadvocacywesupportedin diagnosticsproductsmaygiveerroneousresult includetheworldhepatitisalliancesworktoraise causedbyaproductperformanceoruserhandle awarenessofviralhepatitisandpromoteactionto issuethiscouldeventuallyleadtoanincorrectther improvepatientcarewecontinuedtosupportthe apyforapatientduringthedevelopmentofdiagnos europeanpatientsrightsdayorganisedbyactive ticproductsextensivetestingisperformeduse citizenshipeachyearinpatientgroupsin patientsamplesundervariousrealisticconditionsto europeancountriescelebratedthethirdpatient ensureoptimalperformanceofthefinalproduct rightsday weinvestigateallreportedadverseeventstoascer education awareness tainiftheyarerelatedtoourproductsifthereisa ouraffiliatesoftengetinvolvedininitiativestoraise linkwereevaluatewhetherthebenefitsofthemedi awarenessofdiseaseforexamplerocheturkey cineordiagnosticproductstilloutweightherisk heldaonedaycyclingeventatashoppingmallin wealsohaverobustproceduresinplacetopromptly istanbulinpartnershipwiththeturkishbicycle informpatientsphysicianshealthcareprovider federationandtheministryofhealthscancercontrol andregulatorsofanynewproductsafetyinformation departmentrochemadeadonationtothepatient organisationhandinhandagainstcanceronbe wehavearobustprocesstoensurethatproduct halfofeachpersontakingpartdemonstration canberecalledrapidlyandwithdrawnfromcirculation onprostheticbreastshelpedtrainwomeninself ifunanticipatedissueswiththeirqualityarisein examination therewerenorecallsinvolvingthepublic inbrazilmillionpeoplehavediabetesbut patient advocacy donotrealiseitrochediabetescarechallenge wesharewithpatientgroupsaninterestinhelpe fashionstudentstodesignapracticalandfashionable patientsunderstandandmanagetheirdisease accessoryforcarryingaccuchekbloodsugartest andgainaccesstotheinformationandtreatment andotherdiabetescareitemstoraiseawareness theyneed ofthediseaseamongteenagersandyoungadult whiletheiraimsvaryeachpatientgroupinteract goal withmanypatientsandcarersunderstandstheir initiaterocheoncologysustainabilityinitiativein needsandprioritiesandknowshowtoprovideemo subsaharanafrica tionalsupportandpracticaladvicewedescribe expandpartnershipwithalberteinsteincollegeof ourapproachtoworkingwithpatientgroupsinour medicineinethiopiatoincludeoncologytraine positionstatementandguidelinesforworkingwith hostincollaborationwithnovonordiskandthe patientgroupswhichareavailableonourwebsite worlddiabetesfoundationwdfaleadership foruminafricatoaddressthediabetesepidemic transparencyisfundamentaltosuccessfulpartner shipswithpatientgroupsinwelistedallthe patientgroupswesupportfinanciallyonourwebsite bycountryandwithashortdescriptionoftheactivity lrochearengcorporate responsibility partindd web personalise healthcare wwwrochecomphcinrd roche position statement personalise healthcare access medicine diagnostic pricing neglect disease work patient group wwwrochecompoliciesguidelinesandposition access medicine report wwwrochecomsustaccesspdf programme ldc wwwrochecomprogrammesinleastdevelopedand developedcountrie programme develop country wwwpparxorg wwwgenentechaccesssolutionscom roche trials patient safety wwwrochetrialscom wwwrochecomclinicaltrial wwwrochecommanagingmedicationsafety list patient group support wwwrochecompatientgroup lrochearengcorporate responsibility partindd roche business report corporate responsibility people foroveracenturyrochehasstoodforinnovationand isillustratedbyourconsistentrankingasanemployer entrepreneurshipourhistoryofachievingourbusi ofchoiceseethetablebelowforaselectionofour nessgoalsandexcellinginscienceandinnovationis awards aresultofconsistentlyemployingthebestpeople itrulybelievethatwereinthegoldenageofdisease wesucceedbecauseofourpeoplepeoplewhoare researchanddrugdiscoveryitisnowpossibleto passionateaboutmakingadifferencetopatient tacklediseasebiologywiththesamerigourasbasic livespeoplewholeadanddrivechangepeoplewho biologybecauseofthisconvergenceofmedicine liveourcorporatevaluesintegritycourageand andscienceicantthinkofabetterplacetobethan passionwehaveemployeesbehindourcur genentechthequalityofthesciencehereison rentsuccess parwiththatoftopacademicinstitutionsitisexhila ratingtoexperiencethecombinationofscientific wekeepouremployeesengagedandperformingat excellencewithstateoftheartresourcesenormously thehighestlevelbycreatingaworkingenvironment talentedcolleaguesandthecultureofrisktakingwe inwhicheveryonefeelsvaluedandrespectedwhere havehere theycandeveloptotheirfullestpotentialandcan marc tessierlavigne phd executive vice president maketheirownmarkourprogressinachievingthis research chief scientific officer employer choice select external award ranking award roche site rank description science magazine employer genentech st genentech biopharmaceutical industry prize seventh time san francisco business times genentech st rank base employee response good place work questionnaire include company bay area employee total equality germany roche germany na total equality award second time roche successful sustain equal opportunity commitment arizona bioindustry association ventana medical st award recognise ventanas bioscience company year systemsroche development growth tissue diagnostic good place work survey roche denmark st roche vote good pharmabiotech good pharmabiotech company company denmark fourth consecutive year second sector actualidad econmica roche spain st roche rank st pharma industry good company work th overall trendence employer roche switzerland rd switzerland student vote roche countrys good employer technology science edition lrochearengcorporate responsibility partindd employee fte operating division engage employee thegloballisteningtoyousurveyconductedinearly variance aimedtomeasuretheeffectivenessofinternal new pharma communicationsandemployeesattitudestothecom chugai panyandtheirworkoveremployee diagnostic respond total overallofrespondentsexpressedsatisfactionin theirjobandfelttheywereappropriatelyengage fulltime equivalent fte byrochethevastmajorityfeltproudtowork employee contract type forrocheandwouldrecommendthegrouptoother asagoodplacetowork variance regular fte nearlysaidtheyhaveaccesstotheinformation temporary fte theyneedtodotheirjobwellemployeesfeltwell headcount informedaboutourmajorproductsbusinessstrategy time hc andfinancialperformancewewillcarryoutanother time hc surveyin roche employee worldwide employee variance europe todayweemploysome north america employees asia aroundmorethan inallofthem aredrivenbythesame spiritandpursuethe samegoaltocreate newandbetterwaysto preventdiagnoseand africa australia treatnewdiseases latin america lrochearengcorporate responsibility partindd roche business report corporate responsibility duringtherochegenentechintegrationwepro certaincandidatesandtodemonstrateprogress videdrelevantinformationtoemployeesquicklyand towardsgovernmentgoalsforwomenandminoritie transparentlyusinganintegrationwebportaland employeeroadshowstheelectronicplatformallowe wesponsorandsupportanumberofemployeeaffinity ustocommunicatemanagementdecisionsinstantly groupsassociationsandnetworksthegoe andattractedonaverageuniquevisitorsper genentechoutequalgroupaimstopromote weekbetweenaprilandaugustmainlyfromthe aworkplaceenvironmentthatembracesallemployees usandswitzerlandweheldroadshowsatallaffected regardlessoftheirsexualorientationaaib sitesandusedthemtointroducenewmembersof africanamericansinbiotechnologyisdedicate themanagementteamwefilmedtheseeventsand toachievingaculturallydiverseenvironmentwhich postedthevideosonlinetogetherwithkeypresenta improvesthedevelopmentofdrugstoaddress tionsthesevideosprovideddirectinputonstrategic theunmetmedicalneedsofamoreculturallydiverse directionandothernewsstoriespicturesandper patientpopulation sonalstoriesfromemployeeshelpedpeoplefrom eachcompanyconnectmoreeasily theintegraprojectatrochespainalsoencourage greaterunderstandingofdisabilityamongemployee asurveyatgenentechshowedthatemployeesremain andaimstoincreasethenumberofhireswithdis positiveafterthemergerdespitehavingexperi abilitiesinitalycollaborationwithlocalinstitutions enceduncertaintyandlossasaresultgenentech overthelasttwoyearshasenabledustorecruitand employeesremainproudoftheircultureanditsposi onboardfiveadditionaldisabledperson tiveimpactonpatientslive peoplefromovercountriesfromaustralia thesurveyalsoshowedthatgenentechsfocus uruguaytosouthafricaworkforrocheinswitzer onpatientsandcommitmenttoscienceinspiresand landintotalmorethannationalitiesarerepre motivatesemployeesalmostallemployees sentedworldwideatroche arecommittedtothesuccessofthemergedcompany wanttostaywiththecompanyforatleastayear womenaccountfornearlyhalfofemployeesand orwanttostayatgenentechforalongtime ofmanagersgloballywomenalsomakeupmore thanoftheworkforceinoverofouraffili atesinwomenaccountformorethanofman foster diversity agementexamplesincludeaustraliawherewoman ourfocusistoensurediversityinourworkforce accountforofemployeesandofmanage aninclusiveworkenvironmentallowsustoleverage mentandhungarywithandrespectively thepotentialofallemployeesirrespectiveofage genderethnicitydisabilityworkstyleexperience gender diversity familysituationorworkingneed wedonottoleratediscriminationofanyformas women total statedinourworldwideemploymentpolicywe workforce havemanagementtrainingprogrammesandawide woman management rangeofinitiativesataffiliateleveltoencourage woman senior andsafeguardemployeediversityforexampleour management nutleysiteintheushasadedicateddepartment woman executive tomanagediversityitsetsannualplanstoevaluate management position howemploymentdecisionsmayadverselyaffect ie lrochearengcorporate responsibility partindd womeninleadershipnetworkbaselandgenentech genentechchallengesourscientiststodiscovernew womenprofessionalsbothaimtoprovideaforum biologyandtotranslatethesefindingsintonovel forwomenwhichrecognisestheiruniquestrength medicinestohelppatientssuccessrequiresafear andtalentsandinwhichexperiencescanbeshare lessnessandwillingnesstoattackthemostdifficult andleverage scientificandclinicalproblemsandnottobedeterre bythetrialsandtribulationsofscientificdiscovery encourage innovation andunknownsofmedicineifeelfortunatetohavethe rocheisaglobalinnovationledcompanywehave opportunitytoworkalongsideourresearchdevelop tobalancetheneedforefficiencyandconsistency mentandclinicalscientiststomeetthesechallenge throughstandardisationwithacompetitiveenviron andrew c chan md phd senior vice president immunology mentinwhichinnovationthrive antibody engineering innovationisdrivenbydifferentandoftenconflicte approachesideasandexperienceswhileensure werecogniseinnovationamongouremployeesthrough thatourmainfunctionalprocessesarealignedacross internalawardstheseincludeprizesforimprove therochegroupincludinggenentechwedecide animalwelfareinourtrialsimplementinginnovative tokeeptheresearchanddevelopmentlaboratorie informaticssolutionsandproposalsthatimprove genentechresearchandearlydevelopmentgre patientslivestherochepharmaceoawardsrecog independenttoensureitsinteractionwithexternal niseteamsthathavepassionatelypursuedinnovative researchinstitutionswasnotdisruptedgredhasit solutionsforpatientscreativelyimprovedtheway ownbudgetportfoliomanagementandcultureall weworkandpushedsciencemarketingandopera ofwhicharefundamentaltoinnovationwecreate tionstothenextlevelinmorethanteam aparallelpharmaresearchandearlydevelopment fromeveryregiondiseasebiologyareaandfunction organisationpredcomprisingthevariousrd participatedintheprogrammewinningteam centresoutsidegenentechtostimulatethedifferent includedrocheemployeesateverystageintheir perspectivescriticaltosuccessfulinnovation careersfromyoungpostdocstoseniorresearcher withdecadesofexperience employee fte function ourpostdocfellowshipprogrammeawardsourb scientistswithgrantstoconductexploratoryresearch servicing whichhelpsusreinforceourtalentpipelineinrd manufacturing logistic knowledgeisanessentialaspectinrochethatmulti marketing plieswhenitissharedandcleverlyusedthekey distribution istodevelopaparticipatorymanagementstylewhere research teamssharetheirideasanddevelopdifferentway development ofdoingthingsinaframeworkofmutualunderstand general ingitisaprivilegetoworkinacompanythatrecog administration nisestheperformanceandpotentialofitstalent total regardlessoftheirbackgroundandexperienceseven wherethesemightnotreflectthetraditionalrouteor theexpectedprofilerocheencouragesitsemployee torisetoandfaceprofessionalchallengesthus allowingthemtogrowandreachdifferentposition mara jess alsar oncohematology director spain lrochearengcorporate responsibility partindd roche business report corporate responsibility attract employee turnover regular employee weworkhardtokeepourrecognitionasanemployer ofchoicethisiscriticaltoourabilitytohireand retainoutstandingpeoplewhoarecommittedtoour total goalofimprovingpeopleshealthandqualityoflife europe latin america rochesstrongandsustainablebrandenablesus north america toattracttherightpeoplewehavebuiltalargeand asia diversepoolofcandidatesdedicatedinhouse australia recruitmentteamsandgloballyalignedrecruitment africa processesstandardsandtechnologyourcareer include non standard temporary contract end websiteexpandedintoimprovethelocalvisibility ofallavailablepositionsincludingatgenentech thesitehadsometwomillionuniquevisitorsin reason leave andregisteredmorethanspontaneous applicationswealsocontinuedtorollouttaleoour globalerecruitingplatformlaunchedin employerrelate injustthreecountriestaleoisnowavailableinover employeerelate countriesworldwide neutral temporary contract end health issue retirement wecontinuedtodeployourglobalemployerbrand inmakeyourmarkimprovelivestoimprove rochesturnovershowsastrongdecreasingtrend awarenessofrocheasanemployerofchoiceand thistrendisconfirmedparticularlybythe todifferentiateusfromourcompetitor numberofemployeesleavingoftheirownaccord fromintoinoverofour hire retention alargeintegrationrequire employeeshavebeenwithrocheformorethan asharpfocusonretentionourdecisiontomaintain tenyear genentechsuniqueresearchoperationswasone measuretoaidretentionaccompaniedbyadditional develop employee healthbenefitsoutplacementservicesandcash developmentisapriorityforallemployeesinaninno paymentswehavecontinuedtoattracttopscientist vationdrivenorganisationwewantemployeesto andotherhighprofiletalentsincethedealwa developtotheirfullestpotentialandsupportthemat closedgenentechhiredpeopleinin everystageindoingso creasingitstotalworkforceby performance management regularfeedbackand staffing rate anopendialoguebetweenemployeesandtheir managersisacriticalactivityforwhichweholdboth managersandemployeesaccountablein number vacancy ofouremployeestookpartinperformancemanage new hire mentprogrammesandinformalcareerdevelop internal staffing rate mentplanne external staffing rate lrochearengcorporate responsibility partindd employee training potentialleadersoftotalheadcountofwhich onethirdarewoman total training spend million withinthegloballeadershipportfoliowehavepro chf grammesaddressingeachcategoryofhighpotential training spend employee leadersfromthosewhowillassumeaglobal chf leadershippositioninthelongtermtothosewhocan total number training hour succeedakeypositionholderintheshortterm million intheseprogrammestargetedthetopof average training hour employeesandincluded employee explorationsincludesanassessmentofleader number postdoc student shipskillsfeedbackandcoachingbysenior intern leadersearlyinanemployeescareertoenable themtobuildfocuseddevelopmentplan exclude genentech chugai inemployeesparticipatedwoman learn rocheoffersextensivesupporttoem perspectivesatwoyearprogrammeinwhich ployeesforthedevelopmentoffunctionalprofe weprepareearlyhighpotentialleadersfor sionalandleadershipskillsourmajordiagnostic significantmanagementresponsibilitiestheywork andeuropeanpharmaaffiliatesaccountingfor infourdifferentfunctionsandregionsin ofthetotalrochepopulationofferednearly participantsjoinedforthefirsttimewoman coursesinthroughourcommon horizonsgivesmidtermhighpotentialemploy chrisplatformovertrainingsession eesanacceleratedglobalandcrossfunctional classroomandwebtookplaceandweregistere developmentexperienceincriticalareassucha closetobooking leadershipinnovationrisktakingcustomer orientationandchangeinemployee succession talent management inanorgani participatedwoman sationcharacterisedbychangeleadershipskill reflectionsprovidesanassessmentofthemost areincreasinglyimportantduringweensure seniorhighpotentialemployeesontheirindividual fullcoverageofourgloballeadershipprogramme strengthsareasofimprovementandpotential portfolioprovidingkeyprogrammesateverystagein basedontherochevaluesleadershipcompe theleadershipdevelopmentpipelineinroche tenciesincandidateswomentook learninganddevelopmentdepartmentwillcreate acommonframeworkforleadershipdevelopment linkinggloballeadershipprogrammeswithexiste atatimeofsignificantorganisationalchangeswe localregionalandfunctionalinitiativesthiswill filledmorethanofouropenpositionsinternally giveemployeesandmanagersaccesstoacatalogue ofleadershipprogramme international mobility whilesomevacancie ofthetotalarefilledbyexternalcandidate highpotentialleadersarepeoplewiththeabilityto weofferprofessionalandpersonaldevelopment takeoncriticalseniorrolesintheshortmidor opportunitiestoourownemployeesthroughinternal longtermidentifyinganddevelopingtheseemployee movesthisnotonlyhelpsrocheretainkeypersonnel ensureswehavearobustanddiversepoolofcan itenablesustoleveragepotentialwithinthegroup didatesforcriticalpositionsweidentifyandconfirm anincreasingamountoverofthismobility theseindividualsintalentassessmentsandreviews goesacrossaffiliateandnationalboundariesofour duringtheyearinweidentifiedhigh expatriatesandcrossboundaryemployee lrochearengcorporate responsibility partindd roche business report corporate responsibility arewomenallofthemrepresentingdifferent wealsoreviewedcompensationpracticesatroche nationality andgenentechandmovedgenentech employeestorochelongtermincentivesthismean toencouragemobilitywithinthegroupinwe thatapartfromchugaiemployeesalllongterm introducedtheintercompanytransferandlocal incentivesinthegrouparenowonthesameroche foreignhirepolicythisfacilitatestherecruitmentand holdingssecuritiesmorechangestoalignroche relocationofforeignhiresandofpermanentcross andgenentechcompensationpracticesandthe bordermoveswithinthegrouplocalmobilityinitia performancemetricsusedforincentiveswillcome tivessuchasourlocalpluspolicyinchinahelp intoeffectin attracttoptalenttochinaespeciallyindividualswho haveinternationalexperienceandwanttoreturn benefit throughcompetitivebenefitsprogramme wehelptocreateanattractiveworkplace wehavealsorevisedourinternationalassigneespolicy toimprovetheflexibilityneededtoaddressmarket overofouraffiliatesofferextensivebenefitsplans trendschangingdemographicsandevolvingbusiness mostgobeyondgovernmentschemesandinclude needsthisrevisionrespondstothefindingsof healthchecksandfreeaccesstoawiderangeof asurveyofassigneesandtheirpartnersthe medicalserviceswehavealsointroducedprogramme revisedpolicieswillberolledoutin thatencourageahealthylifestylethroughwellness programmeshealtheducationfitnesscentresswim rewarding recognise employee mingpoolsandrelaxationinitiativeswenowhave thetotalcompensationpackageweoffermake taichiclassesatourbrazilianitalianandmexican asignificantcontributiontoattractingrewarding affiliatesandhaveincorporateditinworkshop recognisingandretainingtherightpeople appliedbyourlifecycleteamswehavebeentrialling powernappingandareofferinghealthyfoodoption ourtotalremunerationcostsinamountedto atourheadquartersinbaselwecontinuetooffer billionswissfrancsanincreaseoffrom benefitstoourretireesatseveralofouraffiliatessuch ourbasepaypackagesrewardindividualperform asswitzerlandincludingaccesstoemployee ancerecognisingbothwhatwasachievedandhow restaurantssportsandleisureactivitiesandtravel itwasdonethroughvariablepayweincentivise check employeeswhocreatenewopportunitiesandstrive foroutstandingresultsvariablepayisdrivenby wehaveincreasedourfocusonflexibleworking individualandteamobjectivesandbythegroupdivi arrangementsaftersuccessfulpilotsatourwelwyn sionalandaffiliateperformance siteintheukourbaselheadquartersintroduced apilottoaccommodatedifferentworkingstyle wewantouremployeestoshareinoursuccess orfamilysituationsthroughhomeworkinganddesk throughrocheconnectemployeesinmostcountries sharingthepilotaimedtoidentifymoreattractive canpurchaserochesnonvotingequitysecuritie andflexibleworkingarrangementsforofficeworker atadiscountofuptoinemployee aswellastestingefficientandsustainableuseof incountriesofthoseeligibleparticipate officespaceandinfrastructure inrocheconnectmorethaninwealso awardnonvotingequitysecuritiestomanagersbase genentechintroducedanonlinetoolallowe ontheirperformancethroughtherochelongterm employeestoassesswhethertheirtasksareeligible incentivesplanatotalofmanagerstookpart forflexibleworkarrangement inwithjoiningforthefirsttime lrochearengcorporate responsibility partindd wealsoaimedtoincreasetheconsistencyofour human right labour relations benefitsprogrammesaroundtheorganisationour rochehasacomprehensiveemploymentpolicy goalistoalignbenefitprogrammeswithincountrie whichcovershumanrightsthegroupcompliance sowecanofferattractivebenefitstoallourem officermonitorsthispolicyandservesasacontact ployeesregardlessofaffiliateordivisionconsistently forallemployee andefficiently rocherespectstherightofemployeestofreedom inwestartedtheharmonisationofthebenefit ofassociationandcollectivebargainingmorethan plansofournorthamericanaffiliatescoincide ofouremployeesareunionmembersand withthegenentechintegrationwewilllaunchthenew overaremembersoforganisationsthatfreely programmeinoctoberanditwillcomeinto representthemincountrieswherethisislegal effectonjanuarysimilarbenefitharmonisa therocheeuropeforumrepresentsnearly tionprogrammesareongoinginswitzerlandspain employeesincountriesatgloballevelwehave franceandtheunitedkingdom recentlyinstalledanemployeerelationsofficer asaresultofthefinancialcrisisandthefallinglobal ourdirectiveontheprotectionofpersonaldatasafe equitymarketssomeofourpensionfundsaroundthe guardsinformationaboutemployeesandcomplie worldfacedchallengesmaintainingahealthyfunde withtherelevantlocallegislationwhereappropriate positionwhereunderfundinghasarisenroche wehavenegotiateddataprivacyagreementsbetween hastakenstepstodevelopappropriatestrategie differentpartsofthebusinessorwithworkscouncil inaccordancewiththelocalstatutoryregulation andpracticesandinconsultationwithemployee web representativesincludingadditionalcashinjection employee wwwrochecomemployee andrecoveryplanssomeofourmajorpension group policy position guideline wwwrochecompoliciesguidelinesandposition fundshaveremovedearlyretirementincentivesand global career portal httpcareersrochecom haveintroducedmoreflexibleretirementmodel employment policy wwwrochecomemploymentpolicypdf anticipatetheimpactofanageingworkforce core standard wwwrochecomcommitment simplify aligning process human resource allofourhrprocessesexceptthoseatgenentech andchugainowrunononecommonhrinformation solutionchristhisusestransactionalandreport ingsystemsandisalignedwithtaleoourglobal erecruitingsolution introducedinjulychrisreplacesseveral legacysolutionsandenablesstandardisedstreamline andsimplifiedhrprocessesacrosstherochegroup ouraimistoensureconsistenthrservicesand increasedefficiencychriscoversaffiliatesand representativeofficesandofrocheemployees genentechandpharmanorthamericawillfully joininchrisismanagedbyaglobalsupport organisationandnetworkofservicinghub lrochearengcorporate responsibility partindd roche business report corporate responsibility society oursupportforcommunitiesfocusesonprogramme community support area andareasthatarealignedwithourbusinessmodel webelievewecanenhancetheinnovationsustainabil total ityandimpactofourbusinessthroughappropriate humanitarian social project donationssponsorshipandemployeevolunteere science education thisinspiresandmotivatesourstaffandensure art culture rocheremainsacommittedcorporatecitizen community environment monitoringtheimpactofourcommunityworkgive support future science amoreaccurateassessmentofourprogramme youngscientistsareourfutureemployeesnurture successthanpublishingdetailedfinancialinformation theirtalentensuresrocheremainsaninnovative aboutourdonationsforexampleourgenetic andsuccessfulcompanyforexamplewehavefoun educationprogrammeforeducatorsinswitzerland dationstosupportresearchandeducationpro andgermanyreachednearlypeoplewith grammesaroundtheworldincludingthefondation teachersenrolledintheworkshopsthesubsequent dentrepriserocheinfrancetheglobalroche knowledgetransferreachedtheircolleaguespupil organtransplantationresearchfoundationandthe andevenfriendsandfamilywewillexpanditin genentechandrochefoundationsintheus switzerlandandneighbouringregionsofgermany therochepostdocfellowshipprogrammecomplete itsfirstfullyearintheprogrammeaims allphilanthropicdonationsandnoncommercial toencouragecreativityinscienceandstrengthen sponsorshipsaremonitoredinternallythroughthe academicnetworksthroughsupportfortalente financialgroupreportingsystemthecorporate postdoctoratestudentsontwotofouryearresearch sustainabilitycommitteeisresponsibleformonitore projectswithleadingacademicinstitutionsin theirimpact weofferedpostdoctoratestakingourtotalsince theprogrammelaunchedintopeople intherochegroupapprovedanupdatedcorpo weplantoincreasethatnumbertobytheend ratepolicyonphilanthropicdonationsandnon ofnextyear commercialsponsorshipthepolicystipulatesthatall philanthropicprojectsshouldfocusoninnovation inwepilotedtheresearchexchangescholar collaborationqualityandsustainabilityitcomfirm programmetheinitiativesupportsscienceeducation ourpriorityareasashumanitarianandsocialscience bygivinggiftedsecondaryschoolstudentsthechance andeducationcultureandartsandcommunityand togooninternationalexchangesthefirstexchange environmentourhumanitarianandsocialprogramme featuredtwobiotechnologyspecialistschoolsfrom involvepromotingsustainableaccesstoourmedi theusandgermanythreestudentsfromeach cinesanddiagnosticsweonlydonatedrugsindisas schoolundertookasixweekinternshipattheother terandpandemicsituation whichincludedindividualmentoringat alocaluniversity thepolicyalsoensuresourdonationstargeta focusednumberofnongovernmentalorganisation thecongressoftheeuropeansocietyformedi ngostowhichwecanmakeasignificantdiffer caloncologyesmoawardedrocheinrecognition enceratherthandilutingourdonationsamong ofoursupportforitsyoungoncologistfellowship alargenumberofngosweexcludegovernmental programmewehavesupportedesmosinceitwas politicalandreligiousorganisation foundedinthroughclinicalandtransnational fellowshipsthesehavehelpedyoungoncologistsgain lrochearengcorporate responsibility partindd researchexperienceinrenownedeuropeancancer wesetuptherocheemployeeactionandcharity centresourongoingeducationprogrammesinclude trustreactinasanindependentcharity atwodaybioethicsteachingworkshopforsecondary organisationtomanageemployeedonationsit schoolteachersintheusandourpartnershipwith distributesfundstocommunityprojectsanddisaster thenewjerseyinstituteoftechnologytosupport reliefeffortsaroundtheworldsinceanearthquake aonedayeducationprogrammeforprimaryand inreacthasmaintainedongoingassistance secondaryteacher andreconstructioninthetownofchocosperu intheprojectbuiltacommunitycanteenand encourage innovation art newhomescapableofwithstandinganother wesupportmusicandtheartsbecausethecreativity quakeaswellascompletingthecommunitysdam andinnovationofthosedisciplinesreflectsour businessmodelwebelievelessonscanbeshare theannualrochechildrenswalkhasbeengoe betweenartsandscienceinweheldthe sincehoweveritdidnottakeplaceinas thirdrochecontinentseventtoencourageartistic ithasbeenmovedfromdecembertojulytoincrease involvementamongyoungpeoplearoundfuture participationnonethelessreactsworkwith chemistsbiologistsmedicspsychologistsmusi theeuropeancoalitionofpositivepeopleandunicef cianssetdesignersrecordingengineersandopera switzerlandwhichbothhavelongtermproject singersfromuniversitiesallovereuropeattende tosupportchildrenimpactedbyhivaidsinmalawi artandscienceworkshopsandcontemporaryclassical continuedrocheemployeeswerestillinvitedto musicperformancesatthesalzburgfestival donateinandweguaranteedfinancialcoverage toensurethechildrendonotsufferintheinterim roche commissionsseesussponsoranewmusical todatethewalkhasraisedenoughmoneytobuildand piecebyanoutstandingcontemporarycomposer furnishnewclassroomsaccompanyingteacher everytwoyearstoshiohosokawawillpresenthis officesandsanitationandhygienefacilitiesfornearly workininadditionchugaiagainsponsoredthe primaryschoolchildrenthesponsoredwalk starphilharmonicchristmasconcertinyokohama hasalsohelpedfundeducationforsecondary japanwhichsupportsearlycancerdiscoveryand schoolstudentsandfivefurthereducationstudents treatment inruralsouthafricathereisjustonedoctorforevery support community patientsthephelophepahealthcaretrain wewantemployeestocontributetotheirlocalcom aimstoreducetheburdenbyprovidingamobilehealth munitiessoweencouragethemtoidentifythe clinictomorethanpeoplewehavesupporte projectsthattheyfeelwouldbemostworthwhile theservicesinceitbeganyearsagoandin whilerochehasarangeofgroupprojectswe additionalfundingfromrochecontributedtoacancer encouragestafftofundraiseandvolunteeralongside healthawarenessservicethenewserviceinclude theirworkcommitment cancerscreeningtrainingforstaffcommunitycancer awarenesseventspatientcounsellingandeducation genentechgoestotownisacommunityrelation focusedonbreastcervicalandprostatecancer projectsetupingenentechgivesemployee usdollarsworthofvoucherstospendinlocal web shopsovertwoweeksencouragingthemtodevelop roche social programme localbusinessestheprogrammehasspentmore wwwrochecomsociety roche n jazz wwwrochenjazznet thanmillionusdollarsinlocalshopssinceincep act httpreactrochecom tionwithmorethanbusinessesparticipate lrochearengcorporate responsibility partindd roche business report corporate responsibility safety security health environmental protection safetysecurityhealthandenvironmentalprotection wetrainemployeeswhohandlechemicalsaspartof shearecriticalforourbusinesswetakeshe theirworktousethemproperlyandweprovide intoconsiderationinallouractivitiestherochecor safetydatasheetsforoverspecificchemical porateprinciplesandshepolicycommitustothe onourwebsite highestshestandardsinweinvestedmil lionswissfrancsinsheinfrastructureandmillion weholdourecompetitioneverythreeyearstoraise swissfrancsinsheoperatingcost awarenessofenvironmentalissuesamongemployees byencouragingthemtosuggestnewwaystoreduce management ourimpactsthecompetitionourfifthelicite astrongteamcoordinatesshewithinrochewe morethanproposalsfrompeopleatsites havefulltimesheemployeestoensureour thewinnersinclude performancenewsheofficersattendedatraining rochepaloaltousretrofittingcoolingequip weektolearnaboutourshepolicystrategyguide menttoreplacehalogenatedhydrocarbon linesandprocessesattendeesdiscussedroche hcfcwithhydrocarbonrefrigerantspropane sheresponsibilitiesandhowtoaccessrelevant orpropylene expertisetheyalsolearnthowtoestablishandmain rochejacarepagubrazilrecoveringsolution tainariskmanagementsystemattheirsiteswe fromtubingusingapolystyreneplugratherthan heldregionalworkshopsforexistingsheofficerson waterandnitrogen topicssuchasenergyefficiencysecurityandindus chugaipharmajapanregeneratingemergency trialhygiene batteriesinuninterruptedpowersuppliesinstead ofreplacingthem everyoneatrocheisresponsibleforensuringhealth andsafetyandforminimisingtheenvironmental theannualrocheresponsiblecareawardsencour impactsofouroperationsweneedeveryonetounder agesitestosuggestenergyefficiencyimprovement standourshestandardssoweoffersitespecific insubmissionsfromsitesstoodout trainingincludinglecturesandpracticalcourseswe include havealsobegunabasiconehoursheelearne rochebezaresmexicosolarboilersinstalle moduleforallemployeesinemployees toprovidehotwater receivedanaveragehoursofshetrainingeach rochediagnosticsuscontrolledlighte duringquietperiod itisimportanttounderstandsherisksacrossthe rochediagnosticsindiaaspecialglassfaade businesssowecandeveloplocalsafetymeasuresas wasinstalledtosaveenergycost wellasgrouplevelresponseswelistallsherisk onawebbasedinventoryaccessiblebyallmanager security acrossthebusinessindividualsitemanagersand weappointedacorporatesecurityofficercso sheofficersimplementtheshepolicyandguide ininwesetupanetworkofmore lineslocallyinthepharmaceuticalsanddiagnostic thansitesecurityofficersssosandissue divisionsecodelegatesraiseawarenessofenviron acorporatedirectivetodefinetheirresponsibilitie mentalissue aswellasoursecurityprinciplesandgeneral processesthedirectivedescribesminimumstand wemonitortheimplementationoftheshepolicy ardstoprotectemployeesvisitorsphysicalasset usingregularsiteauditsandweusetheresult productsandbusinesssensitiveinformation toimproveperformanceinweconducte auditsrevealingnomajordeficienciesbut wealsointroducedaglobalsecurityincident highlightingtheneedtoupdatesiteriskanalyse reportingtoolthatallowsssosandthecsotoanalyse lrochearengcorporate responsibility partindd incidentsandestablishcorrectivemeasuresin agrouplevelbodyinvestigatessignificantshe wefocusedoncounterfeitproductsandpreventedthe incidentsandcommunicatestherelevantfinding saleofsignificantquantitiesoffakeproduct acrossthecompanyincludingforuseintraine programmeswheresuitable health safety therocheaccidentraterarmeasuresthe environmental footprint numberofworkingdayslostduetooccupational ourenvironmentalfootprinttakesintoconsideration accidentsperemployeeperyear researchandproductionaswellasproductpackag ingdistributionuseanddisposal intherarwasthisrepresentsa improvementfromandiscomfortablybelowthe weusetheswissagencyfortheenvironment groupgoalfor bafuecobalancemethodtocalculateourenvi ronmentalfootprintitreflectsresourceuseas health safety wellasemissionsandwasteinourecobalance wasanimprovementoffromthis reflectssignificantlyreducedemissionstoairand roche accident rate organicmaterialsdischargedtowaterweare occupational accident currentlyoperatingwithinourtargetecobalanceof occupational illness workrelate fatality workrelate accident wealsomeasureenvironmentalexpenditureinrela million work tiontosalestohelpensurewetargetourinvestment hour intheareaswhereitwillhavethemostimpact thecalculationgivesusanecoefficiencyrateeer weexpectcontractorswhoworkonrochepremise asshowninthetablebelowthiscombinesdata tofollowthesamesafetyrulesasemployees onenergyusewasteemissionstoairandwaterwith contractorswereinvolvedinaccidentsin expenditureonenvironmentalprotectionandsale inadditiontothosereportedforemployee adetaileddefinitionisavailableontherochegroup resultinginaninjuryfrequencyrateofaccident websiteinoureerwasanimprove perworkinghour mentof employeessufferedcasesofoccupationalillnesse ecoefficiency rate inadecreasefrominthenumber ofworkingdayslostwasthesamelevelasin locomotordisordersespeciallyrepetitivestrain sales million chf injuriesaccountedformorethantwothirdsofthe environmental expend totalweworktoreducetheseinjuriesthroughlocal iture million chf ergonomicprogrammesimprovedofficeequipment environmental damage andindividualassessmentsgenentechsergonomic millions environ programmeaddressescumulativetraumaand mental damage unit includesadedicatedtrainingwebsitethesouthsan eer franciscositehasthreeergonomicsshowroom allowingstafftotestproductsfortheofficeplantand therocheenvironmentalawarenessinchemical laboratory technologyreactprogrammepromotessustainable chemistrypracticesinourrdlabsaroundtheworld lrochearengcorporate responsibility partindd roche business report corporate responsibility reactsetssustainablechemistryguidelinesto energy use type measurethebenefitsforexamplethemassintensity factormeasurestheratioofinputsofrawmaterial fuel againstoutputswhilesolventselectionguidelineshelp company vehicle employeeschooselessharmfulsolventsthepro oil grammeaimstosupportrochessustainabilitygoal fuel business sharebestpracticesaroundthegroupraise air travel employeeawarenessincreaserecognitionforrd sustainabilityworkandreducecost grid electricity energy climate change ourpositionpaperongreenhousegasesandclimate district heating changeguidesourgroupstrategyfordecrease waste emission renewable energy natural gas weregularlyanalyserochesvulnerabilitytothe changingclimatewehavenotidentifiedanysig nificantriskstoourbusinessfromclimatechange sionsfactorsatsomesiteswhoseelectricityprovider oranyspecificbusinessopportunitie recalculatedthelessemissionintensiveproportionof theirenergymix rochesenergyandfueluseintotalle terajoulesanincreaseoffromthis greenhouse gas emission tonne co equivalent ismainlyduetotheinclusionofgenentechscar fleetforthefirsttimeenergyuseisapproximately gigajoulesperemployeeasmalldecreasesince total emission total emission million chf energy use terajoule sale thereductioninemissionsinrelationtosale total energy use showsthatrocheisreducingenergyusewhilethe total energy use businessgrow million chf sale total energy use inwedevelopedastandardforintegrate employee energyefficiencymanagementintobuildingproject thisaccompaniedanewgroupwidemanualon ourclimatestrategyfocusesonenergyusewhich energyefficientdesignwhichwillhelpusdesign accountsformostofourcarbondioxideco emis futurefacilitiesandrefurbishedbuildingstominimise sionsweconvertamountsofco andothergreen energyuse housegasghgemissionssuchashalogenate hydrocarbonsleakingfromrefrigerationequipment milanhasaproblemitisoneofthemostpolluted intocoequivalentsinweemittedthou citiesineuropesmogisatarecordlevelfarabove sandtonnesofcoequivalentsanabsolutedecrease europeanunionlimitsrochemonzaitalybegan offromthisreductioncomesdespite aprogrammetoreduceitsenvironmentalimpactsin increasedenergyconsumptionduetorevisedemis bymodifyingtransportincreasingrecyclingand lrochearengcorporate responsibility partindd reduce total energy consumption greenhouse gas emission energy use select type fuel company vehicle introducedanewtargetforoureuropeancom panycarfleettoincludeonlyvehiclesproduce nomorethangramsofcarbondioxideco perkilometrebytheendof fuel business air travel videoandteleconferencingfacilitieshavebeen establishedatallsitesandarewidelysupporte employeesareencouragedtousetrainsand toconsolidateseveralbusinesstripsintoone grid electricity natural gas ourfirstpriorityistoreduceusageofenergy fortheenergywedousewelookforwaysof improvingtheefficiencysuchasheatrecovery inadditionweencouragetheuseofgreen energywhereversensibletohelpdrivethisin wereleasedourgroupwidemanual onenergyefficientdesignfortheconstruction offuturefacilitiesthatminimiseenergyuse reducingenergyusethroughsensorlightsand genentechmetitsownghgemissionsreduction energysavinglightbulbsinthesiteincrease goaltwoyearsaheadofscheduleitwillnowjointhe itsfocuslifegateanexternalenvironmentalorgani restofrochesusaffiliatesinpursuinganewgoalof sationbasedinmonzanowmonitorsenergyand decreasingemissionsbyby waterusewastedisposallogisticsandemployee transportthesitehasalsostartedbuyingofit rochehasagroupdirectiveonenergyconservation energyfromrenewablesourcesinadditionaninter whichpromoteslocalinitiativesitincludesenergy nalawarenesscampaignhasencouragedemployee efficiencystandardsfornewandexistingelectrical togetinvolvedinenergysavinginitiativessofar equipmentandrequiressitestoconductenergy thesitehasreducedco emissionsbyaround audits theusenvironmentalprotectionagencyepahas theauditsidentifiedopportunitiestoimprove commendedourusaffiliatesformeetingtheirgoalto ourbuildingsutilitiesplantsandprocessesinclude reduceghgemissionsbybetweenand thoseatgenentechtheseincludeimprovedmetering aheadoftimerocheushaspledgedtoreduce andmonitoringretrocommissioningbuilding emissionsbyafurtherfromto andadaptinglightingandairconditioningsystem lrochearengcorporate responsibility partindd roche business report corporate responsibility despitethesecentralfunctionswegivesitesthe ozone depletion freedomtodeveloptheirownemissionsreduction thetargetdateforrochesdirectivetophaseout strategieswebelievethisapproachimprovesresult halogenatedhydrocarbonscfcsandhcfcswhich becausesitesaremorefamiliarwiththeirownneed damagetheozonelayerandaffecttheclimatehas andcircumstancesforexamplerocheshanghai beenextendedfromtoordepende hasanongoingprojecttoincreaseenergyefficiency onthelocalsituationthisisduetoalackofaccepte theprogrammehasseentheintroductionoftriple alternativesinsomecountriesgenentechhasnot anddoubleglazingoptimalinsulationgeothermal yetdefinedatargetdatebutiscommittedtophase heatingandcoolinglowpowerenergysystemsand thesegasesout solarwaterheate replacementsforhcfcsandcfcssuchashfcs businesstravelaccountsforapproximatelyof hydrofluorocarbonsandpfcsperfluorinated ourtotalco emissionsoverallandourcarfleetis carbonsdonotaffecttheozonelayerbuttheycan responsibleforapproximatelyemployeesare contributetoclimatechangeandarepersistentin encouragedtousetrainswhentravelisnecessary theenvironmentsowedonotconsiderthemalong andtoconsolidateseveralbusinesstripsintoone termalternativerochehasatargettophaseout videoandteleconferencingfacilitiesalsohelpusmini hfcsandpfcsbygenentechandotherrecent misetravelforexamplerochefinlandworkedwith acquisitionswillworktoaseparatedeadlinetobe wwffinlandtohosttheamericansocietyofclinical definedinsometechnicalproblemscontinueto oncologysannualmeetingvirtuallyinjune preventusfromreplacingtheseinallapplication aroundcustomersattendedtheconferencefrom butweareworkingtofindalternativetechnologie theirclinicsparticipatingthroughvideostreame severalsitesnowusetelepresencesystemswhich ozonedeplete chemical tonne significantlyimprovethequalityofvideoconference encouragingincreasedusage halogenate anewtargetforoureuropeancompanycarfleet hydrocarbon holding aimstoensurewewillusevehiclesproducingnomore halogenate thangrammesofco perkilometrebytheend hydrocarbon ofthiswillcutco emissionsbytonne emission andsavetwomillionlitresoffuelperyear rocheshalogenatedhydrocarbonsinventoryincrease anumberofsiteshavelaunchedinitiativestoencour induetotheintroductionofgenentechs agestaffnottouseprivatecarstocommutetowork holdingstothegrouptotalwithoutthisincrease atgenentechforexamplethegrideprogrammehas rochesholdingswouldhavedecrease promotedalternativessuchasvanpoolingmass transitcyclingwalkingandgenenbusshuttlessince emission air theshuttleswereupdatedinwithnewer emissionstoairfromouroperationsincludevolatile moreefficientmodelsthatmeettheusepas organiccompoundsvocsparticulatesnitrogen standardforparticulateemissionsatrotkreuz oxidesnoandsulphurdioxideso weaim x switzerlandwehaveintroducedanannualbonusof toreducetheseemissionswhichcancontributeto swissfrancsforstaffwhocommutetowork airpollutionsmogandacidraininwereduce withoutusingacarormotorbike vocemissionsbytotonnesouremis sionsofparticulatesno andso weretonne x lrochearengcorporate responsibility partindd tonnesandtonnesrespectivelythesefluctuate wemonitorlandfillsitestoensureourchemicalwaste atlowlevelsfromyeartoyear doesnotposearisktohumanhealthortheenviron mentsomelandfillsneedtobesustainablyremedi emission air tonne atedinwecompletedaprojecttoremediatethe hirschackerlandfillingrenzachgermanyroche voluntarilyfinancedthisprojectinwemade vocs availableapproximatelymillionswissfrancsfor particulate othersuchproject nitrogen oxides sulphur dioxide water weneedcleanwaterformanufacturingbutwe waste understandtheneedtoreduceourwaterusebased aroundofourchemicalwasteisincinerate ontheglobalreportinginitiativesdefinitionof thedisposalmethodwiththeleastenvironmental waterconsumptionwaterusedinproductscoole impactinweproducedtonnesofchemi andirrigationouruseincreasedbywe calwasteandecreasefromthisdoe usedmillionmofwaterin notincludewastethatcanbereusedasrawmaterial byothercompaniesinwesoldaround thewaterweusecanbecontaminatedduringmanu tonnesmostlysolventsforreuse facturingsowetreatwastewatertoensureitis safeforpeopleandtheenvironmentwecontinueto inweengagedinsignificantbuildingactiv developwaystoincreaseourcapacitytotreatwaste itywhilewascharacterisedbybuilde wateraroundthegroup demolitionwegeneratedlessgeneralwaste tonnesbutourrecyclingratesincrease oneofthewinningsubmissionsofecompetition duetotonnesofbuildingrubblemade camefromrochepenzberggermanythesubmission availableforrecyclingmostlymetalsandconcrete outlinesaproposaltouseresidualwaterfromthe soldtoothercompaniesforreuseexcludingthis distillationofpurifiedwatertogeneratesteamforthe buildingrubblewerecycledtonne plantsboiler morethanlastyearwedecreasedgeneralwastesent tolandfillbyofthetotaltwere inwedecreasedtheamountoforganicmaterial incinerate dischargedintowatercoursesaftertreatmentby totonnesthisismainlyduetoarecalcula waste tonne tionofdatafromtwositesbecauseinvestigationsinto differencesatsimilarsitesrevealedthattheyhad overreportedinpreviousyearswealsorelease general waste kilogramsofheavymetalssuchaschromium produce copperandzinclessthanin general waste million chf ournewgoaltoreducetoxicityofdischarged sale wastewaterreflectsthegenerallylowertoxicityof chemical waste organicmatterfrombiotechoperationsthanfrom produce chemicalproduction chemical waste million chf sale lrochearengcorporate responsibility partindd roche business report corporate responsibility water compliance incident rochedidnotreceiveanysignificantshefinesin wemeetalllocallawsorregulationsasaminimum water withdraw howeverourgrouppoliciesareoftenstricterthan million cubic metre thesewecontrolsubstancesthatcouldbemisused water toproducenarcoticstoxinsorchemicalandbio million cubic metre weaponsthesesubstanceswhichwekeepinsmall wastewater discharge supplyareoftenregulatedandweensurecompliance treatment plant withallapplicablelegislation million cubic metre organic matter objective discharge reducetherocheaccidentratebyby watercourse fromthebaseline treatment tonne improvetotalecobalancebybyfrom heavy metal baselinepointsemployee discharge reducetotalenergyconsumptionbyby watercourse frombaselinegigajoulesemployee treatment receivenosignificantsherelatedfine kilogramme medium longterm objective pharmaceutical environment pie averagefourhoursofshetrainingperemployee tracesofpharmaceuticalproductsendupintheenvi reducetherocheaccidentraterarto ronmentraisingfearsthattheymaylaterbefoundin andworkrelatedaccidentspermillionworke foodandwatersourcesthisisusuallyduetonormal hourstobelowby patientusealthoughmanufacturingandimproper improveourecobalancebybyfrom disposalalsocontributeweofferretailersfinancial abaseline incentivestoreturnunusedoroldproductssowecan improveenergyefficiencymeasuredasgigajoule discardthemproperlyweanalysetheriskofpharma peremployeebybyandby ceuticalsenteringtheenvironmentinourlifecycle comparedwith approachtoproductdevelopmentminimising increasetheproportionofrenewableenergyuse releaseswherepossiblemanufacturingsitesare toby designedandoperatedtoreduceactiveingredient reducethetoxicityofdischargedwastewaterby enteringwastewater byfromabaseline althoughcurrentevidencesuggestslittlepresenceof web piewerecognisetheneedformoreresearchinto performance longtermeffectsinweundertookathorough wwwrochecomsheperformance safety security health environmental protection riskassessmentoftheactiveingredientoseltamivir wwwrochecomenvironment tamiflubeingexcretedintotheenvironmentdure safety security health environmental protection heavypandemicusetheassessmentfoundno signifi policy cantriskourpositionpaperonpiedescribe wwwrochecomsafetyhealthandenvironmental protectionpdf ouraimtomonitorrisksandrocheisamemberof group fact sheet position policy guideline internationalandlocalbodiesstudyingtheimpactsof wwwrochecompoliciesguidelinesandposition tracechemicalsinsurfaceandgroundwater genentech sustainability report wwwgenecomgeneaboutenvironmental lrochearengcorporate responsibility partindd independent assurance report tothecorporatesustainabilitycommitteeof therochecorporatesustainabilitycommitteeisresponsible rocheholdingltdbaselroche forboththesubjectmatterandthecriteriaourresponsibilityis toprovideaconclusiononthesubjectmatterbasedon wehaveperformedassuranceprocedurestoprovideassurance ourassuranceproceduresinaccordancewiththeinternational onthefollowingaspectsofthecorporateresponsibility standardonassuranceengagementsisae reportingofroche main assurance procedure subject matter ourassuranceproceduresincludedthefollowingwork dataandinformationdisclosedinthecorporateresponsibility evaluation application group guideline reportingofrocheanditsconsolidatedsubsidiariesexcluding reviewingtheapplicationoftherocheinternalcorporate chugaipharmaceuticalcoltdforthebusinessyearende responsibilityreportingguideline decemberonthefollowingaspect site visit visitingselectedsitesofrochespharmaceuti themanagementandreportingprocesseswithrespectto calsanddiagnosticsdivisionsinswitzerlandgermany thecorporateresponsibilityreportingandtothepreparation francespainitalyandchinatheselectionwasbasedon ofsheandpeoplekeyfiguresaswellasthecontrol quantitativeandqualitativecriteria environmentinrelationtothedataaggregationofthese interviewingpersonnelresponsibleforcompliancematter keyfigure internalcorporateresponsibilityreportinganddata theshekeyfiguresinthetablesonpagestoand collectionatthesiteswevisitedandatthegrouplevelto someselectedpeoplekeyfiguresdisclosedonpage determinetheunderstandingandapplicationofroche tooftherocheannualreportand internalcorporateresponsibilityguideline complianceinformationconcerningthecompliance visitingthepremisesofpeopleintouchinamsterdam functionsthecomplianceorganisationandthemanagement interviewswithpeopleintouchstaffinvolvedindesign ofcasesreportedthroughtherochegroupspeakupline implementationandoperationsofthespeakupsolution thelatterwithafocusondataprivacyandprotectionof assessment key figure performingtestson individualsanonymityasdisclosedonpageoftheroche asamplebasisofevidencesupportingselectedsheand annualreportexcludingethicalincidentdata peoplekeyfiguresrocheaccidentrateenergyconsump tionco emissionsrelatedtoenergyconsumptionrelease criterion ofhalogenatedhydrocarbonsuseofwaterfinesinrelation therochegroupinternalcorporateresponsibilityreporte tosafetyandenvironmentalprotectionheadcountftedata guidelinesbasedontheresponsiblecareprogramme staffturnoverseniormanagementpositionsandlabor healthsafetyandenvironmentalprotectionreporting practicesinformationconcerningcompletenessaccuracy guidelinespublishedbytheeuropeanchemicalindustry adequacyandconsistency councilceficandthesustainabilityreportingguideline review documentation analysis relevant gpublishedonoctoberbytheglobalreporting policy basic principle reviewingtherelevant initiativegriand documentationonasamplebasisincludinggroupsustain thedefinedproceduresbywhichsheandpeoplekey abilitypoliciesmanagementandreportingstructuresand figuresaregatheredcollatedandaggregatedinternally documentation therochegroupbusinessprinciplestheinternalgroup assessment process datum con solidation speakupguidelinesbasedonthedirectiveonuseof reviewingtheappropriatenessofthemanagementand rochegroupspeakuplineandgoodpracticeprocedure reportingprocessesforcorporateresponsibilityreporte bywhichcompliancefunctionsandspeakuplinesare andassessingtheconsolidationprocessofdataatthe designedmanagedandoperate grouplevel assessment speakup process system responsibility methodology case management walkthroughthespeakupprocess theaccuracyandcompletenessofcorporateresponsibilityindi byusingapracticalexampleandassessingthefollowe catorsaresubjecttoinherentlimitationsgiventheirnatureand protectionagainstunauthorisedaccessconnectionsand methodsfordeterminingcalculatingandestimatingsuchdata processestoexternalserviceprovidersandexternal ourassurancereportshouldthereforebereadinconnection businesspartnersprocessesinplaceforadministration withrochesinternalguidelinesdefinitionsandprocedureson loggingmonitoringandbackuprestoreallinrelationtothe thereportingofitscorporateresponsibilityperformance dataprivacyandanonymity lrochearengcorporate responsibility partindd roche business report independent assurance report conclusion global reporting inouropinion initiative sustainability theinternalcorporateresponsibilityreportingguidelinesare beingappliedproperly report guideline theinternalreportingsystemtocollectandaggregateshe andpeoplekeyfiguresisfunctioningasdesignedand withthisyearsannualreportwecontinueourapproachof providesanappropriatebasisforitsdisclosureand aligningoursustainabilityreportingtotheguidelinesofthe therochegroupspeakuplinesystemsandprocessesare globalreportinginitiativegri designedfollowinggoodpracticeprocedureswithregardto dataprivacyandanonymity forthethirdtimerocheisoftheopinionthatthealevel ofthegrigguidelinesappliestoitsannualreport basedonourworkdescribedinthisreportandtheassessment thiswascheckedwithandconfirmedbythegri ofcriterianothinghascometoourattentionthatcausesusto believethatthedataandinformationmentionedinthesubject detailsofhowwereportagainsteachindicatorcanbefound matteranddisclosedwiththesustainabilityreportingin atwwwrochecomreportingandindice therocheannualreportexcludingethicalincidentdata doesnotgiveafairpictureofrochesperformance zurichjanuary pricewaterhousecoopersag drthomasscheiwiller stephanhirschi severinschwan lrochearengcorporate responsibility partindd publish cautionary statement forwardlooke f hoffmannla roche ltd statement basel switzerland annual report contain certain forwardlooke state tel ment forwardlooke statement identify fax word believe expect anticipate project intend seek estimate future similar expression discussion thing strategy medium office goal plan intention factor cause actual group communication result differ materially future reflect basel switzerland forwardlooke statement contain annual report tel price product initiative competi fax tor legislative regulatory development eco nomic condition delay inability obtain regulatory investor relation approval bring product market fluctuation currency exchange rate general financial market condi basel switzerland tion uncertainty discovery development tel marketing new product new use exist product fax include limitation negative result clinical trial research project unexpected effect pipeline world wide web market product increase government pricing pre wwwrochecom sure interruption production loss inability obtain adequate protection intellectual property right corporate sustainability committee litigation loss key executive employee adverse publicity news coverage tel email corporatesustainabilityrochecom statement earning share growth profit forecast interpret mean order publication roche earning earning share tel subsequent period necessarily match exceed fax historical publish earning earning share roche email baselwebmasterrochecom trademark mention enjoy legal protection annual general meeting link party page provide convenience march express opinion content party page expressly disclaim liability party information use roche annual report publish german english print nonchlorine bleach fsccertified paper roche annual report issue f hoffmannla roche ltd basel group communication cover photograph show ribbon diagram rituximab therapeutic protein heart mabtherarituxan target bio logic medicine treat nonhodgkin lymphoma chronic lymphocytic leukemia rheumatoid arthritis lrochearengimprintindd e roche annual report key figure key figure index figure annual report exceptional item index global reporting initiative gri propose board director indicator report development phase iv wwwrochecomreportingandindice calculation ecoefficiency rate wwwrochecomenvironment e lrochearengkey figuresindd roche finance report fr hyr eng ceonvge rc ver uhr usheri es eite rroocchhee afinnnaunacle r reeppoortrt fhopfufmbalinshnelda bryoche ltd f bhaosfefml asnwnitzlear lranodche ltd basel switzerland aallll ttrraaddeemmaarrkkss mareen lteiognaellyd pernojtoeyc lteegdal protection trademark mention enjoy legal protection wwwrochecom roche halfyear report wwwrochecom lead biotechnology improve patient care excellence science umschlagausgeschossenengindd lrochearengfront coverindd roche finance reporttable content roche group finance brief finance brief financial review roche group consolidated financial statement note roche group consolidated financial statement report roche management internal control financial reporting report statutory auditor consolidated financial statement report independent auditor internal control financial report multiyear overview supplementary information roche security roche holding ltd basel financial statement note financial statement include board executive remuneration disclosure require swiss law appropriation available earning report statutory auditor financial statement roche finance report roche group finance brief finance brief key result local sale growth operate profit margin exceptional item sale pharmaceutical diagnostic group change sales mchf mchf chf lc sales research development operating profit exceptional item operate free cash flow net income net income attributable roche shareholder free cash flow core ep chf dividend sharein chf december december change chf net cash debt capitalisation debt equity definition core ep propose board director lc local currency finance executive committee erich hunziker chief financial officer peter eisenre tax insurance marco frei pension asset management andreas knierzinger treasury karl mahler investor relation carole nuechterlein venture fund erwin schneider accounting control nigel sheail corporate development finance brief roche finance report finance brief sale group sale increase local currency billion swiss franc exclude tamiflu sale theincrease local currency pharmaceutical sale increase local currency billion swiss franc twice globalmarket growth thank virology particular tamiflu key oncology product lucentis inophthalmology achieve spite reduction cellcept sale patent expiry theunite state tamiflu sale grow sharply billion swiss franc billion swiss franc drive current pandemica hn influenza virus swine flu outbreak diagnostic sale increase local currency billion swiss franc drive sale growth professional diagnostic diabetes care twice estimate ivd market growth rate operating result operate profit exceptional item increase local currency billion swiss franc thank strong sale growth continue productivity improvement cover increase investment research development operating profit margin exceptional item constant exchange rate increase percentage point increase percentage point pharmaceutical division percentage point inthediagnostic division exchange rate unfavourable impact approximately percentage point ongroup pharmaceutical diagnostic margin research development expenditure increase local currency billion swiss franc represent group sale mainly continue investment strong latestage pipeline effective march roche obtain ownership genentech total cash consideration bil lion dollar billion swiss franc exceptional restructuring cost billion swiss franc incur respect integration genentech relate restructuring pharmaceutical division notably manufacture operation treasury consequence genentech transaction group treasury result change significantly net financial result expense billion swiss franc primarily drive bythehigher interest expense billion swiss franc bond note issue early finance genentech transaction billion swiss franc repay second half financial condition strong financial condition free cash flow billion swiss franc swing billion swiss franc net cash position billion swiss franc december toa net debt position billion swiss franc december finance genentech transaction follow genentech transaction moodys lower roche rating aa standard poor lower roche rating aa aa net income core eps net income decrease billion swiss franc primarily drive exceptional item relate tothe genentech transaction restructuring pharmaceutical manufacturing operation dilute eps decrease decrease net income positive impact ownership ofgenentech genentech transaction accretive net income attributable roche shareholder exceptional item increase billion swiss franc core ep high constant exchange rate high swiss franc shareholder return increase total shareholder return tsr ie share price growth plus dividend combine performance share nonvoting equity security increase propose dividend swiss franc represent rdconsecutive year dividend growth approve shareholder result increase payout ratio high dividend yield onroche shares nonvoting equity security base yearend price roche finance report roche group financial review roche group financial review group operating result operate profit sale billion chf exceptional item billion chf lc growth sale group continue strong operating performance previous year significant positive contribution increase tamiflu sale group maintain plan investment research development complete transaction ownership genentech make significant progress relate integration restructuring activity total sale grow local currency swiss franc dollar billion swiss franc pharmaceutical division represent group sale diagnostic division contribute demand medicine fromthe group oncology franchise remain strong avastin herceptin mabtherarituxan tarceva andxeloda contribute overall growth additional major growth driver pharmaceutical division tamiflu virology lucentis ophthalmology mircera show steady sale development inwestern europe actemraroactemra continue strong growth japan launch country western europe market positive factor offset reduction sale follow expiry patent cellcept diagnostic division main growth area professional diagnostic diabetes care tissue diagnostic continue strong sale increase sale growth division exceed market growth group operate profit exceptional item increase local currency swiss franc sale growth reflect group focus cost management line growth pharmaceutical division increase operating profit exceptional item local currency drive strong sale growth combine overall underproportionate growth cost research development expense grow local currency reflect investment group strong latestage pipeline include promise compound dalcetrapib taspoglutide pertuzumab tdm rise rd expense drive high impairment intangible asset million swiss franc million swiss franc higher primarily result recent clinical datum technology assessment portfolio prioritisation decision operate profit growth diagnostic division local currency main factor sale growth tight cost management andthe absence accounting impact year acquisition ventana constant exchange rate group operate profit margin exceptional item increase percentage point pharmaceutical division improve percentage point diagnostic division percentage point translate swiss franc group operate profit margin exceptional item increase slightly percentage point particularly unfavourable combina tion exchange rate movement table analysis page group operate free cash flow increase strongly local currency swiss franc billion swiss franc follow improved result business absence net cash outflow associate genentech stock option plan pharmaceutical division incur exceptional operating expense billion swiss franc relate tothe genentech transaction restructuring pharmaceutical division notably manufacture operation increase provision major legal case comparative period containedexceptional operating income million swiss franc litigation settlement genentech expense million swiss franc initial stage pharmaceutical division reorganisation swing billion swiss franc exceptional item total lead decline group operate profit swiss franc local currency noncash item account billion swiss francsof exceptional operating expense relate mainly impairment manufacturing site announce half group operating result pharmaceutical diagnostic corporate group mchf mchf mchf mchf sale operating profit exceptional item margin sale operate free cash flow margin sale group operating result development result compare pharmaceutical diagnostic corporate group sale increase local currency operate profit exceptional item increase local currency margin percentage point increase operate free cash flow increase local currency margin percentage point increase pharmaceutical operating result pharmaceutical division increase sale local currency swiss franc usdollar billion swiss franc double global market growth operating profit exceptional item billion swiss franc constant exchange rate operate profit margin increase percentage point sale growth overall low cost growth spite significantly increase research development expense include impairment charge low gain product disposal translate swiss franc margin increase percentage point particularly unfavourable combination exchange rate movement table analysis page constant exchange rate half margin increase percentage point yearonyear follow reduction percentage point second half reduction primarily drive accelerate rd growth include impairment intangible asset second half account negative swing percentage point roche finance report roche group financial review marketing cost increase moderately local currency promote grow oncology rheumatoid arthritis portfolio investment broad indication particularly avastin aswell launch actemraroactemra western europe country strong increase research development expense significantly increase sale continue high investment strong pipeline expand portfolio large number latestage clinical trial impairment intangible asset information divisional business pipeline business report annual report pharmaceutical division result change change mchf mchf chf local currency sale royalty operate income cost sale marketing distribution research development general administration operating profit exceptional item margin sale operate free cash flow margin sale sale major growth driver strong tamiflu sale virology therapeutic area key product oncology lucentis ophthalmology sale renal anemia therapeutic area remain stable increasingly competitive costsensitive market sale inflammationautoimmunetransplantation decline tothe expected negative impact cellcept patent expiry united states partly offset continued success mabtherarituxan rheumatoid arthritis continue strong growth ofactemraroactemra japan postlaunch market western europe salesin metabolismbone portfolio decline mainly low bonvivaboniva sale follow generic competition decline bisphosphonate market pharmaceutical division sale therapeutic area sale change therapeutic area mchf sale local currency oncology virology inflammationautoimmunetransplantation metabolismbone renal anemia total pharmaceutical product represent pharmaceutical portfolio grow majority product show sale growth tamiflu local sale growth pharmaceutical division primarily come product avastin herceptin mabtherarituxan lucentis mircera tarceva activasetnkase actemraroactemra product represent ofthe portfolio generate billion swiss franc additional sale compare sale cellcept decline patent expiry united states sale decline primarily generic erosion follow patent expiry strong competition certain franchise product disposal voluntary withdrawal raptiva partly compensate steady growth launch impact mircera actemraroactemra pharmaceutical division sale product sale change product mchf sale local currency franchise avastin oncology mabtherarituxan oncologyiat herceptin oncology tamiflu virology pegasys virology cellcept iat neorecormonepogin renal anemia oncology tarceva oncology xeloda oncology lucentis ophthalmology bonvivaboniva metabolismbone xolair respiratory disease valcytecymevene virology pulmozyme respiratory disease activasetnkase cardiovascular disease nutropin metabolismbone xenical metabolismbone neutrogin oncology rocephin infectious disease madopar nervous system total product product total inflammationautoimmunetransplantation avastin sale rise billion swiss franc sustain growth region drive primarily continue uptake colorectal breast lung cancer united states sale growth came mainly use advanced breast cancer new indication glioblastoma kidney cancer whilehigh penetration rate maintain establish indication lung colorectal cancer sale japan avastin approve advanced colorectal nonsmall cell lung cancer remain particularly strong mabtherarituxan overall sale rise billion swiss franc growth oncology segment wasdriven uptake chronic lymphocytic leukemia follow approval eu year low sale growth reflect high level adoption product cancer indication increase sale rheumatoid arthritis ra segment increase early use mabthera rituxan patient inadequate response tumour necrosis factor tnf inhibitor mabtherarituxan establish medicine choice follow inadequate response tnf inhibitor treatment currently market leader segment eu estimate million swiss franc sale generate ra indication represent overall product sale herceptin sale herceptin increase billion swiss franc drive continued uptake early breast cancer especially japan number emerge market increase market penetration eastern europe moderate sale growth western europe reflect high market penetration achieve early advanced breast cancer region roche finance report roche group financial review tamiflu global sale antiinfluenza medicine tamiflu total billion swiss franc anincrease billion swiss franc year high growth drive unprecedented demand government retail pharmacy sector follow pandemic ahn influenza virus swine flu outbreak begin april spread rapidly theworld sale pandemic stockpiling amount billion swiss franc roche cooperate closely world health organization government worldwide support pandemic preparedness supply tamiflu patient need pegasys sale pegasy rise billion swiss franc growth drive marketshare gain major market cellcept sale cellcept prevention solid organ transplant rejection decrease compare billion swiss franc expect sales united states product large market fellsharply yearonyear quarter result expiry product patent continue erosion sale generic competition offset extent bycontinue solid growth particularly latin america japan neorecormonepogin combine sale roche neorecormon chugais epogin epoetin beta weredown compare decline neorecormon sale primarily drive western europe mainly increase price pressure new biosimilar enter market slight decline insale epogin japan reflect stabilisation product market share dialysis segment continue expansion predialysis set tarceva sale increase reflect grow use medicine secondline nonsmall cell lung cancer outside metastatic pancreatic cancer main sale contribution come united states western europe modest growth sale reflect stable penetration nsclc pancreatic cancer competitive environment reserve adjustment take yearfor government programme involve discount xeloda overall sale rise billion swiss franc come primarily growth united statesjapan china growth came use medicine metastatic breast cancer adjuvant colon cancer metastatic colorectal cancer lucentis sale lucentis wet agerelate macular degeneration amd increase billion swiss franc compare strong growth drive primarily increase number ofinjection administer patient second year treatment growth number ofpatient treat wet amd easy reimbursement bonvivaboniva highly competitive market sale bonvivaboniva ibandronic acid treatment postmenopausal osteoporosis decline compare decline drive generic competition decline bisphosphonate market sale western europe international asiapacific cemai latin america canada region increase byand respectively mircera highly competitive pricesensitive market sale renal anemia medication mircera show consistent growth rise million swiss franc sale growth primarily tothe success product predialysis segment actemraroactemra follow eu marketing approval january novel rheumatoid arthritis ra medicine roactemra know actemra outside europe end year medicine launch eu country include germany france spain united kingdom sale uptake initial european launch market strong launch take place additional market include switzerland india brazil global sale rise million swiss franc japan actemra hasbeen approve ra adult relate pediatric indication april adoption market penetration progress doctor prescribe medicine firstline biologic treatment patient sale japan amount million swiss franc increase business report annual report information roche pharmaceutical product sale region sale continue grow region growth united states line local market growth success oncology product tamiflu lucentis cover thepatent expiry cellcept voluntary withdrawal raptiva reduction sale bonvivaboniva pricing pressure cause increase competition pharmaceutical division continue gain market share western europe cemai asiapacific region drive strong sale growth oftamiflu avastin herceptin mabtherarituxan mircera tarceva bonvivaboniva pegasys sales japan increase strongly high tamiflu sale success avastin herceptin actemra compensate low neutrogin sale total tamiflu sale increase strongly particularly inwestern europe japan markets government corporate pandemic stockpiling therewere high seasonal sale result increase demand follow pandemic hn influenza virus case country pharmaceutical division sale region sale change region mchf sale local currency united states western europe japan cemai latin america asiapacific region international total central eastern europe middle east africa central asia indian subcontinent operating result royalty operating income decline million swiss franc local currency particular million swiss franc low gain disposal product partly offset high royalty income income outlicense agreement decline gain disposal product mainly significant product disposal total million swiss franc notably meda actavis gain disposal product million swiss franc partof continuous realignment product portfolio mainly relate divestment tail product latin america increase outlicense income mainly drive significant milestone payment glaxosmithkline million swiss franc relate orlistat otc approval eu million swiss franc bonvivaboniva royalty operating income percentage sale decrease percentage point pharmaceutical division royalty operating income change mchf mchf local currency royalty income income outlicense agreement income disposal product total roche finance report roche group financial review cost sale cost increase local currency drive rise manufacturing cost good sell period cost increase line sale growth efficiency gain production offset unfavourable product mix impact inventory writeoff million swiss franc follow voluntary withdrawal raptiva market royalty expense increase million swiss franc million swiss franc mainly royalty expense high tamiflu sale expense collaboration profitshare agreement increase local currency mainly genentech payment million swiss franc million swiss franc biogen idec novartis osi respect mabtherarituxan xolair tarceva expense profitshare arrangement glaxosmithkline decrease local currency lower bonvivaboniva salesinthe united states reach million swiss franc million swiss franc amortisation intangible asset decrease local currency intangible asset fully amortise percentage sale cost sale decrease percentage point pharmaceutical division cost sale change mchf mchf local currency manufacturing cost good sell period cost royalty expense collaboration profitshare agreement restructuring expense amortisation intangible asset impairment property plant equipment impairment intangible asset total marketing distribution cost increase moderately local currency reach billion swiss franc billion swiss franc focus oncology portfolio rollout additional approve indication avastin high level investment continue pegasys launch actemraroactemra rheumatoid arthritis additionally investment focusse onemerge market marketing distribution cost percentage sale decrease percentage point research development significant increase local currency billion swiss franc reflect investment roche strong laterstage pipeline include promise compound dalcetrapib cetp inhibitor dyslipidemia taspoglutide glp analogue type diabete pertuzumab tdm herpositive breast cancer impairment intangible asset increase million swiss franc compare comparative period million swiss franc impairment intangible asset percent sale relate primarily decision discontinue project recent clinical datum technology assessment portfolio prioritisation research development cost percentage ofsale compare half division spend million swiss franc inlicense pipeline compound technology capitalise asintangible asset require ifrs exclude impairment amortisation charge division spend billion swiss franc internal purchase rd inlicense alliance deal represent sale addition million swiss franc spend acquisition ofmemory pharmaceutical pharmaceutical division investment research development change mchf mchf local currency research development expense noncash item amortisation intangible asset impairment intangible asset research development expense exclude noncash item product intangible available use technology intangible research development relate capital expenditure total investment research development general administration overall cost decrease local currency drive low administration cost onetime effect divestment restructure expense provision legal environmental matter increase overall general administration expense apercentage sale decrease pharmaceutical division general administration change mchf mchf local currency administration legal environmental settlement business combination gain loss divestment business restructure expense gain loss disposal property plant equipment general item total exceptional item major legal case provision major legal case increase million swiss franc base management current estimate ultimate liability expect arise take account development litigation arbitration process negotiation resolve casesin income million swiss franc record release provision follow theapril california supreme court decision city hope litigation additional information isgiven note consolidated financial statement change group organisation effective march group obtain fullownership genentech continue implementation reorganisation group pharmaceuticals business announce july subsequently group commence restructuring pharmaceutical manufacturing operation particularly biotech network expense million swiss franc incur mainly connection discontinuation construction project manu facture site vacaville california termination cost closure manufacturing operation nutley new jersey research development site palo alto california addition cost incur follow reorganisation include transfer research operation palo alto nutley transfer commercial operation nutley south san francisco approximately billion swiss franc exceptional operating expense noncash item relate mainly impairment manufacture site additional information give note consolidated financial statement roche finance report roche group financial review group currently anticipate restructure activity substantially complete endof total cost expect order billion swiss franc include mil lion swiss franc incur approximately billion swiss franc total noncash thecarrying value property plant equipment reduce billion swiss franc end anticipate reduce approximately billion swiss franc total end relate manufacture facility pharmaceutical division total operating result change mchf mchf local currency operate profit exceptional item major legal case change group organisation operate profit operate free cash flow pharmaceutical division continue generate strong cash flow operate free cash flow increase local currency drive excellent operating performance operate profit cash adjustment increase mainly billion swiss franc noncash element change group organisation furthermore noncash provision expense exceed provision payment million swiss franc provision payment exceed noncash provision expense million swiss franc mainly million dollar pay genentech exist provision settle litigation net working capital decrease million swiss franc main factor high account payable primarily defer income prepay tamiflu consignment delivery increase royalty payable gilead respect tamiflu overall inventory level decrease slightly absolute term percent age sale inventory decrease percentage point constant currency operational initiative reduce average product inventory hand especially biologic product account receivable increase local currency underproportional sale growth percent age sale account receivable drop percentage point constant currency overall capital expenditure low percentage sale operate free cash flow pharma ceutical division increase compare pharmaceutical division operate free cash flow mchf mchf operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment increase decrease net work capital account receivable inventory account payable total increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale operate profit cash adjustment include elimination depreciation amortisation impairment charge replacement operating incomeexpense provision equity compensation plan disposal property plant equipment intangible asset cash equivalent detail breakdown provide diagnostic operating result diagnostic division increase sale billion swiss franc grow local currency swiss franc dollar growth twice estimate invitrodiagnostic market rate strengthen division lead market share operate profit increase local currency swiss franc million swiss franc drive thesale growth tight cost management significant oneoff expense item include relate ventana acquisition constant exchange rate operate profit margin increase bypercentage point translate swiss franc margin decrease slightly percentage point particularly unfavourable combination exchange rate movement seetable analysis page constant exchange rate margin increase percentage point half compare follow reduction percentage point second half compare continual improvement operational efficiency fully compensate impact impairment intangible asset additional royalty expense account negative swing percentage point second half ongoing initiative improve operational efficiency include simplify core process consolidation service function establishment regional centre combine streamline product portfolio intensify phase old lowselling product information divisional business pipeline business report annual report diagnostic division result change change mchf mchf chf local currency sale royalty operate income cost sale marketing distribution research development general administration operate profit margin sale operate free cash flow margin sale sale diagnostic business continue grow twice market rate increase local currency major driver professional diagnostic sale growth leverage byimmunodiagnostic diabetes care sale growth sale accuchek blood glucose monitoring system sale molecular diagnostic increase drive virology blood screening product apply science sale grow particular sale system reagent nucleic acid purification pcr analysis sale tissue diagnostic total million swiss franc drive sale advanced tissue stain market comparable yearonyear basis sale tissue diagnostic rise local currency diagnostic division sale business area sale change business area mchf sale local currency professional diagnostic diabetes care molecular diagnostic apply science tissue diagnostic total roche finance report roche group financial review professional diagnostic sale grow roughly twice market rate rise million swiss franc immunoassay business gain additional market share sale growth mainly new placement cobas modular analyser especially cobas strong sale assay forcardiac marker hepatitis c virus clinical chemistry sale rise line growth mature market cobas modular analyser series highthroughput laboratory receive ce mark certification august rollout new flagship serum work area platform commence highspeed c c clinical chemistry module available configuration eu market recognise ce mark cobas clinical chemistry immunoassay module beavailable worldwide offer customisable configuration end diabetes care sale rise million swiss franc sale blood glucose bg monitoring system continue growth significantly market impact theeconomic downturn particularly accuchek aviva accuchek performa remain primary growth driver helped recently launch accuchek aviva performa nano meter thefirst stripfree monitoring system accuchek mobile launch market experience excellent market uptake insulin delivery system post strong growth helped uptake new accuchek combo interactive insulin pumpbg meter combination launch key market promise preliminary result accuchek view outcome study present recent european diabetes congress suggest new diabetes management concept employ structure bg testing contribute improve glycemic control medical outcome noninsulindependent patient type diabete molecular diagnostic sale rise million swiss franc blood screen primary growth driver sale slightly ahead market period new contract spain portugal thailand competitive gain uk unit maintain leadership virology sale growth december molecular diagnostic launch new fully automate cobas system market accept ce mark certification menu currently comprise test chlamydia trachomatisct neisseria gonorrhoeaeng screening test human papillomavirus hpv simultaneously identify highrisk genotype apply science sale total million swiss franc abovemarket increase year magna pure lightcycler system nucleic acid purification pcr analysis large contributor growth help strong demand instrument reagent pandemic influenza testing surveillance realtime pandemic hn influenza virus test launch research use week new virus detect generate strong sale food drug administration fda grant emergency use authorization eua kit november make available clinical use certify labs sale dna sequence reagent overall sale dna sequence system flat economic downturn result decline inresearch funding notably tissue diagnostic sale total million swiss franc increase month sale consolidate follow ventana acquisition february year comparable yearonyear basis sale rise significantly outpace market leverage exist roche infrastructure cover previously underserve market advanced tissue stain remain primary growth driver withreagent immunohistochemistry ihc testing advanced stain instrument like benchmark ultra fuel robust growth segment highvolume primary stain market sale drive automate symphony system reagent hematoxylineosin stain business area launch new ihc reagent use help diagnose cancer include leukemia lymphoma cancer colon prostate lung stomach business report annual report information roche diagnostic product business area sale region divisional sale grow ahead market region japan price cutsoffset volume growth emea europe middle east africa asiapacific region contribute mostto growth business area record solid gain market north america intoughmarket condition main growthdriver tissue diagnostic japan growth professional diagnostic tissue diagnostic apply science offset sale decline molecular diagnostic affect weak market growth price cut diabetes care sale impact competitive pricing pressure sale emerge seven e market brazil russia india chinasouth korea mexico turkey grew account divisional sale growthcame increase investment market sale force sale support combine astrongdemand immunoassay leadingedge product roche portfolio diagnostic division sale region sale change region mchf sale local currency emea north america asiapacific latin america japan region total europe middle east africa operating result royalty operating income income million swiss franc high local currency compare royalty income increase local currency mainly result high probnp hcv royalty income outlicense income vary significantly period period oneoff nature decline local currency diagnostic division royalty operating income change mchf mchf local currency royalty income income outlicense agreement income disposal product total cost sale overall increase local currency high sale growth increase manufacturing cost good sell period cost addition comparative period include anacquisition accounting effect million swiss franc expense relate fairvalue writeup ventanas inventory exclude acquisition accounting effect manufacturing cost good sell period cost grow local currency continue investment expand market share place ment new accuchek meter startup cost accuchek mobile production increase instal instrument base professional diagnostic relate high depreciation impairment product intangible amount million swiss franc reduce revenue expectation acquire product total cost sale percentage sale increase exclude impairment ofintangible asset compare roche finance report roche group financial review diagnostic division cost sale change mchf mchf local currency manufacturing cost good sell period cost royalty expense collaboration profitshare agreement restructuring expense amortisation product intangible impairment property plant equipment impairment product intangible total marketing distribution increase local currency mainly investment competitively fund sequence array cellular analysis business apply science increase global market share recently acquire tissue diagnostic business marketing distribution percentage sale compare research development cost increase local currency reflect investment tissuediagnostic develop new product molecular diagnostic athena trial hpv claim addition intangible asset impairment million swiss franc percentage ofsale research development cost remain stable exclude impairment research anddevelopment expense percentage sale decline slightly diagnostic division investment research development change mchf mchf local currency research development expense noncash item amortisation intangible asset impairment intangible asset research development expense exclude noncash item general administration general administration cost decrease local currency primarily follow absence significant oneoff expense decline administration cost continuous efficiency improvement underlie cost structure inclusion million swiss franc ventana integration cost exclude oneoff expense general administration expense percentage sale remain basically stable compare diagnostic division general administration change mchf mchf local currency administration legal environmental settlement business combination restructuring expense gain loss disposal property plant equipment general item total operate free cash flow operate free cash flow diagnostic division increase local currency drive strong operating performance operate profit cash adjustment increase mainly provision noncash provision expense exceed provision payment million swiss franc provision payment exceed noncash provision expense million swiss franc net work capital increase million swiss franc mainly increase account receivable follow strong sale fourth quarter inventory increase slightly mainly result preparation launch cobas percentage sale operate free cash flow diagnostic division increase compare diagnostic division operate free cash flow mchf mchf operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment increase decrease net work capital account receivable inventory account payable total increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale operate profit cash adjustment include elimination depreciation amortisation impairment charge replacement operating incomeexpense provision equity compensation plan disposal property plant equipment intangible asset cash equivalent detail breakdown provide corporate operating cost general administration local currency cost high million swiss franc million swiss franc primarily increase million swiss franc environmental provision residual vitamin fine chemical business contribution million swiss franc tothe statemanage pension insurance scheme germany operate free cash flow net outflow million swiss franc net outflow million swiss franc mainly high operating expense roche finance report roche group financial review foreign exchange impact operating result group exposure movement foreign currency affect operating result express inswiss franc summarise follow key figure comment growth report local currency swiss franc change local currency change chf sale operating profit exceptional item exchange rate swiss franc december average december average usd eur jpy euro currency weaken swiss franc reduce trans lation swiss franc revenue expense euro currency time dollar stable japanese yen strengthen swiss franc strengthen translation group income statement increase swiss franc revenue expense denominate yen pharmaceutical division sale level negative translation impact euro currency partly offset positive impact yen sale growth local currency compare swiss franc operating profit level effect noticeable relatively high expense asset intensity eurozone country united states compare tojapan operating profit exceptional item increase local currency compare swiss franc margin increase percentage point local currency translate amarginincrease swiss franc diagnostic division effect pronounce relative strength asset intensity ofthe diagnostic division germany business japan represent relatively small proportion oftheoverall diagnostic result time key thirdparty supplier diagnostic instrument japanbase company invoicing yen combination mean negative impact euro strong yen strong positive impact result sale growth local currency translate swiss franc similarly operate profit excep tional item increase local currency translate swiss franc local currency margin increase percentage point translate swiss franc margin decline inswiss franc sensitivity group sale operating profit exceptional item absolute term movement foreign currency swiss franc show table currency sensitivity operate profit impact rise average exchange rate sale exceptional item versus swiss franc mchf mchf dollar euro japanese yen currency nonoperate result nonoperate result change mchf mchf chf operating profit associate financial income financing cost exceptional financing cost profit taxis income taxis income taxis exceptional item net income attributable roche shareholder noncontrolle interest net income exceptional item attributable roche shareholder noncontrolle interest group finance genentech transaction combination group fund bond note andcommercial paper group raise net proceed billion swiss franc series bond note offering consequence underlie dynamic group treasury result change significantly substantial increase interest expense finance cost exceed financial income million swiss franc addition exceptional financing cost million swiss franc record onetime cost directly attributable transaction tax impact financing cost contribute decline group effective tax rate exceptional item compare net income decrease primarily exceptional item exclude net income high financing cost income attributable roche share holder exceptional item higher lower noncontrolling interest follow thegenentech transaction compensate associate high financing cost roche finance report roche group financial review net financial result exceptional item millions chf financing cost financial income net financial result financial income financial income million swiss franc decline compare interest income andincome debt security million swiss franc low market interest rate change asset allocation bond loweryielde money instrument low debt security holding net income equity security million swiss franc compare million swiss franc expect return pension plan asset million swiss franc compare low asset base yearend analysis financial income give note consolidated financial statement financing cost finance cost million swiss franc million swiss franc higher reflect theadditional financing cost new debt issue connection genentech transaction theeffective date march december interest cost pension plan million swiss franc slight increase compare analysis financing cost give note consolidated financial statement exceptional financing cost order execute genentech transaction group liquidate certain debt security cash thisresulte net loss transaction million swiss franc furthermore prevail financial condition quarter group issue bond note advance trans action total billion swiss franc series debt offering interest expense instrument bridge period issue completion genentech transaction march million swiss franc income taxis group effective tax rate exceptional item decline compare rate main driver additional financing cost genentech transaction effective date march december net tax benefit million swiss franc record exceptional operating item connect withthe genentech transaction relate reorganisation pharmaceutical business addition income tax benefit million swiss franc respect genentech stock option clearly attributable genentech transaction exceptional tax item show table analysis group effective tax rate profit income profit income tax taxis tax rate tax taxis tax rate mchf mchf mchf mchf group effective tax rate exceptional item major legal case change group organisation exceptional financing cost group effective tax rate net income earning share net income attributable roche shareholder billions chf core eps chf group net income decrease billion swiss franc compare mainly totheexceptional item relate genentech transaction restructuring pharmaceutical manufacturing operation dilute eps decrease decrease net income thepositive impact ownership genentech net income attributable roche shareholder decline billion swiss franc total million swiss franc noncontrolle interest million swiss franc attributable genentech noncontrolle interest march million swiss franc chugai noncontrolle interest exclude exceptional item net income attributable toroche shareholder rise dilute eps chf chf change group core decrease dilute eps decrease net income attributable roche shareholder asdescribed core ep exclude exceptional item amortisation impairment intangible asset increase local currency swiss franc reflect positive development underlie business roche shareholder supplementary net income ep information givenon include calculation core ep reconcile group publish ifrs result cash flow net cash operate free cash flow billion chf free cash flow billion chf roche finance report roche group financial review free cash flow pharmaceutical diagnostic corporate group mchf mchf mchf mchf operating profit operate profit cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay dividend pay free cash flow operating profit operating profit cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay dividend pay free cash flow operating profit cash adjustment include elimination depreciation amortisation impairment charge replacement operating incomeexpense provision equity compensation plan disposal property plant equipment intangible asset cash equivalent detail breakdown provide free cash flow group increase significantly billion swiss franc billion swissfranc increase primarily high operating free cash flow low tax payment factor cover high dividend payment billion swiss franc underlie business continue good cash generation operate free cash flow increase local currency swiss franc contrast decrease operating profit impact number noncash item notably expense provision areshown breakdown net work capital reduce slightly overall despitethe continue growth business capital expenditure total slightly lower previous year quarter significant interest payment new debt issue major coupon payment date quarter year total taxis pay decrease billion swiss franc compare drive onetime billion swiss franc tax benefit thesettlement stock option genentech employee closing transaction net cash millions chf december cash cash equivalent marketable security longterm debt shortterm debt net cash beginning period free cash flow transaction equity instrument business combination net divestment subsidiary hedge collateral arrangement change ownership interest subsidiarie currency translation fair value movement net change net cash december cash cash equivalent marketable security longterm debt shortterm debt net cash net debt end period purchase outstanding publicly hold share genentech include settlement genentech outstanding employee stock option plan payment relate fee expense result cash outflow billion dollar billion swiss franc describe note consolidated financial statement record equity change ownership interest subsidiary free cash flow describe compensate billion swiss franc cash genentech transaction take account group record dividend payment equity instrument purchase cover group obligation equity compensation plan positive cash flow billion swiss franc generate hedge collateral arrangement set follow financing genentech transaction debt section note consolidated financial statement fair value derivative instrument move weak dollar cash collateral net billion swiss franc deliver roche addition group generate cash flow billion swiss franc realise gain hedge derivative short maturity settle net debt position group billion swiss franc movement billion swiss franc anet cash position billion swiss franc december billion swiss franc genentech transaction roche finance report roche group financial review balance sheet balance sheet billion chf capitalisation billion chf liability asset debt plus equity condense balance sheet december december mchf mchf change property plant equipment goodwill intangible asset noncurrent asset cash marketable security current asset total asset debt current noncurrent noncurrent liability current liability total liability total net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity debt equity capitalisation consolidated balance sheet give consolidated financial statement group complete purchase noncontrolle interest genentech effective march note consolidated financial statement base revised international accounting standard consolidated separate financial statement ias adopt group transaction account equity transaction consequence carrying consolidate equity group reduce billion swiss franc billion swiss franc allocate eliminate book value genentech noncontrolle interest account ing effect significantly impact group net equity effect group business dividend policy transaction account business combination additional goodwill intangible asset record noncurrent asset property plant equipment decline impairment certain pharmaceutical division manufacture site particular discontinuation construction project manufacturing site vacaville california intangible asset decrease amortisation high impairment charge current asset account receivable high local currency reflect growth business inventory level reduce slightly overall show improvement operational efficiency cash marketable security decline current asset increase billion swiss franc fair valuemovement derivative hedge nonus dollardenominate debt debt significant increase debt finance genentech transaction february march group performed series bond note offering generate net proceed billion swiss franc carry value debt december billion swiss franc compare billion swiss franc december noncurrent current liability overall balance increase billion swiss franc mainly billion swiss franc higher accrue current liability include billion swiss franc respect cash collateral receive respect derivate hedge debt anincrease billion swiss franc provision primarily litigation restructure total net assetsequity significant movement equity impact change owner ship interest genentech billion swiss franc change net income billion swiss franc dividend payment billion swiss franc currency translation gain billion swiss franc overall capitalisation total debt plus equity decline decrease second half debt repayment split debt equity change significantly compare debt finance genentech transaction group issue bond note equivalent billion swiss franc february march debt raise early billion swiss franc repay end repayment maturity sixmonth debt early redemption maturity schedule group bond note outstanding december show table include instrument issue prior genentech transaction bond note nominal amount contractual maturity dollar euro uk sterling swiss franc principal principal principal principal total total musd meur mgbp mchf musd mchf total total translate december exchange rate proceed bond note swap dollar financial statement bond note economic characteristic equivalent dollardenominate bond note group enter derivative contract party hedge foreign exchange risk arise bond note issue currency dollar total exposure hedge issuance bond note approximately billion swiss franc note collateral agreement enter derivative counterpartie mitigate counterparty risk note roche finance report roche group financial review group plan meet debt obligation cash generate underlying business freecash flow billion swiss franc include cash generate operation payment interest tax dividend debt raise finance genentech transaction willhave repay end shortterm financing requirement group commercial paper program united states issue billion dollar unsecured commercial paper note commit credit line billion euro million dollar available backstop line commercial paper note total billion dollar outstanding december long term financing group maintain strong longterm investmentgrade credit rating aa standard poor moodys facilitate efficient access international capital market pension postemployment benefit postemployment benefit plan classify define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution expense group define contribution plan million swiss franc million swiss franc plan classify define benefit plan group potential obligation relatively minor relatively remote possibility arise fund asset management group define benefit plan oversee corporate level plan usually establish trust independent group fund payment group employee case plan unfunded group pay pension retire employee directly financial resource funding status define benefit pension postemployment benefit plan mchf mchf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation funding status overall group define benefit plan continue adequately fund despite thefinancial turbulence funding status compare begin ofthe year main movement came increase fair value plan asset follow decline global financial market previous year small overall decline discount rate cause increase define benefit obligation expense record income statement total pension expense relate group define benefit plan million swiss franc compare million swiss franc increase primarily lower expect return plan asset arise mainly consequence low asset base yearend base revise actuarial assumption end total pension expense expect remain broadly stable compare detail group pension postemployment benefit give note consolidated financial statement roche security share price market capitalisation december change share price chf nonvoting equity security genussscheinprice chf market capitalisation billion chf roche rank number peer group healthcare companiesas list term total shareholder return tsr ie share price growth plus dividend measure swiss franc atactual exchange rate yearend return roche share roche nonvoting equity security combine performance share nonvoting equity security compare toaweighte average return peer group actual exchange rate peer group abbott laboratories amgen astella astrazeneca bayer becton dickinson biogen idec bristolmyers squibb eli lilly gilead glaxosmithkline johnson johnson merck co novartis pfizer roche sanofiaventis takeda total shareholder return development dec march june sept dec roche share roche gs peer set index propose dividend board director propose increase dividend swiss franc share nonvoting equity security swiss franc approval annual general meeting rdconsecutive increase dividend dividend proposal approve shareholder dividend payment share nonvoting equity security issue billion swiss franc billion swiss franc result payout ratio base price yearend dividend yield roche share yield nonvoting equity security information roche security give page ofthe finance report roche finance report roche group financial review information share nonvoting equity security chf chf change basic eps diluted ep ep continue business exceptional item core ep equity attributable roche shareholder share dividend share detail refer note consolidated financial statement ofthe finance report payout ratio calculate dividend share divide earning share continue business exceptional item financial risk group risk profile change significantly follow genentech transaction bond note billion swiss franc issue consequence december group net debt position billion swiss franc december net cash position billion swiss franc financial asset group manage conservative way objective meet thegroup financial obligation times asset allocation significant portion cash marketable security group currently hold debt redemption interest service march liquid fund hold cash invest highquality investmentgrade fix income security shortterm investment horizon meet liquidity requirement roche reduced bond portfolio billion swiss franc asbond mature sell high holding share reclassification certain equitysecuritie longterm investment shortterm marketable security long consider strategic investment cash marketable security mchf total mchf total cash cash equivalent money market instrument bond debenture investment share total cash marketable security credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group despite significant market difficulty mid therate profile group billion swiss franc fix income marketable security remain strong invest aaaa range group sign net collateral agreement thederivative counterpartie order mitigate counterparty risk derivative position counterparty profile group billion swiss franc trade receivables remain diversified type customer region wholesaler concentration liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time addition current liquidity position group strong cash generation ability future cash flow repay debt instrument come year genentech transaction roche enjoy strong longterm investmentgrade credit rating aa standard poor moodys time roche rate high available shortterm rating agency event financing requirement rating strong credit roche permit efficient access international capital market include commercial paper market thegroup commit credit line financial institution total billion swiss franc billion swiss franc billion swiss franc serve backstop line commercial paper programme december debt draw credit line market risk market risk arise change market price group financial asset financial liability exposure predominantly relate change interest rate foreign exchange rate equity price group use valueatrisk var assess impact market risk financial instrument var data indicate value range give financial instrument fluctuate apreset probability result movement market price var datum table indicate theeconomic loss level period month probability exceed actual future economic gain loss associate treasury activity differ materially var analysis perform inherent limitation associate predict timing change interest rate foreign currency exchange rate equity investment price particularly period high market volatility furthermore var number include credit risk component market risk financial instrument december december mchf mchf var interest rate component var foreign exchange component var price component diversification var total december total var financial asset liabilitie million swiss franc december million swiss franc interest rate var increase substantially million swiss franc drive billion swiss franc bond note issue quarter asall newly issue debt hold amortise cost interest rate var sole metric economic fair valuechange impact carry value profit loss group foreign exchange var decrease hedge nonus dollar cash flow future royalty income genentech unwound price risk arise mainly movement price equity security remain relatively stable december group hold equity security market value billion swiss franc december billion swiss franc include holding biotechnology company acquire context licensing transaction scientific collaboration information financial risk management financial risk var methodology include innote consolidated financial statement international financial reporting standard roche group international financial reporting standard ifrs report consolidated result group early adopt ifrs operating segment ias revised borrowing cost require implement january late group early adopt revise version ifrs business combination ias consolidated separate financial statement require implement january late group implement revision ias presentation financial statement effect ofwhich describe note consolidated financial statement group implement amendment exist standard interpretation material impact group overall result financial position roche finance report roche group roche group consolidate financial statement roche group consolidated financial statement reference number indicate corresponding note consolidated financial statement roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operating profit exceptional item major legal case change group organisation operate profit associate financial income financing cost exceptional financing cost profit taxis income taxis income taxis exceptional item net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operating profit exceptional item major legal case change group organisation operate profit associate financial income financing cost profit taxis income taxis income taxis exceptional item net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche finance report roche group roche group consolidate financial statement roche group consolidated statement comprehensive income million chf year end december net income recognise income statement comprehensive income availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan comprehensive income net tax total comprehensive income attributable roche shareholder noncontrolle interest total roche group consolidate balance sheet million chf december december december noncurrent asset property plant equipment goodwill intangible asset associate financial longterm asset longterm asset defer income tax asset postemployment benefit asset total noncurrent asset current asset inventory account receivable current income tax asset current asset marketable security cash cash equivalent total current asset total asset noncurrent liability longterm debt defer income tax liability postemployment benefit liability provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable accrue current liability total current liability total liability total net asset equity capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity roche finance report roche group roche group consolidate financial statement roche group consolidate statement cash flow million chf year end december cash flow operating activity cash generate operation increase decrease work capital payment define benefit postemployment plan utilisation provision operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset disposal product business combination divestment subsidiarie interest dividend receive sale marketable security purchase marketable security invest cash flow total cash flow invest activity cash flow financing activity proceed issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt hedge collateral arrangement change ownership interest subsidiary genentech chugai ventana memory interest pay dividend pay genentech genentech equity compensation plan genentech share repurchase equitysettle equity compensation plan net transaction equity instrument chugai share repurchase finance cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent january cash cash equivalent december roche group consolidate statement change equity million chf reserve non share retain control total capital earning fair value hedge translation total interest equity year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan total comprehensive income business combination dividend pay equity compensation plan net transaction equity instrument genentech chugai share repurchase change ownership interest subsidiary chugai ventana change noncontrolle interest december year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan total comprehensive income business combination dividend pay equity compensation plan net transaction equity instrument genentech chugai share repurchase change ownership interest subsidiary genentech memory change noncontrolle interest december roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement reference number indicate corresponding note consolidated financial statement summary significant accounting policy basis preparation consolidate financial statement consolidate financial statement roche group prepare accordance international financial reporting standard ifrs comply swiss law prepare historical cost convention disclose accounting policy certain itemsincluding derivative availableforsale investment show fair value approve issue board director january subject approval annual general meeting shareholder march preparation consolidate financial statement require management estimate assumption affect report amount revenue expense asset liability disclosure contingent liability date financial statement future estimate assumption base management good judgement date financial statement deviate actual circumstance original estimate assumption modify appropriate year inwhich circumstance change change accounting policy arise application new revise standard interpreta tionsare apply retrospectively specify transitional requirement particular standard interpretation retrospective application require result comparative period andthe opening balance period restate new accounting policy apply case transitional requirement particular standard interpretation specify change apply prospectively prospective application require new accounting policy apply result current period comparative period restate addition comparative reclassify extend previously report result account anypresentational change consolidation policy financial statement consolidate financial statement roche holding ltd company register switzerland subsidiary group subsidiary company control directly indirectly roche holding ltd control isdefine power govern financial operating policy enterprise obtain benefit activity control normally evidence roche holding ltd own directly indirectly vote right currently exercisable potential voting right company share capital special purpose entity consolidate substance relationship special purpose entity control group company acquire year consolidate fromthe date control transfer group subsidiary divest include tothedate control pass group intercompany balance transaction result unrealised income eliminate change ownership interest subsidiary account asequity transaction occur control obtain result alossof control investment associate account equity method company group exercise power exercise significant influence control normally evidence group own voting right currently exercisable potential voting right company balance transaction associate result unrealised income areeliminate extent group interest associate interest joint venture report linebyline proportionate consolidation method segment report determination group operate segment base organisation unit informationis report group management group division pharmaceutical diagnostic revenue primarily generate sale prescription pharmaceutical product anddiagnostic instrument reagent consumable respectively division derive revenue sale licensing product technology party certain headquarter activity report ascorporate consist corporate headquarters include corporate executive committee corporate communication corporate human resource corporate finance include treasury taxis pension fund management corporate legal corporate safety environmental service previously pharmaceutical division subdivision roche pharmaceutical genentech chugai follow completion genentech transaction note genentech subdivision merge roche pharmaceutical subdivision chugai subdivision aggregate ofthepharmaceutical division consolidated financial statement transfer price operate segment set arm length basis operate asset liabilitiesconsist property plant equipment goodwill intangible asset trade receivablespayable inventory asset liability provision reasonably attribute report operating segment nonoperate asset liability mainly include current defer income tax balance postemployment benefit assetsliabilitie financial assetsliabilitie cash marketable security investment debt foreign currency translation group company use local currency functional currency certain group company useother currency dollar swiss franc euros functional currency currency primary economic environment entity operate local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge orarise monetary item substance form group net investment foreign entity insuch case gain loss defer equity consolidation asset liability group company functional currency swiss franc foreign entity translate swiss franc yearend rate exchange sale cost expense net income cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly equity disposal foreign entity identify cumulative currency translation difference equity relate foreign entity recognise income gain loss divestment roche finance report roche group note roche group consolidate financial statement revenue sale represent amount receive receivable good supply customer deduct trade discount cash discount volume rebate exclude value add taxis taxis directly link sale revenue sale product recognise transfer customer significant risksand reward trade discount cash discount volume rebate record accrual basis consistent recognition related sale estimate expect sale return chargeback andother rebate include medicaid united states similar rebate country deduct sale record accrue liability provision deduction account receivable estimate base analyse exist contractual legislatively mandate obligation historical trend group experience circumstance level sale return andhence revenue reliably measure sale recognise right return expire generally prescription product patient revenue record asearne service perform necessary single transaction split separately identifiable component reflect substance transaction conversely transaction maybe consider revenue recognition purpose commercial effect understand reference series transaction cost sale cost sale include correspond direct production cost relate production overhead goodssold service render royalty alliance collaboration expense include collaboration profitshare arrangement report cost sale startup cost validation andthe achievement normal production capacity expense incur research development addition internal research development activity group party inlicense similar arrangement alliance partner group acquire inprocess research development asset business combination purchase specific asset internal research cost charge income incur internal development cost capitalise asintangible asset identifiable asset complete generate probable future economic benefit cost asset measure reliably group currently internal development cost qualify capitalisation intangible asset internal development cost charge income incur criterion recognition asset meet inprocess research development asset acquire inlicense arrangement business combination separate purchase capitalise intangible asset describe available use intangible asset amortise straightline basis period expect benefit review impairment reporting date license milestone upfront receipt payment royalty income recognise accrual basis accordance substance respective licensingagreement collectability royalty reasonably assure royalty recognise revenue cash receive certain group company receive party upfront milestone similar payment relate sale licensing product technology revenue associate performance milestone recognise base achievement deliverable define respective agreement upfront payment licence fee subsequent deliverable initially report deferred income recognise income earn period development collaboration manufacturing obligation payment group company party associate item capitalise intangible asset employee benefit wage salary social security contribution pay annual leave sick leave bonus nonmonetary benefit accrue year associate service render employee group group provide longterm employee benefit cost accrue match rendering service employee concerned liability longterm employee benefit discount intoaccount time value money material pension postemployment benefit employee cover define benefit define contribution postemployment plan sponsor group company group contribution define contribution plan charge appropriate income statement head operating result year relate accounting reporting define benefit plan base recent actuarial valuation define benefit obligation service cost calculate project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth longterm expect rate return plan asset discount rate base market yield highquality corpo rate bond country concern past service cost allocate average period benefit vested current past service cost charge appropriate income statement head operating result pension plan administration funding oversee corporate leveland settlement gain loss result change funding arrangement report asgeneral administration expense corporate segment expect return plan asset interest cost charge financial income financing cost respectively actuarial gain loss consist difference assumption actual experience effect change actuarial assumption record directly equity pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit recognition asset define benefit plan record directly equity equity compensation plan certain employee group participate equity compensation plan include separate plan genentech prior genentech transaction chugai fair value equity compensation award grant employee estimate grant date record expense vest period expense charge appropriate income statement head operating resultsforequitysettle plan increase equity record expense subsequent cash flow exercise vested award record change equity cashsettle plan liability record measure fair value report date movement fair value record appropriate income statement head operating result subsequent cash flow exercise vested award record reduction liability property plant equipment property plant equipment initially record cost purchase construction include costsdirectly attributable bring asset location condition necessary capable operating manner intend management include item cost site preparation installation assembly cost professional fee net cost test asset function properly include validation cost include initially record cost construction interest borrowing cost incur respect qualify asset capitalise include carry value asset roche finance report roche group note roche group consolidate financial statement property plant equipment depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow land improvement year building year machinery equipment year diagnostic instrument year office equipment year motor vehicle year part item property plant equipment different useful life account separate component estimate useful life asset regularly review necessary future depreciation charge accelerate repair maintenance cost expense incur lease group lessee lease property plant equipment group substantially allof risk reward ownership classified finance lease finance lease capitalise atthestart lease fair value present value minimum lease payment low rental obligation net finance charge report debt asset acquire finance lease depreciate accordance group policy property plant equipment reasonable certainty group obtain ownership end lease term asset depreciate theshorter lease term useful life interest element lease payment charge income lease term base effective interest rate method lease substantially therisk reward ownership transfer group classify operating lease payment operating lease charge income straightline basis period ofthe lease group lessor primarily occur diagnostic division asset subject finance lease initially report receivables equal net investment lease asset subject operating lease report property plant equipment lease income finance lease subsequently recognise earn income term lease base effective interest rate method lease income operating lease recognise lease term straightline basis business combination goodwill business combination account acquisition method accounting consideration transfer business combination measure fair value date acquisition consideration include cash pay plus fair value date exchange asset give liability incur assume equity instrument issue group fair value consideration transfer include contingent consideration arrangement fair value directly attributable acquisitionrelated cost expense current period report general administration expense date ofacquisition group recognise identifiable asset acquire liability assume non control interest acquire business identifiable asset acquire liability assume initially recognise fair value group acquire ownership acquire businessnoncontrolle interest record proportion fair value acquire net asset attributable noncontrolle interest goodwill record surplus consideration transfer group interest fair value acquire net asset goodwill fair value adjustment record asset liability acquire business functional currency thatbusiness goodwill amortise assess possible impairment reporting date isadditionally test annually impairment goodwill arise investment associate surplus cost investment group share fair value net identifiable asset goodwill record investment associate change ownership interest subsidiary areaccounte equity transaction occur control obtain donot result loss control intangible asset purchase patent licence trademark intangible asset initially record cost theseasset acquire business combination fair value allocate intheacquisition account intangible asset amortise useful life straightline basis beginning point available use estimate useful life low legal duration economic useful life estimate useful life intangible asset regularly review impairment property plant equipment intangible asset impairment assessment carry evidence asset impair addition intangible asset available use test impairment annually recoverable asset high fair value cost sell value use carrying value carry value reduce recoverable reduction report income statement impairment loss value use calculate estimate cash flow generally overa fiveyear period extrapolate projection subsequent year discount anappropriate longterm pretax interest rate impairment loss arise useful life asset inquestion review necessary future depreciationamortisation charge accelerate theimpairment financial asset discuss financial asset policy impairment goodwill goodwill assess possible impairment reporting date additionally test annually impairment goodwill allocate cashgenerating unit describe note recoverable cashgenerate unit high fair value cost sell value use isless carry value carry value goodwill reduce recoverable reduction report income statement impairment loss methodology impairment testing describe note inventory inventory state low cost net realisable value cost finish good work process include raw material direct labour directly attributable cost overhead base uponthe normal capacity production facility cost determine weighted average method netrealisable value estimate selling price cost completion selling expense account receivable account receivable carry original invoice allowance doubtful account trade discount cash discount volume rebate similar allowance allowance doubtful account isrecorde difference carry value recoverable objective evidence group able collect amount trade discount cash discount volume rebate similar allowance record accrual basis consistent recognition relate sale estimate base exist contractual obligation historical trend group experience longterm account receivable discount account time value money material cash cash equivalent cash cash equivalent include cash hand time current balance bank similar institution balance report cash readily convertible know amount cash subject insignificant risk change value maturity month date acquisition definition statement cash flow roche finance report roche group note roche group consolidate financial statement provision provision recognise legal constructive obligation incur probably leadto outflow resource reasonably estimate particular restructuring provision recognise group detailed formal plan commence implementation announce provision record estimate ultimate liability expect arise take account foreign currency effect arise translation functional currency swiss franc time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable fair value fair value financial asset liability instrument exchange knowledgeable willing party arm length transaction determine reference quote market price use establish valuation technique option pricing model discount cash flow method quote price active market available fair value hierarchy valuation technique incorporate observable market datum market condition factor likely affect fair value financial instrument valuation technique typically derivative financial instrument fair value financial asset liability report date materially different report carry value specifically mention note consolidated financial statement information fair value hierarchy include note risk management financial asset financial asset principally investment include marketable security classify fairvalue throughprofitorloss availableforsale heldtomaturity loan receivables fairvaluethrough profitorloss financial asset classify heldfortrade designate initial recognition heldfortrade financial asset acquire principally generate profit shortterm fluctuation price financial asset designate fairvaluethroughprofitorloss result relevant information eliminate measurement recognition inconsistency heldtomaturity financial asset aresecuritie fix maturity group intent ability hold maturity loan receivables financial asset create group acquire issuer primary market theyare nonderivative financial asset fix determinable payment quote active market financial asset consider availableforsale financial asset initially record fair value include transaction cost asset fairvaluethroughprofitorloss exclude transaction cost purchase sale recognise settlement date fairvaluethroughprofitorloss financial asset subsequently carry fair value change fair value record financial income period arise heldtomaturity financial asset subsequently carry amortise cost effective interest rate method available forsale financial asset subsequently carry fair value unrealise change fair value record equity interest calculate effective interest rate method foreign exchange component availableforsale financial asset sell impair dispose thecumulative gain loss previously recognise equity include financial income current period loan receivables subsequently carry amortise cost effective interestrate method financial asset individually assess possible impairment reporting date impairment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty addition availableforsale equity security market value original cost net previous impairment willbeconsidere impair availableforsale equity security market value original cost net previous impairment sustain sixmonth period consider impaired decrease market price original cost net previous impairment arealso sustained sixmonth period consider objective evidence ofimpairment movement fair value record equity objective evidenceof impairment asset sell dispose financial asset carry amortise costany impairment charge difference carry value recoverable calculate estimate future cash flow discount original effective interest rate foravailableforsale financial asset impairment charge currently carry equity thedifference original cost net previous impairment fair value impairment loss reverse reversal relate objectively event occurring impairment loss wasrecognise debt security measure amortise cost availableforsale reversal recognise income equity security hold availableforsale reversal recognise directly equity financial asset derecognise contractual cash flow asset expire group transfer right receive contractual cash flow financial asset transaction whichsubstantially risk reward ownership financial asset transfer interest intransferre financial asset create retain group recognise separate asset liability derivative derivative financial instrument initially record subsequently carry fair value apart derivative designate qualify cash flow hedging instrument discuss hedge policy change fair value record financial income period arise embed derivative recognise separately closely related host contract host contract iscarrie amortise cost hedge accounting purpose hedge accounting hedging relationship type fair value hedge isahedge exposure change fair value recognise asset liability unrecognised firm commitment identify portion asset liability firm commitment attributable aparticular risk affect profit loss cash flow hedge hedge exposure variability incash flow attributable particular risk associate recognise asset liability highlyprobable forecast transaction affect profit loss hedge net investment foreign operation hedge foreign currency exposure net investment foreign operation qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence cash flow hedge hedge effectiveness reliability measurement ifthesecondition meet relationship qualify hedge accounting case thehedging instrument hedge item report independently hedge relation ship particular derivative report fair value change fair value include financial income qualify fair value hedge hedge instrument record fair value hedge item isrecorde previous carrying value adjust change fair value attributable hedged risk change fair value report financial income roche finance report roche group note roche group consolidate financial statement qualify cash flow hedge hedge instrument record fair value portion change fair value effective hedge include equity remain ineffective portion report infinancial income hedge relationship hedge foreign currency risk firm commitment highly probable forecast transaction result recognition nonfinancial asset liability thecumulative change fair value hedge instrument record equity include initial carrying value asset liability date recognition qualify cash flow hedge cumulative change fair value hedge instrument recordedin equity include financial income forecast transaction affect net income qualifying hedge net investment foreign entity hedge instrument record fair value portion change fair value effective hedge include equity remain ineffective portion record financial income hedge instrument derivative equity case entity dispose cumulative change fair value hedge instrumentthat record equity reclassify income debt debt instrument initially record cost proceed receive net transaction cost subsequently report amortise cost discount net proceed receive principal value redemption amortise duration debt instrument recognise aspart financing cost effective interest rate method group derecognise financial liability contractual obligation discharge cancel expire certain debt instrument designate fairvaluethroughprofitorloss result inmore relevant information eliminate significantly reduce measurement recognition inconsistency debt instrument report fair value base quote price active market movement fair value report financial income group instrument redeem july disclose note taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income property capital taxis include general administration expense liability income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary recognise probable earning willbe remit foreseeable future deferred income tax asset liability recognise temporary difference tax basis asset liability carry value financial statement defer income tax asset relate carryforward unused tax loss recognise extent probable future taxable profit available unused tax loss utilise current defer income tax asset liability offset income taxis levy sametaxation authority legally enforceable right offset deferred income taxis determine base currently enact tax rate applicable tax jurisdiction groupoperate discontinue business noncurrent asset hold sale discontinue business component group business represent separate major line business geographical area operation subsidiary acquire exclusively view resale reclassification discontinue business occur disposal operation meet criterion tobe classify hold sale early disposal group group assets dispose group single transaction liability directly associate asset transfer transaction asset liability disposal group reclassify held sale value recover principally sale continue use disposal group available sale current condition sale highly probable immediately classification hold sale measurement asset liability disposal group update accordance applicable accounting policy initial classification hold sale disposal group recognise low carrying value fair value cost sell impairment loss initial classification hold sale include income statement equity instrument group holding equity instrument record deduction equity original purchase cost consideration receive subsequent resale equity instrument movement report change equity instrument acquire primarily meet potential obligation employee arise respect certain group equity compensation plan management judgement apply accounting policy application group accounting policy require management judgement apart involve estimate significant effect amount recognise consolidated financial statement management judgement particularly require assess substance trans action complicated structure legal form include limited follow area revenue recognition nature group business sale transaction havea simple structure sale agreement consist multiple component occur different time group party outlicensing agreement involve upfront milestone payment occur year agreement involve certain future obligation revenue recognise management judgement significant risk reward ownership transfer group retain continue managerial involvement effective control good sell obligation fulfil transaction result cash receipt initially recognise deferred income release income subsequent period basis performance condition specify agreement consolidation subsidiary associate group periodically undertake transaction involve obtain right control significantly influence operation company transaction include acquisition equity company purchase certain asset assumption certain liability contingent liability company enter alliance agreement company include transaction involve special purpose entity similar vehicle case management make assessment group theright control significantly influence company operation base assessment company consolidated subsidiary associate company make assessment management consider underlie economic substance transaction contractual term roche finance report roche group note roche group consolidate financial statement business combination group acquire control business consideration transfer allocate identifiable asset acquire liability assume noncontrolle interest acquire business residual record goodwill process involve management make assessment fair value item management judgement particularly involve recognition measurement follow item intellectual property include patent licence trademark similar right currently market product right scientific knowledge associate project currently research development phase contingency legal environmental matter contingent consideration arrangement recoverability accumulate tax loss previously incur acquire company case management make assessment base underlying economic substance item concern contractual term order fairly present item lease group party leasing arrangement lessee lessor treatment leasing transaction financial statement mainly determine lease consider tobe operate lease finance lease make assessment management look substance ofthe lease legal form make judgement substantially risk andrewards ownership transfer arrangement legal form lease thatnevertheless convey right use asset cover assessment key assumption source estimation uncertainty preparation consolidate financial statement conformity ifrs require management estimate assumption affect application policy report amount asset liability income expense relate disclosure estimate underlying assumption base historical experience factor believe reasonable circumstance result form basis make judgement carry value asset liability readily apparent source actual result differ estimate estimate underlying assumption review ongoing basis change accounting estimate necessary change circumstance estimate base orasa result new information experience change recognise period whichtheestimate revise key assumption future key source estimation uncertainty significant risk ofcause material adjustment carry value asset liability month describe revenue recognition circumstance level sale return revenue reliably measure sale recognise right return expire generally prescription product patient order estimate management use publicly available information prescription information provide wholesaler intermediary sale allowance group provision accrual expect sale return chargeback andother rebate include medicaid united states similar rebate country atdecember total million swiss franc estimate base analyse exist contractual legislativelymandate obligation historical trend group experience management believe total provision accrual item adequate base currently available information deduction base management estimate subject change well information available change arise impact provision accrual recognise balance sheet future period consequently level sale recognise income statement future period property plant equipment intangible asset include goodwill group property plantand equipment carry value million swiss franc disclose note goodwill hasacarrying value million swiss franc note intangible asset carry value ofmillion swiss franc note asset review annually impairment asdescribed assess impairment exist estimate future cash flow expect toresult use asset eventual disposal actual outcome vary significantly estimate discount future cash flow factor change plan useof building machinery equipment closure facility presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment change discount rate lead impairment pension postemployment benefit group employee participate post employment define benefit plan calculation recognise asset liability plan base statistical actuarial calculation particular present value define benefit obligation impact assumption discount rate arrive present value future pension liability assumption future increase salary benefit furthermore group independent actuary use statistically base assumption cover area future withdrawal participant plan estimate life expectancy december present value group define benefit obligation million swiss franc fund plan million swiss franc unfunded plan note actuarial assumption differ materially actual result changesin market economic condition high low withdrawal rate long short life span ofparticipant change factor assess difference impact assetsorliabilitie recognise balance sheet future period legal provision group company party legal proceeding include claim arise trade significant matter describe note legal provision december total million swiss franc management believe total provision legal proceeding adequate base currently available information give inherent difficulty estimate liability inthis area guarantee additional cost incur amount accrue additional claim cover exist provision insurance therecan assurance increase scope matter future lawsuit claim proceeding investigation material change arise impact theprovision recognise balance sheet future period environmental provision group provision environmental remediation cost december total million swiss franc disclose note material component environmental provision consist cost fully clean refurbish contaminate site treat contain contamination certain site future remediation expense affect number uncertainty include limited detection previously unknown contaminate site themethod extent remediation percentage waste material attributable group remediation site relative attributable party financial capability potentially responsible party management believe total provision environmental matter adequate base currently available information give inherent difficulty estimate liability area guarantee additional cost incur amountsaccrue effect resolution environmental matter result operation bepredicte uncertainty concern time future expenditure suchchange arise impact provision recognise balance sheet future period roche finance report roche group note roche group consolidate financial statement income taxis december net liability current income taxis million swiss franc net asset defer income taxis million swiss franc disclose note significant estimate require determine current defer asset liability income taxis ofthese estimate base interpretation exist tax law regulation management believe estimate reasonable recognise liability income taxrelate uncertainty adequate internal external factor favourable unfavourable effect income tax asset liability factor include limited change tax law regulation andor rate change interpretation exist tax law regulation future level research development spending change overall level pretax earning change arise impact asset liability recognise balance sheet future period change accounting policy group early adopt ifrs operating segment ias revised borrowing cost whichwere require implement january late group early adopt revise version ifrs business combination ias consolidated separate financial statement require implement january late group implement revision ias presentation financial statement effect describe group implement amendment exist standard interpretation material impact group overall result financial position ia revise presentation financial statement matter revise standard require change format statement comprehensive income statement change equity require additional disclosure note financial statement notably disclose pretax tax impact item comprehensive income note balance sheet include opening balance begin comparative period reflect relevant note financial statement group simplify presentation equity reporting equity instrument retain earning change implementation ofthe revise standard purely presentational impact group overall result financial position group currently assess potential impact new revise standard interpretation effective january group early adopt group anticipate material impact group overall resultsand financial position operating segment information divisional information millions chf pharmaceutical diagnostic corporate group revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination interdivisional revenue total segment result operate profit exceptional item major legal case change group organisation operate profit capital expenditure business combination addition property plant equipment addition intangible asset total capital expenditure research development research development cost segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset equity compensation plan expense roche finance report roche group note roche group consolidate financial statement net operating asset millions chf asset liability net asset pharmaceutical diagnostic corporate total operating nonoperating group information geographical area millions chf revenue external customer noncurrent asset royalty operate property plant goodwill sale income equipment intangible asset switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total supplementary information sale therapeutic area pharmaceutical division business area diagnostic division give page respectively sale allocate geographical area destination accord location customer royalty operating income allocate accord location group company receive revenue european union information base members eu december major customer national wholesale distributor amerisourcebergen corp represent approximately billion swissfranc billion swiss franc group revenue approximately revenue inthe pharmaceutical operating segment residual diagnostic segment group alsoreporte substantial revenue national wholesale distributor cardinal health inc andmckesson corp total customer represent approximately quarter group revenue genentech effective september roche group acquire majority interest approximately genentech inc biotechnology company united states june group exercise option acquire remain share genentech june point genentech own subsidiary group july october march group complete public offering genentech common stock reduce group majority interest common stock genentech publicly trade list new york stock exchange symbol dna group ownership genentech decrease conversion redemption lyon iv dollar exchangeable note december group interest genentech genentech transaction july group announce proposal purchase outstanding share genentech common stock own roche price usd cash share equivalent total cash payment approximately billion dollar roche proposal july genentech announce special committee board director compose independent director thespecial committee form review evaluate special committee discretion negotiate recommend recommend acceptance roche proposal august genentech announce special committee support proposal february roche investments usa inc wholly own subsidiary group commence acash tender offer publiclyheld genentech share usd share march roche enter merger agreement genentech pursuant group successful tender offer purchase share genentech own group usd pershare cash genentech transaction result genentech whollyowne subsidiary ofthe group effective march cash consideration purchase public share include share issuable genentech outstanding employee stock option plan payment relate fee expense amount approximately billion dollar set table amount record toequity change ownership interest subsidiary roche finance report roche group note roche group consolidate financial statement genentech transaction usd million chf million purchase publicly hold share settlement outstanding employee stock option directly attributable transaction cost total cash consideration income tax effect change ownership interest subsidiary translate spot rate date transaction march usd chf group finance genentech transaction combination group fund bond note andcommercial paper group raise net proceed approximately billion swiss franc aserie debt offering describe note newly issue debt senior unsecured guarantee roche holding ltd impact genentech transaction relate reorganisation roche pharmaceutical business group result describe note genentech share repurchase april genentechs board director approve extension exist stock repurchase programme authorise genentech repurchase million share genentech common stock atotal billion dollar june programme inception december genentech repurchase approximately million share total approximately billion usdollar net cash outflow repurchase genentech common stock million dollar million swiss franc repurchase chugai effective october roche group chugai complete alliance create lead research drive japanese pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche merged company know chugai fully consolidated subsidiary group december group interest chugai common stock chugai publicly trade list tokyo stock exchange stock code tse chugai prepare financial statement conformity accounting principle generally accept japan jgaap file quarterly basis tokyo stock exchange roche relationship chugai chugai enter certain agreement roche discuss basic alliance agreement basic alliance agreement sign december roche andchugai enter certain arrangement cover future operation governance chugai matter cover follow area structure alliance roche right shareholder roche right nominate members chugais board director certain limitation roche ability buy sell chugais common stock chugai issue additional share common stock connection convertible debt equity compensation plan issue additional share purpose affect roche percentage ownership interest basic alliance agreement provide matter chugai guaranteeroche right maintain shareholde percentage chugai licensing agreement japan umbrella right agreement sign december chugai hasexclusive right market roche pharmaceutical product japan chugai right refusal development marketing japan development compound advanced roche rest world umbrella right agreement sign roche right refusal development marketing chugais development compound market outside japan exclude south korea chugai decide require partner activity agreement roche chugai sign series separate agreement certain specific product depend specific circumstance term agreement result inpayment armslength basis roche chugai follow matter upfront payment right refusal license product exercise milestone payment dependent achievement agree performance target royalty future product sale specific product agreement cover manufacture supply respective product tomeet party clinical andor commercial requirement armslength basis research collaboration agreement roche chugai enter research collaboration agreement area small molecule synthetic drug research biotechnology base drug discovery dividend dividend distribute party hold chugai share total million swiss franc million swiss franc record noncontrolle interest note dividend pay chugai roche eliminate consolidation intercompany item tender offer chugai share group announce tender offer acquire additional common share chugai toincrease group ownership chugais issue share tender offer fully subscribe offer price japanese yen share june group acquire million common share chugai cash consideration billion japanese yen million swiss franc take account share previously repurchase chugai retire thegroup ownership chugais outstanding share increase total cash outflow million swiss franc include directly attributable cost million swiss franc record toequity change ownership interest subsidiary chugai share repurchase chugai repurchase common share result group ownership chugaiincrease total cash outflow include repurchase fractional share billion japanese yen million swiss franc share repurchase matter detail chugais equity compensation plan give note detail series chugai pharmaceutical unsecured convertible bond remain outstanding bond fully redeem give note roche finance report roche group note roche group consolidate financial statement financial income financing cost financial income million chf year end december gain sale equity security loss sale equity security dividend income gain loss equity security derivative net writedown impairment equity security net income equity security interest income gain sale debt security loss sale debt security gain loss debt security derivative net gain loss financial asset fairvaluethroughprofitorloss net writedown impairment longterm loan net interest income income debt security expect return plan asset define benefit plan foreign exchange gain loss net gain loss foreign currency derivative net net foreign exchange gain loss net financial income expense total financial income financing cost million chf year end december interest expense amortisation debt discount gain loss debt derivative net gain loss redemption repurchase bond note net gain loss financial liability fairvaluethroughprofitorloss net time cost provision interest cost define benefit plan total financing cost net financial income million chf year end december financial income financing cost net financial income financial result treasury management financial result pension management net financial income exceptional financing cost describe note effective march group purchase publicly own share genentech usd share cash total cash consideration transaction includingshare issuable genentech outstanding employee stock option plan payment ofrelatedfee expense approximately billion swiss franc order execute transaction group liquidate certain debt security cash result inanet loss transaction million swiss franc furthermore prevail financial condition group issue bond note advance transaction total billion swiss franc series debt offering describe note interest expense instrument thebridge period issue completion genentech transaction march million swiss franc amount disclose separately income statement order fairly present group resultsin overall context genentech transaction relate reorganisation group pharmaceutical division total income tax benefit record respect exceptional financing cost million swiss franc exceptional financing cost millions chf gain loss liquidation debt security interest expense incur newly issue bond note bridge period total income expense income taxis income tax expense millions chf current income taxis adjustment recognise current tax prior period defer income taxis total income expense income taxis exceptional item describe note group incur exceptional expense total million swiss franc connection genentech transaction relate reorganisation group pharmaceutical business furthermore describe note group incur exceptional financing cost total million swiss franc connection financing genentech transaction disclose innote expense incur respect major legal case million swiss franc income million swiss franc income tax effect item show table disclose separately income statement order fairly present group result overall context genentech transaction relate reorganisation group pharmaceutical division roche finance report roche group note roche group consolidate financial statement income tax benefit million swiss franc record respect genentech stock option plansin follow increase genentech share price prior completion genentech transaction income tax benefit approximately million swiss franc clearly attributable genentech transaction allocate exceptional income taxis calculate difference income tax benefit calculate share price usd price share roche tender offer february income tax benefit calculate final agree tender offer price merger agreement usd pershare income taxis exceptional item millions chf current income taxis defer income taxis total income tax expense benefit exceptional item group operate internationally subject income taxis different tax jurisdiction thegroup calculate average expect tax rate weight average tax rate tax jurisdiction group operate rate change year year change mix group taxable income change local tax rate average expect rate decrease compare main driver additional financing cost genentech transaction march onwards group effective tax rate reconcile group average expect tax rate follow reconciliation group effective tax rate average expect tax rate tax effect utilisation previously unrecognise tax loss nontaxable incomenondeductible expense genentech equity compensation plan difference group effective tax rate exceptional item profit income profit income tax taxis tax rate tax taxis tax rate mchf mchf mchf mchf group effective tax rate exceptional item major legal case change group organisation exceptional financing cost group effective tax rate tax effect comprehensive income millions chf pretax tax aftertax pretax tax aftertax benefit benefit availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan comprehensive income income tax asset liability millions chf current income taxis asset liability net current income tax asset liability defer income taxis asset liability net defer income tax asset liability defer income tax asset recognise tax loss carry forwards extent realisation oftherelate tax benefit probable group unrecognised tax loss include valuation allowance follow unrecognised tax loss expiry applicable applicable mchf tax rate mchf tax rate year year year total unrecognised tax loss defer income tax liability establish withholding tax taxis payable unremitted earning certain foreign subsidiary amount currently regard permanently reinveste unremitted earning total billion swiss franc december billion swiss franc roche finance report roche group note roche group consolidated financial statement defer income tax asset liability defer income tax charge credit attributable tothe follow item defer income taxis movement recognise net asset liability millions chf property plant equipment temporary intangible asset difference total year end december net defer income tax asset liability january ventana acquisition business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect net defer income tax asset liability december year end december net defer income tax asset liability january lonza singapore acquisition business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect net defer income tax asset liability december business combination acquisition lonza singapore genentech enter supply agreement manufacture certain genentech product facility construction singapore lonza group ltd lonza currently expect receive food drug administration fda licensure genentech wascommitte fund precommissione production qualification cost facility fda licensure genentech commit purchase product successfully manufacture facility period year commission facility genentech receive exclusive option topurchase lonzas singapore facility period year fda licensure forapurchase price million dollar genentech enter loan agreement lonza advance million dollar lonza construction singapore facility genentech exercise option purchase facility outstanding advance offset purchase price genentech exercise purchase option advance offset supply purchase regardless purchase option exercise genentech oblige tomake milestone payment million dollar certain performance milestone meet facility construct accounting purpose nature supply agreement genentech involvement construction building genentech consider owner asset construction period fund construct building shell infrastructure cost arepaid lonza december construction progress total million swiss franc capitalise liability financing obligation total million swiss franc record net million dollar million swiss franc advanced genentech tolonza august genentech singapore pte ltd genentech singapore exercise option purchase ownership lonza biologic singapore pte ltd lonza singapore lonza singapore isacell culture biologic manufacturing facility mechanically complete expect produce avastin bevacizumab bulk drug substance litre fermentation capacity locate onapproximately acre option additional acre integration roche genentechs combine technical operation biotechnology production facility singapore merge operate roche singapore technical operation exercise option resultant merger approximately lonza employee join genentech singapore technical operation total site headcount approximately august previous accounting treatment describe construction progress total million dollar million swiss franc capitalise similar liability financing obligation record addition million dollar advanced genentech lonza transaction value million dollar consist million dollars singapore facility million dollar milestone payment million dollar offset loan previously genentech lonza net transaction value million dollar million swiss franc million dollar million swiss franc cash payment million dollar million swiss franc accrue milestone payment accounting purpose million dollar million swiss franc allocate settle ment exist financing obligation million dollar million swiss franc acquisition ofthelonza singapore business allocate follow lonza singapore acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment intangible asset inventory defer income taxis cash net asset liability net identifiable asset goodwill purchase consideration acquisition effective january group acquire control interest memory pharmaceuticals corp memory publicly own company base montvale new jersey hadbeen list nasdaq symbol memy memory develop innovative drug candidate forthe treatment debilitate central nervous system cns disorder alzheimer disease schizophrenia memory report pharmaceutical operating segment acquisition strengthen group research development pipeline area alzheimer disease purchase consideration million swiss franc pay cash roche finance report roche group note roche group consolidate financial statement minor business combination diagnostic business total purchase consideration million swiss franc million swiss franc cash million swiss franc contingent consideration arrangement liability million swiss franc recognise acquisition date base management well estimate time probabilityadjuste expect cash outflow arrangement december recognise arrangement reduce zero base recent management estimate combined purchase consideration allocate follow acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment goodwill intangible asset product intangible use marketing intangible product intangible available use inventory provision defer income taxis cash net asset liability net identifiable asset liability noncontrolle interest goodwill purchase consideration subsequent effective date acquisition january group purchase remain share memory hold party group interest memory cash consideration million swiss franc record equity change ownership interest subsidiary goodwill represent control premium synergy obtain group exist business goodwill recognise expect deductible income tax purpose fair value net asset liability include receivables fair value million swiss franc include allowance doubtful account million swiss franc directly attributable acquisitionrelated cost million swiss franc incur acquisition report general administration expense current period operating result pharmaceutical operating segment million swiss franc diagnostic operating segment million swiss franc acquisition impact result million chf revenue inventory external fair value amortisation customer adjustment intangible asset operating profit net income impact report result lonza singapore memorya pharmaceuticals division minor business combination diagnostic division group estimate impact result acquisition assume effective january lonza singapore memorya pharmaceuticals division minor business combination diagnostic division group figure exclude directly attributable acquisitionrelated cost million swiss franc relate acquisition pharmaceutical division million swiss franc relate acquisition diagnostic division correspond tax impact arealsoexclude figure exclude integration cost million swiss franc relate memory correspond tax impact exclude acquisition net cash outflow millions chf cash consideration cash net cash pay acquire company outflow lonza singapore acquisitions total cash consideration include subsequent payment million swiss franc purchase remain share memory hold party group interest memory report finance cash flow statement cash flow head change ownership inter est subsidiary acquisition ventana ventana medical systems inc ventana publicly own company base tucson arizona list nasdaq symbol vmsi prior february group own share ventana represent outstanding share ventana effective february group acquire outstanding share ventana obtain control ventana ventana develop manufacture market instrumentreagent system automate slide preparation andstaine clinical histology drug discovery laboratorie ventanas clinical system diagnosis treatment cancer infectious disease drug discovery system pharmaceutical biotechnology company accelerate discovery new drug target evaluate safety new drug compound ventana report diagnostic operating segment acquisition ventana leader fastgrowe histopathology tissuebase diagnostic business segment allow group broaden diagnostic offering complement world leadership bothinvitrodiagnostic system oncology therapie roche finance report roche group note roche group consolidate financial statement purchase consideration million swiss franc cash allocate follow ventana acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment goodwill intangible asset product intangible use product intangible available use inventory defer income taxis cash net asset liability net identifiable asset noncontrolle interest goodwill purchase consideration goodwill represent strategic value group enter tissue diagnostic business area italsorepresent premium pay trade market price obtain control business ofthe goodwill recognise expect deductible income tax purpose noncontrolle interest ventana measure proportionate share ventanas identifiable net asset fair value net asset liability include receivables fair value million swiss franc include fair value allowance doubtful trade account receivable million swiss franc finance lease receivables total million swiss franc include total gross contract million swiss franc group recognise gain million swiss franc result measure fair value equity interest ventana hold prior acquisition date gain include financial income directly attributable acquisitionrelated cost million swiss franc incur transaction report general administration expense current period operatingresult diagnostic operating segment subsequent effective date acquisition february group purchase remain share ventana hold party group interest ventana cash consideration million swiss franc record equity change ownership interest subsidiary acquisition effective group acquire control interest piramed ltd pirame privately own biotechnology company base uk pirame discover develop new medicine primarily treatment cancer immune inflammatory disorder arthritis andasthma pirame lead company discovery highly selective drug inhibit different isoform pik enzyme increasingly recognise key player wide variety disease process pirame report pharmaceutical operating segment acquisition strengthen group research development pipeline oncology inflammatory disease purchase consideration million swiss franc consist million swiss franc pay cash million swiss franc contingent consideration arrangement contingent consideration arrangement consist potential milestone payment million dollar commencement phase ii clinical trial piramed oncology programme liability million dollar million swiss franc recognise acquisition date base management well estimate thattime probabilityadjuste expect cash outflow arrangement december recognise arrangement increase million dollar million swiss franc base recent management estimate consequently additional million swiss franc charge record operating result effective september group acquire control interest arius research inc arius publicly own canadian biotechnology company list tsx symbol ari arius discover develop antibody therapeutic treat cancer disease include proprietary antibody platform rapidly identify select antibodie base functional ability affect disease progress clinical development arius report pharmaceutical operating segment acquisition strengthen group developmental portfolio initially area oncology inflammatory disease new technique offer potentially broad therapeutic application purchase consideration million swiss franc paidincash effective september group acquire control interest mirus bio corporation mirus privately own biotechnology company base madison wisconsin mirus rename roche madison inc focus discovery development innovative nucleic acid base technology include proprietary rnai ribonucleic acid interference delivery platform mirus report ofthepharmaceutical operating segment acquisition strengthen group research development pipeline rnai therapeutic provide capability target complex disease sucha cancer respiratory metabolic disorder purchase consideration million swiss franc pay cash minor business combination total purchase consideration million swiss franc combine purchase consideration acquisition allocate show acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment intangible asset product intangible use product intangible available use technology intangible use deferred income taxis cash net asset liability net identifiable asset goodwill purchase consideration goodwill represent control premium synergy obtain group exist business goodwill recognise expect deductible income tax purpose fair value net asset liability include receivables fair value million swiss franc expect fully collectable acquisition net cash outflow millions chf cash consideration cash net cash pay acquire company outflow ventana acquisition total roche finance report roche group note roche group consolidate financial statement cash consideration pay ventana include subsequent payment million swiss franc purchase remain share ventana hold party group interest ventana report finance cash flow statement cash flow head change ownership interest subsidiary change group organisation describe note july group announce offer purchase outstanding share ofgenentech follow closing transaction genentech south san francisco site theheadquarter group combine pharmaceutical operation united states july group announce roche pharmaceutical business close manufacturing operation site nutley new jersey commercial operation move genentech theresearch site palo alto california closed research activity transfer nutley genentech subsequent announcement initial restructuring activity start atthenutley palo alto site genentech transaction complete effective march follow pharmaceutical division initiate detailed integration programme align genentech business rest theroche pharmaceutical business genentechs south san francisco site establish headquarters pharmaceutical business include commercial operation market genentech research early development set autonomous unit genentech latestage development activity integrate global pharmaceutical division network theintegration programme include prioritise project shared portfolio eliminate activity duplicate long require notably administration function follow completion transaction pharmaceutical division carry detailed reassessment global manufacturing network particular emphasis biotech manufacturing facility result manufacturing facility construction project discontinue notably bulk drug production unit site vacaville california group currently anticipate restructure activity substantially complete endof total cost expect order billion swiss franc include mil lion swiss franc incur approximately billion swiss franc total noncash carry value property plant equipment reduce billion swiss franc end anticipate reduce approximately billion swiss franc total end relate manufacture facility significant cost incur describe disclose separately income statement materiality amount order fairly present group result cost restructure programme material fundamentally change group organisation expense current period report respective functional expense change group organisation millions chf employeerelate cost termination cost pension postemployment benefit genentech employee retention program expense genentech stock option accelerate vest expense retention plan employee benefit employeerelate cost total employeerelate cost site closure cost impairment property plant equipment accelerate depreciation property plant equipment site closure cost total site closure cost impairment intangible asset reorganisation expense total total income tax benefit record respect change group organisation million swiss franc million swiss franc genentech employee retention program august genentech announce broadbase employee retention program consist retention plan cover substantially employee company program estimate cost approximately million dollar payable cash andhas implement lieu genentech annual stock option grant total expense theretention program million swiss franc million swiss franc genentech grant annual stock option award previous year total value retention program cost expensed fouryear vest period expense approximately million swiss franc million swiss franc accordingly additional incremental cost incur retention plan report change ingroup organisation directly attributable genentech transaction genentech employee retention program expense million chf cost sale marketing distribution research development general administration total include operating profit exceptional item change group organisation total genentech employee retention program expense genentech stock option merger agreement march roche genentech successful completion tender offer march remain outstanding genentech employee stock option fully redeem cash accounting purpose remain fairvalue expense option fully vested time roche finance report roche group note roche group consolidate financial statement genentech stock option accelerate vest expense millions chf genentech stock option plan genentech employee stock purchase program total genentech stock option accelerate vest expense employee benefit employee remuneration million chf wage salary social security cost define contribution postemployment plan operating expense define benefit postemployment plan equity compensation plan change group organisation genentech employee retention program genentech stock option accelerate vest expense termination cost employee benefit employee remuneration include operating result expect return plan asset define benefit postemployment plan interest cost define benefit postemployment plan total employee remuneration employee benefit consist mainly life insurance scheme certain insurance scheme provide medical coverage longterm shortterm disability benefit charge employee benefit operating result include relevant expenditure line function expect returnon plan asset interest cost define benefit plan include financial income andfinance cost respectively note pension postemployment benefit group objective provide attractive competitive postemployment benefit employee time ensure plan appropriately finance manage potential impact group longterm financial position employee cover pension plan sponsor group company nature plan vary accord legal regulation fiscal requirement andmarket practice country employee employ postemployment benefit consist postretirement healthcare life insurance scheme principally united states postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution plan classify define benefit plan group potential obligation relatively minor relatively remote possibility arise consequently group postemployment benefit plan classify define benefit plan forthe purpose financial statement define contribution plan define contribution plan typically consist payment employee group fund administer party payment group million swiss franc million swiss franc asset liability recognise group balance sheet respect plan apartfrom regular prepayment accrual contribution withhold employee wage salary group contribution define benefit plan group major define benefit plan locate switzerland united states germany united kingdom japan plan usually establish trust independent group fund payment group employee case notably major define benefit plan ingermany plan unfunded group pay pension retire employee directly financial resource current past service cost charge appropriate income statement head operating result pension plan administration funding oversee corporate level settlement gain loss result change funding arrangement report general administration expense corporate segment expect return plan asset interest cost charge financial income financing cost respectively actuarial gain loss record directly equity recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit recognition asset define benefit plan record directly equity define benefit plan expense millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total current service cost past service cost gain loss curtailment gain loss settlement total operating expense expect return plan asset interest cost total financial income expense total expense recognise income statement funding group define benefit plan oversee corporate level qualified independent actuary carry valuation regular basis major plan annually report date fund plan usually trust independent group finance net assetliability recognise group balance sheet correspond overunder funding plan adjust unrecognised past service cost unfunded plan group meet pension obligation directly financial resource liability define benefit obligation record group balance sheet pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan amountsrecognise balance sheet postemployment benefit predominantly noncurrent andare report noncurrent asset liabilitie roche finance report roche group note roche group consolidate financial statement define benefit plan fund status millions chf fund unfunded fund unfunded plan plan total plan plan total fair value plan asset define benefit obligation funding unrecognise past service cost limit asset recognition reimbursement right net recognise asset liability report define benefit plan reimbursement right postemployment benefit asset postemployment benefit liability net recognise asset liability detailed information plan asset define benefit obligation give define benefit plan fair value plan asset reimbursement right millions chf fair value reim fair value reim plan bursement plan bursement asset right total asset right total january expect return plan asset actuarial gain loss currency translation effect employer contribution employee contribution benefit pay fund plan past service cost divestment subsidiary curtailment settlement december invest share equity instrument bond debenture debt instrument property asset total include fair value plan asset thousand group share fair value million swiss franc thousand share fair value million swiss franc thousand group nonvoting equity security fair value million swiss franc thousand nonvoting equity security total fair value million swiss franc define benefit plan define benefit obligation millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january current service cost interest cost employee contribution actuarial gain loss currency translation effect benefit pay fund plan benefit pay unfunded plan past service cost divestment subsidiary curtailment settlement december fund plan unfunded plan actuarial assumption actuarial assumption unbiase mutually compatible estimate variable determine ultimate cost provide postemployment benefit set annual basis local management actuary subject approval corporate management group actuarie actuarial assumption consist demographic assumption matter mortality employee turnover andfinancial assumption matter salary benefit level interest rate return investment cost medical benefit group operate define benefit plan country actuarial assumption vary base local economic social condition demographic assumption significant demographic assumption relate mortality rate thegroup actuary use mortality table account historic pattern expect change increase longevity mortality table major scheme germany heubeck table g japan national census life table switzerland bvg united kingdom nonpensioner snal table rate year male year female futureimprovement medium cohort underpin united kingdom pensioner snal table rate year future improvement medium cohort underpin united states rp project rate employee turnover disability early retirement base historical behaviour group company financial assumption base market expectation period obligation settle range assumption actuarial valuation significant plan country stable currency interest rate show roche finance report roche group note roche group consolidate financial statement define benefit plan financial actuarial assumption weighted weight average range average range discount rate expect rate return plan asset expect rate salary increase medical cost trend rate discount rate calculate discount present value define benefit obligation determine reference market yield high quality corporate bond government bond incountrie deep market corporate bond currency term bond consistent obligation discount interest cost include income statement calculate multiply discount rate define benefit obligation expect return plan asset base market expectation expect return asset fund plan duration relate obligation take account split plan asset equity bond property investment calculation include assumption concern expect dividend interest income realise unrealised gain plan asset taxis administration cost bear plan arebase longterm market expectation actual performance continually monitor corporate management longterm nature obliga tion assumption matter return investment necessarily consistent recent historical pattern expect return plan asset include income statement calculate multiplying expect rate return fair value plan asset difference expect return actual return month period actuarial gainloss isrecordeddirectly equity actual return plan asset gain million swiss franc loss million swiss franc expect rate salary increase calculate define benefit obligation current service cost include income statement base late expectation historical behaviour group company medical cost trend rate calculate define benefit obligation current service cost include inthe income statement postemployment medical plan account benefit set plan term expect future change medical cost group major post employment medical plan forus employee rate drive development united states effect percentage point increase decrease medical cost trend rate show define benefit plan sensitivity medical cost trend rate millions chf current service cost interest cost define benefit obligation funding summary fiveyear summary funding status group define benefit plan show table define benefit plan summary funding status millions chf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation increase decrease funding status arise experience adjustment fair value plan asset define benefit obligation increase decrease funding status arise change actuarial assumption fair value plan asset define benefit obligation cash flow group incur cash flow define benefit plan show table define benefit plan cash flow million chf employer contribution fund plan benefit pay unfunded plan total cash inflow outflow base recent actuarial valuation group expect employer contribution fund plan approximately million swiss franc include estimate million swiss franc additional contribution benefit pay unfunded plan estimate approximately million swiss franc amount record equity actuarial gain loss recognise statement comprehensive income loss million swiss franc loss million swiss franc pretax total december wasan accumulate loss million swiss franc accumulate loss million swiss franc addition recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past servicecost adjustment arise limit asset recognition record directly equity adjustment decrease million swiss franc increase million swiss franc roche finance report roche group note roche group consolidated financial statement employee stock option equity compensation benefit group operate equity compensation plan include separate plan genentech prior genentech transaction chugai effective january group adopt ifrs sharebased payment matter standard require fair value equity compensation plan award grant employee estimate grant date record expense vest period expense charge appropriate income statement heading expense equity compensation plan millions chf cost sale marketing distribution research development general administration total operating expense exceptional item change group organisation total operating expense share option plan roche option plan genentech stock option plan chugai stock acquisition right total share option plan equity compensation plan special stock award roche connect genentech employee stock purchase program roche stocksettle stock appreciation right roche restrict stock unit plan chugai retirement stock acquisition right roche performance share plan roche stock appreciation right total equity compensation plan total operating expense equitysettle cashsettle cash inflow outflow equity compensation plan millions chf genentech equity compensation plan genentech stock option plan genentech employee stock purchase program total cash inflow genentech equity compensation plan cash outflow genentech share repurchase equitysettle equity compensation plan roche option plan exercise chugai stock acquisition right exercise roche connect cost total equitysettle equity compensation plan cash outflow transaction equity instrument total cash inflow outflow equitysettle equity compensation plan net transaction equity instrument cashsettle plan include movement net work capital roche stock appreciation right net cash outflow transaction equity instrument arise sale purchase non vote equity security genussscheineand derivative instrument thereon hold group potential conversion obligation arise group equitysettle equity compensation plan derivative instrument mainly consist option exercisable time maturity note addition cash flow completion genentech transaction remain outstanding genentech employee stock option fully redeem cash result cash outflow million swiss franc report change ownership interest subsidiary seenote roche longterm group implement new global longterm incentive programme whichis available certain director management employee select discretion group programme consist stocksettle stock appreciation right ssar group thealternative granting award exist roche option plan follow integration ofgenentech group establish restrict stock unit rsu plan awards planwere september employee genentech ssar issue accordance roche ssar plan regulation january include amendment effective january addenda include roche ssar plan addendum united states september remuneration committee determine number nonvoting equity security genussscheine available plan year regulation collectively provide million nonvoting equity security genussscheinewill available issuance roche ssar plan overa tenyear period rsus issue accordance roche restrict stock unit plan theregulation effective september million nonvoting equity security genuss scheinewill available issuance tenyear period detail plan give relevant section meaning section title california corporations codeand section title california code regulation approval consolidated financial statement constitute approval roche ssar plan roche restrict stock unit plan describe consolidated financial statement majority roche hold ltds outstanding security entitle vote roche finance report roche group note roche group consolidated financial statement share option plan roche option plan award plan employee right purchase nonvoting equity security genussscheineat exercise price specify grant date option nontradable equitysettle award sevenyear duration vest phase basis year subject continued employment group cover obligation purchase nonvoting equity security derivative thereon note introduction roche longterm number option grant roche option plan significantly reduce eligible employee receive roche stocksettle stock appreciation right instead roche option plan movement number option outstanding number weight average number weight average option exercise price option exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche option plan term option outstanding december option outstanding option exercisable number weight average weight average number weight average outstanding year remain exercise exercisable exercise year grant thousands contractual life price chf thousand price chf total genentech stock option plan genentech stock option plan adopt amend april genentechs shareholder approve equity incentive plan plan allow grant stock option incentive stock option stock purchase right employee director consultant genentech option grant nontradable equitysettle award tenyear duration vest phase basis year subject continued employment completion genentech transaction note remain outstanding option fully redeem cash accounting purpose remain fair value expense option fully vested time describe note genentech stock option plan movement number option outstanding number weight average number weight average option exercise price option exercise price million usd million usd outstanding january grant forfeit exercise expired genentech transaction outstanding december exercisable chugai stock acquisition right chugai adopt stock acquisition right programme theprogramme allow grant right employee director chugai right entitle theholder purchase chugai share specify exercise price right nontradable equitysettle award tenyear duration vest year chugai stock acquisition right movement number right outstanding weighted average weight average number exercise price number exercise price right jpy right jpy outstanding january grant forfeit exercise expired outstanding december exercisable chugai stock acquisition right term right outstanding december right outstanding right exercisable weighted average weighted average weight average number year remain exercise number exercise year grant outstanding contractual life price jpy exercisable price jpy award total issue share option issue share option include methodology calculate fair value main input valuation model describe roche finance report roche group note roche group consolidate financial statement issue share option plan chugai stock roche genentech stock acquisition option plan option plan right number option grant thousand million underlying equity roche nonvoting genentech chugai share equity security common stock block currency swiss franc dollar japanese yen vest period progressively progressively year year year contractual life year year year weight average fair value option issue option pricing model binomial binomial binomial input option pricing model share price grant date exercise price expect volatility expect dividend yield early exercise factor na expect exit rate volatility roche chugai option determine primarily reference historically observe price underlie equity volatility genentech option determine primarily reference imply volatility genentech trade option riskfree interest rate derive zero coupon swap rate atthe grant date take datastream early exercise factor describe ratio expect market price exercise date exercise price early exercise expect base onhistorically observe behaviour equity compensation plan special stock awards march december group issue special stock award certain director management employee select discretion group award consist immediately vest nonvoting equity security genussscheine fair value award calculate basis market value roche nonvoting equity security date issue special stock awards award issue march december total number award issue thousands fair value unit grant chf total fair value grant chf million roche connect programme enable employee worldwide united states certain country regular deduction salary purchase nonvoting equity security genussscheine administer independent party group contribute programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary nonvoting equity security directly market atdecember administrator hold million nonvoting equity security million theprogramme operational october year cost plan million swiss franc million swiss franc report relevant expenditure line function genentech employee stock purchase program espp genentech employee stock purchase programme allow employee purchase genentech common stock low market value grant date purchase date total million share genentech common stock purchase million share result cash inflow million swiss franc million swiss franc year cost plan million swiss franc million swiss franc report relevant expenditure line function completion ofthe genentech transaction note remain outstanding award fully redeem cash accounting purpose remain fair value expense award fully vested time describe note roche stocksettle stock appreciation right introduction roche longterm thegroup offer stocksettle stock appreciation right ssar certain director management employee select discretion group ssar employee right receive non votingequity security genussscheinereflecting value appreciation market price nonvoting equity security grant date exercise date right nontradable equitysettle award sevenyear duration vest phase basis year subject tocontinued employment group cover obligation purchase nonvoting equity security orderivative thereon note roche ssar movement number right outstanding number weight average number weight average right exercise price right exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche ssar term right outstanding december right outstanding right exercisable weighted weight number weight average average number average outstanding year remain exercise exercisable exercise year grant thousands contractual life price chf thousand price chf total weight average fair value right grant calculate binomial model input model consistent roche option plan award give previously early exercise factor expect exit rate result weight average fair value right chf give total fair value million swiss franc charge vest period year roche finance report roche group note roche group consolidate financial statement roche restrict stock unit plan time september group issue restrict stock unit rsus award certain director management employee select discretion group award employee genentech rsus nontradable represent right receive nonvoting equity security genussscheinewhich vest year period weight average fair value award grant chf calculate basis market value roche nonvoting equity security date issue discount account award accrue dividend vest period roche rsus movement number awards outstanding number award thousand outstanding january grant forfeit transfer participant outstanding december exercisable chugai retirement stock acquisition right time chugai issue stock acquisition right lieu abolition retirement gratuity system director right issue athirtyyear duration vest holder retirement director chugai right entitle theholder purchase chugai share exercise price japanese yen total fair value right issue equivalent million swiss franc calculate binomial model input consistent chugai stock appreciation right give previously roche performance share plan group offer future nonvoting equity security awards discretion board director cash equivalent certain director key senior manager theprogramme establish beginning currently operate annual threeyear cycle term currently outstanding award set table nonvoting equity security allocate depend individual salary level achievement performance target link group total shareholder return share nonvoting equity security combine relative tothe group peer threeyear period date grant discretion board director nontradable equitysettle awards award result zero nonvoting equity security depend achievement performance target roche performance share plan term outstanding award december number award outstanding thousand vest period year year year allocate recipients feb feb feb fair value unit grant chf total fair value grant chf million weight average fair value award grant calculate monte carlo simulation input parameter model covariance matrix roche individual company peer group base threeyear history riskfree rate valuation take account define rank performance structure determine payout psp roche stock appreciation right employee certain north american subsidiary group receive stock appreciation right sar compensation sar nontradable cashsettle award exercise vest period year cash payment base market price group american depositary receipt adr point exercise exceed strike price grant price issuance follow implementation roche longterm group plan award cashsettle sar noaward january ratio adr nonvoting equity security genussscheinewas change information restate change roche stock appreciation right millions chf liability december intrinsic value vest right december roche stock appreciation right term right outstanding december right outstanding exercisable number outstanding exercisable weighted average year grant thousand expiry price usd feb feb total fair value december calculate binomial model input model adr price december usd exercise price give table input consistent roche option plan award give previously roche finance report roche group note roche group consolidate financial statement property plant equipment property plant equipment movement carry value asset millions chf building land machinery construction land improvement equipment progress total january cost accumulate depreciation impairment net book value year end december january addition disposal ventana acquisition business combination divestment subsidiarie transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value year end december january addition disposal lonza singapore acquisition business combination divestment subsidiarie transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value impairment charge arise change estimate future cash flow expect result theuse asset eventual disposal factor change plan use building machinery equipment closure facility presence absence competition technical obso lescence result shorten useful life impairment impairment charge million swiss franc million swiss franc report cost sale million swiss franc zero inresearch development million swiss franc million swiss franc report aspart change group organisation note major impairment report change group organisation relate discontinuation bulk drug production unit site vacaville california fully writtendown borrowing cost total million swiss franc rate million swiss franc arate capitalise property plant equipment leasing arrangement group lessee finance lease december capitalise cost property plant equipment finance lease million swiss franc million swiss franc net book value asset million swiss franc million swiss franc finance lease future minimum lease payment noncancellable lease million chf future minimum lease present value future payment minimum lease payment year year year total future finance charge total future minimum lease payment undiscounte addition genentech leasing arrangement disclose operating lease group company party number operating lease mainly plant machinery include motor vehicle certain shortterm property rental arrangement impose significant restriction group total operating lease rental expense million swissfranc million swiss franc operating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment lease arrangement group lessor finance lease certain asset mainly diagnostic instrument lease party finance lease arrangement asset report receivables equal net investment thelease lease income finance lease recognise term lease base effective interest rate method finance lease future minimum lease payment noncancellable lease millions chf gross investment lease present value future minimum lease payment year year year total unearned finance income na na unguaranteed residual value na na net investment lease roche finance report roche group note roche group consolidate financial statement accumulate allowance uncollectible minimum lease payment million swiss franc million swiss franc contingent rent recognise income operating lease certain asset mainly diagnostic instrument lease party operate lease arrangement asset report property plant equipment lease income operating lease recognise lease term straight line basis operating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment december machinery equipment original cost million swiss franc million swiss franc net book value million swiss franc million swiss franc lease party contingent rent recognise income genentech leasing arrangement december genentech enter master lease agreement slough ssf llc subsequently acquire health care property hcp development property adjacent genentechs south san francisco site development include total building subjectto separate agreement contemplate master lease agreement hcp developer construct building shell building genentech finish interior build laboratory office space applicable construction building complete atwhich point lease term building deem begin construction final building complete lease term expire year occupation final building genentech fiveyear renewal option building option purchase building different date genentech right refusal respect toeach building entire development hcp consider sell development december total carrying value property plant equipment agreement million swiss franc million swiss franc carry value lease obligation million swiss franc million swiss franc estimate total future minimum lease payment anticipate entire master lease agreement show estimate total future minimum lease payment hcp lease millions chf total minimum principal ground lease interest lease payment year year year total capital commitment group noncancellable capital commitment purchase construction property plant equipment total billion swiss franc billion swiss franc goodwill goodwill movement carry value asset millions chf january lonza singapore acquisition ventana acquisition business combination impairment charge currency translation effect december allocate follow cashgenerating unit pharmaceutical division roche pharmaceutical chugai total pharmaceutical division diagnostic division diabetes care professional diagnostic molecular diagnostic apply science tissue diagnostic strategic goodwill hold divisional level allocate business area total diagnostic division total group accumulate impairment loss goodwill goodwill arise investment associate classify investment associate note goodwill impairment testing pharmaceutical division division subdivision cashgenerate unit test ofgoodwill chugai recoverable base fair value cost sell determined reference publicly quote share price chugai share roche pharmaceutical recoverable impairment testing base value use cash flow projection base onthe recent business plan approve management assume significant change theorganisation division include management late estimate sale volume pricing production operating cost reflect past experience project year thecash flow projection extend management recent business plan discount rate base rate derive capital asset pricing model datafrom swiss capital market include swiss federal government tenyear bond swiss market index weight average tax rate calculation management believe reasonably possible change key assumption cause carry value goodwill toexceed recoverable roche finance report roche group note roche group consolidate financial statement diagnostic division division business area cashgenerate unit test goodwill goodwill arise corangeboehringer mannheim acquisition goodwill ventana acquisition record monitor divisional level relate strategic development division meaningfully allocate division business area cashgenerate unit goodwill entire division recoverable intheimpairment testing base value use cash flow projection base recent business plan approve management assume significant change organisation division include management late estimate sale volume pricing production operating cost reflect past experience project year estimate tissue diagnostic business area project year management believe reflect longterm nature business cash flow projection extend management recent business plan discount rate base rate derive capital assetprice model datum swiss capital market include swiss federal government tenyear bond swiss market index weight average tax rate calculation management believe reasonably possible change key assumption cause carry value goodwill exceed recoverable intangible asset intangible asset movement carry value asset millions chf product product intangible marketing technology intangible available intangible intangible use use use use total january cost accumulate amortisation impairment net book value year end december january ventana acquisition business combination addition disposal amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment pharmaceutical diagnostic total group product product intangible marketing technology intangible available intangible intangible use use use use total year end december january lonza singapore acquisition business combination addition disposal amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment pharmaceutical diagnostic total group significant intangible asset december millions chf operate net book remain segment value amortisation period product intangible use tanox acquisition pharmaceutical year chugai acquisition pharmaceutical year corangeboehringer mannheim acquisition diagnostic year igen acquisition diagnostic year ventana acquisition diagnostic year product intangible available use alnylam alliance pharmaceutical na ventana acquisition diagnostic na classification amortisation impairment expense millions chf amortisation impairment amortisation impairment cost sale pharmaceutical diagnostic marketing distribution diagnostic research development pharmaceutical diagnostic change group organisation pharmaceutical total roche finance report roche group note roche group consolidated financial statement internally generate intangible asset group currently internally generate intangible asset development criterion recognition asset meet intangible asset indefinite useful life group currently intangible asset indefinite useful life impairment intangible asset impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment pharmaceutical operating segment record impairment charge million swiss franc diagnostic operating segment record impairment charge million swiss franc pharmaceutical operating segment impairment charge million swiss franc record related pharmaceutical division reorganisation note integration programme include prioritise project shared portfolio asset concern fully write charge impairment charge million swiss franc record respect product intangible available use follow recent clinical datum portfolio prioritisation decision relate certain project alliance partner acquire business combination asset concern amortise write recoverable million swiss franc base value use calculation discount rate addition impairment charge million swiss franc record relate intangible asset use follow regular updating division business plan technology assessment second half asset write recoverable million swiss franc base value use calculation discount rate diagnostic operating segment impairment charge million swiss franc record thiswasin respect intangible asset use follow regular updating division business plan technology assessment second half asset write recoverable million swiss franc base value use calculation discount rate pharmaceutical operating segment impairment charge million swiss franc record half million swiss franc record second half relate product intangible available use follow decision terminate development compound alliance partner asset concern amortise fully write charge diagnostic operating segment impairment charge million swiss franc record second half relate product intangible asset use follow regular updating division business plan technology assessment second half asset write recoverable million swiss franc base value use calculation discount rate intangible asset available use represent inprocess research development asset acquire inlicense arrangement business combination separate purchase asat december carry value asset pharmaceutical division million swiss franc approximately represent project potential decision point withinthe month certain circumstance lead impairment inherent uncertainty research development process asset particularly risk impairment iftheproject question result commercialise product potential commitment alliance collaboration group party inlicense similar arrangement alliance partner arrangement require group certain milestone similar payment dependent achievement agree objective performance target define collaboration agreement group current estimate future thirdparty commitment payment set table figure risk adjust meaning include potential payment canarise assume project currently development successful timing base group current good estimate figure include potential commitment group mayarise roche chugai business potential future thirdparty collaboration payment december millions chf pharmaceutical diagnostic group year year year total associate group investment associate account equity method goodwill arise investment associate classify investment associate investments associate millions chf share net income carry value total investment associate group significant investment associate material transaction thegroup associate additional information associate give note financial longterm asset financial longterm asset millions chf availableforsale investment heldtomaturity investment loan receivable longterm trade receivable restrict cash total financial longterm asset longterm employee benefit total longterm asset roche finance report roche group note roche group consolidate financial statement financial longterm asset hold strategic purpose classify noncurrent available forsale investment mainly equity investment unquote equity investment classify available forsale generally measure cost fair value measure reliably primarily investment private biotechnology company keep group strategic alliance effort carry value equity investment hold cost million swiss franc million swiss franc million swiss franc average effective interest rate heldtomaturity investment loan receivable comprise loan party term year inventory inventory million chf raw material supply work process finish good intermediate provision slowmove obsolete inventory total inventory expense relate inventory expense cost sale total million swiss franc million swiss franc account receivable account receivable million chf trade account receivable note receivable allowance doubtful account chargeback allowance total account receivable december account receivable include amount denominate dollar equivalent bil lionswiss franc billion swiss franc billion swiss franc amount denominate ineuro equivalent billion swiss franc billion swiss franc billion swiss franc allowance doubtful account receivable movement recognise liability million chf january additional allowance create unused amount reverse utilise year currency translation effect december net bad debt expense million swiss franc million swiss franc significant concentration trade receivables counterparty credit risk describe note current asset current asset millions chf accrue interest income derivative financial instrument restrict cash total financial current asset prepaid expense total nonfinancial current asset total current asset derivative financial instrument asset primarily relate hedge nonus dollar denominate bond note issue finance genentech transaction restrict cash include million swiss franc surety bond post genentech connection city hope litigation note follow settlement litigation entirety pledge unrestricted cash available use genentech operation quarter marketable security marketable security millions chf financial asset fairvaluethroughprofitorloss heldfortrade investment bond debenture designate fairvaluethroughprofitorloss bond debenture money market instrument time account month investment total financial asset fairvaluethroughprofitorloss heldtomaturity financial asset money market instrument time account month total heldtomaturity financial asset availableforsale financial asset share bond debenture money market instrument time account month investment total availableforsale financial asset total marketable security roche finance report roche group note roche group consolidate financial statement marketable security hold fund management purpose classify current primarilydenominate dollar investment hold strategic purpose classify noncurrent note heldfortrade investment hold genentech sell share consist primarily readily saleable equity security bond debenture carry value contract maturity average effective interest rate debt security show bond debenture millions chf average effective average effective contract maturity interest rate interest rate year year year total bond debenture money market instrument generally fix interest rate range depend currency denominate contract tomature year december cash cash equivalent cash cash equivalent millions chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent account payable account payable million chf trade account payable taxis payable dividend payable account payable total account payable accrue current liability accrue liability current liability millions chf defer income accrue payroll relate item interest payable derivative financial instrument accrue liability total accrue current liability derivative financial instrument group use derivative financial instrument risk management activity discuss note derivative financial instrument carry fair value method determine fair value describe note derivative financial instrument millions chf asset liability foreign currency derivative forward exchange contract crosscurrency swap interest rate derivative swap derivative total derivative financial instrument hedge accounting group accounting policy hedge accounting describe note require qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement describe note group financial risk management policy foreign exchange risk interest rate risk market risk credit risk liquidity risk deem appropriate certain risk manage derivative transaction consider hedge economic term require condition meet relationship qualify hedge accounting inthis case hedge instrument hedge item report independently hedge relationship mean derivative report fair value change fair value include financial income group generally limit use hedge account certain significant transaction consequently asat december group fair value hedge cash flow hedge hedge net investment foreign entity meet strict requirement qualify hedge accounting apart describe roche finance report roche group note roche group consolidate financial statement cash flow hedge group issue bond note finance genentech transaction note bond note denominate euros sterling group enter crosscurrency swap hedge foreign exchange interest rate risk cash flow hedge qualify hedge accounting december instrument designate qualify hedge accounting arerecorde asset fair value million swiss franc ineffective portion genentech partly hedge nonus dollar cash flow future royalty income development expense expect year genentech enter zerocost collar option contract december option inthemoney cash flow expect derivative option designate qualify hedge accounting record net liability fair value million swiss franc hedge unwound material ineffective portion expect undiscounted cash flow qualify cash flow hedge include interest payment duration derivative contract final settlement maturity show table expect cash flow qualify cash flow hedge millions chf total month month month year year year year year year end december cash inflow cash outflow total year end december cash inflow cash outflow total undiscounted cash flow table affect profit loss show include interest payment duration derivative contract include final settlement maturity expect cash flow qualify cash flow hedge impact profit loss million chf total month month month year year year year year year end december cash inflow cash outflow total year end december cash inflow cash outflow total change hedge reserve equity show note fair value hedge group hedge fixedterm debt instrument interest rate swap december instrument designate qualify fair value hedge record balance sheet asset fair value million swiss franc asset million swiss franc loss million swiss franc record interest rate swap gain million swiss franc fair value hedge highly effective inception result interest rate swap largely offset change fair value hedge debt instrument group equity investment biotechnology company subject great risk ofmarket fluctuation stock market general manage exposure group enter forward contract designate qualify fair value hedge december instrument record asset fair value million swiss franc asset ofmillion swiss franc loss million swiss franc record forward contract gain million swiss franc result forward contract offset changesin fair value hedge equity investment group use derivative designate qualify hedge relationship manage exposure foreign currency interest rate equity market credit risk instrument include interest rate swap crosscurrency swap forwards contract option provision contingent liability provision movement recognise liability million chf legal environmental restructure employee provision provision provision provision provision total year end december january additional provision create unused amount reverse utilise year unwind discount currency translation effect december current portion noncurrent portion total provision roche finance report roche group note roche group consolidate financial statement legal environmental restructure employee provision provision provision provision provision total year end december january additional provision create unused amount reverse utilise year unwind discount business combination currency translation effect december current portion noncurrent portion total provision expect outflow resource year year year year total provision major legal case income expense major legal case disclose separately income statement materiality amount order fairly present group result provision major legal case increase million swiss franc base management current estimate ultimate liability expect arise take account development litigation arbitration process negotiation resolve case income million swiss franc record follow april california supreme court decision city hope litigation consist million dollar release income favourable litigation settlement net amount record respect final settlement negotiation city hope national medical center cost litigation matter material expense current period report general administration expense total income tax record respect major legal case wasa benefit million swiss franc expense million swiss franc legal provision legal provision consist number separate legal matter include claim arise trade group company majority cash outflow matter expect occur thenext year dependent development litigation significant provision discount time value money material environmental provision provision environmental matter include separate environmental issue number country nature amount timing outflow difficult predict estimate timing cash outflow show table significant provision discount time value money material restructuring provision arise plan programme materially change scope business undertake groupor manner business conduct provision include cost necessarily entail restructuring associate recur activity group timing cash outflow reasonably certain global basis show table significantprovision discount time value money material employee provision relate certain employee benefit obligation sabbatical leave longservice benefit timing cash outflow reasonably estimate base past performance areshown table significant provision discount time value money ismaterial provision provision relate sale return provision group company fit category timing cash outflow nature uncertain good estimate show table provision discount time value money material matter contingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protection country operate industry group operate subject risk kind nature frequency development event cover insurance effect future operation earning predictable group enter strategic alliance company order gain access potential new product utilise company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define collaboration agreement group good estimate future commitment payment give note pharmaceutical legal case june genentech announce los angeles county superior court jury vote award city hope national medical center city hope approximately million dollar compensatory damage base find breach agreement genentech city hope june jury vote award city hope million dollar punitive damage case september genentech file notice appeal jury verdict damage awards california court appeal october court appeal affirm verdict damage award respect october genentech announce seek review california supreme court discretion case review november genentech file petition review california supreme court february california supreme court grant petition appeal california supreme court hear february april overturned award million dollar punitive damage city hope upheld award million dollar compensatory damage genentech pay million dollar city hope reflect compensatory damage award plus interest thereon date original decision june march genentech city hope national medical center resolve remain issue additional royalty andother amount genentech owe city hope agreement thirdparty product sale settlement thirdparty patent litigation include occur afterthe judgementby los angeles county superior court jury appeal process interest accrue total damage simple annual rateof interest million swiss franc record time cost provision financing cost provision total million dollar december record award result april california supreme court decision provision total million dollar release income favourable litigation settlement million dollar relate tothe original award record exceptional major legal case expense million dollar relate interest accrue charge financing cost intervene period roche finance report roche group note roche group consolidate financial statement october genentech enter arrangement thirdparty insurance company post surety bond connection judgment arrangement genentech pledge million dollar cash investment secure bond equivalent million swiss franc december record restrict cash current asset annual financial statement quarter court complete certain administrative procedure dismiss case result restriction lift restrict cash investment fund available use genentech operation october genentech receive subpoena united states department justice request document relate promotion rituxan genentech cooperate government associate investigation previously investigation civil criminal nature genentech inform august criminal prosecutor handle matter government decline prosecute genentech criminally connection investigation civil matter ongoing counsel genentech continue discussion government representative status theirinvestigation genentech view matter include potential resolution october government notify genentech decide civil claim genentech thegovernment investigation initiate complaint file seal district court eastern district pennsylvania individual plaintiff complaint unseal december currently basis civil litigation plaintiff roche holdings inc andgenentech group intends vigorously defend outcome civil litigation bedetermine time request file party reexamination patent thecabilly patent coowne genentech city hope national medical center underwhich company license pay royalty july patent andtrademark office patent office order reexamination patent february thepatent office mail final patent office action reject claim cabilly patent genentech file notice appeal challenge rejection august genentech opening appeal brief wasfile december subsequent filing appeal brief patent office continue reexamination february genentech file response patent office thatinclude propose amendment claim patent claim claim thatdepend claim february patent office issue notice intent issue reexamination certificate nirc confirm patentability claim cabilly patent amend amendment commercial impact cabilly patent nirc final nonappealable reexamination certificate issue reflect formal termination ofthese proceeding genentechs favour centocor inc file patent lawsuit genentech city hope district court central district california lawsuit relate cabilly patent seek declaratory judgment patent invalidity unenforceability regard cabilly patent patent noninfringe ment regard certain centocor product centocor file amend complaint september genentech answer complaint september file counterclaim centocor allege centocor product infringe certain genentech patent genentech file amendment counterclaim october centocor answer counterclaim november discovery ongoing lawsuit cabilly patent expire relate method bygenentech certain antibody antibody fragment cell dna inthese method genentech license cabilly patent company derive significant royalty licence outcome matter determined time october glaxo group limited smithkline beecham corporation glaxosmithkline llc collectively gsk file patent lawsuit genentech city hope district court southern district florida lawsuit relate cabilly patent seek declaratory judgment ofpatent invalidity unenforceability regard cabilly patent patent noninfringement regard certain gsk product december genentech file motion dismiss alternative transfer central district california outcome matter determine atthis time genentech development decision involve humanise anticd programme collaborator biogen idec inc disagree certain genentech development decision relate humanise anticd product dispute issue submit arbitration june genentech receive decision arbitrator include certain favourable certain adverse ruling relate genentechs development decision programme decision deny allmonetary damage seek party change collaboration profit split arrangement hoffmannla roche inc hlr roche affiliate name defendant numerous legal action united states relate acne medication accutane litigation allege accutane cause certain condition include limited inflam matory bowel disease ibd birth defect psychiatric disorder december hlr defend approximately action bring federal state court united states personal injury allegedly result use accutane action allege ibd result accutane use june hlr announce follow reevaluation portfolio medicine available generic manufacturer rapidly decline brand sale high cost personalinjury lawsuit continue defend vigorously decide immediately discontinue manufacture distribution product united states action pende federal court allege ibd consolidated pretrial proceeding multidistrict litigation united states district court middle district florida tampa division july district court grant summary judgment favour hlr lead federal ibd case theplaintiff appeal august ruling affirm united states court appeal eleventh circuit october district court grant summary judgment favour hlr thenext federal ibd case plaintiff appeal november recently file matter remain action pende state court new jersey allege ibd consolidated pretrial proceeding superior court new jersey law division atlantic county december juries superior court rule favour plaintiff case assess total compensatory damage total million dollar verdict reverse appeal retrial schedule january hlr appeal second verdict superior court new jersey appellate division currently process posttrial briefing remain trial involve plaintiff october jury circuit court escambia county florida return verdict favour plaintiff assess total compensatory damage million dollar subsequently reduce million dollars court company october district court appeal state florida reverse enter judgment hlr plaintiff seek review supreme court florida additional trial schedule individual trial result depend variety factor include unique particular case trial result date predictive offuture trial result group continue defend vigorously remain personal injury case andclaim roche finance report roche group note roche group consolidate financial statement hlr roche laboratories inc rli approximately brand generic pharma ceutical company name defendant legal action united states relate pricing pharmaceutical drug state medicaid reimbursement primary allegation litigation pharmaceutical company misrepresent report inaccurate average wholesale price awp andor wholesale acquisition cost wac drug price allegedly rely state calculate medicaid reimbursement entities retail pharma cie state respective attorney general seek repayment amount claimwere overreimbursed time period associate case december hlr rli defend action bring seven state include matter new york andone follow states alabama mississippi new jersey kansas hawaii iowa discovery currently pende case hlr rli intend vigorously defend inthese matter outcome matter determine time hlr brand pharmaceutical company name defendant legal action united states bring retail pharmacy relate discount practice forbrandname prescription drug bnpd bnpd litigations plaintiff allege deny discount certain prescription drug offer mail order manage care entity denial claim violation robinsonpatman act rpa rpa federal law prohibit unlawful price discrimination addition plaintiff allege defendant conspire refusal offer certain discount conspiracy claim defendant previously settle rpa claim remain litigate december hlr defend approximately bnpd action bring approximately retail pharmacy federal state court united states discovery currently pende case hlr currently schedule trial bnpd matter hlr intends vigorously defend outcome matter determined time november novartis vaccines diagnostic inc chiron affiliate novartis file alawsuit trimeris inc roche group company hoffmannla roche inc f hoffmann la roche ltd roche laboratories inc roche colorado corp district court eastern district texas complaint seek injunction damage manufacture sale roche antiaid drug fuzeon united states novartis allege activity infringe claim patent roche trimeriss request case transfer district court north carolina outcome matter determined time june mr ubaldo bao martinez file lawsuit porrio town council genentech espaa sl contentious administrative court number pontevedra spain lawsuit challenge town council decision grant license genentech espaa sl construction andoperation warehouse biopharmaceutical manufacturing facility porrio spain january administrative court rule favour mr bao claim lawsuit order theclosing demolition facility subject certain legal proceeding february genentech espaa sl town council file appeals administrative court decision high court galicia spain addition legal counsel spain genentech cooperating lonza group ltd lonza pursue administrative remedy include seek additional permit facility genentech sell assets genentech espaa sl include porrio facility lonza december lonza operate facility time term sale genentech retain control defence lawsuit agree indemnify lonza certain contractually define liability specify limit currently estimate approximately million dollar genentech indemnification obligation lonza determine time june august september genentech name defendant intermune inc chief executive officer w scott harkonen separate classaction com plaint file district court northern district california behalf plaintiff allegedly pay purchase price product license genentech connectic corporation subsequently assign intermune genentech respond complaint motion dismiss matter grant april plaintiff file amend complaint include state law claim genentech respond complaint motion dismiss hold september court grant genentech motion dismiss respect claim leave plaintiff replead specific claim california unfair competition law plaintiff file amend class action complaint december naming genentech defendant inclaim unfair competition law false advertising law consumer remedy law consumer protection lawand unjust enrichment genentech intend seek dismissal amend complaint outcome ofthis matter determine time subsequent announcement roche proposal purchase outstanding share genentech common stock own roche note thirty shareholder lawsuit file genentech andor members board director roche entity include roche holdings inc rhi roche holding ltd roche holding ag case settle july settlement approve delaware court chancery october genentech biogen idec inc file complaint sanofiaventis deutschland gmbh sanofi sanofiaventis llc sanofiaventis inc northern district california seek declaratory judgement certain genentech product include rituxan infringe sanofis patent patent patent declaratory judgement thatthe patent invalid october sanofi file suit genentech biogen idec eastern district texas lufkin division claim rituxan genentech product infringe patent sanofi bring claim preliminary permanent injunction compensatory exemplary damage relief genentech challenge venue thetexas case opinion federal circuit court appeals texas california case consolidated northern district california discovery consolidated matter ongoing addition october hoechst gmbh file icc international court arbitration paris request arbitration genentech relate terminate agreement hoechst predecessor genentech pertain patent relate patent outside united states hoechst seek payment royaltie sale genentech product damage breach ofcontract relief hearing arbitration set august genentech intends vigorously defend outcome matter determine time noncurrent liability noncurrent liability millions chf defer income longterm liability total noncurrent liability roche finance report roche group note roche group consolidate financial statement debt debt movement carry value recognise liability millions chf january proceeds issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt gain loss redemption repurchase bond note net amortisation debt discount gain loss financial liability fairvaluethroughprofitorloss net currency translation effect december consist bond note commercial paper amount bank financial institution genentech leasing obligation finance lease obligation borrowing total debt report longterm debt shortterm debt total debt fair value bond note billion swiss franc billion swiss franc bil lion swiss francs fair value total debt billion swiss franc billion swiss franc billion swiss franc calculate base observable market price debt instrument present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity period pledge group asset connection debt bond note recognise liability effective interest rate bond note million chf effective interest rate underlie include instrument hedge dollardenominated note float rate month libor note february principal billion dollar na note february principal million dollar na dollardenominated note fix rate note march principal billion dollar na note march principal billion dollar na note march principal billion dollar na note march principal billion dollar na european medium term note programme float rate month euribor note march principal billion euro european medium term note programme fix rate note october principal million euro na note march principal billion euro note march principal billion pound sterling note march principal billion euro note march principal billion euro note august principal million pound sterling na swiss franc bond rodeo march principal billion swiss franc na bond march principal billion swiss franc bond march principal billion swiss franc na dollar bond chameleon july principal million dollar na genentech senior note senior note july principal million dollar na senior note july principal billion dollar na senior note july principal million dollar na japanese yen convertible bond issue chugai series chugai pharmaceutical unsecured convertible bond september outstanding principal million japanese yen na total roche finance report roche group note roche group consolidate financial statement bond note maturity millions chf year year year year year year total bond note unamortised discount include carry value bond note millions chf dollar note euro note swiss franc bond sterling note total unamortised discount fair value option group apply fair value option outstanding debt instrument group apply fair value hedge accounting past debt instrument european medium term note programme euro bond chameleon dollar bond rodeo swiss francbond instrument fully redeem date fair value option treatment base elimination accounting mismatch recognise betweenthehedge swap report fair value hedge bond report amortise cost issuance new bond note group finance genentech transaction note combination group fund debtsecuritie commercial paper group raise net proceed approximately billion swiss franc series debt offering describe newly issue debt senior unsecured andha guarantee roche holding ltd dollardenominated note february group complete offer dollar denominate note qualified institutional buyer united states rule person otherthan person outside united states regulation securities act thegroup receive approximately billion dollar aggregate net proceed issuance sale fix float rate note march group complete offer ofus dollardenominated note rule securities act roche receive approximately billion dollar aggregate net proceed issuance sale fix ratenote theterm proceed note follow issuance dollardenominated note principal net proceed usd million chf million float rate note float rate note fix rate note fix rate note fix rate note fix rate note fix rate note total european medium term note programme march group issue euro sterling denominate fix float rate note term proceed note follow issuance european medium term note principal net proceed eur millions gbp millions chf million float rate eur note fix rate eur note fix rate gbp note fix rate eur note fix rate eur note total subsequent debt issuance proceed note swap dollar result inthese financial statement note economic characteristic equivalent dollardenominate note swiss francdenominate bond note march group complete offer swiss francdenominate fixedrate bond term proceed bond follow issuance swiss francdenominate bond principal net proceed chf millions chf million fix rate bond fix rate bond fix rate bond total subsequent debt issuance proceed swiss francdenominate bond swap dollar result financial statement bond economic characteristic equivalent dollardenominate bond cash inflow issuance bond note millions chf dollardenominated note european medium term note programme euro sterlingdenominate note swiss francdenominate note total cash inflow issuance bond note collateral agreement collateral agreement enter derivative counterpartie abovecurrency swap mitigate counterparty risk fair value derivative instrument move weak dollar cash collateral billion swiss franc deliver rocheas december collateral record increase cash correspond increase accrue liability time group deliver cash collateral million swiss franc derivative negative fair value collateral pay record increase current asset correspond decrease cash addition group generate cash flow billion swiss franc realise gain hedge derivative short maturity settle redemption repurchase bond note redemption chameleon dollar bond group redeem bond remain outstanding principal value million dollar date july original issue plus accrue original issue discount oid effective interest rate bond cash outflow million swiss franc gain loss record income statement redemption roche finance report roche group note roche group consolidate financial statement redemption repurchase dollardenominate note group redeem note principal value million dollar date september original issue plus accrue original issue discount oid effective interest rate bond cash outflow million swiss franc gain loss record income statement redemption addition group repurchase float rate note principal value million dollar original date february date open market purchase effective interest rate bond month libor plus cash outflow million swiss franc loss million swiss franc record income statement repurchase redemption swiss francdenominate note group redeem note principal value million swiss franc date september original issue plus accrue original issue discount oid effective interest rate bond include associate hedge instrument cash outflow million swiss franc gain loss record income statement redemption redemption repurchase conversion bond note redemption rodeo swiss franc bond date march group redeem thesebond original issue plus accrue original issue discount oid effective interest rate bond cash outflow million swiss franc gain orlossrecorded redemption redemption european medium term note programme euro bond date october group redeem original issue plus accrue original issue discount oid theeffective interest rate bond cash outflow million swiss franc gain loss record redemption conversion redemption series chugai pharmaceutical unsecured convertible bond remain outstanding bond face value million japanese yen million swissfranc convert share chugai redeem issue price date september group percentage ownership chugai unaffected conversion asthegroup bond convertible chugai share mirror chugai outstanding withthird party gain loss record income statement conversion andredemption cash outflow million swiss franc cash outflow redemption repurchase conversion bond note millions chf chameleon dollar bond dollardenominated note swiss francdenominate note rodeo swiss franc bond european medium term note programme euro bond japanese yen convertible bond issue chugai total cash outflow redemption repurchase conversion bond note commercial paper genentech commercial paper program october genentech establish commercial paper program issue billion dollar unsecured commercial paper note maturity program generally vary overnight week exceed day december unsecured commercial paper note principal million dollars andan average interest rate outstanding amount date january month group fully redeem note maturity theirprincipal value effective interest rate note cash outflow million swiss franc gain loss record redemption issuance genentech terminate commercial paper program noamount outstanding december roche holdings inc commercial paper program march roche holdings inc establish commercial paper program issue billion dollar unsecured commercial paper note guarantee roche holding ltd commit credit line billion euro million usdollar available backstop line maturity note program exceed day date issuance net cash inflow million swiss franc december unsecured commercial paper note principal million dollar average interest rate outstanding amount date january movement commercial paper obligation millions chf january net cash proceed payment currency translation effect december genentech commercial paper program roche holdings inc commercial paper program total amount bank financial institution amount denominate currency notably chinese renminbi average interest rate average interest rate balance primarily denominate inchinese renminbi repayment date year million swiss franc million swiss franc year roche finance report roche group note roche group consolidate financial statement equity attributable roche shareholder change equity attributable roche shareholder millions chf reserve share retain fair capital earning value hedge translation total year end december january net income recognise income statement availableforsale investment valuation gain loss take equity transfer income statement sale impairment income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statementa transfer initial carrying value hedge item income taxis noncontrolle interest currency translation foreign operation exchange difference accumulate difference transfer income statement divestment noncontrolle interest define benefit postemployment plan actuarial gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend pay equity compensation plan net transaction equity instrument genentech chugai share repurchase change ownership interest subsidiary chugai ventana change noncontrolle interest december amount transfer income statement losse million swiss franc report royalty operate income gain million swiss franc financial income change equity attributable roche shareholder millions chf reserve share retain fair capital earning value hedge translation total year end december january net income recognise income statement availableforsale investment valuation gain loss take equity transfer income statement sale impairment income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statementa transfer initial carrying value hedge item income taxis noncontrolle interest currency translation foreign operation exchange difference accumulate difference transfer income statement divestment noncontrolle interest define benefit postemployment plan actuarial gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend pay equity compensation plan net transaction equity instrument genentech chugai share repurchase change ownership interest subsidiary genentech memory change noncontrolle interest december amount transfer income statement losse million swiss franc report royalty operate income gain million swiss franc financial income roche finance report roche group note roche group consolidate financial statement group complete purchase noncontrolle interest genentech effective march asdescribed note base revise international accounting standard consolidated separate financial statement ias adopt group transaction account equity transaction consequence carrying consolidate equity group reduce billion swiss franc billion swiss francs allocatedto eliminate book value genentech noncontrolle interest accounting effect significantly impact group net equity effect group business dividend policy share capital december authorise issue share capital roche holding ltd group parent company consist share nominal value swiss franc precede year share bearer share group maintain register shareholder base information supply group shareholder group pool voting right owns issue share describe note base information supply tothe group novartis ltd basel affiliates participation issue share nonvoting equity security genussscheine december nonvoting equity security authorise issue precede year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right asany share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company entitle times exchange orsome nonvoting equity security share participation certificate dividend march shareholder approve distribution dividend swiss franc share nonvoting equity security swiss franc respect business year distribu tion holder outstanding share nonvoting equity security total million swiss franc million swiss franc record retain earning board director propose dividend business year swiss franc share nonvoting equity security approve result total distribution shareholder million swiss franc subject approval annual general meeting march equity instrument holding equity instrument equivalent number nonvoting equity security december december millions millions nonvoting equity security derivative instrument total equity instrument record equity original purchase cost detail equity instrument hold december show table fair value disclose information purpose equity instrument december supplementary information equivalent number nonvoting equity security strike price market value millions maturity chf chf million nonvoting equity security na na derivative instrument feb jan total nonvoting equity security derivative instrument hold group potential conversion obligation arise roche option plan roche stocksettle stock appreciation right note mainly consist option exercisable time maturity group hold share reserve fair value reserve fair value reserve represent cumulative net change fair value available forsale financial asset asset sell impair dispose hedging reserve hedging reserve represent effective portion cumulative net change fair value cash flow hedge instrument relate hedged transaction occur translation reserve translation reserve represent cumulative currency translation difference relate consolidation group company use functional currency swiss franc earning share nonvoting equity security basic earning share nonvoting equity security calculation basic earning share nonvoting equity security number share non vote equity security reduce weight average number nonvoting equity security hold group period basic earning share nonvoting equity security group net income attributable roche shareholder chf million number share million number nonvoting equity security millions weight average number nonvoting equity security hold million weight average number share nonvoting equity security issue million basic earning share nonvoting equity security chf roche finance report roche group note roche group consolidate financial statement dilute earning share nonvoting equity security calculation dilute earning share nonvoting equity security net income weightedaverage number share nonvoting equity security outstanding adjust effect dilutive potential share nonvoting equity security potential dilutive effect arise employee stock option plan exercise outstanding vested employee stock option dilutive effect exercise outstanding vested chugai priorto genentech transaction genentech employee stock option dilutive effect net income chugai genentech positive diluted earning share nonvoting equity security reflect potential impact dilutive effect earning share figure dilute earning share nonvoting equity security net income attributable roche shareholder chf million increase noncontrolle share group net income net tax assume outstanding genentech chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue million adjustment assume exercise equity compensation plan dilutive million weight average number share nonvoting equity security issue calculate diluted earning share millions diluted earning share nonvoting equity security chf noncontrolle interest change equity attributable noncontrolle interest millions chf january net income recognise income statement genentech chugai noncontrolle interest total net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan comprehensive income net tax total comprehensive income ventana acquisition memory acquisition dividend pay noncontrolle shareholder chugai noncontrolle interest equity compensation plan net transaction equity instrument genentech chugai share repurchase change ownership interest subsidiary genentech chugai ventana memory change noncontrolle interest december genentech chugai noncontrolle interest total noncontrolle interest statement cash flow cash flow operating activity cash flow operating activity arise group primary activity pharmaceutical diagnostic business calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show statement cash flow operate cash flow include income taxis pay activity roche finance report roche group note roche group consolidate financial statement cash generate operation million chf net income add nonoperate income expense associate financial income financing cost exceptional financing cost income taxis income taxis exceptional item operate profit depreciation property plant equipment amortisation intangible asset impairment intangible asset impairment property plant equipment operating expense define benefit postemployment plan operating expense equitysettle equity compensation plan net income expense provision adjustment cash generate operation cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset andthe cash flow effect business combination divestment cash generate thegroup investment interest dividend receive millions chf interest receive dividend receive total cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow fromshortterm borrowing show net movement consist large number transaction short maturity significant noncash transaction total purchase consideration million dollar lonza singapore million dollar million swiss franc noncash settlement loan previously genentech lonza seenote information risk management group risk management risk management fundamental element group business practice level encompass different type risk group level risk management integral business planning controlling process material risk monitor regularly discuss corporate executive committee audit committee board director financial risk management specifically describe detail financial risk management group expose financial risk arise underlie operation corporate finance activity group financial risk exposure predominantly relate change foreign exchange rate interest rate equity price creditworthiness solvency group counterpartie financial risk management group govern policy review board director ofroche chugai appropriate area statutory responsibility policy cover credit risk liquidity risk market risk policy provide guidance risk limit type authorise financial instrument monitor procedure general principle policy prohibit use derivative financial instrument speculative trading purpose policy implementation daytoday risk management carry relevant treasury function regular reporting risk perform relevant accounting controlling function roche chugai carry value fair value financial asset millions chf carry value asset class fvtpla available fvtpla hold hold loan fair line item note forsale designate trading maturity receivables total value year end december account receivable accrue interest income marketable security money market instrument time account month bond debenture share investment cash cash equivalent derivative financial instrument availableforsale investment heldtomaturity investment loan receivable longterm trade receivables financial current asset restrict cash longterm asset total fairvaluethroughprofitorloss roche finance report roche group note roche group consolidate financial statement carry value asset class fvtpla available fvtpla hold hold loan fair line item note forsale designate trading maturity receivables total value year end december account receivable accrue interest income marketable security money market instrument time account month bond debenture share investment cash cash equivalent derivative financial instrument availableforsale investment heldtomaturity investment loan receivable longterm trade receivables financial current asset restrict cash longterm asset total fairvaluethroughprofitorloss follow implementation amendment ifrs financial instrument disclosure publish march group establish fair value hierarchy reflect significance input make fair value measurement fair value hierarchy include follow level level quote price active market identical asset liability level observable input quote price active market identical asset liability level unobservable input fair value hierarchy financial asset liability december millions chf level level level total financial asset recognise fair value marketable security money market instrument time account month bond debenture share derivative financial instrument availableforsale investment total financial liability recognise fair value derivative financial instrument total availablefor sale investment exclude equity security hold cost million swiss franc carry fair value note december level financial asset consist treasury bill bond quote share level financial asset consist primarily commercial paper certificate deposit derivative financial instrument unquoted share level financial asset consist auctionrate student loan security security value base brokerprovide valuation model approximate fair value significant transfer level level vice versa change fair value level financial asset millions chf january impairment charge valuation gain loss take equity gain loss recognise income statement sale currency translation difference december credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group objective manage counterparty credit risk prevent loss liquid fund deposit invest counterpartie maximum exposure credit risk result financial activity consider net agreement take account collateral hold credit enhancement equal thecarrying value group financial asset trade receivables subject policy active credit risk management focus assessment country risk credit availability ongoing credit evaluation account monitor procedure objective management trade receivables sustain growth profitability group byoptimise asset utilisation whilst maintain risk acceptable level note significant concentration counterparty credit risk group large number customer wide geographical spread risk limit exposure continuously monitor country nature counterpartie additionally group obtain credit insurance similar enhancement appropriate protect collection trade receivables december collateral hold loan receivables december group combine trade account receivable balance national wholesale distributor amerisourcebergen corp cardinal health inc mckesson corp equivalent billion swiss franc represent group consolidated trade account receivable billion swiss franc represent nature geographical location trade receivables overdue counterpartie millions chf saler saler region total public distributor private total public distributor private switzerland european union rest europe north america latin america japan rest asia africa australia oceania total roche finance report roche group note roche group consolidate financial statement cash marketable security subject policy restricting exposure highquality counterpartie set define limit individual counterpartie limit counterparty creditrating review regularly investment marketable security enter basis ofguideline regard liquidity quality maximum general rule group invest high quality security adequate liquidity cash shortterm time deposit subject toruleswhich limit group exposure individual financial institution rate analysis cash fix income marketable security market value mchf total mchf total aaarange aarange arange bbbrange bbbrange total derivative group sign net collateral agreement isda international swap andderivative association master agreement respective counterpartie order mitigate counterparty risk derivative position group enter derivative contract party hedge foreign exchange risk arise bond note issue group affiliate roche holdings inc currencie dollar total exposure hedge issuance bond note approximately billion swiss franc note fair value derivative instrument move weak dollar net cash collateral billion swiss franc deliveredto group overdue asset financial asset past impair total billion swiss franc billion swiss franc analysis overdue impair financial asset class millions chf total overdue month month month month year year end december loan receivables year end december loan receivables december financial asset term renegotiate liquidity risk liquidity risk arise surplus financial obligation available financial asset point intime group approach liquidity risk maintain sufficient readily available reserve order tomeet liquidity requirement point time group liquidity report senior management amonthly basis roche chugai enjoy strong credit quality rate major credit rating agency rating permit efficient access international capital market event major financing requirement addition group unused committed credit line financial institution total billion swiss franc billion swiss franc contractual maturity analysis financial liability millions chf total month month month year year year year year year end december total debta trade payable accrual derivative financial instrument liabilitie current noncurrent total financial liability year end december total debta trade payable accrual derivative financial instrument liabilitie current noncurrent total financial liability total debt table show undiscounted cash flow carry value consolidate balance sheet reflect discount cash flow market risk market risk arise change market price group financial asset financial liability market risk affect group financial result value group equity group use valueatrisk var measure impact market risk financial instrument rochehas define var limit manage market risk var datum report monthly basis indicate value range give financial instrument fluctuate preset probability result ofmovement market price var statistical measure implicitly assume value change therecent past indicative value change future var figure represent actual expect loss possible worstcase loss state period var figure calculate historical simulation approach scenario financial instrument fully value total change value earning determine var calculation base ona confidence level hold period trading day past year hold period reflect time require change correspond risk exposure deem appropriate long hold period increase probability high value change lead increase var figure actual future gain loss associate treasury activity differ materially var analysis perform inherent limitation associate predict timing change interest rate foreign currency exchange rate equity investment price particularly period high market volatility furthermore var number include effect ofchange credit spread roche finance report roche group note roche group consolidate financial statement market risk financial instrument millions chf december december var foreign exchange component var interest rate component var price component diversification var total market risk december total var financial asset liabilitie million swiss franc december million swiss franc interest rate var increase substantially million swiss franc drive billion swiss franc bond note issue quarter asall newly issue debt hold amortise cost interest rate var sole metric economic fair valuechange impact carry value profit loss group foreign exchange var decrease hedge nonus dollar cash flow future royalty income genentech unwound price risk arise mainly movement price equity security remainedrelatively stable december group hold equity security market value billion swiss franc december billion swiss franc include holding biotechnology company acquire context licensing transaction scientific collaboration foreign exchange risk group operate world expose movement foreign currency affect groupfinancial result value group equity foreign exchange risk arise local currency pay receive transaction denominate foreign currency vary change inexchange rate transaction exposure foreign currency denominate financial statement group foreign subsidiary vary consolidation swiss franc denominate group financial statement translation exposure objective group foreign exchange risk management activity preserve economic value ofit current future asset minimise volatility group financial result primary focus group foreign exchange risk management activity hedge transaction exposure arise foreign currency flow monetary position hold foreign currency group currently hedge translation exposure financial instrument group monitor transaction exposure daily basis net foreign exchange result correspond var parameter report monthly basis group use forward contract foreign exchange option crosscurrency swap hedge transaction exposure application instrument intends continuously lock favourable development foreign exchange rate reduce exposure potential future movement rate interest rate risk interest rate risk arise movement interest rate affect group financial result orthevalue group equity change interest rate cause variation interest income expense inaddition affect market value certain financial asset liability hedge instrument primary objective group interest rate management protect net interest result interest rate exposure correspond var parameter report monthly basis group use forward contract option swap hedge interest rate exposure depend interest rateenvironment major currency group use instrument generate appropriate mix offixed float rate exposure price risk price risk arise mainly movement price equity security december thegroup hold equity security market value billion swiss franc billion swiss franc include holding biotechnology company acquire context oflicense transaction scientific collaboration nature business biotechnology company expose great equity volatility general stock market fluctuation group manage price risk place limit individual total equity investment limit define percentage total liquid fund absolute number individual equity investment equity price risk report var figure monthly basis senior management impairment financial asset impairment share trigger significant prolong price decline costvalue impairment loan receivables mainly increase expect nonrecoverability trade receivable note impairment loss asset class millions chf loan receivables availableforsale financial asset share investment debt security total impairment loss capital group define capital manage group total capitalisation sum debt plus equity include noncontrolle interest group objective manage capital safeguard group ability continue go concern continue provide benefit patient return investor provide adequate return investor base level risk undertake available necessary financial resource allow group invest area deliver future benefit patient return investor maintain sufficient financial resource mitigate risk unforeseen event group complete purchase noncontrolle interest genentech effective march asdescribed note base revise international accounting standard consolidated separate financial statement ias adopt group transaction account infull equity transaction consequence carrying consolidate equity group reduce billion swiss franc billion swiss franc allocate eliminate book value genentech noncontrolle interest accounting effect significantly impact group net equity effect group business dividend policy capital monitor basis capitalisation calculate debt plus equity includingnoncontrolling interest report senior management group regular internal management reporting group capitalisation show table roche finance report roche group note roche group consolidate financial statement capital millions chf capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity total debt capitalisation group subject regulatory capital adequacy requirement know financial service industry group majority shareholding chugai note chugai public company objective policy process manage capital determine local management relate party control shareholder share capital roche holding ltd group parent company consist bearer share base information supply shareholder group pool voting right comprise december ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri ms maja oeri mr jrg duschmal mr lukas duschmal group hold share precede year represents issue share figure include share pooled voting right hold outside thisgroup individual member group mr andr hoffmann dr andreas oeri members board director roche holding ltd mrhoffmann receive remuneration total swiss franc swiss francs dr oeri receive remuneration total swiss franc swiss franc transaction group individual member shareholder group subsidiary associate list major group subsidiary associate include note transaction parent company subsidiary subsidiary eliminate consolidation nosignificant transaction group associate key management personnel member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee total remuneration board director exclude chairman total million swiss franc million swiss franc chairman board director member corporate executive committee roche holding ltd receive remuneration consist annual salary bonus expense allowance group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan chairman board director member corporate executive committee chairman board director member corporate executive committee participate certain equity compensation plan describe term vest condition fair value award disclose note new member corporate executive committee mr soriot ms ayyoubi include table fullcalendar year join cec remuneration chairman board director member corporate executive committee millions chf salary include bonus expense special stock award social security cost pension postemployment benefit equity compensation plan employee benefit total purpose remuneration disclosure value equity compensation plan include special stock award calculate base fair value employee receive take account thepreliminary assessment complete performance condition information give inthe detailed disclosure executive remuneration require swiss law areinclude inthe financial statement roche holding ltd basel page fair value innote represent cost group grant date reflect matter observe exercisebehaviour exit rate population receive award initial simulation anyperformance condition value calculate cost group equity compensation plansinclude special stock award grant key management personnel million swiss franc million swiss franc special stock awards chairman board director member corporateexecutive committee grant special stock award lieu oftheir cashsettle bonus financial year roche longterm member corporate executive committee grant stocksettle stock appreciation right ssar roche option plan rop restricted stock unit rsu award ssar rop rsu award roche connect contribution pay group respect chairman boardofdirector member corporate executive committee total million swiss franc million swiss franc roche performance share plan member corporate executive committee weretargete award cycle awards cycleeachaward result zero nonvoting equity security depend theachievement performance target transaction member corporate executive committee pension total million swissfranc million swiss franc pay group corporate executive committee member detailed disclosure executive remuneration require swiss law include financial statement roche holding ltd basel page total remuneration key management personnel give million swiss franc million swiss franc correspond sum remuneration chairman board director give remuneration corporate executive committee give postemployment benefit plan transaction group postemployment define benefit plan employee ofthe group describe note roche finance report roche group note roche group consolidated financial statement subsidiary associate divestment subsidiary effective august group sell whollyowne subsidiary lakeside de mxico sa de cv lakeside million swiss franc cash effective october group sell whollyowne subsidiary cenexi sas cenexi include manufacturing facility fontenaysousbois france million swiss franc cash gain loss divestment subsidiary millions chf consideration net asset dispose property plant equipment cash net asset accumulate currency translation adjustment gain loss divestment total gain loss divestment report general administration expense current period segment result pharmaceutical operating segment net cash inflow divestment million swiss franc million swiss franc list company share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange swiss exchange zurich valor share valor genussschein isin share ch isin genussschein ch market capitalisation chf japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo isin jp market capitalisation jpy nonliste company share capital equity interest country company city millions argentina producto roche sa qumica e industrial buenos aire ars australia roche diagnostic australia pty limited castle hill aud roche product pty limited dee aud austria roche austria gmbh vienna eur roche diagnostic gmbh vienna eur roche diagnostic graz gmbh graz eur belgium nv roche sa brussels eur roche diagnostic belgium sa brussels eur bermuda chemical manufacturing trading company limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd brazil produto roche qumico e farmacuticos sa paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn share capital equity interest country company city millions canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd st john cad chile roche chile limitada santiago de chile clp china roche china hold shanghai usd roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai limited shanghai usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia producto roche sa bogot cop costa rica roche servicios sa heredia usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche diagnostic hvidovre dkk dominican republic producto roche dominicana sa santo domingo dop ecuador roche ecuador sa quito usd el salvador productos roche el salvador sa san salvador svc estonia roche eesti tallinn eek finland roche diagnostic oy espoo eur roche oy espoo eur france roche diagnostic sa meylan eur roche sas neuillysurseine eur ventana medical systems sa illkirch eur germany galenus mannheim gmbh mannheim eur nimblegen systems gmbh pleiskirchen eur roche beteiligung gmbh grenzachwyhlen eur roche deutschland hold gmbh grenzachwyhlen dem roche diagnostic deutschland gmbh mannheim eur roche diagnostic gmbh mannheim eur roche innovatis ag bielefeld eur roche kulmbach gmbh kulmbach eur roche pharma ag grenzachwyhlen eur swisslab gmbh berlin eur greece roche hellas sa athens eur roche diagnostic hellas sa athens eur guatemala producto roche guatemala sa guatemala gtq honduras producto roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostic india pvt ltd mumbai inr roche scientific company india pvt ltd mumbai inr indonesia pt roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur italy roche diagnostic spa milan eur roche spa milan eur japan roche diagnostic kk tokyo jpy latvia roche latvija sia riga lvl lithuania uab roche lietuva vilnius light luxembourg pharminvest sa luxembourg eur malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostic malaysia sdn bhd kuala lumpur myr mexico roche servicios de mxico sa de cv mexico city mxn productos roche sa de cv mexico city mxn morocco roche sa casablanca mad netherlands roche diagnostic nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholde bv woerden eur new zealand roche diagnostic nz limited auckland nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio norway roche diagnostic norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr panama producto roche interamericana sa panama city usd producto roche panam sa panama city pab roche products inc panama city usd syntex puerto rico inc panama city usd technical development corp panama city chf peru producto roche qumica farmacutica sa lima pen roche finance report roche group note roche group consolidate financial statement share capital equity interest country company city million philippine roche philippines inc makati php poland roche diagnostic polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico roche operations ltd ponce usd romania roche romania srl bucharest ron russian federation roche moscow ltd moscow rub limited liability company roche diagnostic rus moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche doo pharmaceutical company ljubljana eur south africa roche product proprietary limited johannesburg zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain andreu roche sa madrid eur roche diagnostic sl barcelona eur roche farma sa madrid eur syntex roche sa madrid eur sweden roche ab stockholm sek roche diagnostic scandinavia ab bromma sek switzerland disetronic handel ag burgdorf chf disetronic holding ag burgdorf chf disetronic medical systems ag burgdorf chf f hoffmannla roche ltd basel chf glycart biotechnology ltd schlieren chf hoffmannla roche ltd basel chf imib institute medical informatics biostatistics ltd basel chf rabbitair ltd zurichkloten chf roche capital market ltd basel chf roche diagnostic switzerland ltd rotkreuz chf roche diagnostic ag rotkreuz chf roche diagnostic international ltd steinhausen chf roche finance ltd basel chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev usd united kingdom pirame limited berkshire gbp roche diagnostic ltd lewes gbp roche hold uk limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp united states life sciences corporation branford usd bioveris corporation gaithersburg usd disetronic medical systems inc fishers usd genentech inc south san francisco usd genentech usa inc south san francisco usd hoffmannla roche inc nutley usd igen international inc wilmington usd memory pharmaceuticals corp montvale usd roche carolina inc florence usd roche colorado corporation boulder usd roche diagnostic corporation indianapoli usd roche diagnostic operation inc indianapoli usd roche finance usa inc little fall usd roche holdings inc wilmington usd roche laboratories inc nutley usd roche madison inc madison usd roche molecular systems inc pleasanton usd roche nimblegen inc madison usd roche palo alto llc palo alto usd spring bioscience corp fremont usd therapeutic human polyclonals inc palo alto usd ventana medical systems inc tucson usd uruguay roche international ltd montevideo branch montevideo uyu venezuela producto roche sa caracas vef share capital local currency unit roche group report roche management internal control overfinancial report roche finance report report roche management internal control financial reporting report roche management internal control financial reporting board director management roche holding ltd responsible establish maintain adequate control financial report internal control system design provide reasonable assurance reliability financial reporting preparation fair presentation ofconsolidate financial statement accordance international financial reporting standard internal control system matter design inherent limitation system determine effective prevent detect misstatement provide reason ableassurance respect financial statement preparation presentation projection ofany evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate management assess effectiveness system internal control financial reporting december base criterion effective internal control financial reporting describe ininternal control integrate frameworkissued committee sponsor organization treadway commission coso base assessment management conclude system ofinternal control financial reporting effective december statutory auditor kpmg ag audit consolidated financial statement roche holding ltd forthe year end december accordance swiss auditing standard international standard audit isa issue report effectiveness group system internal control financial reporting report set page franz b humer erich hunziker chairman board director chief financial officer deputy head corporate executive committee basel january roche finance report roche group report statutory auditor consolidated financial statement report statutory auditor consolidated financial statement report statutory auditor consolidated financial statement annual general meeting roche holding ltd basel statutory auditor audit consolidated financial statement income statement statement ofcomprehensive income balance sheet statement cash flow statement change equity note page roche holding ltd year end december board director responsibility board director responsible preparation fair presentation consolidate financial statement accordance international financial reporting standard ifrs requirement swiss law responsibility include design implement andmaintaine internal control system relevant preparation fair presentation consolidate financial statement free material misstatement fraud error board ofdirector responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion consolidated financial statement base audit conduct audit accordance swiss law swiss auditing standard international standard auditing standard require plan perform audit obtain reasonable assurance consolidated financial statement free material misstatement audit involve perform procedure obtain audit evidence amount disclosure theconsolidate financial statement procedure select depend auditor judgment include assessment risk material misstatement consolidated financial statement tofraud error make risk assessment auditor consider internal control system relevant entitys preparation fair presentation consolidate financial statement order design audit procedure appropriate circumstance audit include evaluate appro priateness accounting policy reasonableness accounting estimate evaluate overall presentation consolidated financial statement believe audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion consolidate financial statement year end december atrue fair view financial position result operation cash flow accordance international financial reporting standard ifrs comply swiss law report legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article co article aoa circumstance incompatible independence accordance article paragraph item co swiss auditing standard confirm thataninternal control system exist design preparation consolidated financial statement accord instruction board director recommend consolidated financial statement submit approve kpmg ag john morris franois rouiller license audit expert license audit expert auditor charge basel january roche finance report roche group report independent auditor internal control financial reporting report independent auditor internal control financial reporting report independent auditor internal control financial reporting annual general meeting roche holding ltd basel examine roche group system internal control financial reporting december base criterion establish internal control integrate frameworkissue committee ofsponsore organization treadway commission coso board director management roche holding ltd responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany report roche management internal control overfinancial reporting responsibility express opinion company internal control financial reporting base examination entity internal control financial reporting processeffecte entitys board director management personnel design provide reasonable assurance reliability financial statement prepare accordance international financial reporting standard ifrs include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset entity provide reasonable assurance transaction record necessary permit preparation financial statement accordance applicable financial reporting framework provide reasonable assurance prevention timely detection ofthe unauthorised acquisition use disposition entity asset material effect entitys financial statement conduct examination accordance international standard assurance engagement isae standard require plan perform examination obtain reasonable assurance effective internal control financial reporting maintain material respect examination include obtain understand internal control financial reporting testing evaluate design operating effectiveness internal control perform otherprocedure consider necessary circumstance believe examination provide reasonable basis opinion inherent limitation internal control financial reporting include possibility management override control misstatement error fraud occur detect projection evaluation internal control financial reporting future period subject tothe riskthat internal control inadequate change condition thedegree ofcompliance policy procedure deteriorate opinion roche group maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso audit accordance swiss auditing standard international standard audit consolidated financial statement roche holding ltd year end december report date january express unqualified opinion consolidated financial statement kpmg ag john morris franois rouiller basel january roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information multiyear overview statistic report statement income millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income equity attributable roche shareholder research development sale current ratio equity noncontrolle interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard stock split apply retrospectively dividend propose board director roche finance report roche group multiyear overview supplementary information sale division millions chf pharmaceutical diagnostic total sale geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total addition property plant equipment division millions chf pharmaceutical diagnostic corporate total addition property plant equipment geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total european union information base members eu december comparative information restate toinclude new eu member fiveyear period roche finance report roche group multiyear overview supplementary information supplementary net income ep information group basic diluted earning share information give note consolidated financial statement page supplementary eps information give net income continue business exceptional item core net income additionally exclude amortisation intangible assetsand relate impact income taxis noncontrolle interest profit continue business exceptional item core net income millions chf net income major legal case income taxis change group organisation income taxis exceptional financing cost income taxis profit continue business exceptional item noncontrolle interest net income exceptional item major legal case exceptional item change group organisation net income attributable roche shareholder exceptional item amortisation impairment intangible asset income taxis noncontrolle interest core net income include impairment intangible asset million swiss franc zero include change group organisation note consolidated financial statement ep continue business exceptional item core eps ep continue business exceptional item core ep net income attributable roche shareholderschf million increase noncontrolle share net income net tax assume outstanding genentech chugai stock option exercise net income calculate diluted earning share share information million share nonvoting equity security weight average number share nonvoting equity security issue adjustment assume exercise equity compensation plan dilutive weight average number share nonvoting equity security issue calculate diluted earning share earning share diluted chf supplementary operating free cash flow information divisional operate free cash flow information million chf pharmaceutical diagnostic corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment intangible asset total adjustment add expense equitysettle equity compensation plan net income expense provision net gain disposal noncash work capital item deduct net cash flow equity compensation plan utilisation provision proceed disposal total operating profit cash adjustment ebitda operate profit exceptional item depreciation amortisation impairment total group add exceptional item ebitda margin sale roche finance report roche group roche security roche security price development share chf roche share swiss market index rebase price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase price development american depositary receipt adr usd roche adr sp index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade united states overthecounter market july information table restate change ratio adr effective january change inthe ratio adrs effective january number share nonvoting equity securitiesa number share nominal value chf number nonvoting equity security genussscheineno nominal value total datum share nonvoting equity security chf net income equity dividend c stock price shareb open high low yearend stock price nonvoting equity security genussscheinb opening high low yearend market capitalisation millions chf year end key ratio yearend net income equity dividend yield share dividend yield nonvoting equity security genussscheinein priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussscheinconfer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction asto ownership share nonvoting equity securities b stock price datum reflect daily closing price c dividend propose board director ticker symbol share nonvoting equity security american depositary receipt adr swiss exchange ro rog bloomberg ro sw rog vx rhhby reuters ros rogvx rhhbypk roche finance report roche holding ltd basel financial statement roche holding ltd basel financial statement income statement millions chf year end december income income participation interest income loan group company interest investment income guarantee fee income group company income total income expense financial expense administration expense expense total expense profit year taxis tax net profit year balance sheet millions chf december december noncurrent asset participation longterm loan longterm loan group company total noncurrent asset current asset shortterm loan group company account receivable group company account receivable marketable security liquid fund total current asset total asset equity share capital nonvoting equity security genussscheine pm pm general legal reserve free reserve special reserve available earning balance bring forward previous year net profit year total equity noncurrent liability provision total noncurrent liability current liability account payable group company unrealise foreign currency gain liability total current liability total liability total equity liability pm pro memoria nonvoting equity security nominal value roche finance report roche holding ltd basel note financial statement note financial statement summary significant accounting policy basis preparation financial statement financial statement roche holding ltd basel prepare accordance provision ofswisslaw participation major participation company list note roche group consolidate financial statement valuation method translation foreign currency marketable security report low cost market value asset include partici pation report cost appropriate writedown asset liability denominate foreign currency translate swiss franc yearend rate exchange participation translate historical rate transaction year denominate foreign currency aretranslate exchange rate effective relevant transaction date result exchange gain loss recognise income statement exception unrealise gain defer taxis tax charge include corporate income capital taxis equity share capital previous year share capital amount million swiss franc share capital consist bearer share nominal value swiss franc include equity nonvoting equity security genussscheine share capital confer voting right nonvoting equity security genussscheinconfer right share participate available earning remain proceed liquidation follow repayment ofthe nominal value share capital participation certificate movement recognise amount millions chf general share legal free special available total capital reserve reserve reserve earnings equity january net income dividend pay transfer free reserve december net income dividend pay transfer free reserve december net income dividend pay transfer free reserve december contingent liability guarantee company issue guarantee certain bond note commercial paper credit facility group company nominal outstanding december billion swiss franc million swiss franc increase primarily additional bond note issue group company finance genentech transaction guarantee company describe note roche group consolidated financial statement page significant shareholder share company bearer share reason company register ofshareholder follow figure base information shareholder shareholder validation check annual general meeting march information available company share shareholder group pool voting right comprise atdecember ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann drandreasoeri ms sabine duschmaloeri ms catherine oeri ms maja oeri mr jrg duschmal andmrlukas duschmala share participation novartis ltd basel include affiliate thereofb information supply shareholder figure share include share pooled voting right hold outside group individual member group b figure december supply novartis ltd basel roche finance report roche holding ltd basel note financial statement risk management detailed disclosure risk management require swiss law include roche group consolidated financial statement page board executive remuneration board director member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee remuneration member board director thousands chf b gehrig hoffmann p baschera ji bell p brabeckletmathe ljr de vink w frey da julius oeri w ruttenstorfer h teltschik b weder di mauro total remuneration board director chairman board directors dr franz b humer receive remuneration show table remuneration chairman board director thousands chf annual salary include bonus expense special stock award pension postemployment benefit equity compensation plan employee benefit total remuneration receive social security cost total corporate executive committee member corporate executive committee cec roche holding ltd receive remuneration indirectbenefit participate certain equity compensation plan show table thegroup ceo dr severin schwan member corporate executive committee high total remuneration remuneration disclose new member corporate executivecommittee mr soriot ms ayyoubi include calendar year inwhich join cec remuneration member corporate executive committee thousands chf total cec schwan total cec schwan annual salary include bonus expense special stock award pension postemployment benefit equity compensation plan employee benefit total remuneration receive social security cost total special stock award chairman board director member corporate executive committee grant total special stock awards chairman board ofdirector receive award members cec receive total award award grant dr schwan fair value award employee calculate base fair value nonvoting equity security genussscheineat grant date chf orchf discount account period block year year employer contribution social security scheme pension plan group pay social insurance contribution respect remuneration pay contribution pension post employment benefit plan chairman board director member corporate executive committee equity compensation plan chairman board director member corporate executive committee participate certain equity compensation plan describe term andveste condition award disclose note consolidated financial statement fair value consolidated financial statement represent cost company grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition purpose ofthese remuneration disclosure value calculate base fair value employee receivestaking account preliminary assessment complete performance condition chairman board director member corporate executive committee eligible participate roche connect programme enable employee regular deduction salary purchase nonvoting equity security group contribute programme allow employee purchase nonvoting equity security discount usually member corporate executive committee grant stocksettle stock appreciation right ssar individual award relate show table fair value award employee swiss franc calculate blackschole formula assume hold maturity deduct average twoyear vest period thechairman board director grant ssar roche finance report roche holding ltd basel note financial statement members corporate executive committee member senior management participate theroche performance share plan psp group overlapping threeyear psp target award threeyear cycle define begin cycle award consider form employee remuneration equal annual amount threeyear cycle award result zero nonvoting equity security genussscheine depend achievement performance target discretion board director individual award relate show table number award calculate follow psp end cycle performance target achieve accordingly participant receive originally target nonvoting equity security genussscheine psp nonvoting equity security genussscheinper award psp nonvoting equity security genussscheinper award result allocation multiply nonvoting equity security genussscheinprice december swiss franc fair value remuneration receive employee remuneration equity compensation plan thousand chf roche connect ssar awards psp award employer ssar ssar psp psp psp psp total contribution number fair value number number number fair value fair value total cec schwan total remuneration corporate executive committee equity compensation plan million swiss franc million swiss attributable dr schwan member corporate executive committee high total remuneration employee benefit include tax advisory cost remuneration dr schwan dr hunziker mr burns prof knowle serve chugai board director include special payment dr keller swiss franc year service group transaction member corporate executive committee pension total million swiss franc pay group corporate executive committee member million swiss franc board executive shareholding board director director mr andr hoffmann dr andreas oeri member founder family closely associate belong shareholder group pool voting right end thisgroup hold share issue share detailed information group give note addition end year member board director person closely associate hold share nonvoting equity security genussscheineas show table shareholding member board director nonvoting equity security share genussscheine fb humer bc b gehrig hoffmann e p baschera ji bell p brabeckletmathe ljr de vink f w frey da julius g oeri e w ruttenstorfer h teltschik b weder di mauro total figure include share hold shareholder group pool voting right b special stock award hold december dr humer hold special stock award note c equity compensation award roche option plan ssar roche performance share plan mr hoffmann enter option agreement ubs roche nonvoting equity security period august august e mr hoffmann dr oeri hold ubs longshort certificate roche bearer share ro versus roche nonvoting equity security rog f mr de vink hold roche american depositary receipt adr g close relative dr julius hold roche nonvoting equity security genussscheine zero corporate executive committee member corporate executive committee person closely associate hold share nonvoting equity security genussscheineas show table shareholding member corporate executive committee nonvoting equity security share genussscheine schwan abc ayyoubi ab wm burns ab e hunziker ab ga keller abd jkc knowles b j schwiezer b p soriot na na b total special stock award hold december dr schwan ms ayyoubi mr burn dr hunziker dr keller hold total ofspecial stock award respectively note b equity compensation award roche option plan ssar roche performance share plan c close relative dr schwan hold roche nonvoting equity security genussscheine close relative dr keller hold roche nonvoting equity security genussscheine roche finance report roche holding ltd basel note financial statement december chairman board director member corporate executive committee hold stocksettle stock appreciation right ssar issue roche option plan award issue show table award hold dr humer current chairman board director issue previous capacity member corporate executive committee option entitle holder purchase roche nonvoting equity security genussschein specify strike price term vest condition award disclose note consolidated financial statement additional supplementary information remuneration report include business report annual report page roche option plan ssar award hold december year issue total schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer p soriot total cec fb humer total strike price chf expiry date feb jan feb feb feb feb feb mr soriots award include award strike price chf expire january december chairman board director member corporate executive committee hold psp award psp performance cycle show table award hold dr humer current chairman board director issue previous capacity member corporate executive committee term vest condition award disclose note consolidated financial statement andadditional supplementary information remuneration report page business report annual report award result zero nonvoting equity security genussscheine depend achievement performance target discretion ofthe board director end cycle performance target achieve andaccordingly participant receive originally target nonvoting equity security genussscheine total target number award outstanding cycle december show table roche performance share plan award hold december psp psp schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer p soriot total allocation date feb feb december chairman board director member corporate executive committee time hold total stocksettle stock appreciation right roche optionplan awards outstanding total award grant roche performance share plan roche finance report roche holding ltd basel appropriation available earning appropriation available earning proposal annual general meeting chf available earning balance bring forward previous year net profit year transfer free reserve total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year transfer free reserve total appropriation available earning carry forward account roche holding ltd basel report statutory auditor financial statement roche finance report report statutory auditor financial statement report statutory auditor financial statement annual general meeting roche holding ltd basel statutory auditor audit financial statement income statement balance sheet note onpage roche holding ltd year end december board director responsibility board director responsible preparation financial statement accordance requirement swiss law company article incorporation responsibility include design implement maintain internal control system relevant preparation financial statement free material misstatement fraud error board director responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion financial statement base onour audit conduct audit accordance swiss law swiss auditing standard standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit involve perform procedure obtain audit evidence amount disclosure financial statement procedure select depend auditor judgment include assessment ofthe risk material misstatement financial statement fraud error make risk assessment auditor consider internal control system relevant entitys preparation financial statement order design audit procedure appropriate circumstance butnot purpose express opinion effectiveness entity internal control system audit include evaluate appropriateness accounting policy reasonableness accounting estimate evaluate overall presentation financial statement webelieve audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion financial statement year end december comply swiss law company article incorporation roche finance report roche holding ltd basel report statutory auditor financial statement report legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article co article aoa circumstance incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exist design preparation financial statement accord instruction board director confirm propose appropriation available earning complie swiss law thecompany article incorporation recommend financial statement submit approve kpmg ag john morris franois rouiller license audit expert license audit expert auditor charge basel january publish cautionary statement forwardlooke f hoffmannla roche ltd statement basel switzerland annual report contain certain forwardlooking tel statement forwardlooke statement identi fax fie word believe expect anticipate project intend seek estimate future similar expression discussion thing medium office strategy goal plan intention factor group communication causeactual result differ materially future basel switzerland reflect forwardlooke statement contain tel annual report price product fax initiative competitor legislative regulatory devel opment economic condition delay inability investor relation obtain regulatory approval bring product market fluctuation currency exchange rate general basel switzerland financial market condition uncertaintie discovery tel development marketing new product new use fax exist product include limitation negative result clinical trial research project unexpected effect world wide web pipeline market product increase government wwwrochecom pricing pressure interruption production loss ofor inability obtain adequate protection intellectual order publication property right litigation loss key executive orother employee adverse publicity news tel coverage fax email baselwebmasterrochecom statement earning share growth aprofit forecast interpret mean annual general meeting thatroche earning earning share march subsequent period necessarily match exceed historical publish earning earning share roche trademark mention enjoy legal protection roche annual report publish german english print nonchlorine bleach fsccertified paper roche annual report issue f hoffmannla roche ltd basel group communicationsfhoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom